Document:

Exhibit 10.13

 

EXECUTION COPY

 

CREDIT AGREEMENT

 

Dated as of March 23, 2015

 

among

 

OGLETHORPE POWER CORPORATION 
 (AN ELECTRIC MEMBERSHIP CORPORATION),

as Borrower,

 

BANK OF AMERICA, N.A., BANK OF MONTREAL AND COBANK, ACB,

as L/C Issuers, and any additional L/C Issuers party hereto from time to time,

 

THE LENDERS IDENTIFIED HEREIN

 

and

 

NATIONAL RURAL UTILITIES COOPERATIVE FINANCE CORPORATION,

as Administrative Agent, Swing Line Lender and L/C Issuer

 

*                                         *                                         *                                         *

 

NATIONAL RURAL UTILITIES COOPERATIVE FINANCE CORPORATION

as Lead Arranger

 

COBANK, ACB,
  as Syndication Agent

 

THE BANK OF TOKYO-MITSUBISHI UFJ, LTD.,
  as Documentation Agent

 

 

TABLE OF CONTENTS

 

	
 
    	
 
    	
 
    	
 
    	
Page
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
SECTION 1. DEFINITIONS AND   ACCOUNTING TERMS
    	
 
    	
1
    
	
1.1
    	
 
    	
Definitions
    	
 
    	
1
    
	
1.2
    	
 
    	
Other Interpretive Provisions
    	
 
    	
23
    
	
1.3
    	
 
    	
Accounting Terms
    	
 
    	
24
    
	
1.4
    	
 
    	
Time
    	
 
    	
24
    
	
1.5
    	
 
    	
Letter of Credit Amounts
    	
 
    	
24
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
SECTION 2. THE COMMITMENTS   AND CREDIT EXTENSIONS
    	
 
    	
24
    
	
2.1
    	
 
    	
Committed Loans
    	
 
    	
24
    
	
2.2
    	
 
    	
Borrowings, Conversions and Continuations of Committed   Loans
    	
 
    	
25
    
	
2.3
    	
 
    	
Letters of Credit
    	
 
    	
26
    
	
2.4
    	
 
    	
Swing Line Loans
    	
 
    	
37
    
	
2.5
    	
 
    	
Prepayments
    	
 
    	
40
    
	
2.6
    	
 
    	
Termination or Reduction of Commitments
    	
 
    	
41
    
	
2.7
    	
 
    	
Repayment of Loans
    	
 
    	
41
    
	
2.8
    	
 
    	
Interest
    	
 
    	
41
    
	
2.9
    	
 
    	
Fees
    	
 
    	
42
    
	
2.10
    	
 
    	
Computation of Interest and Fees
    	
 
    	
43
    
	
2.11
    	
 
    	
Evidence of Debt
    	
 
    	
43
    
	
2.12
    	
 
    	
Payments Generally; Administrative Agent’s Clawback
    	
 
    	
44
    
	
2.13
    	
 
    	
Sharing of Payments by Lenders
    	
 
    	
46
    
	
2.14
    	
 
    	
Extension of Maturity Date
    	
 
    	
46
    
	
2.15
    	
 
    	
Increase in Commitments
    	
 
    	
48
    
	
2.16
    	
 
    	
Cash Collateral
    	
 
    	
49
    
	
2.17
    	
 
    	
Defaulting Lenders
    	
 
    	
50
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
SECTION 3. TAXES, YIELD   PROTECTION AND ILLEGALITY
    	
 
    	
52
    
	
3.1
    	
 
    	
Taxes
    	
 
    	
52
    
	
3.2
    	
 
    	
Illegality
    	
 
    	
56
    
	
3.3
    	
 
    	
Inability to Determine Rates
    	
 
    	
57
    
	
3.4
    	
 
    	
Increased Costs
    	
 
    	
57
    
	
3.5
    	
 
    	
Compensation for Losses
    	
 
    	
59
    
	
3.6
    	
 
    	
Mitigation Obligations; Replacement of Lenders
    	
 
    	
59
    
	
3.7
    	
 
    	
Survival
    	
 
    	
61
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
SECTION 4. CONDITIONS   PRECEDENT
    	
 
    	
61
    
	
4.1
    	
 
    	
Closing Conditions
    	
 
    	
61
    
	
4.2
    	
 
    	
Conditions to All Credit Extensions
    	
 
    	
63
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
SECTION 5. REPRESENTATIONS   AND WARRANTIES
    	
 
    	
64
    
	
5.1
    	
 
    	
Organization and Good Standing
    	
 
    	
64
    
	
5.2
    	
 
    	
Due Authorization
    	
 
    	
64
    

 

i

 

	
5.3
    	
 
    	
No Conflicts
    	
 
    	
65
    
	
5.4
    	
 
    	
Consents
    	
 
    	
65
    
	
5.5
    	
 
    	
Enforceable Obligations
    	
 
    	
65
    
	
5.6
    	
 
    	
Financial Condition
    	
 
    	
65
    
	
5.7
    	
 
    	
No Default
    	
 
    	
65
    
	
5.8
    	
 
    	
Litigation
    	
 
    	
66
    
	
5.9
    	
 
    	
Taxes
    	
 
    	
66
    
	
5.10
    	
 
    	
Compliance with Law
    	
 
    	
66
    
	
5.11
    	
 
    	
ERISA
    	
 
    	
66
    
	
5.12
    	
 
    	
Use of Proceeds
    	
 
    	
67
    
	
5.13
    	
 
    	
Government Regulations
    	
 
    	
68
    
	
5.14
    	
 
    	
Solvency
    	
 
    	
68
    
	
5.15
    	
 
    	
Disclosure
    	
 
    	
68
    
	
5.16
    	
 
    	
Environmental Matters
    	
 
    	
68
    
	
5.17
    	
 
    	
Insurance
    	
 
    	
69
    
	
5.18
    	
 
    	
Franchises, Licenses, Etc.
    	
 
    	
69
    
	
5.19
    	
 
    	
Subsidiaries; Affiliates; Members
    	
 
    	
69
    
	
5.20
    	
 
    	
Wholesale Power Contracts
    	
 
    	
69
    
	
5.21
    	
 
    	
Anti-Corruption Laws and Sanctions
    	
 
    	
69
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
SECTION 6. AFFIRMATIVE   COVENANTS
    	
 
    	
70
    
	
6.1
    	
 
    	
Information Covenants
    	
 
    	
70
    
	
6.2
    	
 
    	
Patronage Capital and Membership Fees
    	
 
    	
73
    
	
6.3
    	
 
    	
Notices with Respect to Wholesale Power Contracts
    	
 
    	
73
    
	
6.4
    	
 
    	
Preservation of Existence, Franchises and Assets
    	
 
    	
73
    
	
6.5
    	
 
    	
Books and Records
    	
 
    	
73
    
	
6.6
    	
 
    	
Compliance with Law
    	
 
    	
73
    
	
6.7
    	
 
    	
Payment of Taxes
    	
 
    	
73
    
	
6.8
    	
 
    	
Insurance
    	
 
    	
74
    
	
6.9
    	
 
    	
Use of Proceeds
    	
 
    	
74
    
	
6.10
    	
 
    	
Audits/Inspections
    	
 
    	
74
    
	
6.11
    	
 
    	
CoBank Equity and Security
    	
 
    	
75
    
	
6.12
    	
 
    	
Compliance with Anti-Corruption Laws and Sanctions
    	
 
    	
76
    
	
6.13
    	
 
    	
Rate Covenant
    	
 
    	
76
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
SECTION 7. NEGATIVE   COVENANTS
    	
 
    	
76
    
	
7.1
    	
 
    	
Nature of Business
    	
 
    	
76
    
	
7.2
    	
 
    	
Consolidation and Merger
    	
 
    	
76
    
	
7.3
    	
 
    	
Arm’s-Length Transactions
    	
 
    	
77
    
	
7.4
    	
 
    	
Fiscal Year; Organizational Documents
    	
 
    	
77
    
	
7.5
    	
 
    	
Liens
    	
 
    	
77
    
	
7.6
    	
 
    	
Wholesale Power Contracts
    	
 
    	
77
    
	
7.7
    	
 
    	
Indebtedness
    	
 
    	
78
    
	
7.8
    	
 
    	
No Violation of Anti-Corruption Laws or Sanctions
    	
 
    	
78
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
SECTION 8. EVENTS OF DEFAULT
    	
 
    	
78
    
	
8.1
    	
 
    	
Events of Default
    	
 
    	
78
    

 

ii

 

	
8.2
    	
 
    	
Acceleration; Remedies
    	
 
    	
81
    
	
8.3
    	
 
    	
Allocation of Payments After Event of Default
    	
 
    	
82
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
SECTION 9. ADMINISTRATIVE   AGENT
    	
 
    	
83
    
	
9.1
    	
 
    	
Appointment and Authority
    	
 
    	
83
    
	
9.2
    	
 
    	
Rights as a Lender
    	
 
    	
83
    
	
9.3
    	
 
    	
Exculpatory Provisions
    	
 
    	
84
    
	
9.4
    	
 
    	
Reliance by Administrative Agent
    	
 
    	
85
    
	
9.5
    	
 
    	
Delegation of Duties
    	
 
    	
85
    
	
9.6
    	
 
    	
Resignation of Administrative Agent
    	
 
    	
85
    
	
9.7
    	
 
    	
Non-Reliance on Administrative Agent and Other Lenders
    	
 
    	
87
    
	
9.8
    	
 
    	
No Other Duties, Etc.
    	
 
    	
87
    
	
9.9
    	
 
    	
Administrative Agent May File Proofs of Claim
    	
 
    	
87
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
SECTION 10. MISCELLANEOUS
    	
 
    	
88
    
	
10.1
    	
 
    	
Notices and Other Communications; Facsimile Copies
    	
 
    	
88
    
	
10.2
    	
 
    	
Right of Set-Off; Payments Set Aside
    	
 
    	
90
    
	
10.3
    	
 
    	
Successors and Assigns
    	
 
    	
91
    
	
10.4
    	
 
    	
No Waiver; Remedies Cumulative
    	
 
    	
96
    
	
10.5
    	
 
    	
Payment of Expenses, etc.
    	
 
    	
97
    
	
10.6
    	
 
    	
Amendments, Waivers and Consents
    	
 
    	
99
    
	
10.7
    	
 
    	
Counterparts
    	
 
    	
100
    
	
10.8
    	
 
    	
Headings
    	
 
    	
101
    
	
10.9
    	
 
    	
Interest Rate Limitation
    	
 
    	
101
    
	
10.10
    	
 
    	
Survival of Indemnification and Representations and   Warranties
    	
 
    	
101
    
	
10.11
    	
 
    	
Governing Law
    	
 
    	
101
    
	
10.12
    	
 
    	
Waiver of Jury Trial
    	
 
    	
102
    
	
10.13
    	
 
    	
Severability
    	
 
    	
103
    
	
10.14
    	
 
    	
Further Assurances
    	
 
    	
103
    
	
10.15
    	
 
    	
Entirety
    	
 
    	
103
    
	
10.16
    	
 
    	
Binding Effect; Continuing Agreement
    	
 
    	
103
    
	
10.17
    	
 
    	
Confidentiality
    	
 
    	
104
    
	
10.18
    	
 
    	
USA PATRIOT Act Notice
    	
 
    	
105
    
	
10.19
    	
 
    	
No Advisory or Fiduciary Responsibility
    	
 
    	
105
    
	
10.20
    	
 
    	
Electronic Execution of Assignments and Certain Other   Documents
    	
 
    	
106
    
	
10.21
    	
 
    	
Voting Participants
    	
 
    	
106
    
	
10.22
    	
 
    	
Waiver of Notice of Termination of Existing Credit   Agreement
    	
 
    	
106
    

 

	
Schedule   1.1
    	
 
    	
Commitments   and Applicable Percentages
    
	
Schedule   5.8
    	
 
    	
Litigation
    
	
Schedule   5.19
    	
 
    	
Subsidiaries,   Affiliates and Members
    
	
Schedule   5.20
    	
 
    	
Gross   Member Revenues
    
	
Schedule   10.1
    	
 
    	
Notices
    
	
 
    	
 
    	
 
    
	
Exhibit 2.2(a)-1
    	
 
    	
Form of   Committed Loan Notice
    
	
Exhibit 2.2(a)-2
    	
 
    	
Form of   Interest Election Notice
    
	
Exhibit 2.4
    	
 
    	
Form of   Swing Line Loan Notice
    

 

iii

 

	
Exhibit 2.11
    	
 
    	
Form of   Note
    
	
Exhibit 3.1(g)-1
    	
 
    	
Form of   U.S. Tax Compliance Certificate (For Foreign Lenders That Are Not   Partnerships For U.S. Federal Income Tax Purposes)
    
	
Exhibit 3.1(g)-2
    	
 
    	
Form of   U.S. Tax Compliance Certificate (For Foreign Participants That Are Not   Partnerships For U.S. Federal Income Tax Purposes)
    
	
Exhibit 3.1(g)-3
    	
 
    	
Form of   U.S. Tax Compliance Certificate (For Foreign Participants That Are   Partnerships For U.S. Federal Income Tax Purposes)
    
	
Exhibit 3.1(g)-4
    	
 
    	
Form of   U.S. Tax Compliance Certificate (For Foreign Lenders That Are Partnerships   For U.S. Federal Income Tax Purposes)
    
	
Exhibit 6.1(c)
    	
 
    	
Form of   Officer’s Certificate
    
	
Exhibit 10.3(b)
    	
 
    	
Form of   Assignment and Assumption
    

 

iv

 

CREDIT AGREEMENT

 

THIS CREDIT AGREEMENT, dated as of March 23, 2015, is entered into among OGLETHORPE POWER CORPORATION (AN ELECTRIC MEMBERSHIP CORPORATION) (the “Borrower”), BANK OF AMERICA, N.A., BANK OF MONTREAL AND COBANK, ACB, each as an L/C Issuer (as defined herein), any additional L/C Issuers party hereto from time to time, the Lenders (as defined herein) and NATIONAL RURAL UTILITIES COOPERATIVE FINANCE CORPORATION, as Administrative Agent (as defined herein) for the Lenders and the L/C Issuers, as Swing Line Lender and as an L/C Issuer.

 

SECTION 1.
 DEFINITIONS AND ACCOUNTING TERMS

 

1.1                               Definitions.

 

As used herein, the following terms shall have the meanings herein specified unless the context otherwise requires. Defined terms herein shall include in the singular number the plural and in the plural the singular.

 

“Administrative Agent” means CFC in its capacity as administrative agent under any of the Loan Documents or any successor administrative agent.

 

“Administrative Agent’s Office” means the Administrative Agent’s address and, as appropriate, account as set forth on Schedule 10.1, or such other address or account as the Administrative Agent may from time to time notify to the Borrower and the Lenders.

 

“Administrative Questionnaire” means an Administrative Questionnaire in a form supplied by the Administrative Agent.

 

“Affiliate” means, with respect to a specified Person, another Person that directly, or indirectly through one or more intermediaries, Controls or is Controlled by or is under common Control with the Person specified.  For purposes of this definition neither any Member nor Smarr EMC is an Affiliate.

 

“Aggregate Commitments” means the Commitments of all the Lenders.

 

“Agreement” means this Credit Agreement, as amended, extended, supplemented or otherwise modified in writing from time to time.

 

“Anti-Corruption Laws” means all laws, rules, and regulations of any jurisdiction applicable to the Borrower or its Subsidiaries from time to time concerning or relating to bribery, money laundering or corruption.

 

“Applicable Percentage” means with respect to any Lender at any time, the percentage (carried out to the ninth decimal place) of the Aggregate Commitments represented by such Lender’s Commitment at such time, subject to adjustment as provided in Section 2.17.  If the commitment of each Lender to make Loans and the

 

 

obligation of each L/C Issuer to make L/C Credit Extensions have been terminated pursuant to Section 8.2 or if the Aggregate Commitments have expired, then the Applicable Percentage of each Lender shall be determined based on the Applicable Percentage of such Lender most recently in effect, giving effect to any subsequent assignments.  The initial Applicable Percentage of each Lender is set forth opposite the name of such Lender on Schedule 1.1 or in the Assignment and Assumption pursuant to which such Lender becomes a party hereto, as applicable.

 

“Applicable Rate” means, for Unused Fee, Eurodollar Rate Loans, Letter of Credit Fee and Base Rate Loans, the appropriate applicable percentages, in each case (subject to the exception indicated below), corresponding to the Unsecured Credit Rating of the Borrower in effect as of the most recent Calculation Date (defined below) as shown below:

 

	
Unsecured Credit Rating
   (S&P/Moody’s/Fitch)
    	
 
    	
Applicable Rate for
   Unused Fee
    	
 
    	
Applicable Rate
   for Eurodollar
   Rate Loans and
   Letter of Credit
   Fee
    	
 
    	
Applicable
   Rate for Base
   Rate Loans
    	
 
    
	
Level   1
    >A / A2 / A
    	
 
    	
0.100
    	
%
    	
0.875
    	
%
    	
-0-
    	
 
    
	
Level   2
   A- / A3 / A-
    	
 
    	
0.125
    	
%
    	
1.000
    	
%
    	
-0-
    	
 
    
	
Level   3
   BBB+ / Baal / BBB+
    	
 
    	
0.150
    	
%
    	
1.250
    	
%
    	
0.250
    	
%
    
	
Level   4
   BBB / Baa2 / BBB
    	
 
    	
0.175
    	
%
    	
1.500
    	
%
    	
0.500
    	
%
    
	
Level   5
    <BBB- / Baa3 / BBB-
    	
 
    	
0.200
    	
%
    	
1.750
    	
%
    	
0.750
    	
%
    

 

If, however, the Borrower does not have an Unsecured Credit Rating by all three of S&P, Moody’s and Fitch (the “Rating Agencies”) then the Applicable Rate shall be the appropriate applicable percentages corresponding to the Secured Credit Rating of the Borrower in effect as of the most recent Calculation Date as shown below:

 

2

 

	
Secured Credit Rating
   (S&P/Moody’s/Fitch)
    	
 
    	
Applicable Rate for
   Unused Fee
    	
 
    	
Applicable Rate for
   Eurodollar Rate
   Loans and Letter of
   Credit Fee
    	
 
    	
Applicable
   Rate for Base
   Rate Loans
    	
 
    
	
Level   1
    > A+ / Al / A+
    	
 
    	
0.100
    	
%
    	
0.875
    	
%
    	
-0-
    	
 
    
	
Level   2
   A / A2 / A
    	
 
    	
0.125
    	
%
    	
1.000
    	
%
    	
-0-
    	
 
    
	
Level   3
   A-/ A3 / A-
    	
 
    	
0.150
    	
%
    	
1.250
    	
%
    	
0.250
    	
%
    
	
Level   4
   BBB+ / Baal / BBB+
    	
 
    	
0.175
    	
%
    	
1.500
    	
%
    	
0.500
    	
%
    
	
Level   5
    <BBB / Baa2 / BBB or unrated by all Rating Agencies
    	
 
    	
0.200
    	
%
    	
1.750
    	
%
    	
0.750
    	
%
    

 

The Applicable Rate shall be determined and adjusted on the date (each a “Calculation Date”) one Business Day after the date on which the Borrower’s Credit Rating is upgraded or downgraded in a manner which requires a change in the then applicable pricing level set forth above.  In the event that there is a Credit Rating by only two of the Rating Agencies and there is a split rating, the highest rating (lowest pricing) will apply unless there is more than one pricing level between the ratings and then the pricing level one below the highest rating will apply.  In the event that there is a rating by each of the Rating Agencies and there is a split rating, (a) if two of the three ratings are the same, then such rating will apply and (b) if none of the ratings are the same, the middle rating will apply.  If the Borrower does not have a Secured Credit Rating from any of the Rating Agencies then, with respect to the Secured Credit Rating, pricing level 5 shall apply. Each Applicable Rate shall be effective from one Calculation Date until the next Calculation Date.  Any adjustment in the Applicable Rate shall be applicable to all existing Eurodollar Rate Loans as well as any new Eurodollar Rate Loans made.  The applicable pricing level for the Applicable Rate, as of the Closing Date, is pricing level 2 from the Secured Credit Rating table.

 

“Approved Fund” means any Fund that is administered or managed by (a) a Lender, (b) an Affiliate of a Lender or (c) an entity or an Affiliate of an entity that administers or manages a Lender.

 

3

 

“Assignee Group” means two or more Eligible Assignees that are Affiliates of one another or two or more Approved Funds managed by the same investment advisor.

 

“Assignment and Assumption” means an assignment and assumption entered into by a Lender and an Eligible Assignee (with the consent of any party whose consent is required by Section 10.3), and accepted by the Administrative Agent, in substantially the form of Exhibit 10.3(b) or any other form approved by the Administrative Agent.

 

“Attorney Costs” means all reasonable fees and disbursements of any law firm or other external counsel and all disbursements of internal legal counsel in connection with such services.

 

“Availability Period” means the period from and including the Closing Date to but excluding the earlier of the Maturity Date and the date of termination of the Commitments prior to the Maturity Date pursuant to Section 2.6, Section 8.2 or otherwise.

 

“Bank of America” means Bank of America, N.A. and any successor thereto.

 

“Bankruptcy Code” means the Bankruptcy Code in Title 11 of the United States Code, as amended, modified, succeeded or replaced from time to time.

 

“Base Rate” means, for any day with respect to Committed Loans, a rate per annum equal to the greatest of (a) the Prime Rate in effect on such day, (b) the Federal Funds Effective Rate for such day plus 0.50% and (c) the Eurodollar Rate for a one-month interest period for such day (or if such day is not a Business Day, the immediately preceding Business Day) plus 1.00%.  Any change in the Base Rate due to a change in the Prime Rate, the Federal Funds Effective Rate or the Eurodollar Rate for a one-month interest period shall be effective from and including the effective date of such change in the Prime Rate, the Federal Funds Effective Rate or the Eurodollar Rate for a one-month interest period, as the case may be.

 

“Base Rate Committed Loan” means a Committed Loan that is a Base Rate Loan.

 

“Base Rate Loan” means a Loan that bears interest based on the Base Rate.

 

“Board” means the Board of Governors of the Federal Reserve System of the United States.

 

“Bond Documents” means, with respect to any Bonds, any trust indenture or similar document pursuant to which such Bonds are issued and any loan agreement, promissory note or similar document that provides security or a source of funding for the debt service on such Bonds.

 

“Bond Letter of Credit” means any Letter of Credit that provides credit or liquidity support for Bonds, including each Existing Letter of Credit.

 

4

 

“Bonds” means any bonds, notes or other evidences of indebtedness issued by or on behalf of the Borrower or any Subsidiary of the Borrower.

 

“Borrower” means Oglethorpe Power Corporation (An Electric Membership Corporation) and any permitted successor thereto.

 

“Borrower Materials” has the meaning specified in Section 6.1.

 

“Borrower Obligations” means, without duplication, all of the obligations of the Borrower to the Lenders, including Lenders when acting in the capacity of L/C Issuer, and the Administrative Agent, whenever arising, under this Agreement, the Notes or any of the other Loan Documents.

 

“Borrowing” means a Committed Borrowing or a Swing Line Borrowing, as the context may require.

 

“Business Day” means any day (a) that the office of the Administrative Agent is not closed and (b) other than a Saturday, a Sunday, a legal holiday or a day on which banking institutions are authorized or required by law or other governmental action to close in Atlanta, Georgia or New York, New York; provided that in the case of Eurodollar Rate Loans, such day is also a day on which dealings between banks are carried on in U.S. dollar deposits in the London interbank market.

 

“Capital Stock” means (a) in the case of a corporation, all classes of capital stock of such corporation, (b) in the case of a partnership, partnership interests (whether general or limited), (c) in the case of a limited liability company, membership interests and (d) any other interest or participation that confers on a Person the right to receive a share of the profits and losses of, or distributions of assets of, the issuing Person.

 

“Cash Collateralize” means to pledge and deposit with or deliver to the Administrative Agent, for the benefit of the Administrative Agent, one or more L/C Issuers or the Swing Line Lender (as applicable) and the Lenders, as collateral for L/C Obligations, Obligations in respect of Swing Line Loans, or obligations of Lenders to fund participations in respect of either thereof (as the context may require), cash or deposit account balances or, if each L/C Issuer or Swing Line Lender (as applicable) benefitting from such collateral shall agree in its sole discretion, other credit support, in each case pursuant to documentation in form and substance satisfactory to (a) the Administrative Agent and (b) each such L/C Issuer or the Swing Line Lender (as applicable).  “Cash Collateral” shall have a meaning correlative to the foregoing and shall include the proceeds of such cash collateral and other credit support.

 

“CFC” means National Rural Utilities Cooperative Finance Corporation and any successor thereto.

 

“Change in Law” means the occurrence, after the date of this Agreement, of any of the following: (a) the adoption or taking effect of any law, rule, regulation or treaty, (b) any change in any law, rule, regulation or treaty or in the administration, interpretation, implementation or application thereof by any Governmental Authority or

 

5

 

(c) the making or issuance of any request, rule, guideline or directive (whether or not having the force of law) by any Governmental Authority; provided that notwithstanding anything herein to the contrary, (x) the Dodd-Frank Wall Street Reform and Consumer Protection Act and all requests, rules, guidelines or directives thereunder or issued in connection therewith and (y) all requests, rules, guidelines or directives promulgated by the Bank for International Settlements, the Basel Committee on Banking Supervision (or any successor or similar authority) or the United States or foreign regulatory authorities, in each case pursuant to Basel III, shall in each case be deemed to be a “Change in Law”, regardless of the date enacted, adopted or issued.

 

“Closing Date” means March 23, 2015.

 

“CoBank Equities” has the meaning specified in Section 6.11(a).

 

“Code” means the Internal Revenue Code of 1986, as amended from time to time, and the rules and regulations promulgated thereunder.

 

“Commitment” means, as to each Lender, its obligation to (a) make Committed Loans to the Borrower pursuant to Section 2.1, (b) purchase participations in L/C Obligations and (c) purchase participations in Swing Line Loans, in an aggregate principal amount at any one time outstanding not to exceed the amount set forth opposite such Lender’s name on Schedule 2.1 or in the Assignment and Assumption pursuant to which such Lender becomes a party hereto, as applicable, as such amount may be adjusted from time to time in accordance with this Agreement.

 

“Committed Borrowing” means a borrowing consisting of simultaneous Committed Loans of the same Type and, in the case of Eurodollar Rate Loans, having the same Interest Period made by each of the Lenders pursuant to Section 2.1.

 

“Committed Loan” has the meaning specified in Section 2.1.

 

“Committed Loan Notice” means a notice of a Committed Borrowing, pursuant to Section 2.2(a), which, if in writing, shall be substantially in the form of Exhibit 2.2(a)-1.

 

“Connection Income Taxes” means Other Connection Taxes that are imposed on or measured by net income (however denominated) or that are franchise Taxes or branch profits Taxes.

 

“Control” means the possession, directly or indirectly, of the power to direct or cause the direction of the management or policies of a Person, whether through the ability to exercise voting power, by contract or otherwise.  “Controlling” and “Controlled” have meanings correlative thereto.

 

“Credit Extension” means each of the following: (a) a Borrowing and (b) an L/C Credit Extension.

 

“Credit Rating” means, for any Person, the Unsecured Credit Rating or the Secured Credit Rating, as applicable.

 

6

 

“Debtor Relief Laws” means the Bankruptcy Code of the United States, and all other liquidation, conservatorship, bankruptcy, assignment for the benefit of creditors, moratorium, rearrangement, receivership, insolvency, reorganization, or similar debtor relief Laws of the United States or other applicable jurisdictions from time to time in effect and affecting the rights of creditors generally.

 

“Default” means any event, act or condition which with notice or lapse of time, or both, would constitute an Event of Default.

 

“Default Rate” means (a) when used with respect to Borrower Obligations other than Letter of Credit Fees, an interest rate equal to (i) the Base Rate plus (ii) the Applicable Rate, if any, applicable to Base Rate Loans plus (iii) 2% per annum; provided, however, that with respect to a Eurodollar Rate Loan, the Default Rate shall be an interest rate equal to the interest rate (including any Applicable Rate) otherwise applicable to such Loan plus 2% per annum, and (b) when used with respect to Letter of Credit Fees, a rate equal to the Applicable Rate plus 2% per annum.

 

“Defaulting Lender” means, subject to Section 2.17(b), any Lender that (a) has failed to (i) fund all or any portion of its Loans within two Business Days of the date such Loans were required to be funded hereunder unless such Lender notifies the Administrative Agent (or the Required Lenders if such Lender is the Administrative Agent) and the Borrower in writing that such failure is the result of such Lender’s determination that one or more conditions precedent to funding (each of which conditions precedent, together with any applicable default, shall be specifically identified in such writing) has not been satisfied, or (ii) pay to the Administrative Agent, any L/C Issuer, any Swingline Lender or any other Lender any other amount required to be paid by it hereunder (including in respect of its participation in Letters of Credit or Swingline Loans) within two Business Days of the date when due, (b) has notified the Borrower, the Administrative Agent (or the Required Lenders if such Lender is the Administrative Agent) or any L/C Issuer or Swingline Lender in writing that it does not intend to comply with its funding obligations hereunder, or has made a public statement to that effect (unless such writing or public statement relates to such Lender’s obligation to fund a Loan hereunder and states that such position is based on such Lender’s determination that a condition precedent to funding (which condition precedent, together with any applicable default, shall be specifically identified in such writing or public statement) cannot be satisfied), (c) has failed, within three Business Days after written request by the Administrative Agent (or the Required Lenders if such Lender is the Administrative Agent) or the Borrower, to confirm in writing to the Administrative Agent (or such Required Lenders) and the Borrower that it will comply with its prospective funding obligations hereunder (provided that such Lender shall cease to be a Defaulting Lender pursuant to this clause (c) upon receipt of such written confirmation by the Administrative Agent (or the Required Lenders if such Lender is the Administrative Agent) and the Borrower), or (d) has, or has a direct or indirect parent company that has, (i) become the subject of a proceeding under any Debtor Relief Law, or (ii) had appointed for it a receiver, custodian, conservator, trustee, administrator, assignee for the benefit of creditors or similar Person charged with reorganization or liquidation of its business or assets, including the Federal Deposit Insurance Corporation or any other state or federal 

 

7

 

regulatory authority acting in such a capacity; provided that a Lender shall not be a Defaulting Lender solely by virtue of the ownership or acquisition of any equity interest in that Lender or any direct or indirect parent company thereof by a Governmental Authority so long as such ownership interest does not result in or provide such Lender with immunity from the jurisdiction of courts within the United States or from the enforcement of judgments or writs of attachment on its assets or permit such Lender (or such Governmental Authority) to reject, repudiate, disavow or disaffirm any contracts or agreements made with such Lender. Any determination by the Administrative Agent (or the Required Lenders if such Lender is the Administrative Agent) that a Lender is a Defaulting Lender under clauses (a) through (d) above shall be conclusive and binding absent manifest error, and such Lender shall be deemed to be a Defaulting Lender (subject to Section 2.17(b)) upon delivery of written notice of such determination to the Borrower, each L/C Issuer, each Swingline Lender and each Lender.

 

“Dollars” and “$” means dollars in lawful currency of the United States of America.

 

“Eligible Assignee” means any Person that meets the requirements to be an assignee under Sections 10.3(b)(iii), (v) and (vi) (subject to such consents, if any, as may be required under Section 10.3(b)(iii)).

 

“Engagement Letter” means that certain letter agreement, dated February 12, 2015, among the Administrative Agent, CFC, as the Lead Arranger, and the Borrower, as amended, modified or supplemented from time to time.

 

“Environmental Laws” means any current or future legal requirement of any Governmental Authority pertaining to (a) the protection of health, safety, and the indoor or outdoor environment, (b) the conservation, management, or use of natural resources and wildlife, (c) the protection or use of surface water and groundwater or (d) the management, manufacture, possession, presence, use, generation, transportation, treatment, storage, disposal, release, threatened release, abatement, removal, remediation or handling of, or exposure to, any hazardous or toxic substance or material or (e) pollution (including any release to land surface water and groundwater) and includes, without limitation, the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended by the Superfund Amendments and Reauthorization Act of 1986, 42 USC 9601 et seq., Solid Waste Disposal Act, as amended by the Resource Conservation and Recovery Act of 1976 and Hazardous and Solid Waste Amendment of 1984, 42 USC 6901 et seq., Federal Water Pollution Control Act, as amended by the Clean Water Act of 1977, 33 USC 1251 et seq., Clean Air Act of 1966, as amended, 42 USC 7401 et seq., Toxic Substances Control Act of 1976, 15 USC 2601 et seq., Hazardous Materials Transportation Act, 49 USC App. 1801 et seq., Occupational Safety and Health Act of 1970, as amended, 29 USC 651 et seq., Oil Pollution Act of 1990, 33 USC 2701 et seq., Emergency Planning and Community Right-to-Know Act of 1986, 42 USC 11001 et seq., National Environmental Policy Act of 1969, 42 USC 4321 et seq., Safe Drinking Water Act of 1974, as amended, 42 USC 300(f) et seq., any analogous implementing or successor law, and any amendment, rule, regulation, order, or directive issued thereunder.

 

8

 

“ERISA” means the Employee Retirement Income Security Act of 1974, as amended, and any successor statute thereto, as interpreted by the rules and regulations thereunder, all as the same may be in effect from time to time. References to sections of ERISA shall be construed also to refer to any successor sections.

 

“ERISA Affiliate” means an entity, whether or not incorporated, which is under common control with the Borrower or any of its Subsidiaries within the meaning of Section 4001(a)(14) of ERISA, or is a member of a group which includes the Borrower or any of its Subsidiaries and which is treated as a single employer under Sections 414(b), (c), (m), or (o) of the Code.

 

“Eurodollar Rate” means for any Interest Period with respect to any Eurodollar Rate Loan comprising a Borrowing, an interest rate per annum (rounded upwards, if necessary, to the next 1/100 of 1%) equal to (a) the London Interbank Offered Rate for such Interest Period multiplied by (b) the Statutory Reserve Rate for such Interest Period.

 

“Eurodollar Rate Loan” means a Loan that bears interest at a rate based on the Eurodollar Rate (but not based on clause (c) of the definition of Base Rate).

 

“Event of Default” has the meaning specified in Section 8.1.

 

“Excluded Taxes” means any of the following Taxes imposed on or with respect to a Recipient or required to be withheld or deducted from a payment to a Recipient, (a) Taxes imposed on or measured by net income (however denominated), franchise Taxes, and branch profits Taxes, in each case, (i) imposed as a result of such Recipient being organized under the laws of, or having its principal office or, in the case of any Lender, its applicable Lending Office located in, the jurisdiction imposing such Tax (or any political subdivision thereof) or (ii) that are Other Connection Taxes, (b) in the case of a Lender, U.S. federal withholding Taxes imposed on amounts payable to or for the account of such Lender with respect to an applicable interest in a Loan or Commitment pursuant to a law in effect on the date on which (i) such Lender acquires such interest in the Loan or Commitment (other than pursuant to an assignment request by the Borrower under Section 3.6(b)) or (ii) such Lender changes its Lending Office, except in each case to the extent that, pursuant to Section 3.1, amounts with respect to such Taxes were payable either to such Lender’s assignor immediately before such Lender became a party hereto or to such Lender immediately before it changed its Lending Office, (c) Taxes attributable to such Recipient’s failure to comply with Section 3.1(g) and (d) any U.S. federal withholding Taxes imposed under FATCA.

 

“Existing Credit Agreement” means the Credit Agreement, dated as of June 9, 2011 and as amended prior to the Closing Date, among Oglethorpe Power Corporation (An Electric Membership Corporation), the lenders and letter of credit issuers party thereto and Bank of America, N.A., as administrative agent.

 

“Existing Letters of Credit” means (a) the irrevocable transferable direct-pay letter of credit issued by Bank of America on March 30, 2010 in support of the Development Authority of Burke County Pollution Control Revenue Bonds (Oglethorpe 

 

9

 

Power Corporation Vogtle Project), Series 2010A, (b) the irrevocable transferable direct-pay letter of credit issued by Bank of America on March 30, 2010 in support of the Development Authority of Burke County Pollution Control Revenue Bonds (Oglethorpe Power Corporation Vogtle Project), Series 2010B and (c) the irrevocable transferable direct-pay letter of credit issued by Bank of Montreal on March 28, 2012 in support of the Development Authority of Monroe County Pollution Control Revenue Bonds (Oglethorpe Power Corporation Scherer Project), Series 2010A, in each case as amended prior to or on the Closing Date.

 

“Farm Credit Lender” means a lending institution organized and existing pursuant to the provisions of the Farm Credit Act of 1971 and under the regulation of the Farm Credit Administration.

 

“FATCA” means Sections 1471 through 1474 of the Code, as of the date of this Agreement (or any amended or successor version that is substantively comparable and not materially more onerous to comply with), any current or future regulations or official interpretations thereof and any agreement entered into pursuant to Section 1471(b)(1) of the Code, and any intergovernmental agreement entered into in connection with such sections of the Code and any legislation, law, regulation or practice enacted or promulgated pursuant to such intergovernmental agreement.

 

“Federal Funds Effective Rate” means, for any day, the weighted average (rounded upwards, if necessary, to the next 1/100 of 1%) of the rates on overnight Federal funds transactions with members of the Federal Reserve System arranged by Federal funds brokers, as published on the next succeeding Business Day by the Federal Reserve Bank of New York, or, if such rate is not so published for any day that is a Business Day, the average (rounded upwards, if necessary, to the next 1/100 of 1%) of the quotations for such day for such transactions received by the Administrative Agent from three (3) Federal funds brokers of recognized standing selected by it.

 

“Fee Letters” means the Engagement Letter and any L/C Issuer Fee Letter.

 

“Financial Officer” means any one of the chief financial officer, the chief accounting officer, the senior vice president, finance, vice president, finance and the treasurer of the Borrower.

 

“First Mortgage Indenture” means, collectively, (a) that certain Indenture, dated as of March 1, 1997, from the Borrower, as grantor, to U.S. Bank National Association (as successor to SunTrust Bank (formerly SunTrust Bank, Atlanta)), as trustee, and (b) that certain Security Agreement, dated as of March 1, 1997, from the Borrower, as debtor, to U.S. Bank National Association (as successor to SunTrust Bank (formerly SunTrust Bank, Atlanta)), as trustee and secured party, either as originally executed or as the same may from time to time be supplemented, modified, amended, renewed, extended or consolidated, or any alternate mortgage, deed to secure debt, deed of trust, trust indenture, security agreement or other security instrument entered into by the Borrower as a substitute or replacement for such indenture and security agreement, which secures equally and ratably the payment of principal of and interest on the obligations thereunder 

 

10

 

and creates a lien on substantially all of the real and tangible personal property of the Borrower in favor of such mortgagee or secured party and/or additional and/or substitute mortgagees or secured parties.

 

“First Mortgage Indenture Debt” means that certain secured Indebtedness of the Borrower, not to exceed $12,000,000,000, as secured under the First Mortgage Indenture.

 

“Fitch” means Fitch, Inc., Fitch Ratings Ltd. or, in each case, any successor or assignee of the business of such company in the business of rating securities.

 

“Foreign Lender” means a Lender that is not a U.S. Person

 

“Fronting Commitment” means, with respect to (i) CFC, as L/C Issuer, $500,000,000, (ii) Bank of America, as L/C Issuer, $100,000,000, (iii) Bank of Montreal, as L/C Issuer, $100,000,000, (iv) CoBank, ACB, as L/C Issuer, $150,000,000, and (v) any other L/C Issuer, such amount as may be agreed upon between such L/C Issuer and the Borrower, in each case, as such amount may be modified from time to time pursuant to agreement between the Borrower and the applicable L/C Issuer (with notice thereof to the Administrative Agent).

 

“Fronting Exposure” means, at any time there is a Defaulting Lender, (a) with respect to any L/C Issuer, such Defaulting Lender’s Applicable Percentage of the outstanding L/C Obligations with respect to Letters of Credit issued by such L/C Issuer other than L/C Obligations as to which such Defaulting Lender’s participation obligation has been reallocated to other Lenders or Cash Collateralized in accordance with the terms hereof, and (b) with respect to the Swing Line Lender, such Defaulting Lender’s Applicable Percentage of Swing Line Loans other than Swing Line Loans as to which such Defaulting Lender’s participation obligation has been reallocated to other Lenders or Cash Collateralized in accordance with the terms hereof.

 

“Fund” means any Person (other than a natural person) that is (or will be) engaged in making, purchasing, holding or otherwise investing in commercial loans, bonds and similar extensions of credit in the ordinary course of its activities.

 

“GAAP” means generally accepted accounting principles in the United States applied on a consistent basis and subject to Section 1.3.

 

“Governmental Authority” means the government of the United States or any other nation, or of any political subdivision thereof, whether state or local, and any agency, authority, instrumentality, regulatory body, court, central bank or other entity exercising executive, legislative, judicial, taxing, regulatory or administrative powers or functions of or pertaining to government (including any supra-national bodies such as the European Union or the European Central Bank).

 

“Guaranty Obligations” means, with respect to any Person, without duplication, any obligations (other than endorsements in the ordinary course of business of negotiable instruments for deposit or collection) guaranteeing any Indebtedness of any other Person in any manner, whether direct or indirect, and including without limitation any 

 

11

 

obligation, whether or not contingent, (a) to purchase any such Indebtedness or other obligation or any property constituting security therefor, (b) to advance or provide funds or other support for the payment or purchase of such Indebtedness or obligation or to maintain working capital, solvency or other balance sheet condition of such other Person (including, without limitation, maintenance agreements, comfort letters, take or pay arrangements, put agreements or similar agreements or arrangements) for the benefit of the holder of Indebtedness of such other Person, (c) to lease or purchase property, securities or services primarily for the purpose of assuring the owner of such Indebtedness or (d) to otherwise assure or hold harmless the owner of such Indebtedness or obligation against loss in respect thereof The amount of any Guaranty Obligation hereunder shall (subject to any limitations set forth therein) be deemed to be an amount equal to the outstanding principal amount (or maximum principal amount, if larger) of the Indebtedness in respect of which such Guaranty Obligation is made.

 

“Hedging Agreement” means any interest rate protection agreement, foreign currency exchange agreement, commodity price protection agreement or other interest or currency exchange rate or commodity price hedging arrangement.

 

“Honor Date” has the meaning set forth in Section 2.3(c).

 

“Impacted Interest Period” has the meaning specified for such term in the definition herein of “London Interbank Offered Rate.”

 

“Indebtedness” of any Person means, without duplication, (a) all obligations of such Person for borrowed money, (b) all obligations of such Person evidenced by bonds, debentures, notes or similar instruments (it being agreed that discounting amounts payable by any Member to the Borrower under such Member’s Wholesale Power Contract as a result of such Member’s prepayment of amounts to become due under such Wholesale Power Contract shall not constitute such prepayments as Indebtedness), (c) all Indebtedness of others secured by (or for which the holder of such Indebtedness has an existing right, contingent or otherwise, to be secured by) any Lien on, or payable out of the proceeds of production from, property owned or acquired by such Person, whether or not the obligations secured thereby have been assumed, (d) all Guaranty Obligations of such Person, (e) the principal portion of all obligations of such Person under (i) capital lease obligations and (ii) Off Balance Sheet Indebtedness, (f) all obligations of such Person to repurchase any securities which repurchase obligation is related to the issuance thereof, including, without limitation, obligations commonly known as residual equity appreciation potential shares, (g) all net principal obligations of such Person then due and payable in respect of interest rate protection agreements, foreign currency exchange agreements, commodity purchase or option agreements or other interest or exchange rate or commodity price hedging agreements, but excluding from this clause (g) any net principal obligations of such Person then due and payable in respect of agreements entered into to hedge or mitigate the Borrower’s commercial risk, and (h) the maximum amount of all performance and standby letters of credit issued or bankers’ acceptances facilities created for the account of such Person and, without duplication, all drafts drawn thereunder (to the extent unreimbursed), but excluding from this clause (h) any performance and standby letter of credit or bankers’ acceptance facility that is credit 

 

12

 

enhancement for any indebtedness or obligation, or any indebtedness or obligation that is secured by any indebtedness or obligation (including variable rate demand bonds), that is defined as Indebtedness under any other clause of this definition.  The Indebtedness of the Borrower shall not include obligations under power, energy, transmission or fuel purchase agreements.

 

“Indemnified Liabilities” has the meaning set forth in Section 10.5(b).

 

“Indemnified Taxes” means (a) Taxes, other than Excluded Taxes, imposed on or with respect to any payment made by or on account of any obligation of the Borrower under any Loan Document and (b) to the extent not otherwise described in (a), Other Taxes.

 

“Indemnitee” has the meaning set forth in Section 10.5(b).

 

“Interest Election Notice” means a notice of (a) a conversion of Committed Loans from one Type to the other, or (b) a continuation of Eurodollar Rate Loans, pursuant to Section 2.2(a), which, if in writing, shall be substantially in the form of Exhibit 2.2(a)-2.

 

“Interest Payment Date” means (a) as to Base Rate Loans (including a Swing Line Loan), the last Business Day of each March, June, September and December, commencing with the first such date to occur after the Closing Date, and on the Maturity Date, and (b) as to Eurodollar Rate Loans, the last day of each applicable Interest Period and the Maturity Date, and, in addition, where the applicable Interest Period for a Eurodollar Rate Loan is greater than three months, then also on the last day of each three-month period during such Interest Period.  If an Interest Payment Date falls on a date which is not a Business Day, such Interest Payment Date shall be deemed to be the next succeeding Business Day, except that in the case of Eurodollar Rate Loans where the next succeeding Business Day falls in the next succeeding calendar month, then such Interest Payment Date shall be deemed to be the next preceding day.

 

“Interest Period” means, as to Eurodollar Rate Loans, a period of one, two, three or six months’ duration, as the Borrower may elect, commencing, in each case, on the date of the borrowing (including continuations and conversions of Eurodollar Rate Loans); provided, however, (a) if any Interest Period would end on a day which is not a Business Day, such Interest Period shall be extended to the next succeeding Business Day (except that where the next succeeding Business Day falls in the next succeeding calendar month, then such Interest Period shall end on the next preceding Business Day), (b) no Interest Period shall extend beyond the Maturity Date and (c) with respect to Eurodollar Rate Loans, where an Interest Period begins on a day for which there is no numerically corresponding day in the calendar month in which the Interest Period is to end, such Interest Period shall end on the last Business Day of such calendar month.

 

“Interpolated Rate” means, at any time, for any Interest Period, the rate per annum (rounded upward to the nearest 1/100 of 1%) determined by the Administrative Agent (which determination shall be conclusive and binding absent manifest error) to be equal to the rate that results from interpolating on a linear basis between:  (a) the Screen Rate 

 

13

 

for the longest period for which the Screen Rate is available for the Eurodollar Rate Loan that is shorter than the Impacted Interest Period; and (b) the Screen Rate for the shortest period for which the Screen Rate is available for the Eurodollar Rate Loan that exceeds the Impacted Interest Period, in each case, at such time.

 

“IRS” means the United States Internal Revenue Service.

 

“ISP” means the International Standby Practices, International Chamber of Commerce Publication No. 590.

 

“Issuer Documents” means with respect to any Letter of Credit, the Letter of Credit Application, and any other document, agreement and instrument entered into by an L/C Issuer and the Borrower (or any Subsidiary of the Borrower) or in favor of an L/C Issuer and relating to such Letter of Credit.

 

“Laws” means, collectively, all international, foreign, Federal, state and local statutes, treaties, rules, guidelines, regulations, ordinances, codes and administrative or judicial precedents or authorities, including the interpretation or administration thereof by any Governmental Authority charged with the enforcement, interpretation or administration thereof, and all applicable administrative orders, directed duties, requests, licenses, authorizations and permits of, and agreements with, any Governmental Authority, in each case whether or not having the force of law.

 

“L/C Advance” means, with respect to each Lender, such Lender’s funding of its participation in any L/C Borrowing in accordance with such Lender’s Applicable Percentage.

 

“L/C Borrowing” means an extension of credit resulting from a drawing under any Letter of Credit which has not been reimbursed on the date when made or refinanced as a Committed Borrowing.

 

“L/C Credit Extension” means, with respect to any Letter of Credit, the issuance thereof or extension of the expiry date thereof, or the increase of the amount thereof

 

“L/C Issuer” means any of CFC, Bank of America, Bank of Montreal and CoBank, ACB, each in its capacity as issuer of Letters of Credit, and such other Lender as the Borrower, with the consent of the Administrative Agent, may from time to time select as an L/C Issuer to issue one or more Letters of Credit pursuant to Section 2.3 and that delivers an instrument in form and substance satisfactory to the Borrower and the Administrative Agent whereby such other Lender agrees to issue Letters of Credit and otherwise act as a “L/C Issuer” hereunder, each in its capacity as issuer of Letters of Credit hereunder, or any successor issuer of Letters of Credit hereunder; provided, however, unless otherwise agreed by the Administrative Agent, the number of L/C Issuers at any time shall not exceed three.

 

“L/C Issuer Fee Letter” means any letter agreement between an L/C Issuer and the Borrower providing for the payment of a fronting fee to such L/C Issuer, in each case, as amended, modified or supplemented from time to time.

 

14

 

“L/C Obligations” means, as at any date of determination, the aggregate amount available to be drawn under all outstanding Letters of Credit plus the aggregate of all Unreimbursed Amounts, including all L/C Borrowings. For purposes of computing the amount available to be drawn under any Letter of Credit, the amount of such Letter of Credit shall be determined in accordance with Section 1.5. For all purposes of this Agreement, if on any date of determination a Letter of Credit has expired by its terms but any amount may still be drawn thereunder by reason of the operation of Rule 3.14 of the ISP, such Letter of Credit shall be deemed to be “outstanding” in the amount so remaining available to be drawn.

 

“Lead Arranger” means CFC, in its capacity as lead arranger in connection with the facility under this Agreement.

 

“Lender” means any of the Persons identified as a “Lender” on the signature pages hereto, including the Swing Line Lender, and any Eligible Assignee which may become a Lender by way of assignment in accordance with the terms hereof, together with their successors and permitted assigns.

 

“Lending Office” means, as to any Lender, the office or offices of such Lender described as such in such Lender’s Administrative Questionnaire, or such other office or offices as a Lender may from time to time notify the Borrower and the Administrative Agent.

 

“Letter of Credit” means any standby letter of credit issued hereunder and each Existing Letter of Credit.

 

“Letter of Credit Application” means an application and agreement for the issuance or amendment of a letter of credit in the form from time to time in use by the applicable L/C Issuer.

 

“Letter of Credit Expiration Date” means the day that is thirty days prior to the Maturity Date then in effect (or, if such day is not a Business Day, the next preceding Business Day).

 

“Letter of Credit Fee” has the meaning specified in Section 2.3(h).

 

“Letter of Credit Sublimit” means an amount equal to $500,000,000.  The Letter of Credit Sublimit is part of, and not in addition to, the Aggregate Commitments.

 

“Liquidity Drawing” means, in respect of any Bonds supported by a Bond Letter of Credit, any drawing under such Bond Letter of Credit the proceeds of which are used to pay the purchase price of such Bonds tendered for purchase by the Borrower (or any Subsidiary of the Borrower).

 

“Lien” means any mortgage, pledge, hypothecation, assignment, deposit arrangement, security interest, encumbrance, lien (statutory or otherwise), preference, priority or charge of any kind (including any agreement to give any of the foregoing, any conditional sale or other title retention agreement, any financing or similar statement or

 

15

 

notice filed under the Uniform Commercial Code as adopted and in effect in the relevant jurisdiction or other similar recording or notice statute, and any lease in the nature thereof).

 

“Loan” means an extension of credit by a Lender to the Borrower under Section 2 in the form of a Committed Loan or a Swing Line Loan.

 

“Loan Documents” means this Agreement, each Note, each Issuer Document, any agreement creating or perfecting rights in Cash Collateral pursuant to the provisions of Section 2.16 of this Agreement and the Fee Letters.

 

“London Interbank Offered Rate” means, for any Interest Period with respect to any Eurodollar Rate Loan comprising a Borrowing, the rate per annum (rounded upwards, if necessary, to the nearest 1/100 of 1%) appearing on Reuters Screen LIBOR01 Page (or on any successor or substitute Reuters page or screen that displays such rate, or on the appropriate page or screen of such other comparable information service that publishes such rate from time to time as selected by the Administrative Agent in its discretion) as the London interbank eurodollar market offered rate for deposits in Dollars at approximately 11:00 a.m. (London, England time) two (2) Business Days prior to the first day of such Interest Period for a term comparable to such Interest Period (such rate, the “Screen Rate”); provided, that if the Screen Rate shall be less than zero, such rate shall be deemed to be zero for the purposes of this Agreement, and provided, further, if the Screen Rate shall not be available at such time for such Interest Period (an “Impacted Interest Period”), the Eurodollar Rate for such Borrowing shall be the Interpolated Rate, provided, that if any Interpolated Rate shall be less than zero, such rate shall be deemed to be zero for purposes of this Agreement.

 

“Material Adverse Effect” means an effect on the operations, business, assets, liabilities (actual or contingent) or condition (financial or otherwise) of the Borrower and its Subsidiaries, taken as a whole, the result of which would be to materially adversely affect (a) the ability of the Borrower to perform its obligations under this Agreement or (b) the validity or enforceability of this Agreement or any of the other Loan Documents or the rights and remedies of the Lenders hereunder or thereunder.

 

“Maturity Date” means the later of (a) March 23, 2020 and (b) if the Maturity Date is extended pursuant to Section 2.14, such extended Maturity Date as determined pursuant to such Section; provided, however, that, in each case, if such date is not a Business Day, the Maturity Date shall be the next preceding Business Day.

 

“Members” means the retail electric power distribution cooperative members of the Borrower from time to time.

 

“Moody’s” means Moody’s Investors Service, Inc., or any successor or assignee of the business of such company in the business of rating securities.

 

“Multiemployer Plan” means a Plan covered by Title IV of ERISA which is a multiemployer plan as defined in Section 3(37) or 4001(a)(3) of ERISA.

 

16

 

“Multiple Employer Plan” means a Plan covered by Title IV of ERISA, other than a Multiemployer Plan, which the Borrower or any ERISA Affiliate and at least one employer other than the Borrower or any ERISA Affiliate are contributing sponsors.

 

“Non-Consenting Lender” means any Lender that does not approve any consent, waiver or amendment that (a) requires the approval of all or all affected Lenders in accordance with the terms of Section 10.6 and (b) has been approved by the Required Lenders.

 

“Non-Defaulting Lender” means, at any time, each Lender that is not a Defaulting Lender at such time.

 

“Notes” means the promissory notes of the Borrower in favor of each Lender evidencing the Loans and substantially in the form of Exhibit 2.11, as such promissory notes may be amended, modified, supplemented or replaced from time to time.

 

“Notice of Extension Amendment” means, with respect to any Bond Letter of Credit, a written notice signed by the applicable L/C Issuer with respect to such Letter of Credit and delivered to the Borrower and the trustee for the applicable Bonds evidencing the extension of the expiry date of such Letter of Credit.

 

“Off Balance Sheet Indebtedness” means any obligation of a Person that would be considered indebtedness for tax purposes but is not set forth on the balance sheet of such Person, including, but not limited to, (a) any synthetic lease, tax retention operating lease, off balance sheet loan or similar off-balance sheet financing product of such Person, (b) the aggregate amount of uncollected accounts receivables of such Person subject at such time to a sale of receivables (or similar transaction) and (c) obligations of any partnership or joint venture that is recourse to such Person.

 

“Other Connection Taxes” means, with respect to any Recipient, Taxes imposed as a result of a present or former connection between such Recipient and the jurisdiction imposing such Tax (other than connections arising from such Recipient having executed, delivered, become a party to, performed its obligations under, received payments under, received or perfected a security interest under, engaged in any other transaction pursuant to or enforced any Loan Document, or sold or assigned an interest in any Loan or Loan Document).

 

“Other Taxes” means all present or future stamp, court or documentary, intangible, recording, filing or similar Taxes that arise from any payment made under, from the execution, delivery, performance, enforcement or registration of, from the receipt or perfection of a security interest under, or otherwise with respect to, any Loan Document, except any such Taxes that are Other Connection Taxes imposed with respect to an assignment (other than an assignment made pursuant to Section 3.6(b)).

 

“Outstanding Amount” means (a) with respect to any Committed Loans and Swing Line Loans on any date, the aggregate outstanding principal amount thereof after giving effect to any borrowings and prepayments or repayments of Committed Loans and Swing Line Loans, as the case may be, occurring on such date; and (b) with respect to

 

17

 

any L/C Obligations on any date, the amount of such L/C Obligations on such date after giving effect to any L/C Credit Extension occurring on such date and any other changes in the aggregate amount of the L/C Obligations as of such date, including as a result of any reimbursements by the Borrower of Unreimbursed Amounts.

 

“Participant” has the meaning specified in Section 10.3(d).

 

“Participant Register” has the meaning specified in Section 10.3(d).

 

“Patriot Act” has the meaning specified in Section 10.18.

 

“Patronage Capital” means the combined Patronage Capital and Membership Fees from the Members, as shown in the applicable column on the “Statements of Patronage Capital and Membership Fees and Accumulated Other Comprehensive Margin” of the Borrower.

 

“PBGC” means the Pension Benefit Guaranty Corporation established pursuant to Subtitle A of Title IV of ERISA and any successor thereto.

 

“Pension Plan” means each Plan which is a Single Employer Plan, a Multiple Employer Plan, or a Multiemployer Plan.

 

“Person” means any individual, partnership, joint venture, firm, corporation, association, trust, limited liability company or other enterprise (whether or not incorporated), or any government or political subdivision or any agency, department or instrumentality thereof.

 

“Plan” means any employee benefit plan (as defined in Section 3(3) of ERISA) which is covered by ERISA and with respect to which the Borrower or any ERISA Affiliate is (or, if such plan were terminated at such time, would under Section 4069 of ERISA be deemed to be) an “employer” within the meaning of Section 3(5) of ERISA.

 

“Platform” means DebtX, Debt Domain, Intralinks, Syndtrak or a substantially similar electronic transmission system.

 

“Prime Rate” means the rate of interest per annum published from time to time as the “Prime Rate” by The Wall Street Journal, or, if The Wall Street Journal ceases publishing a “Prime Rate”, any successor publication selected by the Administrative Agent in its reasonable discretion; each change in the Prime Rate shall be effective from and including the date such change is publicly announced as being effective.  The “Prime Rate” published by The Wall Street Journal or any such successor publication is a reference rate and does not necessarily represent the lowest or best rate charged by financial institutions to their customers.  The Lenders may make commercial loans or other loans at rates of interest at, above or below the “Prime Rate” published by The Wall Street Journal or any such successor publication.

 

“Public Lender” has the meaning specified in Section 6.1.

 

18

 

“Rates” has the meaning set forth in Section 6.13.

 

“Recipient” means (a) the Administrative Agent, (b) any Lender or (c) any L/C Issuer, as applicable.

 

“Register” has the meaning specified in Section 10.3(c).

 

“Regulation D, T, U or X” means Regulation D, T, U or X, respectively, of the Board as from time to time in effect, any amendment thereto and any successor to all or a portion thereof.

 

“Related Parties” means, with respect to any Person, such Person’s Affiliates and the partners, directors, officers, employees, agents, trustees, administrators, managers, advisors and representatives of such Person and of such Person’s Affiliates.

 

“Removal Effective Date” has the meaning specified in Section 9.6(b).

 

“Reportable Event” means a “reportable event” as defined in Section 4043 of ERISA with respect to which the notice requirements to the PBGC have not been waived.

 

“Request for Credit Extension” means (a) with respect to a Borrowing of Committed Loans, a Committed Loan Notice, (b) with respect to a conversion or continuation of Committed Loans, an Interest Election Notice, (c) with respect to an L/C Credit Extension, a Letter of Credit Application, and (d) with respect to a Swing Line Loan, a Swing Line Loan Notice.

 

“Required Lenders” means, as of any date of determination, Lenders having more than 50% of the Aggregate Commitments or, if the commitment of each Lender to make Loans and the obligation of each L/C Issuer to make L/C Credit Extensions have been terminated pursuant to Section 8.2, Lenders holding in the aggregate more than 50% of the Total Outstandings (with the aggregate amount of each Lender’s risk participation and funded participation in L/C Obligations and Swing Line Loans being deemed “held” by such Lender for purposes of this definition); provided that the Commitment of, and the portion of the Total Outstandings held or deemed held by, any Defaulting Lender shall be excluded for purposes of making a determination of Required Lenders.

 

“Resignation Effective Date” has the meaning set forth in Section 9.6(a).

 

“Responsible Officer” means the chief executive officer, president, chief financial officer, vice president, treasurer, assistant treasurer or controller of the Borrower and any other officer of the Borrower so designated by any of the foregoing officers in a notice to the Administrative Agent.  Any document delivered hereunder that is signed by a Responsible Officer of the Borrower shall be conclusively presumed to have been authorized by all necessary corporate, partnership and/or other action on the part of the Borrower and such Responsible Officer shall be conclusively presumed to have acted on behalf of the Borrower.

 

19

 

“Sanctions” means economic or financial sanctions or trade embargoes imposed, administered or enforced from time to time by (a) the U.S. government, including those administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury or by the U.S. Department of State, or (b) the United Nations Security Council, the European Union, any EU member state, or Her Majesty’s Treasury of the United Kingdom.

 

“Sanctioned Country” means, at any time of determination, a country or territory which is the subject or target of any Sanctions.

 

“Sanctioned Person” means, at any time of determination, (a) any Person listed in any Sanctions-related list of designated Persons maintained by the Office of Foreign Assets Control of the U.S. Department of the Treasury, the U.S. Department of State, the United Nations Security Council, the European Union or any EU member state, (b) any Person operating, organized or resident in a Sanctioned Country, (c) any Person owned or controlled by or acting on behalf of any such Person described in the preceding clause (a) or (b), or (d) any Person with which any Lender is prohibited under Sanctions relevant to it from dealing or engaging in transactions.  For purposes of the foregoing, control of a Person shall be deemed to include where a Sanctioned Person (i) owns or has power to vote 25% or more of the issued and outstanding equity interests having ordinary voting power for the election of directors of the Person or other individuals performing similar functions for the Person, or (ii) has the power to direct or cause the direction of the management and policies of the Person, whether by ownership of equity interests, contracts or otherwise.

 

“S&P” means Standard & Poor’s Financial Services LLC, a subsidiary of The McGraw-Hill Companies, Inc., or any successor or assignee of the business of such division in the business of rating securities.

 

“Screen Rate” has the meaning specified for such term in the definition herein of “London Interbank Offered Rate.”

 

“SEC” means the United States Securities and Exchange Commission.

 

“Secured Credit Rating” means, for any Person, the long-term, senior, secured, non-credit enhanced debt ratings assigned to such Person by S&P, Fitch and Moody’s.

 

“Single Employer Plan” means any Plan which is covered by Title IV of ERISA, but which is not a Multiemployer Plan or a Multiple Employer Plan.

 

“Solvent” means, with respect to the Borrower as of a particular date, that on such date (a) the Borrower is able to pay its debts and other liabilities, contingent obligations and other commitments as they mature in the normal course of business, (b) the Borrower does not intend to, and does not believe that it will, incur debts or liabilities beyond the Borrower’s ability to pay as such debts and liabilities mature in their ordinary course, (c) the Borrower is not engaged in a business or a transaction, and is not about to engage in a business or a transaction, for which the Borrower’s assets would constitute unreasonably small capital after giving due consideration to the prevailing practice in the industry in

 

20

 

which the Borrower is engaged or is to engage and (d) the fair value of the assets of the Borrower, including the Wholesale Power Contracts, taken as a whole on a going-concern basis, is greater than the total amount of liabilities, including, without limitation, contingent liabilities, of the Borrower. In computing the amount of contingent liabilities at any time, it is intended that such liabilities will be computed as the amount which, in light of all the facts and circumstances existing at such time, represents the amount that can reasonably be expected to become an actual or matured liability.

 

“Special Leases” means any transaction or series of transactions the overall effect of which is the transfer (by sale, head lease or otherwise) of ownership for federal income tax purposes of any asset by the Borrower or any of its Subsidiaries to any other Person or Persons (the “lessor”) while use of such asset is retained by or reconveyed to the Borrower or any of its Subsidiaries under a lease, sublease or other arrangement (the “sublease”) for a substantial period of time and where (a) the Borrower or any of its Subsidiaries shall have set aside financial assets expected to be sufficient to pay or provide for the payment of all or substantially all of the Borrower’s and its Subsidiaries scheduled payment obligations under the sublease, (b) the Borrower or any of its Subsidiaries shall have an option to purchase the lessor’s interest in the asset during or at the end of the sublease term, and (c) the Borrower or any of its Subsidiaries shall have set aside financial assets expected to be sufficient to pay or provide for the payment of all or substantially all of the option price. It is intended that the term “Special Leases” shall include the entire transaction and any and all documents and instruments entered into by the Borrower or any Subsidiary in connection therewith and any obligations thereunder.

 

“Statutory Reserve Rate” means, for the Interest Period for any Eurodollar Rate Loan, a fraction (expressed as a decimal), the numerator of which is the number one and the denominator of which is the number one minus the arithmetic mean, taken over each day in such Interest Period, of the aggregate of the maximum reserve percentages (including any marginal, special, emergency or supplemental reserves) expressed as a decimal established by the Board to which the Administrative Agent is subject for eurocurrency funding (currently referred to as “Eurocurrency liabilities” in Regulation D of the Board).  Such reserve percentages shall include those imposed pursuant to such Regulation D.  Eurodollar Rate Loans shall be deemed to constitute eurocurrency funding and to be subject to such reserve requirements without benefit of or credit for proration, exemptions or offsets that may be available from time to time to any Lender under such Regulation D or any comparable regulation.  The Statutory Reserve Rate shall be adjusted automatically on and as of the effective date of any change in any reserve percentage.

 

“Subsidiary” means, as to any Person, (a) any corporation more than 50% of whose stock of any class or classes having by the terms thereof ordinary voting power to elect a majority of the directors of such corporation (irrespective of whether or not, at the time, any class or classes of such corporation shall have or might have voting power by reason of the happening of any contingency) is at the time owned by such Person directly or indirectly through Subsidiaries and (b) any partnership, association, joint venture, limited liability company or other entity in which such Person directly or indirectly through Subsidiaries has more than 50% equity interest at any time.

 

21

 

“Swing Line Borrowing” means a borrowing of a Swing Line Loan pursuant to Section 2.4.

 

“Swing Line Lender” means CFC in its capacity as provider of Swing Line Loans, or any successor swing line lender hereunder.

 

“Swing Line Loan” has the meaning specified in Section 2.4(a).

 

“Swing Line Loan Notice” means a notice of a Swing Line Borrowing pursuant to Section 2.4(b), which, if in writing, shall be substantially in the form of Exhibit 2.4.

 

“Swing Line Sublimit” means an amount equal to the lesser of (a) $50,000,000 and (b) the Aggregate Commitments.  The Swing Line Sublimit is part of, and not in addition to, the Aggregate Commitments.

 

“Taxes” means all present or future taxes, levies, imposts, duties, deductions, withholdings (including backup withholding), assessments, fees or other charges imposed by any Governmental Authority, including any interest, additions to tax or penalties applicable thereto.

 

“Termination Date” means, with respect to any Letter of Credit, the expiry date of such Letter of Credit or any earlier date on which such Letter of Credit shall terminate in accordance with its terms.

 

“Termination Event” means (a) with respect to any Single Employer Plan, the occurrence of a Reportable Event or the substantial cessation of operations (within the meaning of Section 4062(e) of ERISA), (b) the withdrawal of the Borrower or any ERISA Affiliate from a Multiple Employer Plan during a plan year in which it was a substantial employer (as such term is defined in Section 4001(a)(2) of ERISA), or the termination of a Multiple Employer Plan, (c) the distribution of a notice of intent to terminate or the actual termination of a Pension Plan pursuant to Section 4041(a)(2) or 4041A of ERISA, (d) the institution of proceedings for the termination of, or the appointment of a trustee to administer, or the actual termination of, a Pension Plan by the PBGC under Section 4042 of ERISA, or (e) the complete or partial withdrawal of the Borrower or any ERISA Affiliate from a Multiemployer Plan.

 

“Total Outstandings” means the aggregate Outstanding Amount of all Loans and all L/C Obligations.

 

“Type” means with respect to a Committed Loan, its character as a Base Rate Loan or a Eurodollar Rate Loan.

 

“U.S. Person” means any Person that is a “United States Person” as defined in Section 7701(a)(30) of the Code.

 

“U.S. Tax Compliance Certificate” has the meaning specified in Section 3.1(g)(ii)(B)(3).

 

22

 

“Unreimbursed Amount” has the meaning specified in Section 2.3(c)(i).

 

“Unsecured Credit Rating” means, for any Person, the long-term, senior, unsecured, non-credit enhanced debt ratings assigned to such Person by S&P, Fitch and Moody’s.

 

“Unused Fee” has the meaning specified in Section 2.9(a).

 

“Wholesale Power Contracts” means those certain Amended and Restated Wholesale Power Contracts between the Borrower and each of the Members, each dated as of January 1, 2003, as amended by the First Amendment to Amended and Restated Wholesale Power Contracts, dated as of June 1, 2005 and as further amended, modified or supplemented from time to time.

 

“Withholding Agent” means the Borrower and the Administrative Agent.

 

1.2                               Other Interpretive Provisions.

 

With reference to this Agreement and each other Loan Document, unless otherwise specified herein or in such other Loan Document:

 

(a)                                 The definitions of terms herein shall apply equally to the singular and plural forms of the terms defined.  Whenever the context may require, any pronoun shall include the corresponding masculine, feminine and neuter forms.  The words “include,” “includes” and “including” shall be deemed to be followed by the phrase “without limitation.”  The word “will” shall be construed to have the same meaning and effect as the word “shall.”  Unless the context requires otherwise, (i) any definition of or reference to any agreement, instrument or other document shall be construed as referring to such agreement, instrument or other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein or in any other Loan Document), (ii) any reference herein to any Person shall be construed to include such Person’s successors and assigns, (iii) the words “hereto,” “herein,” “hereof” and “hereunder,” and words of similar import when used in any Loan Document, shall be construed to refer to such Loan Document in its entirety and not to any particular provision thereof, (iv) all references in a Loan Document to Articles, Sections, Exhibits and Schedules shall be construed to refer to Articles and Sections of, and Exhibits and Schedules to, the Loan Document in which such references appear, (v) any reference to any law shall include all statutory and regulatory provisions consolidating, amending, replacing or interpreting such law and any reference to any law or regulation shall, unless otherwise specified, refer to such law or regulation as amended, modified or supplemented from time to time, and (vi) the words “asset” and “property” shall be construed to have the same meaning and effect and to refer to any and all tangible and intangible assets and properties, including cash, securities, accounts and contract rights.

 

(b)                                 In the computation of periods of time from a specified date to a later specified date, the word “from” means “from and including;” the words “to” and “until” each mean “to but excluding;” and the word “through” means “to and including.”

 

23

 

(c)                                  Section headings herein and in the other Loan Documents are included for convenience of reference only and shall not affect the interpretation of this Agreement or any other Loan Document.

 

1.3                               Accounting Terms.

 

Except as otherwise expressly provided herein, all accounting terms used herein shall be interpreted, and all financial statements and certificates and reports as to financial matters required to be delivered to the Lenders hereunder shall be prepared, in accordance with GAAP applied on a consistent basis. All calculations made for the purposes of determining compliance with this Agreement shall (except as otherwise expressly provided herein) be made by application of GAAP applied on a basis consistent with the most recent annual or quarterly financial statements delivered pursuant to Section 6.1 (or, prior to the delivery of the first financial statements pursuant to Section 6.1, consistent with the financial statements described in Section 4.1(d)); provided, however, if (a) the Borrower shall object to determining such compliance on such basis at the time of delivery of such financial statements due to any change in GAAP or the rules promulgated with respect thereto or (b) the Administrative Agent or the Required Lenders shall so object in writing within 30 days after delivery of such financial statements, then such calculations shall be made on a basis consistent with the most recent financial statements delivered by the Borrower to the Lenders as to which no such objection shall have been made.

 

1.4                               Time.

 

All references to time herein shall be references to Eastern Standard Time or Eastern Daylight time, as the case may be, unless specified otherwise.

 

1.5                               Letter of Credit Amounts.

 

Unless otherwise specified herein, the amount of a Letter of Credit at any time shall be deemed to be the stated amount of such Letter of Credit in effect at such time; provided, however, that with respect to any Letter of Credit that, by its terms or the terms of any Issuer Document related thereto, provides for one or more automatic increases in the stated amount thereof, the amount of such Letter of Credit shall be deemed to be the maximum stated amount of such Letter of Credit after giving effect to all such increases, whether or not such maximum stated amount is in effect at such time.

 

SECTION 2.

 

THE COMMITMENTS AND CREDIT EXTENSIONS

 

2.1                               Committed Loans.

 

Subject to the terms and conditions set forth herein, each Lender severally agrees to make loans (each such loan, a “Committed Loan”) to the Borrower from time to time, on any Business Day during the Availability Period, in an aggregate amount not to exceed at any time outstanding the amount of such Lender’s Commitment; provided, however, that after giving effect to any Committed Borrowing, (i) the Total Outstandings shall not exceed the Aggregate Commitments,

 

24

 

and (ii) the aggregate Outstanding Amount of the Committed Loans of any Lender, plus such Lender’s Applicable Percentage of the Outstanding Amount of all L/C Obligations, plus such Lender’s Applicable Percentage of the Outstanding Amount of all Swing Line Loans shall not exceed such Lender’s Commitment.  Within the limits of each Lender’s Commitment, and subject to the other terms and conditions hereof, the Borrower may borrow under this Section 2.1, prepay under Section 2.5 and reborrow under this Section 2.1.  Committed Loans may be Base Rate Loans or Eurodollar Rate Loans, as further provided herein.

 

2.2                               Borrowings, Conversions and Continuations of Committed Loans.

 

(a)                                 Each Committed Borrowing, each conversion of Committed Loans from one Type to the other, and each continuation of Eurodollar Rate Loans shall be made upon the Borrower’s irrevocable notice to the Administrative Agent, which may be given by telephone.  Each such notice must be received by the Administrative Agent not later than 11:00 a.m. (i) three Business Days prior to the requested date of any Borrowing of, conversion to or continuation of Eurodollar Rate Loans or of any conversion of Eurodollar Rate Loans to Base Rate Committed Loans, and (ii) on the requested date of any Borrowing of Base Rate Committed Loans.  Each telephonic notice by the Borrower pursuant to this Section 2.2(a) must be confirmed promptly by delivery to the Administrative Agent of a written Committed Loan Notice, in the case of such request for a Committed Borrowing, or a written Interest Election Notice, in the case of such request for a conversion or continuation, in each case, appropriately completed and signed by a Responsible Officer of the Borrower.  Each Borrowing of, conversion to or continuation of Eurodollar Rate Loans shall be in a principal amount of $5,000,000 or a whole multiple of $1,000,000 in excess thereof.  Except as provided in Sections 2.3(c) and 2.4(c), each Borrowing of or conversion to Base Rate Committed Loans shall be in a principal amount of $500,000 or a whole multiple of $100,000 in excess thereof.  Each Committed Loan Notice (whether telephonic or written) shall specify (i) the requested date of the Borrowing (which shall be a Business Day), (ii) the principal amount of Committed Loans to be borrowed, (iii) the Type of Committed Loans to be borrowed and (iv) if applicable, the duration of the Interest Period with respect thereto.  Each Interest Election Notice (whether telephonic or written) shall specify (i) the requested date of the conversion or continuation (which shall be a Business Day), (ii) the principal amount of Committed Loans to be converted or continued, (iii) the Type of Committed Loans to which existing Committed Loans are to be converted and (iv) if applicable, the duration of the Interest Period with respect thereto. If the Borrower fails to specify a Type of Committed Loan in a Committed Loan Notice or if the Borrower fails to give a timely notice requesting a conversion or continuation, then the applicable Committed Loans shall be made as, or converted to, Base Rate Loans.  Any such automatic conversion to Base Rate Loans shall be effective as of the last day of the Interest Period then in effect with respect to the applicable Eurodollar Rate Loans.  If the Borrower requests a Borrowing of, conversion to, or continuation of Eurodollar Rate Loans in any such Committed Loan Notice or Interest Election Notice, but fails to specify an Interest Period, it will be deemed to have specified an Interest Period of one month.

 

(b)                                 Following receipt of a Committed Loan Notice or an Interest Election Notice, as applicable, the Administrative Agent shall promptly notify each Lender of the

 

25

 

amount of its Applicable Percentage of the applicable Committed Loans, and if no timely notice of a conversion or continuation is provided by the Borrower, the Administrative Agent shall notify each Lender of the details of any automatic conversion to Base Rate Loans described in the preceding subsection.  In the case of a Committed Borrowing, each Lender shall make the amount of its Committed Loan available to the Administrative Agent in immediately available funds at the Administrative Agent’s Office not later than 1:00 p.m. on the Business Day specified in the applicable Committed Loan Notice.  Upon satisfaction of the applicable conditions set forth in Section 4.2 (and, if such Borrowing is the initial Credit Extension, Section 4.1), the Administrative Agent shall make all funds so received available to the Borrower in like funds as received by the Administrative Agent either by (i) crediting the account of the Borrower on the books of CFC with the amount of such funds or (ii) wire transfer of such funds, in each case in accordance with instructions provided to (and reasonably acceptable to) the Administrative Agent by the Borrower; provided, however, that if, on the date the Committed Loan Notice with respect to such Borrowing is given by the Borrower, there are L/C Borrowings outstanding that are then due and payable, then the proceeds of such Borrowing, first, shall be applied to the payment in full of any such L/C Borrowings, and second, shall be made available to the Borrower as provided above.

 

(c)                                  Except as otherwise provided herein, a Eurodollar Rate Loan may be continued or converted only on the last day of an Interest Period for such Eurodollar Rate Loan.  During the existence of an Event of Default, no Loans may be requested as, converted to or continued as Eurodollar Rate Loans without the consent of the Required Lenders.

 

(d)                                 The Administrative Agent shall promptly notify the Borrower and the Lenders of the interest rate applicable to any Interest Period for Eurodollar Rate Loans upon determination of such interest rate.  At any time that Base Rate Loans are outstanding, the Administrative Agent shall notify the Borrower and the Lenders of any change in the Prime Rate used in determining the Base Rate promptly following the public announcement of such change.

 

(e)                                  After giving effect to all Committed Borrowings, all conversions of Committed Loans from one Type to the other, and all continuations of Committed Loans as the same Type, there shall not be more than ten Interest Periods in effect with respect to Committed Loans.

 

2.3                               Letters of Credit.

 

(a)                                 The Letter of Credit Commitment.

 

(i)                                     Subject to the terms and conditions set forth herein, (A) each L/C Issuer agrees, in reliance upon the agreements of the Lenders set forth in this Section 2.3, (1) from time to time on any Business Day during the period from the Closing Date until the Letter of Credit Expiration Date, to issue Letters of Credit for the account of the Borrower, or any of its Subsidiaries as provided in Section 2.3(k), and to amend or extend Letters of Credit previously issued by it, in

 

26

 

accordance with subsection (b) below, and (2) to honor drawings under the Letters of Credit; and (B) the Lenders severally agree to participate in Letters of Credit issued for the account of the Borrower, or any of its Subsidiaries as provided in Section 2.3(k), and any drawings thereunder; provided that after giving effect to any L/C Credit Extension with respect to any Letter of Credit, (w) the Total Outstandings shall not exceed the Aggregate Commitments, (x) the aggregate Outstanding Amount of the Committed Loans of any Lender, plus such Lender’s Applicable Percentage of the Outstanding Amount of all L/C Obligations, plus such Lender’s Applicable Percentage of the Outstanding Amount of all Swing Line Loans shall not exceed such Lender’s Commitment, (y) the Outstanding Amount of the L/C Obligations shall not exceed the Letter of Credit Sublimit and (z) the aggregate Stated Amount of all Letters of Credit issued by each L/C Issuer shall not exceed such L/C Issuer’s Fronting Commitment.  Each request by the Borrower for the issuance or amendment of a Letter of Credit shall be deemed to be a representation by the Borrower that the L/C Credit Extension so requested complies with the conditions set forth in the proviso to the preceding sentence.  Within the foregoing limits, and subject to the terms and conditions hereof, the Borrower’s ability to obtain Letters of Credit shall be fully revolving, and accordingly the Borrower may, during the foregoing period, obtain Letters of Credit to replace Letters of Credit that have expired or that have been drawn upon and reimbursed.  All Existing Letters of Credit shall be deemed to have been issued pursuant hereto, and from and after the Closing Date shall be subject to and governed by the terms and conditions hereof.

 

(ii)                                  An L/C Issuer shall not issue any Letter of Credit if the expiry date of the requested Letter of Credit would occur after the Letter of Credit Expiration Date, unless all the Lenders (and such L/C Issuer) have approved such expiry date.

 

(iii)                               An L/C Issuer shall not be under any obligation to issue any Letter of Credit if:

 

(A)                               any order, judgment or decree of any Governmental Authority or arbitrator shall by its terms purport to enjoin or restrain such L/C Issuer from issuing the Letter of Credit, or any Law applicable to such L/C Issuer or any request or directive (whether or not having the force of law) from any Governmental Authority with jurisdiction over such L/C Issuer shall prohibit, or request that such L/C Issuer refrain from, the issuance of letters of credit generally or the Letter of Credit in particular or shall impose upon such L/C Issuer with respect to the Letter of Credit any restriction, reserve or capital requirement (for which such L/C Issuer is not otherwise compensated hereunder) not in effect on the Closing Date, or shall impose upon such L/C Issuer any unreimbursed loss, cost or expense which was not applicable on the Closing Date and which such L/C Issuer in good faith deems material to it;

 

27

 

(B)                               the issuance of the Letter of Credit would violate one or more policies of such L/C Issuer applicable to letters of credit generally;

 

(C)                               except as otherwise agreed by the Administrative Agent and the applicable L/C Issuer, the Letter of Credit is in an initial stated amount less than $100,000;

 

(D)                               the Letter of Credit is to be denominated in a currency other than Dollars;

 

(E)                                any Lender is at that time a Defaulting Lender, unless such L/C Issuer has entered into arrangements, including the delivery of Cash Collateral, satisfactory to such L/C Issuer (in its sole discretion) with the Borrower or such Lender to eliminate such L/C Issuer’s actual or potential Fronting Exposure (after giving effect to Section 2.17(a)(iv)) with respect to the Defaulting Lender arising from either the Letter of Credit then proposed to be issued or that Letter of Credit and all other L/C Obligations as to which such L/C Issuer has actual or potential Fronting Exposure, as it may elect in its sole discretion; or

 

(F)                                 the Letter of Credit contains any provisions for automatic reinstatement of the stated amount after any drawing thereunder; provided, however, a Bond Letter of Credit may provide that (1) after any drawing thereunder to pay interest on Bonds, the stated amount of such Bond Letter of Credit shall be automatically reinstated in the amount of such drawing after a specified period of time unless, prior to the expiration of such period, the beneficiary of such Bond Letter of Credit has received notice from such L/C Issuer that it has not been reimbursed for such drawing; and (2) after any Liquidity Drawing thereunder, the stated amount of such Bond Letter of Credit shall be automatically reinstated in an amount equal to the principal amount of any Bonds previously purchased with the proceeds of such Liquidity Drawing that have been remarketed to investors where the proceeds of such remarketing have been received by applicable L/C Issuer and applied to the repayment of the Unreimbursed Amount, Committed Loans or Liquidity Advances related to such Liquidity Drawing.

 

(iv)                              An L/C Issuer shall not amend any Letter of Credit, including any extension or renewal thereof, if such L/C Issuer would not be permitted at such time to issue the Letter of Credit in its amended form under the terms hereof.

 

(v)                                 An L/C Issuer shall be under no obligation to amend any Letter of Credit if (A) such L/C Issuer would have no obligation at such time to issue the Letter of Credit in its amended form under the terms hereof, or (B) the beneficiary of the Letter of Credit does not accept the proposed amendment to the Letter of Credit.

 

28

 

(vi)                              An L/C Issuer shall act on behalf of the Lenders with respect to any Letters of Credit issued by it and the documents associated therewith, and each L/C Issuer shall have all of the benefits and immunities (A) provided to the Administrative Agent in Section 9 with respect to any acts taken or omissions suffered by such L/C Issuer in connection with Letters of Credit issued by it or proposed to be issued by it and Issuer Documents pertaining to such Letters of Credit as fully as if the term “Administrative Agent” as used in Section 9 included such L/C Issuer with respect to such acts or omissions, and (B) as additionally provided herein with respect to the L/C Issuers.

 

(b)                                 Procedures for Issuance and Amendment of Letters of Credit.

 

(i)                                     Each Letter of Credit shall be issued or amended, as the case may be, including, without limitation, extended or renewed, upon the request of the Borrower delivered to an L/C Issuer (with a copy to the Administrative Agent) in the form of a Letter of Credit Application, appropriately completed and signed by a Responsible Officer of the Borrower.  Such Letter of Credit Application must be received by such L/C Issuer and the Administrative Agent not later than 11:00 a.m. at least thirty days, in the case of a Bond Letter of Credit, and two Business Days, in the case of any other Letter of Credit (or such later date and time in each case as the Administrative Agent and such L/C Issuer may agree in a particular instance in their sole discretion), prior to the proposed issuance date or date of amendment, as the case may be.  In the case of a request for an initial issuance of a Letter of Credit, such Letter of Credit Application shall specify in form and detail reasonably satisfactory to the applicable L/C Issuer:  (A) the proposed issuance date of the requested Letter of Credit (which shall be a Business Day); (B) the amount thereof; (C) the expiry date thereof; (D) the name and address of the beneficiary thereof; (E) the documents to be presented by such beneficiary in case of any drawing thereunder; (F) the full text of any certificate to be presented by such beneficiary in case of any drawing thereunder; (G) the purpose and nature of the requested Letter of Credit; (H) in the case of a Bond Letter of Credit, the Bond Documents; and (I) such other information as such L/C Issuer may require.  In the case of a request for an amendment of any outstanding Letter of Credit, such Letter of Credit Application shall specify in form and detail satisfactory to such L/C Issuer (A) the Letter of Credit to be amended; (B) the proposed date of amendment thereof (which shall be a Business Day); (C) the nature of the proposed amendment; and (D) such other matters as such L/C Issuer may require.  Additionally, the Borrower shall furnish to such L/C Issuer and the Administrative Agent such other documents and information pertaining to such requested Letter of Credit issuance or amendment, including any Issuer Documents, as such L/C Issuer or the Administrative Agent may require.

 

(ii)                                  Promptly after receipt of any Letter of Credit Application, the applicable L/C Issuer will confirm with the Administrative Agent (by telephone or in writing) that the Administrative Agent has received a copy of such Letter of Credit Application from the Borrower and, if not, such L/C Issuer will provide the Administrative Agent with a copy thereof.  Unless such L/C Issuer has received

 

29

 

written notice from any Lender, the Administrative Agent or the Borrower, at least one Business Day prior to the requested date of issuance or amendment of the applicable Letter of Credit, that one or more applicable conditions contained in Section 4 shall not then be satisfied, then, (i) such L/C Issuer may conclusively presume that such conditions are satisfied and (ii) subject to the terms and conditions hereof, and in reliance thereon, such L/C Issuer shall, on the requested date, issue a Letter of Credit for the account of the Borrower or a Subsidiary of the Borrower, as applicable, or enter into the applicable amendment, as the case may be, in each case in accordance with such L/C Issuer’s usual and customary business practices.  Immediately upon the issuance of each Letter of Credit, each Lender shall be deemed to, and hereby irrevocably and unconditionally agrees to, purchase from such L/C Issuer a risk participation in such Letter of Credit in an amount equal to the product of such Lender’s Applicable Percentage times the amount of such Letter of Credit.

 

(iii)                               If the Borrower so requests in any Letter of Credit Application, the applicable L/C Issuer may, in its sole and absolute discretion, agree to issue a Letter of Credit that has automatic extension provisions (each, an “Auto-Extension Letter of Credit”); provided that any such Auto-Extension Letter of Credit must permit such L/C Issuer to prevent any such extension at least once in each twelve-month period (commencing with the date of issuance of such Letter of Credit) by giving prior notice to the beneficiary thereof not later than a day (the “Non-Extension Notice Date”) in each such twelve-month period to be agreed upon at the time such Letter of Credit is issued.  Unless otherwise directed by the applicable L/C Issuer, the Borrower shall not be required to make a specific request to such L/C Issuer for any such extension.  Once an Auto-Extension Letter of Credit has been issued by an L/C Issuer, the Lenders shall be deemed to have authorized (but may not require) such L/C Issuer to permit the extension of such Letter of Credit at any time to an expiry date not later than the Letter of Credit Expiration Date; provided, however, that such L/C Issuer shall not permit any such extension if (A) such L/C Issuer has determined that it would not be permitted, or would have no obligation, at such time to issue such Letter of Credit in its revised form (as extended) under the terms hereof (by reason of the provisions of clause (ii) or (iii) of Section 2.3(a) or otherwise), or (B) it has received notice (which may be by telephone or in writing) on or before the day that is seven Business Days before the Non-Extension Notice Date (1) from the Administrative Agent that the Required Lenders have elected not to permit such extension or (2) from the Administrative Agent, any Lender or the Borrower that one or more of the applicable conditions specified in Section 4.2 is not then satisfied, and in each case directing such L/C Issuer not to permit such extension.

 

(iv)                              Promptly after its delivery of any Letter of Credit or any amendment to a Letter of Credit to an advising bank with respect thereto or to the beneficiary thereof, the applicable L/C Issuer will also deliver to the Borrower and the Administrative Agent a true and complete copy of such Letter of Credit or amendment. In the case of any extension of a Bond Letter of Credit, the applicable L/C Issuer shall, upon satisfaction of the conditions applicable thereto,

 

30

 

deliver to the trustee for the applicable Bonds a Notice of Extension Amendment to the Bond Letter of Credit designating the new expiry date and thereafter all references in any Bond Documents to the expiry date or stated expiration date of such Bond Letter of Credit shall be deemed to be references to the date designated as such in the most recent Notice of Extension Amendment delivered to such trustee.

 

(v)                                 Notwithstanding the foregoing, upon execution and delivery of this Agreement the Existing Letters of Credit shall become Letters of Credit for all purposes of this Agreement without the execution and delivery of a Letter of Credit Application with respect thereto or other documents or any other action being taken.

 

(c)                                  Drawings and Reimbursements; Funding of Participations.

 

(i)                                     Upon receipt from the beneficiary of any Letter of Credit of any notice of a drawing under such Letter of Credit, the applicable L/C Issuer shall notify the Borrower and the Administrative Agent thereof.  Except in the case of a Liquidity Drawing, on the date of payment by such L/C Issuer in respect of such drawing (each such date, an “Honor Date”), the Borrower shall reimburse such L/C Issuer, in the manner specified in the last sentence of this paragraph, in an amount equal to the amount of such drawing.  If the Borrower fails to so reimburse such L/C Issuer by 11:00 a.m. on the Honor Date, such L/C Issuer shall promptly notify the Administrative Agent and the Borrower of such failure (such a notification being herein called a “Failure to Reimburse Notice”) and thereafter the Administrative Agent shall promptly notify each Lender of the Honor Date, the amount of the unreimbursed drawing (the “Unreimbursed Amount”) and the amount of such Lender’s Applicable Percentage thereof.  In such event, the Borrower shall be deemed to have requested a Committed Borrowing of Base Rate Loans to be disbursed on the Honor Date in an amount equal to the Unreimbursed Amount, without regard to the minimum and multiples specified in Section 2.2 for the principal amount of Base Rate Loans, but subject to the amount of the unutilized portion of the Aggregate Commitments and the conditions set forth in Section 4.2 (other than the delivery of a Committed Loan Notice).  Reimbursement of such L/C Issuer pursuant to the second sentence of this paragraph shall (a) if transmitted by the Borrower prior to the Borrower’s receipt of a Failure to Reimburse Notice, be made directly to such L/C Issuer at its Lending Office and (b) if transmitted by the Borrower after the Borrower’s receipt of a Failure to Reimburse Notice, be made to such L/C Issuer through the Administrative Agent.

 

In the case of a Liquidity Drawing, if the Borrower has not reimbursed the applicable L/C Issuer through the Administrative Agent by 3:00 p.m. on the Honor Date, the Administrative Agent shall promptly notify each Lender of the Honor Date, the Unreimbursed Amount and the amount of such Lender’s Applicable Percentage thereof.  In such event, the Borrower shall be deemed to have requested a Committed Borrowing of Base Rate Loans to be disbursed in an

 

31

 

amount equal to the Unreimbursed Amount, without regard to the minimum and multiples specified in Section 2.2 for the principal amount of Base Rate Loans, but subject to the amount of the unutilized portion of the Aggregate Commitments and the conditions set forth in Section 4.2 (other than the delivery of a Committed Loan Notice).

 

Any notice given by an L/C Issuer or the Administrative Agent pursuant to this Section 2.3(c)(i) may be given by telephone if immediately confirmed in writing; provided that the lack of such an immediate confirmation shall not affect the conclusiveness or binding effect of such notice.

 

(ii)                                  Each Lender shall upon any notice pursuant to Section 2.3(c)(i) make funds available (and the Administrative Agent may apply Cash Collateral provided for this purpose) for the account of the applicable L/C Issuer at the Administrative Agent’s Office in an amount equal to the Lender’s Applicable Percentage of the Unreimbursed Amount not later than 1:00 p.m. on the Business Day specified in such notice by the Administrative Agent, whereupon, subject to the provisions of Section 2.3(c)(iii), each Lender that so makes funds available shall be deemed to have made a Base Rate Committed Loan to the Borrower in such amount.  The Administrative Agent shall promptly remit the funds so received to such L/C Issuer.

 

(iii)                               With respect to any Unreimbursed Amount that is not fully refinanced by a Committed Borrowing of Base Rate Loans on the Honor Date because the conditions set forth in Section 4.2 cannot be satisfied or for any other reason, including without limitation the failure to satisfy the required notice period set forth in Section 2.2, the Borrower shall be deemed to have incurred from the applicable L/C Issuer an L/C Borrowing in the amount of the Unreimbursed Amount that is not so refinanced, which L/C Borrowing shall be due and payable on demand (together with interest) and shall bear interest at the Default Rate until such time as such L/C Borrowing is refinanced with a Committed Borrowing of Base Rate Loans; provided, however, that, unless an Event of Default shall have occurred and be continuing, an L/C Borrowing in respect of a Liquidity Drawing (a) shall be due and payable in full on the Termination Date and (b) shall bear interest at the Base Rate plus the Applicable Rate. In such event, each Lender’s payment to the Administrative Agent for the account of the applicable L/C Issuer pursuant to Section 2.3(c)(ii) shall be deemed payment in respect of its participation in such L/C Borrowing and shall constitute an L/C Advance from such Lender in satisfaction of its participation obligation under this Section 2.3.

 

(iv)                              Until each Lender funds its Committed Loan or L/C Advance pursuant to this Section 2.3(c) to reimburse the applicable L/C Issuer for any amount drawn under any Letter of Credit, interest in respect of such Lender’s Applicable Percentage of such amount shall be solely for the account of such L/C Issuer.

 

32

 

(v)                                 Each Lender’s obligation to make Committed Loans or L/C Advances to reimburse an L/C Issuer for amounts drawn under Letters of Credit, as contemplated by this Section 2.3(c), shall be absolute and unconditional and shall not be affected by any circumstance, including (A) any setoff, counterclaim, recoupment, defense or other right which such Lender may have against such L/C Issuer, the Borrower or any other Person for any reason whatsoever; (B) the occurrence or continuance of a Default, or (C) any other occurrence, event or condition, whether or not similar to any of the foregoing; provided, however, that each Lender’s obligation to make Committed Loans pursuant to this Section 2.3(c) is subject to the conditions set forth in Section 4.2 (other than the delivery of a Committed Loan Notice).  No such making of an L/C Advance shall relieve or otherwise impair the obligation of the Borrower to reimburse such L/C Issuer for the amount of any payment made by such L/C Issuer under any Letter of Credit, together with interest as provided herein.

 

(vi)                              If any Lender fails to make available to the Administrative Agent for the account of the applicable L/C Issuer any amount required to be paid by such Lender pursuant to the foregoing provisions of this Section 2.3(c) by the time specified in Section 2.3(c)(ii), then, without limiting the other provisions of this Agreement, such L/C Issuer shall be entitled to recover from such Lender (acting through the Administrative Agent), on demand, such amount with interest thereon for the period from the date such payment is required to the date on which such payment is immediately available to such L/C Issuer at a rate per annum equal to the greater of the Prime Rate and a rate determined by such L/C Issuer in accordance with banking industry rules on interbank compensation, plus any administrative, processing or similar fees customarily charged by such L/C Issuer in connection with the foregoing.  If such Lender pays such amount (with interest and fees as aforesaid), the amount so paid shall constitute such Lender’s Committed Loan included in the relevant Committed Borrowing or L/C Advance in respect of the relevant L/C Borrowing, as the case may be.  A certificate of such L/C Issuer submitted to any Lender (through the Administrative Agent) with respect to any amounts owing under this clause (vi) shall be conclusive absent manifest error.

 

(d)                                 Repayment of Participations.

 

(i)                                     At any time after an L/C Issuer has made a payment under any Letter of Credit and has received from any Lender such Lender’s L/C Advance in respect of such payment in accordance with Section 2.3(c), if the Administrative Agent receives for the account of such L/C Issuer any payment in respect of the related Unreimbursed Amount or interest thereon (whether directly from the Borrower or otherwise, including proceeds of Cash Collateral applied thereto by the Administrative Agent), the Administrative Agent will distribute to such Lender its Applicable Percentage thereof in the same funds as those received by the Administrative Agent.

 

33

 

(ii)                                  If any payment received by an L/C Issuer, or the Administrative Agent for the account of an L/C Issuer, pursuant to Section 2.3(c)(i) is required to be returned under any of the circumstances described in Section 10.2(b) (including pursuant to any settlement entered into by an L/C Issuer in its discretion), each Lender shall pay to the Administrative Agent for the account of such L/C Issuer its Applicable Percentage thereof on demand of the Administrative Agent, plus interest thereon from the date of such demand to the date such amount is returned by such Lender, at a rate per annum equal to the Prime Rate from time to time in effect.  The obligations of the Lenders under this clause shall survive the payment in full of the Obligations and the termination of this Agreement.

 

(e)                                  Obligations Absolute.  The obligation of the Borrower to reimburse the L/C Issuers for each drawing under each Letter of Credit and to repay each L/C Borrowing shall be absolute, unconditional and irrevocable, and shall be paid strictly in accordance with the terms of this Agreement under all circumstances, including the following:

 

(i)                                     any lack of validity or enforceability of such Letter of Credit, this Agreement or any other Loan Document;

 

(ii)                                  the existence of any claim, counterclaim, setoff, defense or other right that the Borrower or any Subsidiary may have at any time against any beneficiary or any transferee of such Letter of Credit (or any Person for whom any such beneficiary or any such transferee may be acting), the L/C Issuer or any other Person, whether in connection with this Agreement, the transactions contemplated hereby or by such Letter of Credit or any agreement or instrument relating thereto, or any unrelated transaction;

 

(iii)                               any draft, demand, certificate or other document presented under such Letter of Credit proving to be forged, fraudulent, invalid or insufficient in any respect or any statement therein being untrue or inaccurate in any respect; or any loss or delay in the transmission or otherwise of any document required in order to make a drawing under such Letter of Credit;

 

(iv)                              any payment by the L/C Issuer under such Letter of Credit against presentation of a draft or certificate that does not strictly comply with the terms of such Letter of Credit; or any payment made by the L/C Issuer under such Letter of Credit to any Person purporting to be a trustee in bankruptcy, debtor-in-possession, assignee for the benefit of creditors, liquidator, receiver or other representative of or successor to any beneficiary or any transferee of such Letter of Credit, including any arising in connection with any proceeding under any Debtor Relief Law; or

 

(v)                                 any other circumstance or happening whatsoever, whether or not similar to any of the foregoing, including any other circumstance that might

 

34

 

otherwise constitute a defense available to, or a discharge of, the Borrower or any Subsidiary.

 

The Borrower shall promptly examine a copy of each Letter of Credit and each amendment thereto that is delivered to it and, in the event of any claim of noncompliance with the Borrower’s instructions or other irregularity, the Borrower will immediately notify the applicable L/C Issuer.  The Borrower shall be conclusively deemed to have waived any such claim against such L/C Issuer and its correspondents unless such notice is given as aforesaid.

 

(f)                                   Role of L/C Issuer.  Each Lender and the Borrower agree that, in paying any drawing under a Letter of Credit, the applicable L/C Issuer shall not have any responsibility to obtain any document (other than any sight draft, certificates and documents expressly required by the Letter of Credit) or to ascertain or inquire as to the validity or accuracy of any such document or the authority of the Person executing or delivering any such document.  None of the L/C Issuers, the Administrative Agent, any of their respective Related Parties nor any correspondent, participant or assignee of any L/C Issuer shall be liable to any Lender for (i) any action taken or omitted in connection herewith at the request or with the approval of the Lenders or the Required Lenders, as applicable; (ii) any action taken or omitted in the absence of gross negligence or willful misconduct; or (iii) the due execution, effectiveness, validity or enforceability of any document or instrument related to any Letter of Credit or Issuer Document.  The Borrower hereby assumes all risks of the acts or omissions of any beneficiary or transferee with respect to its use of any Letter of Credit; provided, however, that this assumption is not intended to, and shall not, preclude the Borrower’s pursuing such rights and remedies as it may have against the beneficiary or transferee at law or under any other agreement.  None of the L/C Issuers, the Administrative Agent, any of their respective Related Parties nor any correspondent, participant or assignee of any L/C Issuer shall be liable or responsible for any of the matters described in clauses (i) through (v) of Section 2.3(e); provided, however, that anything in such clauses to the contrary notwithstanding, the Borrower may have a claim against an L/C Issuer, and such L/C Issuer may be liable to the Borrower, to the extent, but only to the extent, of any direct, as opposed to consequential or exemplary, damages suffered by the Borrower which (a) are determined by a court of competent jurisdiction by final and nonappealable judgment to have been caused by such L/C Issuer’s willful misconduct or gross negligence or (b) the Borrower proves were caused by such L/C Issuer’s willful failure to pay under any Letter of Credit issued by such L/C Issuer after the presentation to it by the beneficiary of a sight draft and certificate(s) strictly complying with the terms and conditions of such Letter of Credit.  In furtherance and not in limitation of the foregoing, an L/C Issuer may accept documents that appear on their face to be in order, without responsibility for further investigation, regardless of any notice or information to the contrary, and no L/C Issuer shall be responsible for the validity or sufficiency of any instrument transferring or assigning or purporting to transfer or assign a Letter of Credit or the rights or benefits thereunder or proceeds thereof, in whole or in part, which may prove to be invalid or ineffective for any reason.

 

35

 

(g)                                  Applicability of ISP.  Unless otherwise expressly agreed by the applicable L/C Issuer and the Borrower when a Letter of Credit is issued (including any such agreement applicable to an Existing Letter of Credit), the rules of the ISP shall apply to each Letter of Credit.

 

(h)                                 Letter of Credit Fees.  The Borrower shall pay to the Administrative Agent for the account of each Lender in accordance with its Applicable Percentage a Letter of Credit fee (the “Letter of Credit Fee”) equal to the Applicable Rate times the daily amount available to be drawn under such Letter of Credit; provided, however, any Letter of Credit Fees otherwise payable for the account of a Defaulting Lender with respect to any Letter of Credit as to which such Defaulting Lender has not provided Cash Collateral satisfactory to each applicable L/C Issuer pursuant to this Section 2.3 shall be payable, to the maximum extent permitted by applicable Law, to the other Lenders in accordance with the upward adjustments in their respective Applicable Percentages allocable to such Letter of Credit pursuant to Section 2.17(a)(iii), with the balance of such fee, if any, payable to each applicable L/C Issuer for its own account.  For purposes of computing the daily amount available to be drawn under any Letter of Credit, the amount of such Letter of Credit shall be determined in accordance with Section 1.5.  Letter of Credit Fees shall be (i) due and payable on the first Business Day after the end of each March, June, September and December, commencing with the first such date to occur after the issuance of such Letter of Credit, on the expiry date and thereafter on demand and (ii) computed on a quarterly basis in arrears.  If there is any change in the Applicable Rate during any quarter, the daily amount available to be drawn under each Letter of Credit shall be computed and multiplied by the Applicable Rate separately for each period during such quarter that such Applicable Rate was in effect.  Notwithstanding anything to the contrary contained herein, upon the request of the Required Lenders, while any Event of Default exists, all Letter of Credit Fees shall accrue at the Default Rate.

 

(i)                                     Fronting Fee and Documentary and Processing Charges Payable to L/C Issuer.  The Borrower shall pay directly to each L/C Issuer for its own account a fronting fee with respect to each Letter of Credit, at the rate per annum specified in the applicable L/C Issuer Fee Letter, computed on the daily amount available to be drawn under such Letter of Credit and due and payable quarterly in arrears (no longer than 30 days following billing).  For purposes of computing the daily amount available to be drawn under any Letter of Credit, the amount of such Letter of Credit shall be determined in accordance with Section 1.5.  In addition, the Borrower shall pay directly to each L/C Issuer for its own account the customary issuance, presentation, amendment and other processing fees, and other standard costs and charges, of such L/C Issuer relating to letters of credit as from time to time in effect.  Such customary fees and standard costs and charges are due and payable in arrears (no longer than 30 days following billing) and are nonrefundable.

 

(j)                                    Conflict with Issuer Documents.  In the event of any conflict between the terms hereof and the terms of any Issuer Document, the terms hereof shall control.

 

(k)                                 Letters of Credit Issued for Subsidiaries. Notwithstanding that a Letter of Credit issued or outstanding hereunder is in support of any obligations of, or is for the

 

36

 

account of, a Subsidiary, the Borrower shall be obligated to reimburse the applicable L/C Issuer hereunder for any and all drawings under such Letter of Credit. The Borrower hereby acknowledges that the issuance of Letters of Credit for the account of Subsidiaries inures to the benefit of the Borrower, and that the Borrower’s business derives substantial benefits from the businesses of such Subsidiaries.

 

2.4                               Swing Line Loans.

 

(a)                                 The Swing Line.  Subject to the terms and conditions set forth herein, the Swing Line Lender, in reliance upon the agreements of the other Lenders set forth in this Section 2.4, may in its sole discretion make loans (each such loan, a “Swing Line Loan”) to the Borrower from time to time on any Business Day during the Availability Period in an aggregate amount not to exceed at any time outstanding the amount of the Swing Line Sublimit, notwithstanding the fact that such Swing Line Loans, when aggregated with the Applicable Percentage of the Outstanding Amount of Committed Loans and L/C Obligations of the Lender acting as Swing Line Lender, may exceed the amount of such Lender’s Commitment; provided, however, that after giving effect to any Swing Line Loan, (i) the Total Outstandings shall not exceed the Aggregate Commitments, and (ii) the aggregate Outstanding Amount of the Committed Loans of any Lender, plus such Lender’s Applicable Percentage of the Outstanding Amount of all L/C Obligations, plus such Lender’s Applicable Percentage of the Outstanding Amount of all Swing Line Loans shall not exceed such Lender’s Commitment, and provided, further, that the Borrower shall not use the proceeds of any Swing Line Loan to refinance any outstanding Swing Line Loan.  Within the foregoing limits, and subject to the other terms and conditions hereof, the Borrower may borrow under this Section 2.4, prepay under Section 2.5 and reborrow under this Section 2.4.  Each Swing Line Loan shall be a Base Rate Loan.  Immediately upon the making of a Swing Line Loan, each Lender shall be deemed to, and hereby irrevocably and unconditionally agrees to, purchase from the Swing Line Lender a risk participation in such Swing Line Loan in an amount equal to the product of such Lender’s Applicable Percentage times the amount of such Swing Line Loan.

 

(b)                                 Borrowing Procedures.  Each Swing Line Borrowing shall be made upon the Borrower’s irrevocable notice to the Swing Line Lender and the Administrative Agent, which may be given by telephone. Each such notice must be received by the Swing Line Lender and the Administrative Agent not later than 1:00 p.m. on the requested borrowing date, and shall specify (i) the amount to be borrowed, which shall be a minimum of $100,000, and (ii) the requested borrowing date, which shall be a Business Day.  Each such telephonic notice must be confirmed promptly by delivery to the Swing Line Lender and the Administrative Agent of a written Swing Line Loan Notice, appropriately completed and signed by a Responsible Officer of the Borrower.  Promptly after receipt by the Swing Line Lender of any telephonic Swing Line Loan Notice, the Swing Line Lender will confirm with the Administrative Agent (by telephone or in writing) that the Administrative Agent has also received such Swing Line Loan Notice and, if not, the Swing Line Lender will notify the Administrative Agent (by telephone or in writing) of the contents thereof.  Unless the Swing Line Lender has received notice (by telephone or in writing) from the Administrative Agent (including at the request of any Lender) prior to 2:00 p.m. on the date of the proposed Swing Line Borrowing (A)

 

37

 

directing the Swing Line Lender not to make such Swing Line Loan as a result of the limitations set forth in the first proviso to the first sentence of Section 2.4(a), or (B) that one or more of the applicable conditions specified in Section 4 is not then satisfied, then, subject to the terms and conditions hereof, the Swing Line Lender will, not later than 3:00 p.m. on the borrowing date specified in such Swing Line Loan Notice, make the amount of its Swing Line Loan available to the Borrower at its office by crediting the account of the Borrower on the books of the Swing Line Lender in immediately available funds.

 

(c)                                  Refinancing of Swing Line Loans.

 

(i)                                     The Swing Line Lender at any time in its sole discretion may request, on behalf of the Borrower (which hereby irrevocably authorizes the Swing Line Lender to so request on its behalf), that each Lender make a Base Rate Committed Loan in an amount equal to such Lender’s Applicable Percentage of the amount of Swing Line Loans then outstanding.  Such request shall be made in writing (which written request shall be deemed to be a Committed Loan Notice for purposes hereof) and in accordance with the requirements of Section 2.2, without regard to the minimum and multiples specified therein for the principal amount of Base Rate Loans, but subject to the unutilized portion of the Aggregate Commitments and the conditions set forth in Section 4.2.  The Swing Line Lender shall furnish the Borrower with a copy of the applicable Committed Loan Notice promptly after delivering such notice to the Administrative Agent.  Each Lender shall make an amount equal to its Applicable Percentage of the amount specified in such Committed Loan Notice available to the Administrative Agent in immediately available funds (and the Administrative Agent may apply Cash Collateral available with respect to the applicable Swing Line Loan) for the account of the Swing Line Lender at the Administrative Agent’s Office not later than 1:00 p.m. on the day specified in such Committed Loan Notice, whereupon, subject to Section 2.4(c)(ii), each Lender that so makes funds available shall be deemed to have made a Base Rate Committed Loan to the Borrower in such amount.  The Administrative Agent shall remit the funds so received to the Swing Line Lender.

 

(ii)                                  If for any reason any Swing Line Loan cannot be refinanced by such a Committed Borrowing in accordance with Section 2.4(c)(i), the request for Base Rate Committed Loans submitted by the Swing Line Lender as set forth herein shall be deemed to be a request by the Swing Line Lender that each of the Lenders fund its risk participation in the relevant Swing Line Loan and each Lender’s payment to the Administrative Agent for the account of the Swing Line Lender pursuant to Section 2.4(c)(i) shall be deemed payment in respect of such participation.

 

(iii)                               If any Lender fails to make available to the Administrative Agent for the account of the Swing Line Lender any amount required to be paid by such Lender pursuant to the foregoing provisions of this Section 2.4(c) by the time specified in Section 2.4(c)(i), the Swing Line Lender shall be entitled to recover

 

38

 

from such Lender (acting through the Administrative Agent), on demand, such amount with interest thereon for the period from the date such payment is required to the date on which such payment is immediately available to the Swing Line Lender at a rate per annum equal to the greater of the Prime Rate and a rate determined by the Swing Line Lender in accordance with banking industry rules on interbank compensation, plus any administrative, processing or similar fees customarily charged by the Swing Line Lender in connection with the foregoing.  If such Lender pays such amount (with interest and fees as aforesaid), the amount so paid shall constitute such Lender’s Committed Loan included in the relevant Committed Borrowing or funded participation in the relevant Swing Line Loan, as the case may be.  A certificate of the Swing Line Lender submitted to any Lender (through the Administrative Agent) with respect to any amounts owing under this clause (iii) shall be conclusive absent manifest error.

 

(iv)                              Each Lender’s obligation to make Committed Loans or to purchase and fund risk participations in Swing Line Loans pursuant to this Section 2.4(c) shall be absolute and unconditional and shall not be affected by any circumstance, including (A) any setoff, counterclaim, recoupment, defense or other right which such Lender may have against the Swing Line Lender, the Borrower or any other Person for any reason whatsoever, (B) the occurrence or continuance of a Default, or (C) any other occurrence, event or condition, whether or not similar to any of the foregoing; provided, however, that each Lender’s obligation to make Committed Loans pursuant to this Section 2.4(c) is subject to the conditions set forth in Section 4.2.  No such funding of risk participations shall relieve or otherwise impair the obligation of the Borrower to repay Swing Line Loans, together with interest as provided herein.

 

(d)                                 Repayment of Participations.

 

(i)                                     At any time after any Lender has purchased and funded a risk participation in a Swing Line Loan, if the Swing Line Lender receives any payment on account of such Swing Line Loan, the Swing Line Lender will distribute to such Lender its Applicable Percentage thereof in the same funds as those received by the Swing Line Lender.

 

(ii)                                  If any payment received by the Swing Line Lender in respect of principal or interest on any Swing Line Loan is required to be returned by the Swing Line Lender under any of the circumstances described in Section 10.2(b) (including pursuant to any settlement entered into by the Swing Line Lender in its discretion), each Lender shall pay to the Swing Line Lender its Applicable Percentage thereof on demand of the Administrative Agent, plus interest thereon from the date of such demand to the date such amount is returned, at a rate per annum equal to the Prime Rate.  The Administrative Agent will make such demand upon the request of the Swing Line Lender.  The obligations of the Lenders under this clause shall survive the payment in full of the Obligations and the termination of this Agreement.

 

39

 

(e)                                  Interest for Account of Swing Line Lender.  The Swing Line Lender shall be responsible for invoicing the Borrower for interest on the Swing Line Loans.  Until each Lender funds its Base Rate Committed Loan or risk participation pursuant to this Section 2.4 to refinance such Lender’s Applicable Percentage of any Swing Line Loan, interest in respect of such Applicable Percentage shall be solely for the account of the Swing Line Lender.

 

(f)                                   Payments Directly to Swing Line Lender.  The Borrower shall make all payments of principal and interest in respect of the Swing Line Loans directly to the Swing Line Lender.

 

2.5                               Prepayments.

 

(a)                                 The Borrower may, upon notice to the Administrative Agent, at any time or from time to time voluntarily prepay Committed Loans in whole or in part without premium or penalty; provided that (i) such notice must be received by the Administrative Agent not later than 11:00 a.m. (A) three Business Days prior to any date of prepayment of Eurodollar Rate Loans and (B) on the date of prepayment of Base Rate Committed Loans; (ii) any prepayment of Eurodollar Rate Loans shall be in a principal amount of $5,000,000 or a whole multiple of $1,000,000 in excess thereof; and (iii) any prepayment of Base Rate Committed Loans shall be in a principal amount of $500,000 or a whole multiple of $100,000 in excess thereof or, in each case, if less, the entire principal amount thereof then outstanding.  Each such notice shall specify the date and amount of such prepayment and the Type(s) of Committed Loans to be prepaid and, if Eurodollar Rate Loans are to be prepaid, the Interest Period(s) of such Loans.  The Administrative Agent will promptly notify each Lender of its receipt of each such notice, and of the amount of such Lender’s Applicable Percentage of such prepayment.  If such notice is given by the Borrower, the Borrower shall make such prepayment and the payment amount specified in such notice shall be due and payable on the date specified therein.  Any prepayment of a Eurodollar Rate Loan shall be accompanied by all accrued interest on the amount prepaid, together with any additional amounts required pursuant to Section 3.5.  Subject to Section 2.17, each such prepayment shall be applied to the Committed Loans of the Lenders in accordance with their respective Applicable Percentages.

 

(b)                                 The Borrower shall prepay any Unreimbursed Amount relating to any Liquidity Drawing under a Bond Letter of Credit (and any L/C Borrowings and, if an Event of Default shall have occurred and be continuing, Committed Loans the proceeds of which were applied to the refinancing of such Unreimbursed Amount) on the earlier of (i) the date of the remarketing to investors of the Bonds purchased with the proceeds of such Liquidity Drawing, the amount of such prepayment to be equal to the principal amount of the Bonds so remarketed, and (ii) the date on which such Bond Letter of Credit is replaced with another liquidity or credit facility pursuant to the applicable Issuer Documents, the amount of such prepayment to be equal to the full amount of such Unreimbursed Amount, L/C Borrowings or Committed Loans, as the case may be.

 

(c)                                  The Borrower may, upon notice to the Swing Line Lender (with a copy to the Administrative Agent), at any time or from time to time, voluntarily prepay Swing

 

40

 

Line Loans in whole or in part without premium or penalty; provided that (i) such notice must be received by the Swing Line Lender and the Administrative Agent not later than 1:00 p.m. on the date of the prepayment, and (ii) any such prepayment shall be in a minimum principal amount of $100,000.  Each such notice shall specify the date and amount of such prepayment.  If such notice is given by the Borrower, the Borrower shall make such prepayment and the payment amount specified in such notice shall be due and payable on the date specified therein.

 

(d)                                 If for any reason the Total Outstandings at any time exceed the Aggregate Commitments then in effect, the Borrower shall immediately prepay Loans and/or Cash Collateralize the L/C Obligations in an aggregate amount equal to such excess; provided, however, that the Borrower shall not be required to Cash Collateralize the L/C Obligations pursuant to this Section 2.5(d) unless after the prepayment in full of the Committed Loans and Swing Line Loans the Total Outstandings exceed the Aggregate Commitments then in effect.

 

2.6                               Termination or Reduction of Commitments.

 

The Borrower may, upon notice to the Administrative Agent, terminate the Aggregate Commitments, or from time to time permanently reduce the Aggregate Commitments; provided that (i) any such notice shall be received by the Administrative Agent not later than 11:00 a.m. five Business Days prior to the date of termination or reduction, (ii) any such partial reduction shall be in an aggregate amount of $25,000,000 or any whole multiple of $5,000,000 in excess thereof, (iii) the Borrower shall not terminate or reduce the Aggregate Commitments if, after giving effect thereto and to any concurrent prepayments hereunder, the Total Outstandings would exceed the Aggregate Commitments, and (iv) if, after giving effect to any reduction of the Aggregate Commitments, the Letter of Credit Sublimit or the Swing Line Sublimit exceeds the amount of the Aggregate Commitments, such Sublimit shall be automatically reduced by the amount of such excess.  The Administrative Agent will promptly notify the Lenders of any such notice of termination or reduction of the Aggregate Commitments.  Any reduction of the Aggregate Commitments shall be applied to the Commitment of each Lender according to its Applicable Percentage.  All fees accrued until the effective date of any termination of the Aggregate Commitments shall be paid on the effective date of such termination.

 

2.7                               Repayment of Loans.

 

(a)                                 The Borrower shall repay to the Lenders on the Maturity Date the aggregate principal amount of Committed Loans outstanding on such date.

 

(b)                                 The Borrower shall repay each Swing Line Loan on the earlier to occur of (i) the date ten Business Days after such Loan is made and (ii) the Maturity Date.

 

2.8                               Interest.

 

(a)                                 Subject to the provisions of subsection (b) below, (i) each Eurodollar Rate Loan shall bear interest on the outstanding principal amount thereof for each Interest Period at a rate per annum equal to the Eurodollar Rate for such Interest Period plus the Applicable Rate; (ii) each Base Rate Committed Loan shall bear interest on the

 

41

 

outstanding principal amount thereof from the applicable borrowing date at a rate per annum equal to the Base Rate plus the Applicable Rate; and (iii) each Swing Line Loan shall bear interest on the outstanding principal amount thereof from the applicable borrowing date at a rate per annum equal to the Base Rate plus the Applicable Rate.

 

(b)                                 (i)                                     If any amount of principal of any Loan is not paid when due (without regard to any applicable grace periods), whether at stated maturity, by acceleration or otherwise, such amount shall thereafter bear interest at a fluctuating interest rate per annum at all times equal to the Default Rate to the fullest extent permitted by applicable Laws.

 

(ii)                                  If any amount (other than principal of any Loan) payable by the Borrower under any Loan Document is not paid when due (without regard to any applicable grace periods), whether at stated maturity, by acceleration or otherwise, then upon the request of the Required Lenders, such amount shall thereafter bear interest at a fluctuating interest rate per annum at all times equal to the Default Rate to the fullest extent permitted by applicable Laws.

 

(iii)                               Accrued and unpaid interest on past due amounts (including interest on past due interest) shall be due and payable upon demand.

 

(c)                                  Interest on each Loan shall be due and payable in arrears on each Interest Payment Date applicable thereto and at such other times as may be specified herein.  Interest hereunder shall be due and payable in accordance with the terms hereof before and after judgment, and before and after the commencement of any proceeding under any Debtor Relief Law.

 

2.9                               Fees.

 

In addition to certain fees described in subsections (h) and (i) of Section 2.3:

 

(a)                                 Unused Fee.  The Borrower shall pay to the Administrative Agent for the account of each Lender in accordance with its Applicable Percentage a commitment fee (the “Unused Fee”) equal to the Applicable Rate times the actual daily amount by which the Aggregate Commitments exceed the sum of (i) the Outstanding Amount of Committed Loans and (ii) the Outstanding Amount of L/C Obligations, subject to adjustment as provided in Section 2.17.  The Unused Fee shall accrue at all times during the Availability Period, including at any time during which one or more of the conditions in Article IV is not met, and shall be due and payable quarterly in arrears on the last Business Day of each March, June, September and December, commencing with the first such date to occur after the Closing Date, and on the last day of the Availability Period.  The Unused Fee shall be calculated quarterly in arrears, and if there is any change in the Applicable Rate during any quarter, the actual daily amount shall be computed and multiplied by the Applicable Rate separately for each period during such quarter that such Applicable Rate was in effect.

 

(b)                                 Other Fees.  The Borrower shall pay to the Lead Arranger and the Administrative Agent for their own respective accounts or the accounts of the Lenders, as

 

42

 

the case may be, fees in the amounts and at the times specified in the Fee Letters.  Such fees shall be fully earned when paid and shall not be refundable for any reason whatsoever.

 

2.10                        Computation of Interest and Fees.

 

All computations of interest for Base Rate Loans (including Base Rate Loans determined by reference to the Eurodollar Rate) shall be made on the basis of a year of 365 or 366 days, as the case may be, and actual days elapsed.  All other computations of fees and interest shall be made on the basis of a 360-day year and actual days elapsed (which results in more fees or interest, as applicable, being paid than if computed on the basis of a 365-day year).  Interest shall accrue on each Loan for the day on which the Loan is made, and shall not accrue on a Loan, or any portion thereof, for the day on which the Loan or such portion is paid, provided that any Loan that is repaid on the same day on which it is made shall, subject to Section 2.12(a), bear interest for one day.  Each determination by the Administrative Agent of an interest rate or fee hereunder shall be conclusive and binding for all purposes, absent manifest error.

 

2.11                        Evidence of Debt.

 

(a)                                 The Credit Extensions made by each Lender shall be evidenced by one or more accounts or records maintained by such Lender and by the Administrative Agent in the ordinary course of business.  The accounts or records maintained by the Administrative Agent and each Lender shall be conclusive absent manifest error of the amount of the Credit Extensions made by the Lenders to the Borrower and the interest and payments thereon.  Any failure to so record or any error in doing so shall not, however, limit or otherwise affect the obligation of the Borrower hereunder to pay any amount owing with respect to the Obligations.  In the event of any conflict between the accounts and records maintained by any Lender and the accounts and records of the Administrative Agent in respect of such matters, the accounts and records of the Administrative Agent shall control in the absence of manifest error.  Upon the request of any Lender made through the Administrative Agent, the Borrower shall execute and deliver to such Lender (through the Administrative Agent) a Note, which shall evidence such Lender’s Loans in addition to such accounts or records.  Each Lender may attach schedules to its Note and endorse thereon the date, Type (if applicable), amount and maturity of its Loans and payments with respect thereto.

 

(b)                                 In addition to the accounts and records referred to in subsection (a), each Lender and the Administrative Agent shall maintain in accordance with its usual practice accounts or records evidencing the purchases and sales by such Lender of participations in Letters of Credit and Swing Line Loans.  In the event of any conflict between the accounts and records maintained by the Administrative Agent and the accounts and records of any Lender in respect of such matters, the accounts and records of the Administrative Agent shall control in the absence of manifest error.

 

43

 

2.12                        Payments Generally; Administrative Agent’s Clawback.

 

(a)                                 General.  All payments to be made by the Borrower shall be made without condition or deduction for any counterclaim, defense, recoupment or setoff.  Except as otherwise expressly provided herein, all payments by the Borrower hereunder shall be made to the Administrative Agent, for the account of the respective Lenders to which such payment is owed, at the Administrative Agent’s Office in Dollars and in immediately available funds not later than 2:00 p.m. on the date specified herein.  The Administrative Agent will promptly distribute to each Lender its Applicable Percentage (or other applicable share as provided herein) of such payment in like funds as received by wire transfer to such Lender’s Lending Office.  All payments received by the Administrative Agent after 2:00 p.m. shall be deemed received on the next succeeding Business Day and any applicable interest or fee shall continue to accrue.  If any payment to be made by the Borrower shall come due on a day other than a Business Day, payment shall be made on the next following Business Day, and such extension of time shall be reflected in computing interest or fees, as the case may be.

 

(b)                                 Funding by Lenders; Presumption by Administrative Agent.

 

(i)                                     Funding by Lenders.  Unless the Administrative Agent shall have received notice from a Lender prior to the proposed date of any Committed Borrowing of Eurodollar Rate Loans (or, in the case of any Committed Borrowing of Base Rate Loans, prior to 12:00 noon on the date of such Committed Borrowing) that such Lender will not make available to the Administrative Agent such Lender’s share of such Committed Borrowing, the Administrative Agent may assume that such Lender has made such share available on such date in accordance with Section 2.2 (or, in the case of a Committed Borrowing of Base Rate Loans, that such Lender has made such share available in accordance with and at the time required by Section 2.2) and may, in reliance upon such assumption, make available to the Borrower a corresponding amount.  In such event, if a Lender has not in fact made its share of the applicable Committed Borrowing available to the Administrative Agent, then the applicable Lender and the Borrower severally agree to pay to the Administrative Agent forthwith on demand such corresponding amount in immediately available funds with interest thereon, for each day from and including the date such amount is made available to the Borrower to but excluding the date of payment to the Administrative Agent, at (A) in the case of a payment to be made by such Lender, the greater of the Prime Rate and a rate determined by the Administrative Agent in accordance with banking industry rules on interbank compensation, plus any administrative, processing or similar fees customarily charged by the Administrative Agent in connection with the foregoing, and (B) in the case of a payment to be made by the Borrower, the interest rate applicable to Base Rate Loans.  If the Borrower and such Lender shall pay such interest to the Administrative Agent for the same or an overlapping period, the Administrative Agent shall promptly remit to the Borrower the amount of such interest paid by the Borrower for such period.  If such Lender pays its share of the applicable Committed Borrowing to the Administrative Agent, then the amount so paid shall constitute such Lender’s

 

44

 

Committed Loan included in such Committed Borrowing.  Any payment by the Borrower shall be without prejudice to any claim the Borrower may have against a Lender that shall have failed to make such payment to the Administrative Agent.

 

(ii)                                  Payments by Borrower; Presumptions by Administrative Agent.  Unless the Administrative Agent shall have received notice from the Borrower prior to the date on which any payment is due to the Administrative Agent for the account of the Lenders or the L/C Issuers hereunder that the Borrower will not make such payment, the Administrative Agent may assume that the Borrower has made such payment on such date in accordance herewith and may, in reliance upon such assumption, distribute to the Lenders or the L/C Issuers, as the case may be, the amount due.  In such event, if the Borrower has not in fact made such payment, then each of the Lenders or the L/C Issuers, as the case may be, severally agrees to repay to the Administrative Agent forthwith on demand the amount so distributed to such Lender or the L/C Issuers, in immediately available funds with interest thereon, for each day from and including the date such amount is distributed to it to but excluding the date of payment to the Administrative Agent, at the greater of the Prime Rate and a rate determined by the Administrative Agent in accordance with banking industry rules on interbank compensation.

 

A notice of the Administrative Agent to any Lender, and L/C Issuer or the Borrower with respect to any amount owing under this subsection (b) shall be conclusive, absent manifest error.

 

(c)                                  Failure to Satisfy Conditions Precedent.  If any Lender makes available to the Administrative Agent funds for any Loan to be made by such Lender as provided in the foregoing provisions of this Section 2, and such funds are not made available to the Borrower by the Administrative Agent because the conditions to the applicable Credit Extension set forth in Section 4 are not satisfied or waived in accordance with the terms hereof, the Administrative Agent shall promptly return such funds (in like funds as received from such Lender) to such Lender, without interest.

 

(d)                                 Obligations of Lenders Several.  The obligations of the Lenders hereunder to make Committed Loans, to fund participations in Letters of Credit and Swing Line Loans and to make payments pursuant to Section 10.5(c) are several and not joint.  The failure of any Lender to make any Committed Loan, to fund any such participation or to make any payment under Section 10.5(c) on any date required hereunder shall not relieve any other Lender of its corresponding obligation to do so on such date, and no Lender shall be responsible for the failure of any other Lender to so make its Committed Loan, to purchase its participation or to make its payment under Section 10.5(c).

 

(e)                                  Funding Source.  Nothing herein shall be deemed to obligate any Lender to obtain the funds for any Loan in any particular place or manner or to constitute a representation by any Lender that it has obtained or will obtain the funds for any Loan in any particular place or manner.

 

45

 

2.13                        Sharing of Payments by Lenders.

 

If any Lender shall, by exercising any right of setoff or counterclaim or otherwise, obtain payment in respect of any principal of or interest on any of the Committed Loans made by it, or the participations in L/C Obligations or in Swing Line Loans held by it resulting in such Lender’s receiving payment of a proportion of the aggregate amount of such Committed Loans or participations and accrued interest thereon greater than its pro rata share thereof as provided herein, then the Lender receiving such greater proportion shall (a) notify the Administrative Agent of such fact, and (b) purchase (for cash at face value) participations in the Committed Loans and subparticipations in L/C Obligations and Swing Line Loans of the other Lenders, or make such other adjustments as shall be equitable, so that the benefit of all such payments shall be shared by the Lenders ratably in accordance with the aggregate amount of principal of and accrued interest on their respective Committed Loans and other amounts owing them, provided that:

 

(i)                                     if any such participations or subparticipations are purchased and all or any portion of the payment giving rise thereto is recovered, such participations or subparticipations shall be rescinded and the purchase price restored to the extent of such recovery, without interest; and

 

(ii)                                  the provisions of this Section shall not be construed to apply to (x) any payment made by or on behalf of the Borrower pursuant to and in accordance with the express terms of this Agreement (including the application of funds arising from the existence of a Defaulting Lender), (y) the application of Cash Collateral provided for in Section 2.16, or (z) any payment obtained by a Lender as consideration for the assignment of or sale of a participation in any of its Committed Loans or subparticipations in L/C Obligations or Swing Line Loans to any assignee or participant, other than an assignment to the Borrower or any Subsidiary thereof (as to which the provisions of this Section shall apply).

 

The Borrower consents to the foregoing and agrees, to the extent it may effectively do so under applicable law, that any Lender acquiring a participation pursuant to the foregoing arrangements may exercise against the Borrower rights of setoff and counterclaim with respect to such participation as fully as if such Lender were a direct creditor of the Borrower in the amount of such participation.

 

2.14                        Extension of Maturity Date.

 

(a)                                 Requests for Extension.  The Borrower may, by notice to the Administrative Agent (who shall promptly notify the Lenders) not earlier than the first anniversary of the Closing Date, request that, effective on a specified date (the “Extension Date”), each Lender agree to an extension of the Maturity Date then in effect (the “Existing Maturity Date”) to a specified new date (the “New Maturity Date”) that shall be at least one year after the Existing Maturity Date.

 

(b)                                 Lender Elections to Extend.  Each Lender, acting in its sole and individual discretion, by the date (the “Notice Date”) that is 35 days after the date of such request, 

 

46

 

shall, by notice to the Administrative Agent, advise the Administrative Agent whether or not such Lender agrees to such extension (and each Lender that determines not to so extend its Maturity Date (a “Non Extending Lender”) shall notify the Administrative Agent of such fact promptly after such determination, and any Lender that does not so advise the Administrative Agent on or before the Notice Date shall be deemed to be a Non Extending Lender).  The election of any Lender to agree to such extension shall not obligate any other Lender to so agree.

 

(c)                                  Notification by Administrative Agent.  The Administrative Agent shall notify the Borrower of each Lender’s determination under this Section promptly following the Notice Date.

 

(d)                                 Payment to Non Extending Lender; Additional Commitment Lenders.  The Commitment of each Non Extending Lender automatically will terminate on the Existing Maturity Date as in effect immediately prior to the applicable extension and the Borrower shall pay all Committed Loans and other Borrower Obligations owing to such Non Extending Lender on the Existing Maturity Date to the extent not paid by an Additional Commitment Lender pursuant to an Assignment and Assumption as hereinafter set forth. The Borrower shall have the right to replace each Non Extending Lender with, and add as “Lenders” under this Agreement in place thereof, one or more Eligible Assignees (each, an “Additional Commitment Lender”) as provided in Section 3.6; provided that each of such Additional Commitment Lenders shall enter into an Assignment and Assumption pursuant to which such Additional Commitment Lender shall, effective as of the Extension Date, undertake a Commitment (and, if any such Additional Commitment Lender is already a Lender, its Commitment shall be in addition to such Lender’s Commitment hereunder on such date).

 

(e)                                  Minimum Extension Requirement.  If (and only if) (i) the total of the Commitments of the Lenders that have agreed so to extend their Maturity Date (each, an “Extending Lender”) and the additional Commitments of the Additional Commitment Lenders shall be more than 75% of the aggregate amount of the Commitments previously in effect and (ii) the aggregate Commitments shall be at least equal to the Outstanding Amount of Committed Loans, Swing Line Loans and L/C Obligations on and after the Existing Maturity Date, then, effective as of the Extension Date, the Maturity Date shall be extended to the New Maturity Date (except that, if such date is not a Business Day, such Maturity Date as so extended shall be the next preceding Business Day) and each Additional Commitment Lender shall thereupon become a “Lender” for all purposes of this Agreement.

 

(f)                                   Conditions to Effectiveness of Extensions.  As a condition precedent to such extension, the Borrower shall deliver to the Administrative Agent a certificate of the Borrower dated as of the Extension Date (in sufficient copies for each Extending Lender and each Additional Commitment Lender) signed by a Responsible Officer of the Borrower (i) certifying and attaching the resolutions adopted by the Borrower approving or consenting to such extension and (ii) certifying that, before and after giving effect to such extension, (A) the representations and warranties contained in Article V and the other Loan Documents are true and correct on and as of the Extension Date, except to the 

 

47

 

extent that such representations and warranties specifically refer to an earlier date, in which case they are true and correct as of such earlier date, and except that for purposes of this Section 2.14, the representations and warranties contained in subsections (a) and (b) of Section 5.6 shall be deemed to refer to the most recent statements furnished pursuant to subsections (a) and (b), respectively, of Section 6.1, and (B) no Default exists.  In addition, on the Extension Date, the Borrower shall prepay any Committed Loans outstanding on such date (and pay any additional amounts required pursuant to Section 3.5) to the extent necessary to keep outstanding Committed Loans ratable with any revised Applicable Percentages of the respective Lenders effective as of such date.

 

(g)                                  Conflicting Provisions.  This Section shall supersede any provisions in Section 2.13 or 10.6 to the contrary.

 

2.15                        Increase in Commitments.

 

Prior to the Maturity Date and upon at least 45 days’ prior written notice to the Administrative Agent (which notice shall be promptly transmitted by the Administrative Agent to each Lender), the Borrower shall have the revocable right, from time to time during the term of this Agreement and subject to the terms and conditions set forth below, to increase the aggregate amount of the Aggregate Commitments; provided that (a) no Default or Event of Default shall exist at the time of the request or the proposed increase in the Aggregate Commitments, (b) any such increase must be in a minimum amount of $25,000,000 and in integral multiples of $5,000,000 above such amount, (c) the sum of any increases to the Commitment during the term of this Agreement shall not exceed FIVE HUNDRED MILLION DOLLARS ($500,000,000), (d) no individual Lender’s Commitment may be increased without such Lender’s written consent, (e) the Borrower shall execute and deliver such Note(s) as are necessary to reflect the increase in the respective Commitments, (f) Schedule 1.1 shall be amended to reflect the revised Commitments and revised Applicable Percentages of the Lenders and (g) if any Loans are outstanding at the time of an increase in the Aggregate Commitments, the Borrower will prepay (provided that any such prepayment shall not be subject to any minimum amount of prepayment or any requirements regarding pro rata repayments but shall be subject to Section 3.5) one or more existing Loans in an amount necessary such that after giving effect to the increase in the Aggregate Commitments each Lender will hold its pro rata share (based on its share of the revised Aggregate Commitments) of outstanding Loans.

 

Any such increase in the Aggregate Commitments shall apply, at the option of the Borrower, to (x) the Commitment of one or more existing Lenders; provided that any Lender whose Commitment is being increased must consent in writing thereto and if more than one Lender wishes to participate then such increase shall be allocated pro rata among such Lenders (based on the amount that each such Lender was willing to increase its Commitment) and/or (y) a new Commitment for one or more institutions that is not an existing Lender so long as such institution (A) conforms to the definition of Eligible Assignee, (B) is approved by the Administrative Agent (such approval not to be unreasonably withheld or delayed), (C) receives a Commitment of at least $5,000,000 and (D) becomes a Lender under this Agreement by execution and delivery of an appropriate joinder agreement or of counterparts to this Agreement in a manner acceptable to the Borrower and the Administrative Agent.

 

48

 

This Section shall supersede any provisions in Section 2.13 or 10.6 to the contrary.

 

2.16                        Cash Collateral.

 

(a)                                 Certain Credit Support Events.  Upon the request of the Administrative Agent or an L/C Issuer (i) if an L/C Issuer has honored any full or partial drawing request under any Letter of Credit and such drawing has resulted in an L/C Borrowing, or (ii) if, as of the Letter of Credit Expiration Date, any L/C Obligation for any reason remains outstanding, the Borrower shall, in each case, immediately Cash Collateralize the then Outstanding Amount of all L/C Obligations.  At any time that there shall exist a Defaulting Lender, immediately upon the request of the Administrative Agent, the affected L/C Issuer or the Swing Line Lender, the Borrower shall deliver to the Administrative Agent Cash Collateral in an amount sufficient to cover all Fronting Exposure (after giving effect to Section 2.17(a)(iii) and any Cash Collateral provided by the Defaulting Lender).

 

(b)                                 Grant of Security Interest.  All Cash Collateral (other than credit support not constituting funds subject to deposit) shall be maintained in blocked, non-interest bearing deposit accounts at the Administrative Agent.  The Borrower, and to the extent provided by any Lender, such Lender, hereby grants to (and subjects to the control of) the Administrative Agent, for the benefit of the Administrative Agent, the L/C Issuers and the Lenders (including the Swing Line Lender), and agrees to maintain, a first priority security interest in all such cash, deposit accounts and all balances therein, and all other property so provided as collateral pursuant hereto, and in all proceeds of the foregoing, all as security for the obligations to which such Cash Collateral may be applied pursuant to Section 2.16(c).  If at any time the Administrative Agent determines that Cash Collateral is subject to any right or claim of any Person other than the Administrative Agent as herein provided, or that the total amount of such Cash Collateral is less than the applicable Fronting Exposure and other obligations secured thereby, the Borrower or the relevant Defaulting Lender will, promptly upon demand by the Administrative Agent, pay or provide to the Administrative Agent additional Cash Collateral in an amount sufficient to eliminate such deficiency.

 

(c)                                  Application.  Notwithstanding anything to the contrary contained in this Agreement, Cash Collateral provided under any of this Section 2.16 or Section 2.3, 2.4, 2.5, 2.17 or 8.2 in respect of Letters of Credit or Swing Line Loans shall be held and applied to the satisfaction of the specific L/C Obligations, Swing Line Loans, obligations to fund participations therein (including, as to Cash Collateral provided by a Defaulting Lender, any interest accrued on such obligation) and other obligations for which the Cash Collateral was so provided, prior to any other application of such property as may be provided for herein.

 

(d)                                 Release.  Cash Collateral (or the appropriate portion thereof) provided to reduce Fronting Exposure or other obligations shall be released promptly following (i) the elimination of the applicable Fronting Exposure or other obligations giving rise thereto (including by the termination of Defaulting Lender status of the applicable Lender (or, as appropriate, its assignee following compliance with Section 10.3(b)(vii))) or (ii) 

 

49

 

the Administrative Agent’s good faith determination that there exists excess Cash Collateral; provided, however, (x) that Cash Collateral furnished by or on behalf of the Borrower shall not be released during the continuance of a Default or Event of Default (and following application as provided in this Section 2.16 may be otherwise applied in accordance with Section 8.3), and (y) the Person providing Cash Collateral and each applicable L/C Issuer or Swing Line Lender, as applicable, may agree that Cash Collateral shall not be released but instead held to support future anticipated Fronting Exposure or other obligations.

 

2.17                        Defaulting Lenders.

 

(a)                                 Adjustments.  Notwithstanding anything to the contrary contained in this Agreement, if any Lender becomes a Defaulting Lender, then, until such time as that Lender is no longer a Defaulting Lender, to the extent permitted by applicable Law:

 

(i)                                     Waivers and Amendments.  That Defaulting Lender’s right to approve or disapprove any amendment, waiver or consent with respect to this Agreement shall be restricted as set forth in Section 10.6.

 

(ii)                                  Reallocation of Payments.  Any payment of principal, interest, fees or other amounts received by the Administrative Agent for the account of that Defaulting Lender (whether voluntary or mandatory, at maturity, pursuant to Section 8 or otherwise, and including any amounts made available to the Administrative Agent by that Defaulting Lender pursuant to Section 10.2), shall be applied at such time or times as may be determined by the Administrative Agent as follows: first, to the payment of any amounts owing by that Defaulting Lender to the Administrative Agent hereunder; second, to the payment on a pro rata basis of any amounts owing by that Defaulting Lender to the L/C Issuers or Swing Line Lender hereunder; third, if so determined by the Administrative Agent or requested by the L/C Issuers or the Swing Line Lender, to be held as Cash Collateral for future funding obligations of that Defaulting Lender of any participation in any Swing Line Loan or Letter of Credit; fourth, as the Borrower may request (so long as no Default or Event of Default exists), to the funding of any Loan in respect of which that Defaulting Lender has failed to fund its portion thereof as required by this Agreement, as determined by the Administrative Agent; fifth, if so determined by the Administrative Agent and the Borrower, to be held in a non-interest bearing deposit account and released in order to satisfy obligations of that Defaulting Lender to fund Loans under this Agreement; sixth, to the payment of any amounts owing to the Lenders, the L/C Issuers or Swing Line Lender as a result of any judgment of a court of competent jurisdiction obtained by any Lender, any L/C Issuer or Swing Line Lender against that Defaulting Lender as a result of that Defaulting Lender’s breach of its obligations under this Agreement; seventh, so long as no Default or Event of Default exists, to the payment of any amounts owing to the Borrower as a result of any judgment of a court of competent jurisdiction obtained by the Borrower against that Defaulting Lender as a result of that Defaulting Lender’s breach of its obligations under this Agreement; and eighth, to that Defaulting Lender or as otherwise directed by a 

 

50

 

court of competent jurisdiction; provided that if (x) such payment is a payment of the principal amount of any Loans or L/C Borrowings in respect of which that Defaulting Lender has not fully funded its appropriate share and (y) such Loans or L/C Borrowings were made at a time when the conditions set forth in Section 4.2 were satisfied or waived, such payment shall be applied solely to pay the Loans of, and L/C Borrowings owed to, all Non-Defaulting Lenders on a pro rata basis prior to being applied to the payment of any Loans of, or L/C Borrowings owed to, that Defaulting Lender.  Any payments, prepayments or other amounts paid or payable to a Defaulting Lender that are applied (or held) to pay amounts owed by a Defaulting Lender or to post Cash Collateral pursuant to this Section 2.17(a)(ii) shall be deemed paid to and redirected by that Defaulting Lender, and each Lender irrevocably consents hereto.

 

(iii)                               Certain Fees.  The Defaulting Lender (x) shall be entitled to receive any commitment fee pursuant to Section 2.9(a) for any period during which that Lender is a Defaulting Lender only to the extent allocable to the sum of (1) the Outstanding Amount of the Committed Loans funded by it and (2) its Applicable Percentage of the stated amount of Letters of Credit and Swing Line Loans for which it has provided Cash Collateral pursuant to Section 2.3, Section 2.4, Section 2.16 or Section 2.17(a)(ii), as applicable (and the Borrower shall (A) be required to pay to each of the L/C Issuers and the Swing Line Lender, as applicable, the amount of such fee allocable to its Fronting Exposure arising from that Defaulting Lender and (B) not be required to pay the remaining amount of such fee that otherwise would have been required to have been paid to that Defaulting Lender) and (y) shall be limited in its right to receive Letter of Credit Fees as provided in Section 2.3(h).

 

(iv)                              Reallocation of Applicable Percentages to Reduce Fronting Exposure.  During any period in which there is a Defaulting Lender, for purposes of computing the amount of the obligation of each Non-Defaulting Lender to acquire, refinance or fund participations in Letters of Credit or Swing Line Loans pursuant to Sections 2.3 and 2.4, the “Applicable Percentage” of each Non-Defaulting Lender shall be computed without giving effect to the Commitment of that Defaulting Lender; provided, that (i) each such reallocation shall be given effect only if, at the date the applicable Lender becomes a Defaulting Lender, no Default or Event of Default exists; and (ii) the aggregate obligation of each Non-Defaulting Lender to acquire, refinance or fund participations in Letters of Credit and Swing Line Loans shall not exceed the positive difference, if any, of (1) the Commitment of that Non-Defaulting Lender minus (2) the aggregate Outstanding Amount of the Committed Loans of that Lender.

 

(b)                                 Defaulting Lender Cure.  If the Borrower, the Administrative Agent, Swing Line Lender and the L/C Issuers agree in writing in their sole discretion that a Defaulting Lender should no longer be deemed to be a Defaulting Lender, the Administrative Agent will so notify the parties hereto, whereupon as of the effective date specified in such notice and subject to any conditions set forth therein (which may include arrangements with respect to any Cash Collateral), that Lender will, to the extent 

 

51

 

applicable, purchase that portion of outstanding Loans of the other Lenders or take such other actions as the Administrative Agent may determine to be necessary to cause the Committed Loans and funded and unfunded participations in Letters of Credit and Swing Line Loans to be held on a pro rata basis by the Lenders in accordance with their Applicable Percentages (without giving effect to Section 2.17(a)(iv)), whereupon that Lender will cease to be a Defaulting Lender; provided that no adjustments will be made retroactively with respect to fees accrued or payments made by or on behalf of the Borrower while that Lender was a Defaulting Lender; and provided, further, that except to the extent otherwise expressly agreed by the affected parties, no change hereunder from Defaulting Lender to Lender will constitute a waiver or release of any claim of any party hereunder arising from that Lender’s having been a Defaulting Lender.

 

SECTION 3.

 

TAXES, YIELD PROTECTION AND ILLEGALITY

 

3.1                               Taxes.

 

(a)                                 Defined Terms.  For purposes of this Section 3.1, the term “Lender” includes any L/C Issuer and the term “Laws” includes FATCA.

 

(b)                                 Payments Free of Taxes.  Any and all payments by or on account of any obligation of the Borrower under any Loan Document shall be made without deduction or withholding for any Taxes, except as required by applicable Laws.  If any applicable Law (as determined in the good faith discretion of an applicable Withholding Agent) requires the deduction or withholding of any Tax from any such payment by a Withholding Agent, then the applicable Withholding Agent shall be entitled to make such deduction or withholding and shall timely pay the full amount deducted or withheld to the relevant Governmental Authority in accordance with applicable Law and, if such Tax is an Indemnified Tax, then the sum payable by the Borrower shall be increased as necessary so that after such deduction or withholding has been made (including such deductions and withholdings applicable to additional sums payable under this Section) the applicable Recipient receives an amount equal to the sum it would have received had no such deduction or withholding been made.

 

(c)                                  Payment of Other Taxes by the Borrower.  The Borrower shall timely pay to the relevant Governmental Authority in accordance with applicable Law, or at the option of the Administrative Agent timely reimburse it for the payment of, any Other Taxes.

 

(d)                                 Indemnification by the Borrower.  The Borrower shall indemnify each Recipient, within 10 days after demand therefor, for the full amount of any Indemnified Taxes (including Indemnified Taxes imposed or asserted on or attributable to amounts payable under this Section) payable or paid by such Recipient or required to be withheld or deducted from a payment to such Recipient and any reasonable expenses arising therefrom or with respect thereto, whether or not such Indemnified Taxes were correctly or legally imposed or asserted by the relevant Governmental Authority.  A certificate as to 

 

52

 

the amount of such payment or liability delivered to the Borrower by a Lender (with a copy to the Administrative Agent), or by the Administrative Agent on its own behalf or on behalf of a Lender, shall be conclusive absent manifest error.

 

(e)                                  Indemnification by the Lenders.  Each Lender shall severally indemnify the Administrative Agent, within 10 days after demand therefor, for (i) any Indemnified Taxes attributable to such Lender (but only to the extent that the Borrower has not already indemnified the Administrative Agent for such Indemnified Taxes and without limiting the obligation of the Borrower to do so), (ii) any Taxes attributable to such Lender’s failure to comply with the provisions of Section 10.3(d) relating to the maintenance of a Participant Register and (iii) any Excluded Taxes attributable to such Lender, in each case, that are payable or paid by the Administrative Agent in connection with any Loan Document, and any reasonable expenses arising therefrom or with respect thereto, whether or not such Taxes were correctly or legally imposed or asserted by the relevant Governmental Authority.  A certificate as to the amount of such payment or liability delivered to any Lender by the Administrative Agent shall be conclusive absent manifest error.  Each Lender hereby authorizes the Administrative Agent to set off and apply any and all amounts at any time owing to such Lender under any Loan Document or otherwise payable by the Administrative Agent to the Lender from any other source against any amount due to the Administrative Agent under this paragraph (e).

 

(f)                                   Evidence of Payments.  As soon as practicable after any payment of Taxes by the Borrower to a Governmental Authority pursuant to this Section 3.1, the Borrower shall deliver to the Administrative Agent the original or a certified copy of a receipt issued by such Governmental Authority evidencing such payment, a copy of the return reporting such payment or other evidence of such payment reasonably satisfactory to the Administrative Agent.

 

(g)                                  Status of Lenders.  (i) Any Lender that is entitled to an exemption from or reduction of withholding Tax with respect to payments made under any Loan Document shall deliver to the Borrower and the Administrative Agent, at the time or times reasonably requested by the Borrower or the Administrative Agent, such properly completed and executed documentation reasonably requested by the Borrower or the Administrative Agent as will permit such payments to be made without withholding or at a reduced rate of withholding.  In addition, any Lender, if reasonably requested by the Borrower or the Administrative Agent, shall deliver such other documentation prescribed by applicable Laws or reasonably requested by the Borrower or the Administrative Agent as will enable the Borrower or the Administrative Agent to determine whether or not such Lender is subject to backup withholding or information reporting requirements.  Notwithstanding anything to the contrary in the preceding two sentences, the completion, execution and submission of such documentation (other than such documentation set forth in Section 3.1(g)(ii)(A), (ii)(B) and (ii)(D) below) shall not be required if in the Lender’s reasonable judgment such completion, execution or submission would subject such Lender to any material unreimbursed cost or expense or would materially prejudice the legal or commercial position of such Lender.

 

(ii) Without limiting the generality of the foregoing,

 

53

 

(A) any Lender that is a U.S. Person shall deliver to the Borrower and the Administrative Agent on or prior to the date on which such Lender becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request of the Borrower or the Administrative Agent), executed copies of IRS Form W-9 certifying that such Lender is exempt from U.S. federal backup withholding tax;

 

(B) any Foreign Lender shall, to the extent it is legally entitled to do so, deliver to the Borrower and the Administrative Agent (in such number of copies as shall be requested by the recipient) on or prior to the date on which such Foreign Lender becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request of the Borrower or the Administrative Agent), whichever of the following is applicable:

 

(1)  in the case of a Foreign Lender claiming the benefits of an income tax treaty to which the United States is a party (x) with respect to payments of interest under any Loan Document, executed copies of IRS Form W-8BEN or W-8BEN-E establishing an exemption from, or reduction of, U.S. federal withholding Tax pursuant to the “interest” article of such tax treaty and (y) with respect to any other applicable payments under any Loan Document, IRS Form W-8BEN or W-8BEN-E establishing an exemption from, or reduction of, U.S. federal withholding Tax pursuant to the “business profits” or “other income” article of such tax treaty;

 

(2)  executed copies of IRS Form W-8ECI;

 

(3) in the case of a Foreign Lender claiming the benefits of the exemption for portfolio interest under Section 881(c) of the Code, (x) a certificate substantially in the form of Exhibit 3.1(g)-1 to the effect that such Foreign Lender is not a “bank” within the meaning of Section 881(c)(3)(A) of the Code, a “10 percent shareholder” of the Borrower within the meaning of Section 881(c)(3)(B) of the Code, or a “controlled foreign corporation” described in Section 881(c)(3)(C) of the Code (a “U.S. Tax Compliance Certificate”) and (y) executed copies of IRS Form W-8BEN or W-8BEN-E; or

 

(4) to the extent a Foreign Lender is not the beneficial owner, executed copies of IRS Form W-8IMY, accompanied by IRS Form W-8ECI, IRS Form W-8BEN, W-8BEN-E, a U.S. Tax Compliance Certificate substantially in the form of Exhibit 3.1(g)-2 or Exhibit 3.1(g)-3, IRS Form W-9, and/or other certification 

 

54

 

documents from each beneficial owner, as applicable; provided that if the Foreign Lender is a partnership and one or more direct or indirect partners of such Foreign Lender are claiming the portfolio interest exemption, such Foreign Lender may provide a U.S. Tax Compliance Certificate substantially in the form of Exhibit 3.1(g)-4 on behalf of each such direct and indirect partner;

 

(C)  any Foreign Lender shall, to the extent it is legally entitled to do so, deliver to the Borrower and the Administrative Agent (in such number of copies as shall be requested by the recipient) on or prior to the date on which such Foreign Lender becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request of the Borrower or the Administrative Agent), executed copies of any other form prescribed by applicable Laws as a basis for claiming exemption from or a reduction in U.S. federal withholding Tax, duly completed, together with such supplementary documentation as may be prescribed by applicable Laws to permit the Borrower or the Administrative Agent to determine the withholding or deduction required to be made; and

 

(D) if a payment made to a Lender under any Loan Document would be subject to U.S. federal withholding Tax imposed by FATCA if such Lender were to fail to comply with the applicable reporting requirements of FATCA (including those contained in Section 1471(b) or 1472(b) of the Code, as applicable), such Lender shall deliver to the Borrower and the Administrative Agent at the time or times prescribed by law and at such time or times reasonably requested by the Borrower or the Administrative Agent such documentation prescribed by applicable Laws (including as prescribed by Section 1471(b)(3)(C)(i) of the Code) and such additional documentation reasonably requested by the Borrower or the Administrative Agent as may be necessary for the Borrower and the Administrative Agent to comply with their obligations under FATCA and to determine that such Lender has complied with such Lender’s obligations under FATCA or to determine the amount to deduct and withhold from such payment.  Solely for purposes of this clause (D), “FATCA” shall include any amendments made to FATCA after the date of this Agreement.

 

Each Lender agrees that if any form or certification it previously delivered expires or becomes obsolete or inaccurate in any respect, it shall update such form or certification or promptly notify the Borrower and the Administrative Agent in writing of its legal inability to do so.

 

(h)                                 Treatment of Certain Refunds.  If any party determines, in its sole discretion exercised in good faith, that it has received a refund of any Taxes as to which it has been indemnified pursuant to this Section 3.1 (including by the payment of additional

 

55

 

amounts pursuant to this Section 3.1), it shall pay to the indemnifying party an amount equal to such refund (but only to the extent of indemnity payments made under this Section with respect to the Taxes giving rise to such refund), net of all out-of-pocket expenses (including Taxes) of such indemnified party and without interest (other than any interest paid by the relevant Governmental Authority with respect to such refund).  Such indemnifying party, upon the request of such indemnified party, shall repay to such indemnified party the amount paid over pursuant to this paragraph (h) (plus any penalties, interest or other charges imposed by the relevant Governmental Authority) in the event that such indemnified party is required to repay such refund to such Governmental Authority.  Notwithstanding anything to the contrary in this paragraph (h), in no event will the indemnified party be required to pay any amount to an indemnifying party pursuant to this paragraph (h) the payment of which would place the indemnified party in a less favorable net after-Tax position than the indemnified party would have been in if the Tax subject to indemnification and giving rise to such refund had not been deducted, withheld or otherwise imposed and the indemnification payments or additional amounts with respect to such Tax had never been paid.  This paragraph shall not be construed to require any indemnified party to make available its Tax returns (or any other information relating to its Taxes that it deems confidential) to the indemnifying party or any other Person.

 

(i)                                     Survival.  Each party’s obligations under this Section 3.1 shall survive the resignation or replacement of the Administrative Agent or any assignment of rights by, or the replacement of, a Lender, the termination of the Commitments and the repayment, satisfaction or discharge of all obligations under any Loan Document.

 

3.2                               Illegality.

 

If any Lender determines that any Law has made it unlawful, or that any Governmental Authority has asserted that it is unlawful, for any Lender or its applicable Lending Office to make, maintain or fund Loans whose interest is determined by reference to the Eurodollar Rate, or to determine or charge interest rates based upon the Eurodollar Rate, or any Governmental Authority has imposed material restrictions on the authority of such Lender to purchase or sell, or to take deposits of, Dollars in the London interbank market, then, on notice thereof by such Lender to the Borrower through the Administrative Agent, (i) any obligation of such Lender to make or continue Eurodollar Rate Loans or to convert Base Rate Committed Loans to Eurodollar Rate Loans shall be suspended, and (ii) if such notice asserts the illegality of such Lender making or maintaining Base Rate Loans the interest rate on which is determined by reference to the Eurodollar Rate component of the Base Rate, the interest rate on which Base Rate Loans of such Lender shall, if necessary to avoid such illegality, be determined by the Administrative Agent without reference to the Eurodollar Rate component of the Base Rate, in each case until such Lender notifies the Administrative Agent and the Borrower that the circumstances giving rise to such determination no longer exist.  Upon receipt of such notice, (x) the Borrower shall, upon demand from such Lender (with a copy to the Administrative Agent), prepay or, if applicable, convert all Eurodollar Rate Loans of such Lender to Base Rate Loans (the interest rate on which Base Rate Loans of such Lender shall, if necessary to avoid such illegality, be determined by the Administrative Agent without reference to the Eurodollar Rate component of the Base Rate), either on the last day of the Interest Period therefor, if such Lender may lawfully 

 

56

 

continue to maintain such Eurodollar Rate Loans to such day, or immediately, if such Lender may not lawfully continue to maintain such Eurodollar Rate Loans and (y) if such notice asserts the illegality of such Lender determining or charging interest rates based upon the Eurodollar Rate, the Administrative Agent shall during the period of such suspension compute the Base Rate applicable to such Lender without reference to the Eurodollar Rate component thereof until the Administrative is advised in writing by such Lender that it is no longer illegal for such Lender to determine or charge interest rates based upon the Eurodollar Rate.  Upon any such prepayment or conversion, the Borrower shall also pay accrued interest on the amount so prepaid or converted.

 

3.3                               Inability to Determine Rates.

 

If the Required Lenders determine that for any reason in connection with any request for a Eurodollar Rate Loan or a conversion to or continuation thereof that (a) Dollar deposits are not being offered to banks in the London interbank eurodollar market for the applicable amount and Interest Period of such Eurodollar Rate Loan, (b) adequate and reasonable means do not exist for determining the Eurodollar Rate for any requested Interest Period with respect to a proposed Eurodollar Rate Loan or in connection with an existing or proposed Base Rate Loan, or (c) the Eurodollar Rate for any requested Interest Period with respect to a proposed Eurodollar Rate Loan does not adequately and fairly reflect the cost to such Lenders of funding such Loan, the Administrative Agent will promptly so notify the Borrower and each Lender.  Thereafter, (x) the obligation of the Lenders to make or maintain Eurodollar Rate Loans shall be suspended, and (y) in the event of a determination described in the preceding sentence with respect to the Eurodollar Rate component of the Base Rate, the utilization of the Eurodollar Rate component in determining the Base Rate shall be suspended, in each case until the Administrative Agent (upon the instruction of the Required Lenders) revokes such notice.  Upon receipt of such notice, the Borrower may revoke any pending request for a Borrowing of, conversion to or continuation of Eurodollar Rate Loans or, failing that, will be deemed to have converted such request into a request for a Committed Borrowing of Base Rate Loans in the amount specified therein.

 

3.4                               Increased Costs.

 

(a)                                 Increased Costs Generally.  If any Change in Law shall:

 

(i)                                     impose, modify or deem applicable any reserve, special deposit, compulsory loan, insurance charge or similar requirement against assets of, deposits with or for the account of, or credit extended or participated in by, any Lender (except any reserve requirement reflected in the Eurodollar Rate) or any L/C Issuer;

 

(ii)                                  subject any Recipient to any Taxes (other than (A) Indemnified Taxes, (B) Taxes described in clauses (b) through (d) of the definition of Excluded Taxes and (C) Connection Income Taxes) on its loans, loan principal, letters of credit, commitments, or other obligations, or its deposits, reserves, other liabilities or capital attributable thereto; or

 

57

 

(iii)                               impose on any Lender or any L/C Issuer or the London interbank market any other condition, cost or expense (other than Taxes) affecting this Agreement or Loans made by such Lender or any Letter of Credit or participation therein;

 

and the result of any of the foregoing shall be to increase the cost to such Lender or such other Recipient of making, converting to, continuing or maintaining any Loan or of maintaining its obligation to make any such Loan, or to increase the cost to such Lender, such L/C Issuer or such other Recipient of participating in, issuing or maintaining any Letter of Credit (or of maintaining its obligation to participate in or to issue any Letter of Credit), or to reduce the amount of any sum received or receivable by such Lender, L/C Issuer or other Recipient hereunder (whether of principal, interest or any other amount) then, upon request of such Lender, L/C Issuer or other Recipient, the Borrower will pay to such Lender, L/C Issuer or other Recipient, as the case may be, such additional amount or amounts as will compensate such Lender, L/C Issuer or other Recipient, as the case may be, for such additional costs incurred or reduction suffered.

 

(b)                                 Capital Requirements.  If any Lender or any L/C Issuer determines that any Change in Law affecting such Lender or such L/C Issuer or any Lending Office of such Lender or such Lender’s or such L/C Issuer’s holding company, if any, regarding capital or liquidity requirements has or would have the effect of reducing the rate of return on such Lender’s or such L/C Issuer’s capital or on the capital of such Lender’s or such L/C Issuer’s holding company, if any, as a consequence of this Agreement, the Commitments of such Lender or the Loans made by, or participations in Letters of Credit or Swingline Loans held by, such Lender, or the Letters of Credit issued by such L/C Issuer, to a level below that which such Lender or such L/C Issuer or such Lender’s or such L/C Issuer’s holding company could have achieved but for such Change in Law (taking into consideration such Lender’s or such L/C Issuer’s policies and the policies of such Lender’s or such L/C Issuer’s holding company with respect to capital adequacy), then from time to time the Borrower will pay to such Lender or such L/C Issuer, as the case may be, such additional amount or amounts as will compensate such Lender or such L/C Issuer or such Lender’s or such L/C Issuer’s holding company for any such reduction suffered.

 

(c)                                  Certificates for Reimbursement.  A certificate of a Lender or an L/C Issuer setting forth the amount or amounts necessary to compensate such Lender or such L/C Issuer or its holding company, as the case may be, as specified in subsection (a) or (b) of this Section and delivered to the Borrower shall be conclusive absent manifest error.  The Borrower shall pay such Lender or such L/C Issuer, as the case may be, the amount shown as due on any such certificate within 10 days after receipt thereof.

 

(d)                                 Delay in Requests.  Failure or delay on the part of any Lender or any L/C Issuer to demand compensation pursuant to the foregoing provisions of this Section shall not constitute a waiver of such Lender’s or such L/C Issuer’s right to demand such compensation, provided that the Borrower shall not be required to compensate a Lender or an L/C Issuer pursuant to the foregoing provisions of this Section for any increased costs incurred or reductions suffered more than six months prior to the date that such 

 

58

 

Lender or such L/C Issuer, as the case may be, notifies the Borrower of the Change in Law giving rise to such increased costs or reductions and of such Lender’s or such L/C Issuer’s intention to claim compensation therefor (except that, if the Change in Law giving rise to such increased costs or reductions is retroactive, then the six-month period referred to above shall be extended to include the period of retroactive effect thereof).

 

3.5                               Compensation for Losses.

 

Upon demand of any Lender (with a copy to the Administrative Agent) from time to time, the Borrower shall promptly compensate such Lender for and hold such Lender harmless from any loss, cost or expense incurred by it as a result of:

 

(a)                                 any continuation, conversion, payment or prepayment of any Loan other than a Base Rate Loan on a day other than the last day of the Interest Period for such Loan (whether voluntary, mandatory, automatic, by reason of acceleration, or otherwise);

 

(b)                                 any failure by the Borrower (for a reason other than the failure of such Lender to make a Loan) to prepay, borrow, continue or convert any Loan other than a Base Rate Loan on the date or in the amount notified by the Borrower; or

 

(c)                                  any assignment of a Eurodollar Rate Loan on a day other than the last day of the Interest Period therefor as a result of a request by the Borrower pursuant to Section 3.6.

 

including any loss of anticipated profits and any loss or expense arising from the liquidation or reemployment of funds obtained by it to maintain such Loan or from fees payable to terminate the deposits from which such funds were obtained.  The Borrower shall also pay any customary administrative fees charged by such Lender in connection with the foregoing.

 

For purposes of calculating amounts payable by the Borrower to the Lenders under this Section 3.5, each Lender shall be deemed to have funded each Eurodollar Rate Loan made by it at the Eurodollar Rate for such Loan by a matching deposit or other borrowing in the London interbank eurodollar market for a comparable amount and for a comparable period, whether or not such Eurodollar Rate Loan was in fact so funded.

 

3.6                               Mitigation Obligations; Replacement of Lenders.

 

(a)                                 Designation of a Different Lending Office.  If any Lender delivers a notice pursuant to Section 3.2, any Lender requests compensation under Section 3.4 or the Borrower is required to pay any Indemnified Taxes or additional amounts to any Lender, any L/C Issuer or any Governmental Authority for the account of any Lender or any L/C Issuer pursuant to Section 3.1, then such Lender or such L/C Issuer, as applicable, shall (at the request of the Borrower) use reasonable efforts to designate a different Lending Office for funding or booking its Loans hereunder or to assign its rights and obligations hereunder to another of its offices, branches or affiliates, if, in the judgment of such Lender or such L/C Issuer, such designation or assignment (i) would eliminate or reduce amounts payable pursuant to Section 3.1 or 3.4, as the case may be, in the future, or eliminate the need for the notice pursuant to Section 3.2, as applicable, and (ii) in each 

 

59

 

case, would not subject such Lender or such L/C Issuer, as the case may be, to any unreimbursed cost or expense and would not otherwise be disadvantageous to such Lender or such L/C Issuer, as the case may be.  The Borrower hereby agrees to pay all reasonable costs and expenses incurred by any Lender or any L/C Issuer in connection with any such designation or assignment.

 

(b)                                 Replacement of Lenders.  If any Lender requests compensation under Section 3.4, or if the Borrower is required to pay any Indemnified Taxes or additional amounts to any Lender or any Governmental Authority for the account of any Lender pursuant to Section 3.1 and, in each case, such Lender has declined or is unable to designate a different Lending Office in accordance with Section 3.6(a), or if any Lender is a Defaulting Lender or a Non-Consenting Lender, then the Borrower may, at its sole expense and effort, upon notice to such Lender and the Administrative Agent, require such Lender to assign and delegate, without recourse (in accordance with and subject to the restrictions contained in, and consents required by, Section 10.3), all of its interests, rights (other than its existing rights to payments pursuant to Section 3.1 or Section 3.4) and obligations under this Agreement and the related Loan Documents to an Eligible Assignee that shall assume such obligations (which assignee may be another Lender, if a Lender accepts such assignment); provided that:

 

(i)                                     the Borrower shall have paid to the Administrative Agent the assignment fee (if any) specified in Section 10.3;

 

(ii)                                  such Lender shall have received payment of an amount equal to the outstanding principal of its Loans and L/C Advances, accrued interest thereon, accrued fees and all other amounts payable to it hereunder and under the other Loan Documents (including any amounts under Section 3.5) from the assignee (to the extent of such outstanding principal and accrued interest and fees) or the Borrower (in the case of all other amounts);

 

(iii)                               in the case of any such assignment resulting from a claim for compensation under Section 3.4 or payments required to be made pursuant to Section 3.1, such assignment will result in a reduction in such compensation or payments thereafter;

 

(iv)                              such assignment does not conflict with applicable Laws; and

 

(v)                                 in the case of any assignment resulting from a Lender becoming a Non-Consenting Lender, the applicable assignee shall have consented to the applicable amendment, waiver or consent.

 

A Lender shall not be required to make any such assignment or delegation if, prior thereto, as a result of a waiver by such Lender or otherwise, the circumstances entitling the Borrower to require such assignment and delegation cease to apply.

 

60

 

3.7                               Survival.

 

All of the Borrower’s obligations under this Section 3 shall survive termination of the Aggregate Commitments, repayment of all other Obligations hereunder, and resignation of the Administrative Agent.

 

SECTION 4.

 

CONDITIONS PRECEDENT

 

4.1                               Closing Conditions.

 

The obligation of the Lenders and the L/C Issuers to enter into this Agreement is subject to satisfaction (or waiver) of the following conditions:

 

(a)                                 Executed Loan Documents.  Receipt by the Administrative Agent of duly executed copies of (i) this Agreement, (ii) the Notes and (iii) all other Loan Documents, each in form and substance acceptable to the Lenders and the Administrative Agent.

 

(b)                                 Corporate Documents.  Receipt by the Administrative Agent of the following:

 

(i)                                     Charter Documents.  Copies of the articles of incorporation or other charter documents of the Borrower certified to be true and complete as of a recent date by the appropriate Governmental Authority of the state or other jurisdiction of its incorporation and certified by a secretary or assistant secretary of the Borrower to be true and correct as of the Closing Date.

 

(ii)                                  Bylaws.  A copy of the bylaws of the Borrower certified by a secretary or assistant secretary of the Borrower to be true and correct as of the Closing Date.

 

(iii)                               Resolutions.  Copies of resolutions of the Board of Directors of the Borrower approving and adopting the Loan Documents to which it is a party and the transactions contemplated herein and therein and authorizing execution and delivery hereof and thereof, certified by a secretary or assistant secretary of the Borrower to be true and correct and in force and effect as of the Closing Date.

 

(iv)                              Good Standing.  Certificates of good standing, existence or its equivalent with respect to the Borrower certified as of a recent date by the appropriate Governmental Authorities of the state or other jurisdiction of its incorporation and each other jurisdiction in which the failure to so qualify and be in good standing would have a Material Adverse Effect.

 

(v)                                 Incumbency.  An incumbency certificate of the Borrower certified by a secretary or assistant secretary of the Borrower to be true and correct as of the Closing Date.

 

61

 

(c)                                  Opinion of Counsel.  Receipt by the Administrative Agent of an opinion, or opinions, from legal counsel to the Borrower addressed to the Administrative Agent on behalf of the Lenders and dated as of the Closing Date, in each case satisfactory in form and substance to the Administrative Agent.

 

(d)                                 Financial Statements.  Receipt by the Lenders of the consolidated audited financial statements of the Borrower and its Subsidiaries dated as of December 31, 2011, December 31, 2012 and December 31, 2013, and the unaudited financial statements for the quarters ended March 31, 2014, June 30, 2014 and September 30, 2014, including balance sheets, income and cash flow statements and, in the case of annual statements, a statement of the current combined amount of patronage capital and membership fees, in each case audited (except for the quarterly financial statements) by independent public accountants of recognized standing reasonably acceptable to the Administrative Agent and prepared in accordance with GAAP.

 

(e)                                  Fees and Expenses.  Payment by the Borrower of all fees and expenses owed by it to the Lenders and the Administrative Agent, including, without limitation, payment to the Administrative Agent of the fees set forth in the Fee Letters.

 

(f)                                   Litigation.  Except as set forth on Schedule 5.8, or in the Borrower’s Annual Report on Form 10-K for the fiscal year ended December 31, 2013 or Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2014, June 30, 2014 or September 30, 2014, each filed with the Securities and Exchange Commission, there shall not exist any action, suit, investigation or legal, equitable, arbitration or administrative proceeding, nor shall any action, suit, investigation, or legal, equitable, arbitration or administrative proceeding be pending or threatened before any arbitrator or Governmental Authority against the Borrower, any of its Subsidiaries, any of its properties or any transaction contemplated by the Loan Documents the outcome of which could be reasonably expected to have a Material Adverse Effect.

 

(g)                                  Material Adverse Effect.  No event or condition shall have occurred since December 31, 2013 that has had or would be reasonably expected to have a Material Adverse Effect.

 

(h)                                 Officer’s Certificates.  The Administrative Agent shall have received a certificate or certificates executed by a Financial Officer of the Borrower as of the Closing Date stating that (i) the Borrower is in compliance with all existing material financial obligations, (ii) the condition set forth in clause (f) has been satisfied, (iii) the financial statements and information delivered to the Administrative Agent on or before the Closing Date were prepared in good faith and in accordance with GAAP and (iv) immediately after giving effect to this Agreement, the other Loan Documents and all the transactions contemplated herein and therein to occur on such date, (A) no Default or Event of Default exists, (B) all representations and warranties contained herein and in the other Loan Documents are true and correct in all material respects on and as of the date made, (C) the Borrower is in compliance with the financial covenant set forth in Section 6.2, (D) the Borrower is Solvent and (E) since December 31, 2013, there has been no 

 

62

 

sale, transfer or other disposition by the Borrower of any material part of the business or property of the Borrower.

 

(i)                                     Existing Credit Agreement.  All loans and obligations due and payable under the Existing Credit Agreement shall have been paid in full and all commitments thereunder shall have terminated.

 

(j)                                    Existing Letters of Credit.  The Borrower’s obligation to reimburse Bank of America and Bank of Montreal for drawings under the Existing Letters of Credit shall be evidenced by this Agreement.

 

(k)                                 KYC Information.  Receipt by the Administrative Agent of all documentation and information required by regulatory authorities under applicable “know your customer” and anti-money laundering rules and regulations, including, without limitation, the Patriot Act, to the extent such documentation or information is requested by the Administrative Agent on behalf of the Lenders prior to the Closing Date.

 

(l)                                     Other.  Receipt by the Lenders of such other documents, instruments, agreements or information as reasonably requested by any Lender.

 

Without limiting the generality of the provisions of Section 10.3, for purposes of determining compliance with the conditions specified in this Section, each Lender that has signed this Agreement shall be deemed to have consented to, approved or accepted or to be satisfied with, each document or other matter required thereunder to be consented to or approved by or acceptable or satisfactory to a Lender unless the Administrative Agent shall have received notice from such Lender prior to the proposed Closing Date specifying its objection thereto.

 

4.2                               Conditions to All Credit Extensions.

 

In addition to the conditions precedent stated elsewhere herein, which conditions precedent set forth in Section 4.1 shall have been satisfied or waived on the Closing Date, the obligation of each Lender and each L/C Issuer to honor any Request for Credit Extension (other than an Interest Election Notice) is subject to the following conditions:

 

(a)                                 Request.  The Administrative Agent and, if applicable, each applicable L/C Issuer and/or the Swing Line Lender shall have received a Request for Credit Extension in accordance with requirements hereof.

 

(b)                                 Representations and Warranties.  The representations and warranties made by the Borrower (other than the representations and warranties set forth in Sections 5.8, 5.15 and 5.16) are true and correct in all material respects at and as if made as of such date, except to the extent that such representations and warranties relate to an earlier date, in which case such representations and warranties shall be true and correct in all material respects as of such earlier date.

 

(c)                                  No Default.  No Default or Event of Default shall exist or be continuing either prior to or after giving effect thereto.

 

63

 

(d)                                 Members’ Ability to Perform Wholesale Power Contracts.  There shall not have occurred (i) any modification, termination or enactment of any law, rule, regulation, order or decree of any Governmental Authority, including, without limitation, the Georgia Territorial Electric Service Act of 1973, or (ii) any other action or event that, in either case of clause (i) or (ii), would have the effect of materially altering the service area of any Member or eliminating the exclusive right of any Member to distribute electricity within such area (subject to the exception to exclusivity existing on the Closing Date as set forth in the Georgia Territorial Electric Service Act of 1973), in each case of clauses (i) and (ii) so as to adversely affect the ability of a Member to perform its obligations under its Wholesale Power Contract, other than in connection with an assignment of such Member’s service territory and Wholesale Power Contract where such Member’s rights to substantially all of its service territory and obligations under its Wholesale Power Contract are simultaneously assumed by another Member or other assignee; provided that in the case of a non-Member assignee, such assignee must have either (x) a Credit Rating equal to or better than the Credit Rating of the assigning Member as published by S&P, Moody’s or Fitch or (y) if the assigning Member has no such published Credit Rating, a Credit Rating equal to or better than the Borrower’s Credit Rating as published by S&P, Moody’s or Fitch.

 

Each Request for Credit Extension (other than an Interest Election Notice) submitted by the Borrower shall be deemed to be a representation and warranty that the conditions specified in Sections 4.2(b), (c) and (d) have been satisfied on and as of the date of the applicable Credit Extension.

 

SECTION 5.

 

REPRESENTATIONS AND WARRANTIES

 

The Borrower hereby represents and warrants to each Lender that:

 

5.1                               Organization and Good Standing.

 

The Borrower (a) is a corporation duly organized, validly existing and in good standing under the Georgia Electric Membership Corporation Act, (b) is duly qualified and in good standing as a foreign corporation authorized to do business in every jurisdiction where the failure to so qualify would have or would reasonably be expected to have a Material Adverse Effect and (c) has the requisite corporate power and authority to own its properties and to carry on its business as now conducted and as proposed to be conducted.

 

5.2                               Due Authorization.

 

The Borrower (a) has the requisite corporate power and authority to execute, deliver and perform this Agreement and the other Loan Documents and to incur the obligations herein and therein provided for and (b) has been authorized by all necessary corporate action, to execute, deliver and perform this Agreement and the other Loan Documents.  No action on the part of any Member is required in connection with the execution and delivery by the Borrower of the Loan Documents or the performance of its obligations thereunder.

 

64

 

5.3                               No Conflicts.

 

Neither the execution and delivery of the Loan Documents, nor the consummation of the transactions contemplated therein, nor performance of and compliance with the terms and provisions thereof by the Borrower will (a) violate or conflict with any provision of its organizational documents or bylaws, (b) violate, contravene or conflict with any law (including without limitation, the Public Utility Holding Company Act of 2005, as amended), regulation (including without limitation, Regulation U, Regulation X or any regulation promulgated by the Federal Energy Regulatory Commission), order, writ, judgment, injunction, decree or permit applicable to it, (c) violate, contravene or conflict with contractual provisions of, or cause an event of default under, any of the Wholesale Power Contracts, the First Mortgage Indenture, or any other material indenture, loan agreement, mortgage, deed of trust, contract or other agreement or instrument to which it is a party or by which it or its properties may be bound, or (d) result in or require the creation of any Lien upon or with respect to its properties (other than Liens created by this Agreement), except to the extent such violation, contravention or conflict referred to in the preceding clause (b) or (c), or the creation of any such Lien referred to in the preceding clause (d), individually or in the aggregate, would not have and would not reasonably be expected to have a Material Adverse Effect.

 

5.4                               Consents.

 

No consent, approval, authorization or order of, or filing, registration or qualification with, any court or Governmental Authority, Member or third party is required in connection with the execution, delivery or performance of this Agreement or any of the other Loan Documents.

 

5.5                               Enforceable Obligations.

 

This Agreement and the other Loan Documents have been duly executed and delivered and constitute legal, valid and binding obligations of the Borrower enforceable against the Borrower in accordance with their respective terms, except as may be limited by bankruptcy or insolvency laws or similar laws affecting creditors’ rights generally or by general equitable principles.

 

5.6                               Financial Condition.

 

The financial statements delivered to the Lenders pursuant to Section 4.1(d) and pursuant to Sections 6.1(a) and 6.1(b):  (i) have been prepared in accordance with GAAP (subject to the provisions of Section 1.3 and subject, with respect to any quarterly financial statements, to such changes resulting from audit and normal year-end adjustments) and (ii) present fairly in all material respects the financial condition, results of operations, patronage capital, membership fees and cash flows of the Borrower and its Subsidiaries as of such date and for such periods.

 

5.7                               No Default.

 

No Default or Event of Default presently exists and is continuing.

 

65

 

5.8                               Litigation.

 

Except as set forth on Schedule 5.8, or in the Borrower’s Annual Report on Form 10-K for the fiscal year ended December 31, 2013 or Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2014, June 30, 2014 or September 30, 2014, each filed with the Securities and Exchange Commission, there are no actions, suits, investigations or legal, equitable, arbitration or administrative proceedings, pending or, to the knowledge of the Borrower, threatened against the Borrower, any of its Subsidiaries or any of its properties that are reasonably likely to have a Material Adverse Effect.

 

5.9                               Taxes.

 

The Borrower has filed, or caused to be filed, all tax returns (federal, state, local and foreign) required to be filed and paid all amounts of taxes shown thereon to be due (including interest and penalties) and has paid all other taxes, fees, assessments and other governmental charges (including mortgage recording taxes, documentary stamp taxes and intangibles taxes) owing by it, except for (i) such taxes which are not yet delinquent or that are being contested in good faith and by proper proceedings, and against which adequate reserves are being maintained in accordance with GAAP, or (ii) where the failure to so file or pay would not have or would not reasonably be expected to have a Material Adverse Effect.

 

5.10                        Compliance with Law.

 

The Borrower is in compliance with all laws, rules, regulations, orders and decrees applicable to it or to its properties, except where the failure to be in compliance would not have or would not reasonably be expected to have a Material Adverse Effect.

 

5.11                        ERISA.

 

Except as would not result or be reasonably expected to result in a Material Adverse Effect:

 

(a)                                 During the five-year period prior to the date on which this representation is made or deemed made: (i) no Termination Event has occurred, and, to the best knowledge of the Borrower, no event or condition has occurred or exists as a result of which any Termination Event is reasonably expected to occur, with respect to any Plan; (ii) no “unpaid required minimum contribution” or “accumulated funding deficiency” (as defined or otherwise set forth in Section 4971 of the Code or Part 3 of Subtitle B of Title I of ERISA) whether or not waived, exists with respect to any Pension Plan; (iii) each Plan (other than a Multiemployer Plan), and, to the best knowledge of the Borrower, each Multiemployer Plan, has been maintained, operated, and funded in compliance with its own terms and in compliance with the provisions of ERISA, the Code, and any other applicable federal or state laws; and (iv) no Lien in favor of the PBGC or a Plan has arisen or is reasonably expected to arise on account of any Plan.

 

(b)                                 No liability has been or is reasonably expected by the Borrower to be incurred under Sections 4062, 4063 or 4064 of ERISA with respect to any Single Employer Plan.

 

66

 

(c)                                  The actuarial present value of all “benefit liabilities” under Section 4001(a)(16) of ERISA under each Single Employer Plan (determined in accordance with the assumptions used for funding such Single Employer Plan pursuant to Section 412 of the Code for the applicable plan year),  whether or not vested, did not, as of the last annual valuation date prior to the date on which this representation is made or deemed made, exceed the fair market value of the assets of such Plan allocable to such liabilities under Title IV of ERISA (excluding any accrued but unpaid contributions), except as disclosed in the Borrower’s financial statements.

 

(d)                                 Neither the Borrower nor any ERISA Affiliate has incurred, or, to the best knowledge of the Borrower, is reasonably expected to incur, any withdrawal liability under ERISA to any Multiemployer Plan or Multiple Employer Plan.  Neither the Borrower nor any ERISA Affiliate has received any notification that any Multiemployer Plan is in reorganization (within the meaning of Section 4241 of ERISA), is insolvent (within the meaning of Section 4245 of ERISA), is in endangered or critical status under Section 305 of ERISA, or has been terminated (within the meaning of Title IV of ERISA), and no Multiemployer Plan is, to the best knowledge of the Borrower, reasonably expected to be in reorganization, insolvent, or terminated.

 

(e)                                  No non-exempt prohibited transaction (within the meaning of Section 406 of ERISA or Section 4975 of the Code) or breach of fiduciary responsibility has occurred with respect to a Plan which has subjected or is reasonably likely to subject the Borrower or any Subsidiary of the Borrower to any liability under Sections 406, 407, 409, 502(i), or 502(1) of ERISA or Section 4975 of the Code, or under any agreement or other instrument pursuant to which the Borrower or any Subsidiary of the Borrower has agreed or is required to indemnify any person against any such liability.

 

(f)                                   The present value (determined using actuarial and other assumptions which are reasonable with respect to the benefits provided and the employees participating) of the liability of the Borrower and each ERISA Affiliate for post-retirement welfare benefits to be provided to their current and former employees under Plans which are welfare benefit plans (as defined in Section 3(1) of ERISA), net of all assets under all such Plans allocable to such benefits, are reflected on the financial statements referenced in Section 6.1 in accordance with FASB 106.

 

(g)                                  Each Plan which is a welfare plan (as defined in Section 3(1) of ERISA) to which Sections 601-609 of ERISA and Section 4980B of the Code apply has been administered in compliance in all material respects with such sections.

 

5.12                        Use of Proceeds.

 

The proceeds of the Loans hereunder will be used solely for the purposes specified in Section 6.9.  None of such proceeds will be used for the acquisition of another Person unless the board of directors (or other comparable governing body) or stockholders, as appropriate, of such Person has approved such acquisition.

 

67

 

5.13                        Government Regulations.

 

(a)                                 No proceeds of the Loans will be used, directly or indirectly, for the purpose of purchasing or carrying any “margin stock” within the meaning of Regulation U, or for the purpose of purchasing or carrying or trading in any securities. If requested by any Lender or the Administrative Agent, the Borrower will furnish to the Administrative Agent and each Lender a statement to the foregoing effect in conformity with the requirements of FR Form U-1 referred to in Regulation U. No Indebtedness being reduced or retired out of the proceeds of the Loans was or will be incurred for the purpose of purchasing or carrying any margin stock within the meaning of Regulation U or any “margin security” within the meaning of Regulation T. “Margin stock” within the meaning of Regulation U does not constitute more than 25% of the value of the consolidated assets of the Borrower and its Subsidiaries. None of the transactions contemplated by the Loan Documents (including, without limitation, the direct or indirect use of the proceeds of the Loans) will violate or result in a violation of (i) the Securities Act of 1933, as amended, (ii) the Securities Exchange Act of 1934, as amended, or (iii) regulations issued pursuant to the Securities Act of 1933 or the Securities Exchange Act of 1934.

 

(b)                                 Neither the Borrower nor any of its Subsidiaries is subject to (i) rate or debt incurrence regulation under the Federal Power Act, as amended, or (ii) regulation under the Investment Company Act of 1940, as amended.  In addition, neither the Borrower nor any of its Subsidiaries is an “investment company” registered or required to be registered under the Investment Company Act of 1940, as amended, and is not controlled by an “investment company.”

 

5.14                        Solvency.

 

The Borrower is and, after the consummation of the transactions contemplated by this Agreement and the other Loan Documents, will be Solvent.

 

5.15                        Disclosure.

 

Neither this Agreement nor any financial statements delivered to the Lenders nor any other document, certificate or statement furnished to the Lenders by or on behalf of the Borrower in connection with the transactions contemplated hereby, as of the date of delivery, taken as a whole, contained any untrue statement of a material fact or omitted to state a material fact necessary in order to make the statements contained therein or herein, taken as a whole, not misleading; provided that, with respect to projected financial information, the Borrower represents only that such information was prepared in good faith based upon assumptions believed to be reasonable at the time.

 

5.16                        Environmental Matters.

 

Except as would not result or be reasonably expected to result in a Material Adverse Effect:  (a) each of the properties of the Borrower (the “Properties”) and all operations at the Properties are in compliance with all applicable Environmental Laws, (b) there is no violation of any Environmental Law with respect to the Properties or the businesses operated by the 

 

68

 

Borrower (the “Businesses”), and (c) there are no conditions relating to the Businesses or the Properties that would reasonably be expected to give rise to a liability under any applicable Environmental Laws.

 

5.17                        Insurance.

 

The Borrower maintains insurance for the benefit of the Borrower with responsible and reputable insurance companies or associations in such amounts and covering such risks as is usually carried by companies engaged in similar business and owning similar properties in the same general areas in which the Borrower operates.

 

5.18                        Franchises, Licenses, Etc.

 

The Borrower possesses all franchises, certificates, licenses, permits and other authorizations necessary for the operation of its businesses, except such as the failure to possess would not result or be reasonably expected to result in a Material Adverse Effect.

 

5.19                        Subsidiaries; Affiliates; Members.

 

As of the Closing Date, Schedule 5.19 is a complete list of all Subsidiaries, Affiliates and Members of the Borrower.

 

5.20                        Wholesale Power Contracts.

 

As of the Closing Date:

 

(a)                                 The Borrower has no knowledge of any default under any Wholesale Power Contract, and each Wholesale Power Contract is in full force and effect.

 

(b)                                 No Member has provided the Borrower with any (i) “Notice of Intent to Withdraw” pursuant to Section 17 of such Member’s Wholesale Power Contract or (ii) written notice of its intent to assign any of its rights and obligations under its Wholesale Power Contract.

 

(c)                                  Set forth on Schedule 5.20 is each Member’s percentage share of the gross member revenues of the Borrower for the fiscal year ended December 31, 2014.

 

5.21                        Anti-Corruption Laws and Sanctions.

 

The Borrower has implemented and maintains in effect policies and procedures designed to ensure compliance by the Borrower, its Subsidiaries and their respective directors, officers, employees and agents with Anti-Corruption Laws and applicable Sanctions, and the Borrower, its Subsidiaries and their respective officers and employees and, to the knowledge of the Borrower, its directors and agents, are in compliance with Anti-Corruption Laws and applicable Sanctions in all material respects.  None of (a) the Borrower, any Subsidiary or any of their respective officers or employees, or (b) to the knowledge of the Borrower, any director or agent of the Borrower or any Subsidiary that will act in any capacity in connection with or benefit from the credit facility established hereby, is a Sanctioned Person.  No Borrowing, Letter of Credit, or 

 

69

 

use of proceeds thereof or other transaction contemplated by this Agreement will violate Anti-Corruption Laws or applicable Sanctions.

 

SECTION 6.

 

AFFIRMATIVE COVENANTS

 

The Borrower hereby covenants and agrees that so long as any Lender shall have any Commitment hereunder, any Loan or Borrower Obligation hereunder shall remain unpaid or unsatisfied, or any Letter of Credit shall remain outstanding:

 

6.1                               Information Covenants.

 

The Borrower will furnish, or cause to be furnished, to the Administrative Agent:

 

(a)                                 Annual Financial Statements.  As soon as available, and in any event within 120 days after the close of each fiscal year of the Borrower, a consolidated balance sheet and income statement of the Borrower and its Subsidiaries, as of the end of such fiscal year, together with consolidated statements of retained earnings and cash flows for such fiscal year and a statement of the combined amount of patronage capital and membership fees, setting forth in comparative form figures for the preceding fiscal year, all such financial information described above to be in reasonable form and detail and audited by independent certified public accountants of recognized national standing reasonably acceptable to the Administrative Agent and whose opinion shall be furnished to the Administrative Agent, shall be to the effect that such financial statements have been prepared in accordance with GAAP (except for changes with which such accountants concur) and shall not be limited as to the scope of the audit or qualified in any respect.  The delivery by the Borrower to the Administrative Agent within the time period required above of an annual report for the Borrower on Form 10-K for such fiscal year as filed with the SEC (and including the opinion required above) shall satisfy the requirements of this Section 6.1(a).

 

(b)                                 Quarterly Financial Statements.  As soon as available, and in any event within 60 days after the close of each fiscal quarter of the Borrower (other than the fourth fiscal quarter) a consolidated balance sheet and income statement of the Borrower and its Subsidiaries, as of the end of such fiscal quarter, together with a related consolidated statement of cash flows for such fiscal quarter in each case setting forth in comparative form figures for the corresponding period of the preceding fiscal year, all such financial information described above to be in reasonable form and detail and reasonably acceptable to the Administrative Agent, and accompanied by a certificate of a Financial Officer of the Borrower to the effect that such quarterly financial statements fairly present in all material respects the financial condition of the Borrower and have been prepared in accordance with GAAP, subject to changes resulting from audit and normal year-end audit adjustments.  The delivery by the Borrower to the Administrative Agent within the time period required above of a quarterly report for the Borrower on Form 10-Q for such fiscal quarter as filed with the SEC (and including the certification required above) shall satisfy the requirements of this Section 6.1(b).

 

70

 

(c)                                  Officer’s Certificate.  (i) At the time of delivery of the financial statements provided for in Sections 6.1(a) and 6.1(b) above, a certificate of a Financial Officer of the Borrower, substantially in the form of Exhibit 6.1(c), (A) certifying compliance with Section 6.2 as of the end of such fiscal period and (B) stating that no Default or Event of Default exists, or if any Default or Event of Default does exist, specifying the nature and extent thereof and what action the Borrower proposes to take with respect thereto and (ii) at the time of delivery of the financial statements provided for in Section 6.1(a) above, an updated Schedule 5.20 as of the last day of the previous fiscal year.

 

(d)                                 Reports.  Upon the Administrative Agent’s request, copies of any filings and registrations with, and reports to or from, any Governmental Authority, including, without limitation, the Securities and Exchange Commission or any successor agency and any utility regulatory body.

 

(e)                                  Notices.  Upon the Borrower obtaining knowledge thereof, the Borrower will give written notice to the Administrative Agent immediately (and in no event more than ten Business Days after obtaining such knowledge) of (i) the occurrence of a Default or Event of Default, specifying the nature and existence thereof and what action the Borrower proposes to take with respect thereto, and (ii) the occurrence of any of the following with respect to the Borrower: (A) the pendency or commencement of any litigation, arbitration or governmental proceeding against the Borrower, or (B) the institution of any proceedings against the Borrower with respect to, or the receipt of notice by the Borrower of potential liability or responsibility for, violation or alleged violation of any federal, state or local law, rule or regulation (including, without limitation, any Environmental Law), in each case under this clause (ii) that would have or would be reasonably expected to have a Material Adverse Effect.

 

(f)                                   ERISA.  Upon the Borrower or any ERISA Affiliate obtaining knowledge thereof, the Borrower will give written notice to the Administrative Agent and each of the Lenders promptly (and in any event within five Business Days) of: (i) any event or condition, including, but not limited to, any Reportable Event, that constitutes, or would be reasonably expected to lead to, a Termination Event; (ii) any communication from the PBGC stating its intention to terminate any Pension Plan or to have a trustee appointed to administer any Pension Plan together with a statement of the amount of liability, if any, incurred or expected to be incurred by the Borrower or any Subsidiary in connection therewith; (iii) with respect to any Multiemployer Plan, the receipt of notice as prescribed in ERISA or otherwise of any withdrawal liability assessed against the Borrower or any ERISA Affiliate, or of a determination that any Multiemployer Plan is in reorganization or insolvent (both within the meaning of Title IV of ERISA) or is in endangered or critical status under Section 305 of ERISA; (iv) the failure to make full payment on or before the due date (including extensions) thereof of all amounts which the Borrower or any of its Subsidiaries or ERISA Affiliates is required to contribute to each Pension Plan and each Plan that is subject to Section 412 of the Code pursuant to its terms and as required to meet the minimum funding standard set forth in ERISA and the Code with respect thereto; or (v) any change in the funding status of any Plan that would have or would be reasonably expected to have a Material Adverse Effect; together, with a description of any such event or condition or a copy of any such notice and a statement 

 

71

 

by an officer of the Borrower briefly setting forth the details regarding such event, condition, or notice, and the action, if any, which has been or is being taken or is proposed to be taken with respect thereto.  Promptly upon request, the Borrower shall furnish the Administrative Agent and each of the Lenders with such additional information concerning any Plan as may be reasonably requested, including, but not limited to, copies of each annual report/return (Form 5500 series), as well as all schedules and attachments thereto required to be filed with the Department of Labor and/or the Internal Revenue Service pursuant to ERISA and the Code, respectively, for each “plan year” (within the meaning of Section 3(39) of ERISA).

 

(g)                                  Members.  With reasonable promptness upon any request of the Administrative Agent, information, including annual financial information, with respect to any Member; provided that the Administrative Agent shall, upon request, always have access to information made available to the Borrower regarding a Member that such Member is required to provide under the terms of its Wholesale Power Contract with respect to financing of the Borrower; provided, further, that information shall only be furnished by the Borrower pursuant to this subsection (g) to the extent such information is made available by such Member to the Borrower and permitted by such Member to be shared with Persons other than the Borrower.

 

(h)                                 Ratings Changes.  The Borrower shall promptly deliver to the Administrative Agent information regarding any change in the Borrower’s Credit Ratings.

 

(i)                                     Other Information.  With reasonable promptness upon any such request, such other information regarding the business, properties or financial condition of the Borrower as the Administrative Agent or any Lender may reasonably request.

 

The Borrower hereby acknowledges that (a) the Administrative Agent and/or the Joint Arrangers will make available to the Lenders materials and/or information provided by or on behalf of the Borrower hereunder (collectively, “Borrower Materials”) by posting the Borrower Materials on the Platform and (b) certain of the Lenders (each, a “Public Lender”) may have personnel who do not wish to receive material non-public information with respect to the Borrower or its Affiliates, or the respective securities of any of the foregoing, and who may be engaged in investment and other market-related activities with respect to such Persons’ securities. The Borrower hereby agrees that (w) all Borrower Materials that are to be made available to Public Lenders shall be clearly and conspicuously marked “PUBLIC” which, at a minimum, shall mean that the word “PUBLIC” shall appear prominently on the first page thereof; (x) by marking Borrower Materials “PUBLIC,” the Borrower shall be deemed to have authorized the Administrative Agent, the Joint Arrangers and the Lenders to treat such Borrower Materials as either publicly available information or not material information (although it may be sensitive and proprietary) with respect to the Borrower or its securities for purposes of United States Federal and state securities laws; (y) all Borrower Materials marked “PUBLIC” are permitted to be made available through a portion of the Platform designated “Public Investor;” and (z) the Administrative Agent and the Joint Arrangers shall be entitled to treat any Borrower Materials that are not marked “PUBLIC” as being suitable only for posting on a portion of the Platform not designated “Public Investor.”

 

72

 

6.2                               Patronage Capital and Membership Fees.

 

The Borrower shall, as of the end of any fiscal quarter of the Borrower, maintain Patronage Capital of at least $675,000,000.

 

6.3                               Notices with Respect to Wholesale Power Contracts.

 

The Borrower shall promptly notify the Administrative Agent, after becoming aware thereof, of (a) any material modification to any of the Wholesale Power Contracts, (b) any default in the performance of any Member’s payment obligations under any Wholesale Power Contact that has continued unremedied for five or more Business Days, (c) its receipt of a “Notice of Intent to Withdraw” by any Member pursuant to Section 17 of such Member’s Wholesale Power Contract, (d) its receipt of any written notice from a Member of such Member’s intent to assign any of its rights and obligations under its Wholesale Power Contract, (e) the filing by a Member of any official judicial or regulatory filing seeking as a remedy the declaration of the unenforceability of any material provision of or the material modification of its Wholesale Power Contract, (f) any release or termination of a Member’s payment obligations under a Wholesale Power Contract, or (g) the filing by a Member of any official judicial or regulatory filing claiming the bankruptcy or insolvency of such Member.

 

6.4                               Preservation of Existence, Franchises and Assets.

 

The Borrower will do all things necessary to preserve and keep in full force and effect its existence, material franchises and authority.  The Borrower shall generally maintain its properties, real and personal, in good condition, and the Borrower shall not waste or otherwise permit such properties to deteriorate, reasonable wear and tear excepted.

 

6.5                               Books and Records.

 

Subject to Section 1.3, the Borrower will keep complete and accurate books and records of its transactions in accordance with good accounting practices on the basis of GAAP (including the establishment and maintenance of appropriate reserves).

 

6.6                               Compliance with Law.

 

The Borrower will comply with, and obtain all permits and licenses required by, all laws (including, without limitation, all Environmental Laws and ERISA laws), rules, regulations and orders, and all applicable restrictions imposed by all Governmental Authorities, applicable to it and its property, if the failure to comply would have or would be reasonably expected to have a Material Adverse Effect.

 

6.7                               Payment of Taxes.

 

The Borrower will pay, settle or discharge all taxes, assessments and governmental charges or levies imposed upon it, or upon its income or profits, or upon any of its properties, before they shall become delinquent; provided, however, that the Borrower shall not be required to pay any such tax, assessment, charge, levy or claim (i) which is being contested in good faith by appropriate proceedings and as to which adequate reserves therefor have been established in 

 

73

 

accordance with GAAP, unless the failure to make any such payment would give rise to an immediate right to foreclose or collect on a Lien securing such amounts or (ii) to the extent the failure to make any such payment, either singly or in the aggregate, would not have or would not reasonably be expected to have a Material Adverse Effect.

 

6.8                               Insurance.

 

The Borrower will at all times maintain in full force and effect insurance (including worker’s compensation insurance, liability insurance, casualty insurance and business interruption insurance) with responsible and reputable insurance companies in such amounts, covering such risks and liabilities and with such deductibles or self-insurance retentions as is usually carried by companies engaged in similar businesses and owning similar properties in the same general areas in which the Borrower operates.

 

6.9                               Use of Proceeds.

 

The proceeds of the Loans shall be used for general corporate purposes, including, without limitation, (i) to refinance the indebtedness under the Existing Credit Agreement, (ii) to refinance the indebtedness under certain of the Borrower’s other existing credit agreements, (iii) to pay, at maturity, commercial paper issued by the Borrower, provided that the unpaid Borrowings incurred for such purpose shall at no one time exceed $1,000,000,000, (iv) to issue Letters of Credit, including Letters of Credit to support liquidity or credit requirements under tax-exempt variable rate demand bond financings or in connection with posting collateral to third parties under construction, equipment procurement, hedging and other arrangements, and (v) working capital purposes.  In the case of any Bond Letters of Credit, the Borrower’s reimbursement obligations in respect thereof shall remain unsecured, without the use of purchased bonds, pledged bonds, bank bonds or similar structures (and the Administrative Agent, Lenders and L/C Issuers, at the request of the Borrower, will expressly waive any right to pledged bonds, bank bonds or similar structures), and the Lenders and the L/C Issuers shall not have any rights or remedies under the related Bond Documents for Events of Default hereunder or thereunder (and the Lenders agree not to deliver any notice of any such Events of Default, other than a failure of the Borrower to reimburse an L/C Issuer for any drawing under the related Bond Letter of Credit).

 

6.10                        Audits/Inspections.

 

To the extent permitted by Law and, with respect to the Borrower’s co-owned facilities, subject to any applicable limitations in the Borrower’s corresponding co-ownership arrangements, upon reasonable prior notice and during normal business hours and, unless a Default under this Agreement has occurred and is continuing, at the expense of the Administrative Agent, the Borrower will permit representatives appointed by the Administrative Agent, including, without limitation, independent accountants, agents, attorneys, and appraisers to visit and inspect the Borrower’s property, including its books and records, its accounts receivable and inventory, the Borrower’s facilities and its other business assets, and to make photocopies or photographs thereof and to write down and record any information such representative obtains and shall permit the Administrative Agent or its representatives to 

 

74

 

investigate and verify the accuracy of information provided to the Lenders and to discuss all such matters with the officers, employees and representatives of the Borrower.

 

6.11                        CoBank Equity and Security.

 

(a)                                 So long as CoBank is a Lender hereunder, the Borrower will acquire equity in CoBank in such amounts and at such times as CoBank may require in accordance with CoBank’s Bylaws and Capital Plan (as each may be amended from time to time), except that the maximum amount of equity that the Borrower may be required to purchase in CoBank in connection with the Loans made by CoBank may not exceed the maximum amount permitted by the Bylaws and the Capital Plan at the time this Agreement is entered into.  The Borrower acknowledges receipt of a copy of (i) CoBank’s most recent annual report, and if more recent, CoBank’s latest quarterly report, (ii) CoBank’s Notice to Prospective Stockholders and (iii) CoBank’s Bylaws and Capital Plan, which describe the nature of all of the Borrower’s stock and other equities in CoBank acquired in connection with its patronage loan from CoBank (the “CoBank Equities”) as well as capitalization requirements, and agrees to be bound by the terms thereof.

 

(b)                                 Each party hereto acknowledges that CoBank’s Bylaws and Capital Plan (as each may be amended from time to time) shall govern (x) the rights and obligations of the parties with respect to the CoBank Equities and any patronage refunds or other distributions made on account thereof or on account of Borrower’s patronage with CoBank, (y) the Borrower’s eligibility for patronage distributions from CoBank (in the form of CoBank Equities and cash) and (z) patronage distributions, if any, in the event of a sale of a participation interest. CoBank reserves the right to assign or sell participations in all or any part of its Commitments or outstanding Loans hereunder on a non-patronage basis.

 

(c)                                  Each party hereto acknowledges that CoBank has a statutory first lien pursuant to the Farm Credit Act of 1971 (as amended from time to time) on all CoBank Equities that the Borrower may now own or hereafter acquire, which statutory lien shall be for CoBank’s sole and exclusive benefit. The CoBank Equities shall not constitute security for the Obligations due to any other Lender. To the extent that any of the Loan Documents create a Lien on the CoBank Equities or on patronage accrued by CoBank for the account of the Borrower (including, in each case, proceeds thereof), such Lien shall be for CoBank’s sole and exclusive benefit and shall not be subject to pro rata sharing hereunder. Neither the CoBank Equities nor any accrued patronage shall be offset against the Obligations except that, in the event of an Event of Default, CoBank may elect, solely at its discretion, to apply the cash portion of any patronage distribution or retirement of equity to amounts due under this Agreement. The Borrower acknowledges that any corresponding tax liability associated with such application is the sole responsibility of the Borrower. CoBank shall have no obligation to retire the CoBank Equities upon any Event of Default, Default or any other default by the Borrower, or at any other time, either for application to the Obligations or otherwise.

 

75

 

6.12                        Compliance with Anti-Corruption Laws and Sanctions.

 

The Borrower will maintain in effect and enforce policies and procedures designed to ensure compliance by the Borrower, its Subsidiaries and their respective directors, officers, employees and agents with Anti-Corruption Laws and applicable Sanctions in all material respects.

 

6.13                        Rate Covenant.

 

Subject to any necessary regulatory approval or determination of RUS, if required, the Borrower shall establish and collect rates, rents, charges, fees and other compensation (the “Rates”) for the use or the sale of output, capacity or service of the System that, together with other revenues available to the Borrower, are reasonably expected to yield Margins for Interest for each fiscal year of the Borrower equal to at least 1.10 times Interest Charges for such period.  Promptly upon any material change in the circumstances which were contemplated at such time Rates were most recently reviewed, but not less frequently than once every twelve (12) months, the Borrower shall review the Rates so established and shall promptly establish or revise such Rates, as necessary to comply with the foregoing requirements, subject in the case of the foregoing Margins for Interest requirement to any necessary regulatory approval or determination, including that of RUS, if required.  The Borrower will not furnish or supply or cause to be furnished or supplied any use, output, capacity or service of the System with respect to which a charge is regularly or customarily made, free of charge to any Person, and the Borrower will use commercially reasonable efforts to enforce the payment of any and all accounts owing to the Borrower with respect to the use, output, capacity or service of the System.  Capitalized terms used in this Section 6.13 without definition shall have the meanings provided in the First Mortgage Indenture (as in effect as of the date hereof).

 

SECTION 7.

 

NEGATIVE COVENANTS

 

The Borrower hereby covenants and agrees that so long as any Lender has any Commitment hereunder, any Loan or other Borrower Obligation shall remain unpaid or unsatisfied, or any Letter of Credit shall remain outstanding:

 

7.1                               Nature of Business.

 

The Borrower will not engage, to any material extent, in any business other than the business of providing, directly or indirectly, electric power and energy and related services to or on behalf of the Members.

 

7.2                               Consolidation and Merger.

 

The Borrower will not (a) enter into any transaction of merger, or (b) consolidate, liquidate, wind up or dissolve itself (or suffer any liquidation or dissolution); provided that, so long as no Default or Event of Default shall exist or be caused thereby, a Person may be merged or consolidated with or into the Borrower so long as the Borrower shall be the continuing or surviving corporation.

 

76

 

7.3                               Arm’s-Length Transactions.

 

Except in connection with any Special Leases, the Borrower will not enter into any transaction or series of transactions, whether or not in the ordinary course of business, with any officer, director or Affiliate other than on terms and conditions substantially as favorable as would be obtainable in a comparable arm’s-length transaction with a Person other than an officer, director or Affiliate; provided, however, that this Section 7.3 shall not be applicable to transactions with any Affiliate if such transactions are made on a cost basis.

 

7.4                               Fiscal Year; Organizational Documents.

 

The Borrower will not (a) change its fiscal year or (b) change its form of organization from a corporation organized under the Georgia Electric Membership Corporation Act.

 

7.5                               Liens.

 

The Borrower will not, nor will it permit any of its Subsidiaries to, contract, create, incur, assume or permit to exist any Lien with respect to any of its property or assets of any kind (whether real or personal, tangible or intangible, and whether now owned or after acquired) securing Indebtedness, except for the following: (a) Liens securing Borrower Obligations, (b) Liens securing Special Leases, (c) Liens with respect to any interest, debt or equity of the Borrower in CoBank or CFC purchased or otherwise acquired by the Borrower in connection with membership in any such entity or any borrowing from any such entity, (d) Liens on cash, securities or accounts receivable under such obligations or obligations with the same counterparty to the extent provided by the Borrower as collateral for any obligation of the Company under any letter of credit issued on behalf of the Borrower or other similar obligation, commitment or liability of the Borrower arising in connection with the Borrower’s business and properties, (e) Liens securing other Indebtedness (including without limitation the First Mortgage Indenture Debt) in an aggregate amount not to exceed $12,000,000,000 at any time outstanding, and (f) any modification, extension, renewal or replacement (or successive modifications, extensions, renewals or replacements), as a whole or in part, of any Liens referred to in the foregoing clauses (a) through (e), for amounts not exceeding the principal amount of the Indebtedness secured by the Lien so modified, extended, renewed or replaced; provided that such modification, extension, renewal or replacement Lien is limited to all or a part of the same property or assets that were covered by the Lien modified, extended, renewed or replaced (plus improvements on such property or assets).

 

7.6                               Wholesale Power Contracts.

 

The Borrower shall not agree to release or terminate the payment obligations of any Member or Members, the aggregate of which, pursuant to Schedule 5.20 (as updated pursuant to Section 6.1(c)), constitute fifteen percent (15%) or more of the Borrower’s gross member revenues, under its or their Wholesale Power Contracts other than in connection with a simultaneous assumption of such payment obligations by another Member or other assignee; provided that in the case of a non-Member assignee, such assignee must have either (x) a Credit Rating equal to or better than the Credit Rating of the assigning Member as published by S&P, Moody’s or Fitch or (y) if the assigning Member has no such published Credit Rating, a Credit

 

77

 

Rating equal to or better than the Borrower’s Credit Rating as published by S&P, Moody’s or Fitch.

 

7.7                               Indebtedness.

 

The Borrower will not, nor will it permit any of its Subsidiaries to, contract, create, incur, assume or permit to exist any Indebtedness other than (a) Indebtedness consisting of Special Leases, (b) Indebtedness secured by Liens permitted under Section 7.5(e), in an aggregate amount at any time outstanding not to exceed $12,000,000,000, (c) the Loans and the L/C Obligations, (d) unsecured Indebtedness, ranking pari passu with the Loans and the L/C Obligations, in an aggregate amount at any time outstanding not to exceed $4,000,000,000 (it being agreed that Indebtedness secured solely by a Lien permitted under Section 7.5(c) or 7.5(d) shall be deemed unsecured Indebtedness ranking pari passu with the Loans and the L/C Obligations), and (e) unsecured Indebtedness subordinated to the Loans and the L/C Obligations on terms reasonably satisfactory to the Required Lenders and the L/C Issuers.

 

7.8                               No Violation of Anti-Corruption Laws or Sanctions.

 

The Borrower will not request any Borrowing or Letter of Credit, or use or permit any of its Subsidiaries or its or their respective directors, officers, employees and agents to use any Letter of Credit or the proceeds of any Borrowing or Letter of Credit (A) in furtherance of an offer, payment, promise to pay, or authorization of the payment or giving of money, or anything else of value, to any Person in violation of any Anti-Corruption Laws, (B) for the purpose of funding, financing or facilitating any activities, business or transaction of or with any Sanctioned Person, or in any Sanctioned Country, or (C)  in any manner that would result in the violation of any Sanctions applicable to any party hereto.

 

SECTION 8.

 

EVENTS OF DEFAULT

 

8.1                               Events of Default.

 

An Event of Default shall exist upon the occurrence of any of the following specified events (each an “Event of Default”):

 

(a)                                 Payment.  The Borrower (i) shall default in the payment when due of any principal of any of the Loans or any L/C Obligations or (ii) shall default in the payment when due of any interest on the Loans or any L/C Obligations or of any fees or other amounts owing hereunder or under any Fee Letter, under any of the other Loan Documents or in connection herewith or therewith, and such default under this clause (ii) shall continue unremedied for a period of five or more days.

 

(b)                                 Representations.  Any representation, warranty or statement made or deemed to be made by the Borrower herein, in any of the other Loan Documents, or in any statement or certificate delivered or required to be delivered pursuant hereto or thereto shall prove untrue in any material respect on the date as of which it was deemed to have been made.

 

78

 

(c)                                  Covenants.  The Borrower shall:

 

(i)                                     default in the due performance or observance of any term, covenant or agreement contained in Section 6.2, 6.4 or 7.1 through 7.8 inclusive; or

 

(ii)                                  default in the due performance or observance by it of any term, covenant or agreement contained in Section 6.1 or 6.3, and such default shall continue unremedied for a period of five Business Days after the earlier of the Borrower becoming aware of such default or notice thereof given by the Administrative Agent; or

 

(iii)                               default in the due performance or observance by it of any term, covenant or agreement (other than those referred to in subsections (a), (b), (c)(i), or (c)(ii) of this Section 8.1) contained in this Agreement or any other Loan Document and such default shall continue unremedied for a period of more than 30 days after the earlier of the Borrower becoming aware of such default or notice thereof given by the Administrative Agent.

 

(d)                                 Loan Documents.  The Borrower shall default in the due performance or observance of any term, covenant or agreement in any of the other Loan Documents and such default shall continue unremedied for a period of more than 30 days after the earlier of the Borrower becoming aware of such default or notice thereof given by the Administrative Agent or any Loan Document shall fail to be in full force and effect or the Borrower shall so assert or any Loan Document shall fail to give the Administrative Agent and/or the Lenders the rights, powers and privileges purported to be created thereby.

 

(e)                                  Bankruptcy, etc.  The occurrence of any of the following with respect to the Borrower or any of its Subsidiaries (i) a court or governmental agency having jurisdiction in the premises shall enter a decree or order for relief in respect of the Borrower or any of its Subsidiaries in an involuntary case under any applicable bankruptcy, insolvency or other similar law now or hereafter in effect, or appoint a receiver, liquidator, assignee, custodian, trustee, sequestrator or similar official of the Borrower or any of its Subsidiaries or for any substantial part of its property or order the winding up or liquidation of its affairs; or (ii) an involuntary case under any applicable bankruptcy, insolvency or other similar law now or hereafter in effect is commenced against the Borrower or any of its Subsidiaries and such petition remains unstayed and in effect for a period of 60 days; or (iii) the Borrower or any of its Subsidiaries shall commence a voluntary case under any applicable bankruptcy, insolvency or other similar law now or hereafter in effect, or consent to the entry of an order for relief in an involuntary case under any such law, or consent to the appointment or taking possession by a receiver, liquidator, assignee, custodian, trustee, sequestrator or similar official of the Borrower or such Subsidiary or any substantial part of its property or make any general assignment for the benefit of creditors; or (iv) the Borrower or any of its Subsidiaries shall admit in writing its inability to pay its debts generally as they become due or any action shall be taken by any Person in furtherance of any of the aforesaid purposes.

 

79

 

(f)                                   Other Indebtedness.  With respect to any Indebtedness of the Borrower in excess of $25,000,000 (other than Indebtedness outstanding under this Agreement), the Borrower shall (i) default in any payment (beyond the applicable grace period with respect thereto, if any) with respect to such Indebtedness, the effect of which default is to cause, or permit the holder or holders of such Indebtedness (or trustee or agent on behalf of such holders) to cause (determined without regard to whether any notice or lapse of time is required), any such Indebtedness to become due and payable, or required to be prepaid other than by a regularly scheduled required prepayment, prior to the stated maturity thereof or (ii) default in the observance or performance of any covenant or agreement relating to such Indebtedness or contained in any instrument or agreement evidencing, securing or relating thereto, the effect of which default results in any such Indebtedness becoming due and payable, or required to be prepaid other than by a regularly scheduled required prepayment, prior to the stated maturity thereof.

 

(g)                                  Judgments.  One or more judgments, orders, or decrees shall be entered against the Borrower involving a liability of $25,000,000 or more, in the aggregate, (to the extent not paid or covered by insurance provided by a carrier who has acknowledged coverage) and such judgments, orders or decrees shall continue unsatisfied, undischarged and unstayed for a period ending on the first to occur of (i) the last day on which such judgment, order or decree becomes final and unappealable and, where applicable, with the status of a judicial lien or (ii) 60 days; provided that if such judgment, order or decree provides for periodic payments over time then the Borrower shall have a grace period of 30 days with respect to each such periodic payment.

 

(h)                                 ERISA.  The occurrence of any of the following events or conditions if the same, individually or in the aggregate, would be reasonably expected to result in a liability to the Borrower of an amount greater than or equal to $25,000,000: (A) any “unfunded required minimum contribution” or “accumulated funding deficiency” (as defined or otherwise set forth in Section 4971 of the Code or Part 3 of Subtitle B of Title I of ERISA ) whether or not waived, shall exist with respect to any Pension Plan, or any lien shall arise on the assets of the Borrower or any ERISA Affiliate in favor of the PBGC or a Plan; (B) a Termination Event shall occur with respect to a Single Employer Plan, which is, in the reasonable opinion of the Lender, likely to result in the termination of such Plan for purposes of Title IV of ERISA; (C) a Termination Event shall occur with respect to a Multiemployer Plan or Multiple Employer Plan, which is, in the reasonable opinion of the Lender, likely to result in (i) the termination of such Plan for purposes of Title IV of ERISA, or (ii) the Borrower or any ERISA Affiliate incurring any liability in connection with a withdrawal from, reorganization of (within the meaning of Section 4241 of ERISA), or insolvency (within the meaning of Section 4245 of ERISA) of such Plan; or (D) any non-exempt prohibited transaction (within the meaning of Section 406 of ERISA or Section 4975 of the Code) or breach of fiduciary responsibility shall occur which would be reasonably expected to subject the Borrower or any of its Subsidiaries to any liability under Sections 406, 409, 502(i), or 502(1) of ERISA or Section 4975 of the Code, or under any agreement or other instrument pursuant to which the Borrower or any of its Subsidiaries has agreed or is required to indemnify any person against any such liability.

 

80

 

(i)                                     Wholesale Power Contracts.  One or more Members, the aggregate of which, pursuant to Schedule 5.20 (as updated pursuant to Section 6.1(c)), constitute fifteen percent (15%) or more of the Borrower’s gross member revenues, at any time shall (A) be in default in the performance of any payment obligations under its or their Wholesale Power Contracts where the aggregate principal amount of such default or defaults exceeds $25,000,000 and such default or defaults have continued for thirty-five (35) days beyond the due date with respect thereto, (B) have contested the validity or enforceability of its or their Wholesale Power Contracts by filing any official judicial or regulatory filing seeking as a remedy the declaration of the unenforceability or the material modification of its or their Wholesale Power Contracts, and such judicial or regulatory body shall have issued a final and non-appealable order (i) declaring all or a material provision of such Wholesale Power Contract unenforceable, or (ii) modifying such Wholesale Power Contract in any material manner, or (C) have its or their payment obligations under the Wholesale Power Contracts released or terminated (other than in connection with a simultaneous assumption of such obligations by another Member or other assignee; provided that in the case of a non-Member assignee, such assignee must have either (x) a Credit Rating equal to or better than the Credit Rating of the assigning Member as published by S&P, Moody’s or Fitch or (y) if the assigning Member has no such published Credit Rating, a Credit Rating equal to or better than the Borrower’s Credit Rating as published by S&P, Moody’s or Fitch).

 

8.2                               Acceleration; Remedies.

 

Upon the occurrence of an Event of Default, and at any time thereafter unless and until such Event of Default has been waived by the Required Lenders (or the Lenders as may be required hereunder) the Administrative Agent may, with the consent of the Required Lenders, and shall, upon the request and direction of the Required Lenders, by written notice to the Borrower take any of the following actions without prejudice to the rights of the Administrative Agent or any Lender to enforce its claims against the Borrower, except as otherwise specifically provided for herein:

 

(i)                                     Termination of Commitments.  Declare the Commitments and any obligations of the L/C Issuers to make L/C Credit Extensions terminated whereupon the Commitments and obligations shall be immediately terminated.

 

(ii)                                  Acceleration of Loans.  Declare the unpaid amount of all Borrower Obligations to be due whereupon the same shall be immediately due and payable without presentment, demand, protest or other notice of any kind, all of which are hereby waived by the Borrower.

 

(iii)                               Enforcement of Rights.  Enforce any and all rights and interests created and existing under the Loan Documents, including, without limitation, all rights of set-off.

 

(iv)                              Letters of Credit.  Require that the Borrower Cash Collateralize the L/C Obligations (in an amount equal to the then Outstanding Amount thereof).

 

81

 

(v)                                 Mandatory Tender.  In the case of a failure of the Borrower to make timely reimbursement of a drawing under a Bond Letter of Credit to pay principal of or interest on Bonds, give notice to the trustee under the applicable Issuer Documents of such failure and directing such trustee to effect a mandatory tender or the acceleration of such Bonds as may be permitted under such Issuer Documents.

 

Notwithstanding the foregoing, if an Event of Default specified in Section 8.1(e) shall occur, then the Commitments and any obligations of the L/C Issuers to make L/C Credit Extensions shall automatically terminate and all Loans, all accrued interest in respect thereof, all accrued and unpaid fees and other indebtedness or obligations owing to the Lenders and the Administrative Agent hereunder shall immediately become due and payable and the obligations of the Borrower to Cash Collateralize the L/C Obligations as aforesaid shall automatically become effective, in each case without the giving of any notice or other action by the Administrative Agent or the Lenders.

 

Notwithstanding the fact that enforcement powers reside primarily with the Administrative Agent, each Lender has, to the extent permitted by law, a separate right of payment and shall be considered a separate “creditor” holding a separate “claim” within the meaning of Section 101(5) of the Bankruptcy Code or any other insolvency statute.

 

8.3                               Allocation of Payments After Event of Default.

 

Notwithstanding any other provisions of this Agreement, after the exercise of any remedies by the Administrative Agent or the Lenders pursuant to Section 8.2 (or after the Commitments shall automatically terminate and the Loans (with accrued interest thereon) and all other amounts under the Loan Documents shall automatically become due and payable in accordance with the terms of such Section) and the L/C Obligations have automatically been required to be Cash Collateralized, all amounts collected or received by the Administrative Agent or any Lender on account of amounts outstanding under any of the Loan Documents shall be paid over or delivered as follows:

 

FIRST, to the payment of all reasonable out-of-pocket costs and expenses (including without limitation reasonable Attorney Costs) of the Administrative Agent or any of the Lenders, including Lenders when acting in the capacity of L/C Issuer, in connection with enforcing the rights of the Lenders under the Loan Documents, pro rata as set forth below;

 

SECOND, to payment of any fees (other than Letter of Credit Fees) owed to the Administrative Agent, any L/C Issuer, or any Lender, pro rata as set forth below;

 

THIRD, to the payment of all accrued interest and Letter of Credit Fees payable to the Lenders hereunder, pro rata as set forth below;

 

FOURTH, to (a) the payment of the outstanding principal amount of the Loans and L/C Borrowings and (b) Cash Collateralize that portion of L/C Obligations comprised of the aggregate undrawn amount of Letters of Credit, as set forth below;

 

82

 

FIFTH, to all other obligations which shall have become due and payable under the Loan Documents and not repaid pursuant to clauses “FIRST” through “FOURTH” above; and

 

SIXTH, to the payment of the surplus, if any, to whoever may be lawfully entitled to receive such surplus.

 

In carrying out the foregoing, (a) amounts received shall be applied in the numerical order provided until exhausted prior to application to the next succeeding category and (b) each of the Lenders shall receive an amount equal to its pro rata share (based on the proportion that the then outstanding Loans held by such Lender bears to the aggregate then outstanding Loans) of amounts available to be applied.

 

Subject to Section 2.3(c) and Section 2.16, amounts used to Cash Collateralize the aggregate undrawn amount of Letters of Credit pursuant to clause Fourth above shall be applied to satisfy drawings under such Letters of Credit as they occur.  If any amount remains on deposit as Cash Collateral after all Letters of Credit have either been fully drawn or expired, such remaining amount shall be applied to the other Obligations, if any, in the order set forth above.

 

SECTION 9.

 

ADMINISTRATIVE AGENT

 

9.1                               Appointment and Authority.

 

Each of the Lenders and the L/C Issuers hereby irrevocably appoints CFC to act on its behalf as the Administrative Agent hereunder and under the other Loan Documents and authorizes the Administrative Agent to take such actions on its behalf and to exercise such powers as are delegated to the Administrative Agent by the terms hereof or thereof, together with such actions and powers as are reasonably incidental thereto.  The provisions of this Article are solely for the benefit of the Administrative Agent, the Lenders and the L/C Issuers, and the Borrower shall not have rights as a third party beneficiary of any of such provisions.  It is understood and agreed that the use of the term “agent” herein or in any other Loan Documents (or any other similar term) with reference to the Administrative Agent is not intended to connote any fiduciary or other implied (or express) obligations arising under agency doctrine of any applicable law.  Instead such term is used as a matter of market custom, and is intended to create or reflect only an administrative relationship between contracting parties.

 

9.2                               Rights as a Lender.

 

The Person serving as the Administrative Agent hereunder shall have the same rights and powers in its capacity as a Lender as any other Lender and may exercise the same as though it were not the Administrative Agent and the term “Lender” or “Lenders” shall, unless otherwise expressly indicated or unless the context otherwise requires, include the Person serving as the Administrative Agent hereunder in its individual capacity.  Such Person and its Affiliates may accept deposits from, lend money to, own securities of, act as the financial advisor or in any other advisory capacity for and generally engage in any kind of business with the Borrower or 

 

83

 

any Subsidiary or other Affiliate thereof as if such Person were not the Administrative Agent hereunder and without any duty to account therefor to the Lenders.

 

9.3                               Exculpatory Provisions.

 

The Administrative Agent shall not have any duties or obligations except those expressly set forth herein and in the other Loan Documents, and its duties hereunder shall be administrative in nature.  Without limiting the generality of the foregoing, the Administrative Agent:

 

(a)                                 shall not be subject to any fiduciary or other implied duties, regardless of whether a Default has occurred and is continuing;

 

(b)                                 shall not have any duty to take any discretionary action or exercise any discretionary powers, except discretionary rights and powers expressly contemplated hereby or by the other Loan Documents that the Administrative Agent is required to exercise as directed in writing by the Required Lenders (or such other number or percentage of the Lenders as shall be expressly provided for herein or in the other Loan Documents); provided that the Administrative Agent shall not be required to take any action that, in its opinion or the opinion of its counsel, may expose the Administrative Agent to liability or that is contrary to any Loan Document or applicable law, including for the avoidance of doubt any action that may be in violation of the automatic stay under any Debtor Relief Law or that may effect a forfeiture, modification or termination of property of a Defaulting Lender in violation of any Debtor Relief Law; and

 

(c)                                  shall not, except as expressly set forth herein and in the other Loan Documents, have any duty to disclose, and shall not be liable for the failure to disclose, any information relating to the Borrower or any of its Affiliates that is communicated to or obtained by the Person serving as the Administrative Agent or any of its Affiliates in any capacity.

 

The Administrative Agent shall not be liable for any action taken or not taken by it (i) with the consent or at the request of the Required Lenders (or such other number or percentage of the Lenders as shall be necessary, or as the Administrative Agent shall believe in good faith shall be necessary, under the circumstances as provided in Sections 10.6 and 8.2) or (ii) in the absence of its own gross negligence or willful misconduct as determined by a court of competent jurisdiction by final and nonappealable judgment.  The Administrative Agent shall be deemed not to have knowledge of any Default unless and until notice describing such Default is given to the Administrative Agent in writing by the Borrower, a Lender or an L/C Issuer.

 

The Administrative Agent shall not be responsible for or have any duty to ascertain or inquire into (i) any statement, warranty or representation made in or in connection with this Agreement or any other Loan Document, (ii) the contents of any certificate, report or other document delivered hereunder or thereunder or in connection herewith or therewith, (iii) the performance or observance of any of the covenants, agreements or other terms or conditions set forth herein or therein or the occurrence of any Default, (iv) the validity, enforceability, effectiveness or genuineness of this Agreement, any other Loan Document or any other agreement, instrument or document or (v) the satisfaction of any condition set forth in Section 4  

 

84

 

or elsewhere herein, other than to confirm receipt of items expressly required to be delivered to the Administrative Agent.

 

9.4                               Reliance by Administrative Agent.

 

The Administrative Agent shall be entitled to rely upon, and shall not incur any liability for relying upon, any notice, request, certificate, consent, statement, instrument, document or other writing (including any electronic message, Internet or intranet website posting or other distribution) believed by it to be genuine and to have been signed, sent or otherwise authenticated by the proper Person.  The Administrative Agent also may rely upon any statement made to it orally or by telephone and believed by it to have been made by the proper Person, and shall not incur any liability for relying thereon.  In determining compliance with any condition hereunder to the making of a Loan, or the issuance, extension, renewal or increase of a Letter of Credit, that by its terms must be fulfilled to the satisfaction of a Lender or an L/C Issuer, the Administrative Agent may presume that such condition is satisfactory to such Lender or such L/C Issuer unless the Administrative Agent shall have received notice to the contrary from such Lender or such L/C Issuer prior to the making of such Loan or the issuance, extension, renewal or increase of such Letter of Credit.  The Administrative Agent may consult with legal counsel (who may be counsel for the Borrower), independent accountants and other experts selected by it, and shall not be liable for any action taken or not taken by it in accordance with the advice of any such counsel, accountants or experts.

 

9.5                               Delegation of Duties.

 

The Administrative Agent may perform any and all of its duties and exercise its rights and powers hereunder or under any other Loan Document by or through any one or more sub-agents appointed by the Administrative Agent.  The Administrative Agent and any such sub-agent may perform any and all of its duties and exercise its rights and powers by or through their respective Related Parties.  The exculpatory provisions of this Article shall apply to any such sub-agent and to the Related Parties of the Administrative Agent and any such sub-agent, and shall apply to their respective activities in connection with the syndication of the credit facilities provided for herein as well as activities as Administrative Agent.  The Administrative Agent shall not be responsible for the negligence or misconduct of any sub-agents except to the extent that a court of competent jurisdiction determines in a final and nonappealable judgment that the Administrative Agent acted with gross negligence or willful misconduct in the selection of such sub-agents.

 

9.6                               Resignation of Administrative Agent.

 

(a)                                 The Administrative Agent may at any time give notice of its resignation to the Lenders, the L/C Issuers and the Borrower.  Upon receipt of any such notice of resignation, the Required Lenders shall have the right, in consultation with the Borrower, to appoint a successor.  If no such successor shall have been so appointed by the Required Lenders and shall have accepted such appointment within 30 days after the retiring Administrative Agent gives notice of its resignation (or such earlier day as shall be agreed by the Required Lenders) (the “Resignation Effective Date”), then the retiring Administrative Agent may (but shall not be obligated to), on behalf of the Lenders and

 

85

 

the L/C Issuers, appoint a successor Administrative Agent meeting the qualifications set forth above.  Whether or not a successor has been appointed, such resignation shall become effective in accordance with such notice on the Resignation Effective Date.

 

(b)                                 If the Person serving as Administrative Agent is a Defaulting Lender pursuant to clause (d) of the definition thereof, the Required Lenders may, to the extent permitted by applicable law, by notice in writing to the Borrower and such Person remove such Person as Administrative Agent and, in consultation with the Borrower, appoint a successor.  If no such successor shall have been so appointed by the Required Lenders and shall have accepted such appointment within 30 days (or such earlier day as shall be agreed by the Required Lenders) (the “Removal Effective Date”), then such removal shall nonetheless become effective in accordance with such notice on the Removal Effective Date.

 

(c)                                  With effect from the Resignation Effective Date or the Removal Effective Date (as applicable) (1) the retiring or removed Administrative Agent shall be discharged from its duties and obligations hereunder and under the other Loan Documents (except that in the case of any collateral security held by the Administrative Agent on behalf of the Lenders or the L/C Issuers under any of the Loan Documents, the retiring Administrative Agent shall continue to hold such collateral security until such time as a successor Administrative Agent is appointed) and (2) except for any indemnity payments owed to the retiring or removed Administrative Agent, all payments, communications and determinations provided to be made by, to or through the Administrative Agent shall instead be made by or to each Lender and the L/C Issuers directly, until such time, if any, as the Required Lenders appoint a successor Administrative Agent as provided for above.  Upon the acceptance of a successor’s appointment as Administrative Agent hereunder, such successor shall succeed to and become vested with all of the rights, powers, privileges and duties of the retiring or removed Administrative Agent (other than any rights to indemnity payments owed to the retiring or removed Administrative Agent), and the retiring or removed Administrative Agent shall be discharged from all of its duties and obligations hereunder or under the other Loan Documents.  The fees payable by the Borrower to a successor Administrative Agent shall be the same as those payable to its predecessor unless otherwise agreed between the Borrower and such successor.  After the retiring or removed Administrative Agent’s resignation or removal hereunder and under the other Loan Documents, the provisions of this Article and Section 10.5 shall continue in effect for the benefit of such retiring or removed Administrative Agent, its sub-agents and their respective Related Parties in respect of any actions taken or omitted to be taken by any of them while the retiring or removed Administrative Agent was acting as Administrative Agent.

 

(d)                                 Any resignation by or removal of CFC as Administrative Agent pursuant to this Section shall also constitute its resignation as L/C Issuer and Swing Line Lender.  Upon the acceptance of a successor’s appointment as Administrative Agent hereunder, (a) such successor shall succeed to and become vested with all of the rights, powers, privileges and duties of such retiring L/C Issuer and Swing Line Lender, (b) such retiring L/C Issuer and Swing Line Lender shall be discharged from all of their respective duties and obligations hereunder or under the other Loan Documents, and (c) the successor L/C 

 

86

 

Issuer shall issue letters of credit in substitution for the Letters of Credit, if any, outstanding at the time of such succession or make other arrangements satisfactory to such retiring L/C Issuer to effectively assume the obligations of the retiring L/C Issuer with respect to such Letters of Credit.

 

9.7                               Non-Reliance on Administrative Agent and Other Lenders.

 

Each Lender and each L/C Issuer acknowledges that it has, independently and without reliance upon the Administrative Agent or any other Lender or any of their Related Parties and based on such documents and information as it has deemed appropriate, made its own credit analysis and decision to enter into this Agreement.  Each Lender and each L/C Issuer also acknowledges that it will, independently and without reliance upon the Administrative Agent or any other Lender or any of their Related Parties and based on such documents and information as it shall from time to time deem appropriate, continue to make its own decisions in taking or not taking action under or based upon this Agreement, any other Loan Document or any related agreement or any document furnished hereunder or thereunder.

 

9.8                               No Other Duties, Etc.

 

Anything herein to the contrary notwithstanding, none of the Lead Arranger, the Syndication Agent or the Documentation Agent listed on the cover page hereof shall have any powers, duties or responsibilities under this Agreement or any of the other Loan Documents, except in its capacity, as applicable, as the Administrative Agent, a Lender or an L/C Issuer hereunder.

 

9.9                               Administrative Agent May File Proofs of Claim.

 

In case of the pendency of any proceeding under any Debtor Relief Law or any other judicial proceeding relative to the Borrower, the Administrative Agent (irrespective of whether the principal of any Loan or L/C Obligation shall then be due and payable as herein expressed or by declaration or otherwise and irrespective of whether the Administrative Agent shall have made any demand on the Borrower) shall be entitled and empowered (but not obligated), by intervention in such proceeding or otherwise:

 

(a)                                 to file and prove a claim for the whole amount of the principal and interest owing and unpaid in respect of the Loans, L/C Obligations and all other obligations that are owing and unpaid and to file such other documents as may be necessary or advisable in order to have the claims of the Lenders, the L/C Issuers and the Administrative Agent (including any claim for the reasonable compensation, expenses, disbursements and advances of the Lenders, the L/C Issuers and the Administrative Agent and their respective agents and counsel and all other amounts due the Lenders, the L/C Issuers and the Administrative Agent under Sections 2.3(h) and (i), 2.9 and 10.5) allowed in such judicial proceeding; and

 

(b)                                 to collect and receive any monies or other property payable or deliverable on any such claims and to distribute the same;

 

87

 

and any custodian, receiver, assignee, trustee, liquidator, sequestrator or other similar official in any such judicial proceeding is hereby authorized by each Lender and each L/C Issuer to make such payments to the Administrative Agent and, in the event that the Administrative Agent shall consent to the making of such payments directly to the Lenders and the L/C Issuers, to pay to the Administrative Agent any amount due for the reasonable compensation, expenses, disbursements and advances of the Administrative Agent and its agents and counsel, and any other amounts due the Administrative Agent under Sections 2.9 and 10.5.

 

Nothing contained herein shall be deemed to authorize the Administrative Agent to authorize or consent to or accept or adopt on behalf of any Lender or any L/C Issuer any plan of reorganization, arrangement, adjustment or composition affecting the Obligations or the rights of any Lender or any L/C Issuer to authorize the Administrative Agent to vote in respect of the claim of any Lender or any L/C Issuer in any such proceeding.

 

SECTION 10.

 

MISCELLANEOUS

 

10.1                        Notices and Other Communications; Facsimile Copies.

 

(a)                                 Notices Generally. Except in the case of notices and other communications expressly permitted to be given by telephone (and except as provided in subsection (b) below), all notices and other communications provided for herein shall be in writing and shall be delivered by hand or overnight courier service, mailed by certified or registered mail or sent by facsimile as follows, and all notices and other communications expressly permitted hereunder to be given by telephone shall be made to the applicable telephone number, as follows:

 

(i)                                     if to the Borrower, the Administrative Agent, CFC as an L/C Issuer or the Swing Line Lender, to the address, facsimile number, electronic mail address or telephone number specified for such Person on Schedule 10.1; and

 

(ii)                                  if to any other Lender or L/C Issuer, to the address, facsimile number, electronic mail address or telephone number specified in its Administrative Questionnaire.

 

Notices sent by hand or overnight courier service, or mailed by certified or registered mail, shall be deemed to have been given when received; notices sent by facsimile shall be deemed to have been given when sent (except that, if not given during normal business hours for the recipient, shall be deemed to have been given at the opening of business on the next business day for the recipient). Notices delivered through electronic communications to the extent provided in subsection (b) below, shall be effective as provided in such subsection (b).

 

(b)                                 Electronic Communications. Notices and other communications to the Lenders and the L/C Issuers hereunder may be delivered or furnished by electronic communication (including e-mail and Internet or intranet websites) pursuant to procedures approved by the Administrative Agent, provided that the foregoing shall not

 

88

 

apply to notices to any Lender or L/C Issuer pursuant to Section 2 if such Lender or L/C Issuer, as applicable, has notified the Administrative Agent that it is incapable of receiving notices under such Section by electronic communication. The Administrative Agent or the Borrower may, in its discretion, agree to accept notices and other communications to it hereunder by electronic communications pursuant to procedures approved by it, provided that approval of such procedures may be limited to particular notices or communications.

 

Unless the Administrative Agent otherwise prescribes, (i) notices and other communications sent to an e-mail address shall be deemed received upon the sender’s receipt of an acknowledgement from the intended recipient (such as by the “return receipt requested” function, as available, return e-mail or other written acknowledgement), and (ii) notices or communications posted to an Internet or intranet website shall be deemed received upon the deemed receipt by the intended recipient at its e-mail address as described in the foregoing clause (i) of notification that such notice or communication is available and identifying the website address therefor; provided that, for both clauses (i) and (ii) above, if such notice or other communication is not sent during the normal business hours of the recipient, such notice or communication shall be deemed to have been sent at the opening of business on the next business day for the recipient.

 

(c)                                  The Platform. THE PLATFORM IS PROVIDED “AS IS” AND “AS AVAILABLE.” THE AGENT PARTIES (AS DEFINED BELOW) DO NOT WARRANT THE ACCURACY OR COMPLETENESS OF THE BORROWER MATERIALS OR THE ADEQUACY OF THE PLATFORM, AND EXPRESSLY DISCLAIM LIABILITY FOR ERRORS IN OR OMISSIONS FROM THE BORROWER MATERIALS. NO WARRANTY OF ANY KIND, EXPRESS, IMPLIED OR STATUTORY, INCLUDING ANY WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT OF THIRD PARTY RIGHTS OR FREEDOM FROM VIRUSES OR OTHER CODE DEFECTS, IS MADE BY ANY AGENT PARTY IN CONNECTION WITH THE BORROWER MATERIALS OR THE PLATFORM. In no event shall the Administrative Agent or any of its Related Parties (collectively, the “Agent Parties”) have any liability to the Borrower, any Lender, any L/C Issuer or any other Person for losses, claims, damages, liabilities or expenses of any kind (whether in tort, contract or otherwise) arising out of the Borrower’s or the Administrative Agent’s transmission of Borrower Materials through the Internet, except to the extent that such losses, claims, damages, liabilities or expenses are determined by a court of competent jurisdiction by a final and nonappealable judgment to have resulted from the gross negligence or willful misconduct of such Agent Party; provided, however, that in no event shall any Agent Party have any liability to the Borrower, any Lender, any L/C Issuer or any other Person for indirect, special, incidental, consequential or punitive damages (as opposed to direct or actual damages).

 

(d)                                 Change of Address, Etc. Each of the Borrower and the Administrative Agent may change its address, facsimile or telephone number for notices and other communications hereunder by notice to the other parties hereto.  Each Lender and each L/C Issuer may change its address, facsimile or telephone number for notices and other communications hereunder by notice to the Borrower, the Administrative Agent and the

 

89

 

L/C Issuers.  In addition, each Lender and each L/C Issuer agree to notify the Administrative Agent from time to time to ensure that the Administrative Agent has on record (i) an effective address, contact name, telephone number, facsimile number and electronic mail address to which notices and other communications may be sent and (ii) accurate wire instructions for such Lender or such L/C Issuer, as applicable.  Furthermore, each Public Lender agrees to cause at least one individual at or on behalf of such Public Lender to at all times have selected the “Private Side Information” or similar designation on the content declaration screen of the Platform in order to enable such Public Lender or its delegate, in accordance with such Public Lender’s compliance procedures and applicable Law, including United States Federal and state securities Laws, to make reference to Borrower Materials that are not made available through the “Public Side Information” portion of the Platform and that may contain material non-public information with respect to the Borrower or its securities for purposes of United States Federal or state securities laws.

 

(e)                                  Reliance by Administrative Agent, the L/C Issuers and Lenders. The Administrative Agent and the Lenders shall be entitled to rely and act upon any notices (including telephonic Committed Loan Notices, Interest Election Notices and Swing Line Loan Notices purportedly given by or on behalf of the Borrower even if (i) such notices were not made in a manner specified herein, were incomplete or were not preceded or followed by any other form of notice specified herein, or (ii) the terms thereof, as understood by the recipient, varied from any confirmation thereof. The Borrower shall indemnify the Administrative Agent, each Lender, each L/C Issuer and the Related Parties of each of them from all losses, costs, expenses and liabilities resulting from the reliance by such Person on each notice purportedly given by or on behalf of the Borrower. All telephonic notices to and other telephonic communications with the Administrative Agent may be recorded by the Administrative Agent, and each of the parties hereto hereby consents to such recording.

 

10.2                        Right of Set-Off; Payments Set Aside.

 

(a)                                 Right of Set-Off.  In addition to any rights now or hereafter granted under applicable law or otherwise, and not by way of limitation of any such rights, upon the occurrence of an Event of Default and the commencement of remedies described in Section 8.2, the Administrative Agent, each Lender and each L/C Issuer is authorized at any time and from time to time, without presentment, demand, protest or other notice of any kind (all of which rights being hereby expressly waived), to set-off and to appropriate and apply any and all deposits (general or special) and any other indebtedness at any time held or owing by the Administrative Agent, such Lender (including, without limitation branches, agencies or Affiliates of such Lender wherever located) or such L/C Issuer to or for the credit or the account of the Borrower against the Borrower Obligations irrespective of whether the Administrative Agent, the L/C Issuers or the Lenders shall have made any demand hereunder and although such Borrower Obligations, or any of them, may be contingent or unmatured, and any such set-off shall be deemed to have been made immediately upon the occurrence of an Event of Default even though such charge is made or entered on the books of such Lender subsequent thereto.  The Borrower hereby agrees that any Person purchasing a participation in the Loans and Commitments

 

90

 

hereunder pursuant to Section 10.3(d) may exercise all rights of set-off with respect to its participation interest as fully as if such Person were a Lender hereunder.

 

(b)                                 Payments Set Aside.  To the extent that any payment by or on behalf of the Borrower is made to the Administrative Agent, any L/C Issuer or any Lender, or the Administrative Agent, any L/C Issuer or any Lender exercises its right of setoff, and such payment or the proceeds of such setoff or any part thereof is subsequently invalidated, declared to be fraudulent or preferential, set aside or required (including pursuant to any settlement entered into by the Administrative Agent, such L/C Issuer or such Lender in its discretion) to be repaid to a trustee, receiver or any other party, in connection with any proceeding under any Debtor Relief Law or otherwise, then (a) to the extent of such recovery, the obligation or part thereof originally intended to be satisfied shall be revived and continued in full force and effect as if such payment had not been made or such setoff had not occurred, and (b) each Lender and each L/C Issuer severally agrees to pay to the Administrative Agent upon demand its applicable share (without duplication) of any amount so recovered from or repaid by the Administrative Agent, plus interest thereon from the date of such demand to the date such payment is made at a rate per annum equal to the Prime Rate from time to time in effect.  The obligations of the Lenders and the L/C Issuers under clause (b) of the preceding sentence shall survive the payment in full of the Obligations and the termination of this Agreement.

 

10.3                        Successors and Assigns.

 

(a)                                 Generally. The provisions of this Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors and assigns permitted hereby, except that the Borrower may not assign or otherwise transfer any of its rights or obligations hereunder without the prior written consent of the Administrative Agent and each Lender, and no Lender may assign or otherwise transfer any of its rights or obligations hereunder except (i) to an assignee in accordance with the provisions of subsection (b) of this Section, (ii) by way of participation in accordance with the provisions of subsection (d) of this Section, or (iii) by way of pledge or assignment of a security interest subject to the restrictions of subsection (e) or (f) of this Section (and any other attempted assignment or transfer by any party hereto shall be null and void). Nothing in this Agreement, expressed or implied, shall be construed to confer upon any Person (other than the parties hereto, their respective successors and assigns permitted hereby, Participants to the extent provided in subsection (d) of this Section and, to the extent expressly contemplated hereby, the Indemnitees) any legal or equitable right, remedy or claim under or by reason of this Agreement.

 

(b)                                 Assignments by Lenders. Any Lender may at any time assign to one or more assignees all or a portion of its rights and obligations under this Agreement (including all or a portion of its Commitment and the Loans (including for purposes of this subsection (b), participations in L/C Obligations and Swing Line Loans) at the time owing to it); provided that any such assignment shall be subject to the following conditions:

 

91

 

(i)                                     Minimum Amounts.

 

(A)                               in the case of an assignment of the entire remaining amount of the assigning Lender’s Commitment and/or the Loans at the time owing to it or contemporaneous assignments to related Approved Funds (determined after giving effect to such assignments) that equal at least the amount specified in paragraph (b)(i)(B) of this Section in the aggregate or in the case of an assignment to a Lender, an Affiliate of a Lender or an Approved Fund, no minimum amount need be assigned; and

 

(B)                               in any case not described in subsection (b)(i)(A) of this Section, the aggregate amount of the Commitment (which for this purpose includes Loans outstanding thereunder) or, if the applicable Commitment is not then in effect, the principal outstanding balance of the Loans of the assigning Lender subject to each such assignment (determined as of the date the Assignment and Assumption with respect to such assignment is delivered to the Administrative Agent or, if “Trade Date” is specified in the Assignment and Assumption, as of the Trade Date) shall not be less than $5,000,000 and an integral multiple of $1,000,000 in excess thereof unless each of the Administrative Agent and, so long as no Event of Default has occurred and is continuing, the Borrower otherwise consents (each such consent not to be unreasonably withheld or delayed); provided, however, that concurrent assignments to members of an Assignee Group and concurrent assignments from members of an Assignee Group to a single assignee (or to an assignee and members of its Assignee Group) will be treated as a single assignment for purposes of determining whether such minimum amount has been met.

 

(ii)                                  Proportionate Amounts.  Each partial assignment shall be made as an assignment of a proportionate part of all the assigning Lender’s Loans and Commitments, and rights and obligations with respect thereto, assigned, except that this clause (ii) shall not prohibit any Lender from assigning all or a portion of its rights and obligations in respect of its Commitment (and the related Loans thereunder) on a non-pro rata basis;

 

(iii)                               Required Consents.  No consent shall be required for any assignment except to the extent required by subsection (b)(i)(B) of this Section and, in addition:

 

(A)                               the consent of the Borrower (such consent not to be unreasonably withheld or delayed) shall be required unless (1) an Event of Default has occurred and is continuing at the time of such assignment or (2) such assignment is to a Lender, an Affiliate of a Lender or an Approved Fund; provided that the Borrower shall be deemed to have consented to any such assignment unless it shall object thereto by written notice to the Administrative Agent within five Business Days after having received notice thereof;

 

92

 

(B)                               the consent of the Administrative Agent (such consent not to be unreasonably withheld or delayed) shall be required for assignments in respect of any Commitment if such assignment is to a Person that is not a Lender with a Commitment, an Affiliate of such Lender or an Approved Fund with respect to such Lender; and

 

(C)                               the consent of each L/C Issuer and the Swing Line Lender (each such consent not to be unreasonably withheld or delayed) shall be required for any assignment.

 

(iv)                              Assignment and Assumption.  The parties to each assignment shall execute and deliver to the Administrative Agent an Assignment and Assumption, together with a processing and recordation fee in the amount of $3,500; provided, however, that the Administrative Agent may, in its sole discretion, elect to waive such processing and recordation fee in the case of any assignment. The assignee, if it is not a Lender, shall deliver to the Administrative Agent an Administrative Questionnaire.

 

(v)                                 No Assignment to Certain Persons.  No such assignment shall be made (A) to the Borrower or any of the Borrower’s Affiliates or Subsidiaries or (B) to any Defaulting Lender or any of its Subsidiaries, or any Person who, upon becoming a Lender hereunder, would constitute a Defaulting Lender or a Subsidiary thereof.

 

(vi)                              No Assignment to Natural Persons.  No such assignment shall be made to a natural Person (or a holding company, investment vehicle or trust for, or owned and operated for the primary benefit of, a natural Person).

 

(vii)                           Certain Additional Payments.  In connection with any assignment of rights and obligations of any Defaulting Lender hereunder, no such assignment shall be effective unless and until, in addition to the other conditions thereto set forth herein, the parties to the assignment shall make such additional payments to the Administrative Agent in an aggregate amount sufficient, upon distribution thereof as appropriate (which may be outright payment, purchases by the assignee of participations or subparticipations, or other compensating actions, including funding, with the consent of the Borrower and the Administrative Agent, the applicable pro rata share of Loans previously requested but not funded by the Defaulting Lender, to each of which the applicable assignee and assignor hereby irrevocably consent), to (x) pay and satisfy in full all payment liabilities then owed by such Defaulting Lender to the Administrative Agent, each L/C Issuer, the Swing Line Lender and each other Lender hereunder (and interest accrued thereon), and (y) acquire (and fund as appropriate) its full pro rata share of all Loans and participations in Letters of Credit and Swing Line Loans in accordance with its Applicable Percentage.  Notwithstanding the foregoing, in the event that any assignment of rights and obligations of any Defaulting Lender hereunder shall become effective under applicable Law without compliance with the provisions of this paragraph, then the assignee of such interest shall be deemed to be a

 

93

 

Defaulting Lender for all purposes of this Agreement until such compliance occurs.

 

Subject to acceptance and recording thereof by the Administrative Agent pursuant to subsection (c) of this Section, from and after the effective date specified in each Assignment and Assumption, the assignee thereunder shall be a party to this Agreement and, to the extent of the interest assigned by such Assignment and Assumption, have the rights and obligations of a Lender under this Agreement, and the assigning Lender thereunder shall, to the extent of the interest assigned by such Assignment and Assumption, be released from its obligations under this Agreement (and, in the case of an Assignment and Assumption covering all of the assigning Lender’s rights and obligations under this Agreement, such Lender shall cease to be a party hereto) but shall continue to be entitled to the benefits of Sections 3.1, 3.4, 3.5 and 10.5 with respect to facts and circumstances occurring prior to the effective date of such assignment; provided, that except to the extent otherwise expressly agreed by the affected parties, no assignment by a Defaulting Lender will constitute a waiver or release of any claim of any party hereunder arising from that Lender’s having been a Defaulting Lender.  Upon request, the Borrower (at its expense) shall execute and deliver a Note to the assignee Lender.  Any assignment or transfer by a Lender of rights or obligations under this Agreement that does not comply with this subsection shall be treated for purposes of this Agreement as a sale by such Lender of a participation in such rights and obligations in accordance with subsection (d) of this Section.

 

(c)                                  Register. The Administrative Agent, acting solely for this purpose as an agent of the Borrower, shall maintain at one of its offices in the United States a copy of each Assignment and Assumption delivered to it and a register for the recordation of the names and addresses of the Lenders, and the Commitments of, and principal amounts (and stated interest) of the Loans and L/C Obligations owing to, each Lender pursuant to the terms hereof from time to time (the “Register”). The entries in the Register shall be conclusive absent manifest error, and the Borrower, the Administrative Agent and the Lenders shall treat each Person whose name is recorded in the Register pursuant to the terms hereof as a Lender hereunder for all purposes of this Agreement.  The Register shall be available for inspection by the Borrower and any Lender, at any reasonable time and from time to time upon reasonable prior notice.

 

(d)                                 Participations. Any Lender may at any time, without the consent of, or notice to, the Borrower or the Administrative Agent, sell participations to any Person (other than a natural Person, or a holding company, investment vehicle or trust for, or owned and operated for the primary benefit of, a natural Person, or the Borrower or any of the Borrower’s Affiliates or Subsidiaries) (each, a “Participant”) in all or a portion of such Lender’s rights and/or obligations under this Agreement (including all or a portion of its Commitment and/or the Loans (including such Lender’s participation in L/C Obligations and/or Swing Line Loans) owing to it); provided that (i) such Lender’s obligations under this Agreement shall remain unchanged, (ii) such Lender shall remain solely responsible to the other parties hereto for the performance of such obligations, and (iii) the Borrower, the Administrative Agent, the L/C Issuers and the Lenders shall continue to deal solely and directly with such Lender in connection with such Lender’s

 

94

 

rights and obligations under this Agreement.  For the avoidance of doubt, each Lender shall be responsible for the indemnity under Section 10.5(c) with respect to any payments made by such Lender to its Participant(s).

 

Any agreement or instrument pursuant to which a Lender sells such a participation shall provide that such Lender shall retain the sole right to enforce this Agreement and to approve any amendment, modification or waiver of any provision of this Agreement; provided that such agreement or instrument may provide that such Lender will not, without the consent of the Participant, agree to any amendment, modification or waiver described in Sections 10.6(a) through 10.6(h) that directly affects such Participant.  The Borrower agrees that each Participant shall be entitled to the benefits of Sections 3.1, 3.4 and 3.5 (subject to the requirements and limitations therein, including the requirements under Section 3.1(g) (it being understood that the documentation required under Section 3.1(g) shall be delivered to the participating Lender)) to the same extent as if it were a Lender and had acquired its interest by assignment pursuant to subsection (b) of this Section; provided that such Participant (A) agrees to be subject to the provisions of Section 3.6 as if it were an assignee under paragraph (b) of this Section; and (B) shall not be entitled to receive any greater payment under Sections 3.1 or 3.4, with respect to any participation, than its participating Lender would have been entitled to receive, except to the extent such entitlement to receive a greater payment results from a Change in Law that occurs after the Participant acquired the applicable participation.  Each Lender that sells a participation agrees, at the Borrower’s request and expense, to use reasonable efforts to cooperate with the Borrower to effectuate the provisions of Section 3.6(b) with respect to any Participant.  To the extent permitted by law, each Participant also shall be entitled to the benefits of Section 10.2 as though it were a Lender; provided that such Participant agrees to be subject to Section 2.13 as though it were a Lender.  Each Lender that sells a participation shall, acting solely for this purpose as a non-fiduciary agent of the Borrower, maintain a register on which it enters the name and address of each Participant and the principal amounts (and stated interest) of each Participant’s interest in the Loans or other obligations under the Loan Documents (the “Participant Register”); provided that no Lender shall have any obligation to disclose all or any portion of the Participant Register (including the identity of any Participant or any information relating to a Participant’s interest in any Commitments, Loans, Letters of Credit or its other obligations under any Loan Document) to any Person except to the extent that such disclosure is necessary to establish that such Commitment, Loan, Letter of Credit or other obligation is in registered form under Section 5f.103-1(c) of the United States Treasury Regulations.  The entries in the Participant Register shall be conclusive absent manifest error, and such Lender shall treat each Person whose name is recorded in the Participant Register as the owner of such participation for all purposes of this Agreement notwithstanding any notice to the contrary.  For the avoidance of doubt, the Administrative Agent (in its capacity as Administrative Agent) shall have no responsibility for maintaining a Participant Register.

 

(e)                                  Certain Pledges.  Any Lender may at any time pledge or assign a security interest in all or any portion of its rights under this Agreement to secure obligations of such Lender, including any pledge or assignment to secure obligations to a Federal Reserve Bank; provided that no such pledge or assignment shall release such Lender

 

95

 

from any of its obligations hereunder or substitute any such pledgee or assignee for such Lender as a party hereto.

 

(f)                                   Fund Lenders.  Notwithstanding anything to the contrary contained herein, any Lender that is a Fund may create a security interest in all or any portion of the Loans owing to it and the Note, if any, held by it to the trustee for holders of obligations owed, or securities issued, by such Fund as security for such obligations or securities, provided that unless and until such trustee actually becomes a Lender in compliance with the other provisions of this Section 10.3, (i) no such pledge shall release the pledging Lender from any of its obligations under the Loan Documents and (ii) such trustee shall not be entitled to exercise any of the rights of a Lender under the Loan Documents even though such trustee may have acquired ownership rights with respect to the pledged interest through foreclosure or otherwise.

 

(g)                                  Resignation as L/C Issuer or Swing Line Lender after Assignment. Notwithstanding anything to the contrary contained herein, if at any time CFC or another Lender serving as an L/C Issuer assigns all of its Commitment and Loans pursuant to subsection (b) above, (i) CFC or such other Lender, as the case may be, may, upon thirty days’ notice to the Borrower and the Lenders, resign as one of the L/C Issuers and/or (ii) CFC may, upon thirty days’ notice to the Borrower, resign as Swing Line Lender.  In the event of any such resignation as L/C Issuer or Swing Line Lender, the Borrower shall be entitled to appoint from among the Lenders a successor L/C Issuer or Swing Line Lender hereunder; provided, however, that no failure by the Borrower to appoint any such successor shall affect the resignation of CFC or the other Lender as L/C Issuer or of CFC as Swing Line Lender, as the case may be.  If CFC or another Lender resigns as L/C Issuer, it shall retain all the rights, powers, privileges and duties of an L/C Issuer hereunder with respect to all its Letters of Credit outstanding as of the effective date of its resignation as L/C Issuer and all L/C Obligations with respect thereto (including the right to require the Lenders to make Base Rate Committed Loans or fund risk participations in Unreimbursed Amounts pursuant to Section 2.3(c)).  If CFC resigns as Swing Line Lender, it shall retain all the rights of the Swing Line Lender provided for hereunder with respect to Swing Line Loans made by it and outstanding as of the effective date of such resignation, including the right to require the Lenders to make Base Rate Committed Loans or fund risk participations in outstanding Swing Line Loans pursuant to Section 2.4(c).  Upon the appointment of a successor L/C Issuer and/or Swing Line Lender, (1) such successor shall succeed to and become vested with all of the rights, powers, privileges and duties of the retiring L/C Issuer or Swing Line Lender, as the case may be, and (2) the successor L/C Issuer shall issue letters of credit in substitution for the Letters of Credit, if any, outstanding at the time of such succession or make other arrangements satisfactory to CFC or another Lender resigning as an L/C Issuer to effectively assume the obligations of CFC or such other Lender, as the case may be, with respect to such Letters of Credit.

 

10.4                        No Waiver; Remedies Cumulative.

 

No failure or delay on the part of the Administrative Agent, any L/C Issuer or any Lender in exercising any right, power or privilege hereunder or under any other Loan Document and no

 

96

 

course of dealing between the Borrower and the Administrative Agent or any Lender shall operate as a waiver thereof; nor shall any single or partial exercise of any right, power or privilege hereunder or under any other Loan Document preclude any other or further exercise thereof or the exercise of any other right, power or privilege hereunder or thereunder. The rights and remedies provided herein are cumulative and not exclusive of any rights or remedies which the Administrative Agent or any Lender would otherwise have. No notice to or demand on the Borrower in any case shall entitle the Borrower to any other or further notice or demand in similar or other circumstances or constitute a waiver of the rights of the Administrative Agent or the Lenders to any other or further action in any circumstances without notice or demand.

 

Notwithstanding anything to the contrary contained herein or in any other Loan Document, the authority to enforce rights and remedies hereunder and under the other Loan Documents against the Borrower shall be vested exclusively in, and all actions and proceedings at law in connection with such enforcement shall be instituted and maintained exclusively by, the Administrative Agent in accordance with Section 8.2 for the benefit of all the Lenders and the L/C Issuers; provided, however, that the foregoing shall not prohibit (a) the Administrative Agent from exercising on its own behalf the rights and remedies that inure to its benefit (solely in its capacity as Administrative Agent) hereunder and under the other Loan Documents, (b) the L/C Issuers or the Swing Line Lender from exercising the rights and remedies that inure to its benefit (solely in their/its capacity as L/C Issuers or Swing Line Lender, as the case may be) hereunder and under the other Loan Documents, (c) any Lender from exercising setoff rights in accordance with Section 10.2 (subject to the terms of Section 2.13), or (d) any Lender from filing proofs of claim or appearing and filing pleadings on its own behalf during the pendency of a proceeding relative to the Borrower under any Debtor Relief Law; and provided, further, that if at any time there is no Person acting as Administrative Agent hereunder and under the other Loan Documents, then (i) the Required Lenders shall have the rights otherwise ascribed to the Administrative Agent pursuant to Section 8.2 and (ii) in addition to the matters set forth in clauses (b), (c) and (d) of the preceding proviso and subject to Section 2.13, any Lender may, with the consent of the Required Lenders, enforce any rights and remedies available to it and as authorized by the Required Lenders.

 

10.5                        Payment of Expenses, etc.

 

(a)                                 Costs and Expenses.  The Borrower shall pay (i) all reasonable out-of-pocket expenses incurred by the Administrative Agent and its Affiliates (including the reasonable fees, charges and disbursements of counsel for the Administrative Agent), in connection with the syndication of the credit facilities provided for herein, the preparation, negotiation, execution, delivery and administration of this Agreement and the other Loan Documents or any amendments, modifications or waivers of the provisions hereof or thereof (whether or not the transactions contemplated hereby or thereby shall be consummated) (ii) all reasonable out-of-pocket expenses incurred by the L/C Issuers in connection with the issuance, amendment, renewal or extension of any Letter of Credit or any demand for payment thereunder and (iii) all reasonable out-of-pocket expenses incurred by the Administrative Agent, any L/C Issuer or any Lender (including the reasonable fees, charges and disbursements of any counsel for the Administrative Agent, any L/C Issuer or any Lender), in connection with the enforcement or protection of its rights (A) in connection with this Agreement and the other Loan

 

97

 

Documents, including its rights under this Section, or (B) in connection with the Loans made hereunder, including all such out-of-pocket expenses incurred during any workout, restructuring or negotiations in respect of such Loans or Letters of Credit

 

(b)                                 Indemnification by the Borrower.  The Borrower shall indemnify the Administrative Agent (and any sub-agent thereof) and each Lender and each L/C Issuer, and each Related Party of any of the foregoing Persons (each such Person being called an “Indemnitee”) against, and hold each Indemnitee harmless from, any and all losses, claims, damages, liabilities and related expenses (including the fees, charges and disbursements of any counsel for any Indemnitee), incurred by any Indemnitee or asserted against any Indemnitee by any third party or by the Borrower or any Subsidiary of the Borrower arising out of, in connection with, or as a result of (i) the execution or delivery of this Agreement, any other Loan Document or any agreement or instrument contemplated hereby or thereby, the performance by the parties hereto of their respective obligations hereunder or thereunder or the consummation of the transactions contemplated hereby or thereby, (ii) any Loan or Letter of Credit or the use or proposed use of the proceeds therefrom (including any refusal by an L/C Issuer to honor a demand for payment under a Letter of Credit if the documents presented in connection with such demand do not strictly comply with the terms of such Letter of Credit), (iii) any Loan or the use or proposed use of the proceeds therefrom, (iv) any actual or alleged presence or release of hazardous materials on or from any property currently or formerly owned or operated by the Borrower, any Subsidiary of the Borrower, or any liability resulting from any actual or alleged violation of Environmental Laws related in any way to the Borrower, any Subsidiary of the Borrower, or (v) any actual or prospective claim, litigation, investigation or proceeding relating to any of the foregoing, whether based on contract, tort or any other theory, whether brought by a third party or by the Borrower, and regardless of whether any Indemnitee is a party thereto; provided that such indemnity shall not, as to any Indemnitee, be available to the extent that such losses, claims, damages, liabilities or related expenses (x) are determined by a court of competent jurisdiction by final and nonappealable judgment to have resulted from the gross negligence or willful misconduct of such Indemnitee or (y) result from a claim brought by the Borrower against an Indemnitee for breach of such Indemnitee’s obligations hereunder or under any other Loan Document, if the Borrower has obtained a final and nonappealable judgment in its favor on such claim as determined by a court of competent jurisdiction.

 

(c)                                  Reimbursement by Lenders.  To the extent that the Borrower for any reason fails to indefeasibly pay any amount required under subsection (a) or (b) of this Section to be paid by it to the Administrative Agent (or any sub-agent thereof), the L/C Issuers or any Related Party of any of the foregoing, each Lender severally agrees to pay to the Administrative Agent (or any such sub-agent), the L/C Issuers or such Related Party, as the case may be, such Lender’s pro rata share in accordance with its Applicable Percentage (determined as of the time that the applicable unreimbursed expense or indemnity payment is sought) of such unpaid amount, provided that the unreimbursed expense or indemnified loss, claim, damage, liability or related expense, as the case may be, was incurred by or asserted against the Administrative Agent (or any such sub-agent) or the L/C Issuers in their capacity as such, or against any Related Party of any of the

 

98

 

foregoing acting for the Administrative Agent (or any such sub-agent) or the L/C Issuers in connection with such capacity.  The obligations of the Lenders under this subsection (c) are subject to the provisions of Section 2.12(d).

 

(d)                                 Waiver of Consequential Damages, Etc. To the fullest extent permitted by applicable law, the Borrower shall not assert, and hereby waives, any claim against any Indemnitee, on any theory of liability, for special, indirect, consequential or punitive damages (as opposed to direct or actual damages) arising out of, in connection with, or as a result of, this Agreement, any other Loan Document or any agreement or instrument contemplated hereby, the transactions contemplated hereby or thereby, any Loan or Letter of Credit or the use of the proceeds thereof.  No Indemnitee referred to in subsection (b) above shall be liable for any damages arising from the use by unintended recipients of any information or other materials distributed by it through telecommunications, electronic or other information transmission systems in connection with this Agreement or the other Loan Documents or the transactions contemplated hereby or thereby.

 

(e)                                  Payments. All amounts due under this Section shall be payable within ten Business Days after demand therefor.

 

(f)                                   Survival. The agreements in this Section shall survive the resignation of the Administrative Agent, any L/C Issuer and the Swing Line Lender, the replacement of any Lender, the termination of the Commitments and the repayment, satisfaction or discharge of all other Borrower Obligations.

 

10.6                        Amendments, Waivers and Consents.

 

Neither this Agreement, nor any other Loan Document nor any of the terms hereof or thereof may be amended, changed, waived, discharged or terminated unless such amendment, change, waiver, discharge or termination is in writing and signed by the Required Lenders and the Borrower; provided that no such amendment, change, waiver, discharge or termination shall without the consent of each Lender affected thereby:

 

(a)                                 extend the Maturity Date, or postpone or extend the time for any payment or prepayment of principal;

 

(b)                                 reduce the rate or extend the time of payment of interest (other than as a result of waiving the applicability of any post-default increase in interest rates) thereon or fees or other amounts payable hereunder;

 

(c)                                  reduce or waive the principal amount of any Loan or L/C Borrowing;

 

(d)                                 increase or extend the Commitment of a Lender (it being understood and agreed that a waiver of any Default or Event of Default or a waiver of any mandatory reduction in the Commitments shall not constitute a change in the terms of any Commitment of any Lender);

 

(e)                                  release the Borrower from its obligations under the Loan Documents;

 

99

 

(f)                                   amend, modify or waive any provision of this Section 10.6 or Sections 2.12(a), 2.13, 2.14, 8.1(a), 10.2, 10.3 or 10.5;

 

(g)                                  reduce any percentage specified in, or otherwise modify, the definition of Required Lenders;

 

(h)                                 consent to the assignment or transfer by the Borrower of any of its rights and obligations under (or in respect of) the Loan Documents;

 

(i)                                     unless also signed by the L/C Issuers, affect the rights or duties of the L/C Issuers under this Agreement or any Issuer Document relating to any Letter of Credit issued or to be issued by them;

 

(j)                                    unless also signed by the Swing Line Lender, affect the rights or duties of the Swing Line Lender under this Agreement; or

 

(k)                                 unless also signed by the Administrative Agent, affect the rights or duties of the Administrative Agent under this Agreement or any other Loan Document.

 

No provision of Section 9 may be amended or modified without the consent of the Administrative Agent.

 

Notwithstanding anything to the contrary herein, no Defaulting Lender shall have any right to approve or disapprove any amendment, waiver or consent hereunder (and any amendment, waiver or consent which by its terms requires the consent of all Lenders or each affected Lender may be effected with the consent of the applicable Lenders other than Defaulting Lenders), except that (x) the Commitment of any Defaulting Lender may not be increased or extended without the consent of such Lender and (y) any waiver, amendment or modification requiring the consent of all Lenders or each affected Lender that by its terms affects any Defaulting Lender more adversely than other affected Lenders shall require the consent of such Defaulting Lender.

 

Notwithstanding the fact that the consent of all the Lenders is required in certain circumstances as set forth above, (x) each Lender is entitled to vote as such Lender sees fit on any reorganization plan that affects the Loans, and each Lender acknowledges that the provisions of Section 1126(c) of the Bankruptcy Code supersede the unanimous consent provisions set forth herein and (y) the Required Lenders may consent to allow the Borrower to use cash collateral in the context of a bankruptcy or insolvency proceeding.

 

10.7                        Counterparts.

 

This Agreement may be executed in any number of counterparts, each of which where so executed and delivered shall be an original, but all of which shall constitute one and the same instrument.

 

100

 

10.8                        Headings.

 

The headings of the sections and subsections hereof are provided for convenience only and shall not in any way affect the meaning or construction of any provision of this Agreement.

 

10.9                        Interest Rate Limitation.

 

Notwithstanding anything to the contrary contained in any Loan Document, the interest paid or agreed to be paid under the Loan Documents shall not exceed the maximum rate of non-usurious interest permitted by applicable Law (the “Maximum Rate”).  If the Administrative Agent or any Lender shall receive interest in an amount that exceeds the Maximum Rate, the excess interest shall be applied to the principal of the Loans or, if it exceeds such unpaid principal, refunded to the Borrower.  In determining whether the interest contracted for, charged, or received by the Administrative Agent or a Lender exceeds the Maximum Rate, such Person may, to the extent permitted by applicable Law, (a) characterize any payment that is not principal as an expense, fee, or premium rather than interest, (b) exclude voluntary prepayments and the effects thereof, and (c) amortize, prorate, allocate, and spread in equal or unequal parts the total amount of interest throughout the contemplated term of the Obligations hereunder.

 

10.10                 Survival of Indemnification and Representations and Warranties.

 

All indemnities set forth herein and all representations and warranties made hereunder and in any other Loan Document or other document delivered pursuant hereto or thereto or in connection herewith or therewith shall survive the execution and delivery hereof and thereof. Such representations and warranties have been or will be relied upon by the Administrative Agent and each Lender, regardless of any investigation made by the Administrative Agent or any Lender and notwithstanding that the Administrative Agent or any Lender may have had notice or knowledge of any Default or Event of Default at the time of the making of any Loan, and shall continue in full force and effect as long as any Loan or any other Borrower Obligation hereunder shall remain unpaid or unsatisfied or any Letter of Credit shall remain outstanding.

 

10.11                 Governing Law.

 

(a)                                 GOVERNING LAW. THIS AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAW OF THE STATE OF GEORGIA.

 

(b)                                 SUBMISSION TO JURISDICTION.  THE BORROWER IRREVOCABLY AND UNCONDITIONALLY SUBMITS, FOR ITSELF AND ITS PROPERTY, TO THE NONEXCLUSIVE JURISDICTION OF THE COURTS OF THE STATE OF GEORGIA SITTING IN FULTON COUNTY AND OF THE UNITED STATES DISTRICT COURT OF THE NORTHERN DISTRICT OF GEORGIA, AND ANY APPELLATE COURT FROM ANY THEREOF, IN ANY ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT OR ANY OTHER LOAN DOCUMENT, OR FOR RECOGNITION OR ENFORCEMENT OF ANY JUDGMENT, AND EACH OF THE PARTIES HERETO IRREVOCABLY AND UNCONDITIONALLY AGREES THAT ALL CLAIMS IN RESPECT OF ANY SUCH ACTION OR PROCEEDING MAY BE HEARD AND DETERMINED IN SUCH

 

101

 

GEORGIA STATE COURT OR, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, IN SUCH FEDERAL COURT. EACH OF THE PARTIES HERETO AGREES THAT A FINAL JUDGMENT IN ANY SUCH ACTION OR PROCEEDING SHALL BE CONCLUSIVE AND MAY BE ENFORCED IN OTHER JURISDICTIONS BY SUIT ON THE JUDGMENT OR IN ANY OTHER MANNER PROVIDED BY LAW. NOTHING IN THIS AGREEMENT OR IN ANY OTHER LOAN DOCUMENT SHALL AFFECT ANY RIGHT THAT THE ADMINISTRATIVE AGENT, ANY LENDER, OR ANY L/C ISSUER MAY OTHERWISE HAVE TO BRING ANY ACTION OR PROCEEDING RELATING TO THIS AGREEMENT OR ANY OTHER LOAN DOCUMENT AGAINST THE BORROWER OR ITS PROPERTIES IN THE COURTS OF ANY JURISDICTION.

 

(c)                                  WAIVER OF VENUE.  THE BORROWER IRREVOCABLY AND UNCONDITIONALLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY OBJECTION THAT IT MAY NOW OR HEREAFTER HAVE TO THE LAYING OF VENUE OF ANY ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT OR ANY OTHER LOAN DOCUMENT IN ANY COURT REFERRED TO IN PARAGRAPH (B) OF THIS SECTION. EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, THE DEFENSE OF AN INCONVENIENT FORUM TO THE MAINTENANCE OF SUCH ACTION OR PROCEEDING IN ANY SUCH COURT.

 

(d)                                 SERVICE OF PROCESS. EACH PARTY HERETO IRREVOCABLY CONSENTS TO SERVICE OF PROCESS IN THE MANNER PROVIDED FOR NOTICES IN SECTION 10.1. NOTHING IN THIS AGREEMENT WILL AFFECT THE RIGHT OF ANY PARTY HERETO TO SERVE PROCESS IN ANY OTHER MANNER PERMITTED BY APPLICABLE LAW.

 

10.12                 Waiver of Jury Trial.

 

EACH PARTY HERETO HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN ANY LEGAL PROCEEDING DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT OR ANY OTHER LOAN DOCUMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY (WHETHER BASED ON CONTRACT, TORT OR ANY OTHER THEORY). EACH PARTY HERETO (A) CERTIFIES THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PERSON HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PERSON WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER AND (B) ACKNOWLEDGES THAT IT AND THE OTHER PARTIES HERETO HAVE BEEN INDUCED TO ENTER INTO THIS AGREEMENT AND THE OTHER LOAN DOCUMENTS BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION.

 

102

 

10.13                 Severability.

 

If any provision of this Agreement or the other Loan Documents is held to be illegal, invalid or unenforceable, (a) the legality, validity and enforceability of the remaining provisions of this Agreement and the other Loan Documents shall not be affected or impaired thereby and (b) the parties shall endeavor in good faith negotiations to replace the illegal, invalid or unenforceable provisions with valid provisions the economic effect of which comes as close as possible to that of the illegal, invalid or unenforceable provisions.  The invalidity of a provision in a particular jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction.  Without limiting the foregoing provisions of this Section 10.13, if and to the extent that the enforceability of any provisions in this Agreement relating to Defaulting Lenders shall be limited by Debtor Relief Laws, as determined in good faith by the Administrative Agent, the L/C Issuers and/or the Swing Line Lender, as applicable, then such provisions shall be deemed to be in effect only to the extent not so limited.

 

10.14                 Further Assurances.

 

The Borrower agrees, upon the request of the Administrative Agent, to promptly take such actions, as reasonably requested, as are necessary to carry out the intent of this Agreement and the other Loan Documents.

 

10.15                 Entirety.

 

This Agreement together with the other Loan Documents represent the entire agreement of the parties hereto and thereto, and supersede all prior agreements and understandings, oral or written, if any, including any commitment letters or correspondence relating to the Loan Documents or the transactions contemplated herein and therein.

 

10.16                 Binding Effect; Continuing Agreement.

 

(a)                                 This Agreement shall become effective at such time as all of the conditions set forth in Section 4.1 have been satisfied or waived by the Lenders and it shall have been executed by the Borrower, the Administrative Agent and the Lenders, and thereafter this Agreement shall be binding upon and inure to the benefit of the Borrower, the Administrative Agent and each Lender and their respective successors and assigns. Upon this Agreement becoming effective, the Existing Credit Agreement shall be deemed terminated, and the Borrower and the lenders party to the Existing Credit Agreement shall no longer have any obligations thereunder (other than those obligations in the Existing Credit Agreement that expressly survive the termination of the Existing Credit Agreement).

 

(b)                                 This Agreement shall be a continuing agreement and shall remain in full force and effect until all Loans, interest, fees and other Borrower Obligations have been paid in full and all Commitments have been terminated. Upon termination, the Borrower shall have no further obligations (other than the indemnification provisions that survive) under the Loan Documents; provided that should any payment, in whole or in part, of the Borrower Obligations be rescinded or otherwise required to be restored or returned by the Administrative Agent or any Lender, whether as a result of any proceedings in

 

103

 

bankruptcy or reorganization or otherwise, then the Loan Documents shall automatically be reinstated and all amounts required to be restored or returned and all costs and expenses incurred by the Administrative Agent or any Lender in connection therewith shall be deemed included as part of the Borrower Obligations.

 

10.17                 Confidentiality.

 

Each of the Administrative Agent, the L/C Issuers and the Lenders agrees to maintain the confidentiality of the Information (as defined below), except that Information may be disclosed (a) to its Affiliates and to its Related Parties (it being understood that the Persons to whom such disclosure is made will be informed of the confidential nature of such Information and instructed to keep such Information confidential); (b) to the extent requested by any regulatory authority purporting to have jurisdiction over such Person or its Related Parties (including any self-regulatory authority, such as the National Association of Insurance Commissioners); (c) to the extent required by applicable laws or regulations or by any subpoena or similar legal process (provided, in the event of any disclosure pursuant to this clause (c), the Administrative Agent, the L/C Issuers or the Lenders, as applicable, shall promptly notify the Borrower of its disclosure of such Information); (d) to any other party to this Agreement; (e) in connection with the exercise of any remedies hereunder or under any other Loan Document or any action or proceeding relating to this Agreement or any other Loan Document or the enforcement of rights hereunder or thereunder; (f) subject to an agreement containing provisions substantially the same as those of this Section 10.17, to (i) any assignee of or Participant in, or any prospective assignee of or Participant in, any of its rights or obligations under this Agreement or (ii) any actual or prospective counterparty (or its Related Parties) to any swap, derivative or other transaction under which payments are to be made by reference to the Borrower and its obligations, this Agreement or payments hereunder; (g) on a confidential basis to (i) any rating agency in connection with rating the Borrower or its Subsidiaries or the Indebtedness under this Agreement or (ii) the CUSIP Service Bureau or any similar agency in connection with the issuance and monitoring of CUSIP numbers with respect to this Agreement; (h) with the consent of the Borrower; (i) any nationally recognized rating agency that requires access to information about a Lender’s or its Affiliates’ investment portfolio in connection with ratings issued with respect to such Lender or its Affiliates; or (j) to the extent such Information (x) becomes publicly available other than as a result of a breach of this Section 10.17, or (y) becomes available to the Administrative Agent, any Lender, any L/C Issuer or any of their respective Affiliates on a nonconfidential basis from a source other than the Borrower.

 

For the purposes of this Section 10.17, “Information” means all information received from the Borrower or any of its Subsidiaries relating to the Borrower or its Subsidiary or any of their respective businesses, other than any such information that is available to the Administrative Agent, any Lender or any L/C Issuer on a nonconfidential basis prior to disclosure by the Borrower or any Subsidiary, provided that, in the case of information received from the Borrower or any Subsidiary after the date hereof, such information is clearly identified at the time of delivery as confidential.  Any Person required to maintain the confidentiality of Information as provided in this Section 10.17 shall be considered to have complied with its obligation to do so if such Person has exercised the same degree of care to maintain the confidentiality of such Information as such Person would accord to its own confidential information.

 

104

 

Each of the Administrative Agent, the L/C Issuers and the Lenders acknowledges that (a) the Information may include material non-public information concerning the Borrower or a Subsidiary, as the case may be, (b) it has developed compliance procedures regarding the use of material non-public information and (c) it will handle such material non-public information in accordance with applicable Law, including United States Federal and state securities Laws.

 

10.18                 USA PATRIOT Act Notice.

 

Each Lender, each L/C Issuer and the Administrative Agent (for itself and not on behalf of any Lender) hereby notifies the Borrower that pursuant to the requirements of the USA Patriot Act (Title III of Pub. L. 107-56 (signed into law October 26, 2001)) (as amended, restated, modified or otherwise supplemented from time to time, the “Patriot Act”), it is required to obtain, verify and record information that identifies the Borrower, which information includes the name and address of the Borrower and other information that will allow such Lender, such L/C Issuer or the Administrative Agent, as applicable, to identify the Borrower in accordance with the Patriot Act.  The Borrower shall, promptly following a request by the Administrative Agent, any Lender or L/C Issuer, provide all documentation and other information that the Administrative Agent, such Lender or such L/C Issuer requests in order to comply with its ongoing obligations under applicable “know your customer” and anti-money laundering rules and regulations, including the Patriot Act.

 

10.19                 No Advisory or Fiduciary Responsibility.

 

In connection with all aspects of each transaction contemplated hereby (including in connection with any amendment, waiver or other modification hereof or of any other Loan Document), the Borrower acknowledges and agrees, and acknowledges its Affiliates’ understanding, that: (i) (A) the arranging and other services regarding this Agreement provided by the Administrative Agent, the Lenders and the Lead Arranger, are arm’s-length commercial transactions between the Borrower its Affiliates, on the one hand, and the Administrative Agent, the Lenders and the Lead Arranger, on the other hand, (B) the Borrower has consulted its own legal, accounting, regulatory and tax advisors to the extent it has deemed appropriate, and (C) the Borrower is capable of evaluating, and understands and accepts, the terms, risks and conditions of the transactions contemplated hereby and by the other Loan Documents; (ii) (A) each of the Administrative Agent, the Lenders and the Lead Arranger is and has been acting solely as a principal and, except as expressly agreed in writing by the relevant parties, has not been, is not, and will not be acting as an advisor, agent or fiduciary for the Borrower or any of its respective Affiliates, or any other Person and (B) neither the Administrative Agent nor the Lenders nor the Lead Arranger have any obligation to the Borrower or any of its respective Affiliates with respect to the transactions contemplated hereby except those obligations expressly set forth herein and in the other Loan Documents; and (iii) the Administrative Agent, the Lenders and the Lead Arranger and their respective Affiliates may be engaged in a broad range of transactions that involve interests that differ from those of the Borrower and its respective Affiliates, and neither the Administrative Agent nor the Lenders nor the Lead Arranger have any obligation to disclose any of such interests to the Borrower and its respective Affiliates.  To the fullest extent permitted by law, the Borrower hereby waives and releases any claims that it may have against the Administrative Agent, the Lenders and the Lead Arranger with respect to any breach or

 

105

 

alleged breach of agency or fiduciary duty in connection with any aspect of any transaction contemplated hereby.

 

10.20                 Electronic Execution of Assignments and Certain Other Documents.

 

The words “execution,” “signed,” “signature,” and words of like import in any Assignment and Assumption or in any amendment or other modification hereof (including waivers and consents) shall be deemed to include electronic signatures or the keeping of records in electronic form, which shall be of the same legal effect, validity or enforceability as a manually executed signature or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for in any applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, Georgia’s Uniform Electronic Transactions Act or any other similar state laws based on the Uniform Electronic Transactions Act.

 

10.21                 Voting Participants.

 

Notwithstanding anything in Section 10.3 to the contrary, any Farm Credit Lender that (i) has purchased a participation in the minimum aggregate amount of $5,000,000 on or after the Closing Date, (ii) is, by written notice to the Borrower and the Administrative Agent (“Voting Participant Notification”), designated by the selling Lender (including any existing Voting Participant) as being entitled to be accorded the rights of a Voting Participant hereunder and (iii) receives the prior written consent of the Borrower and the Administrative Agent, in its sole discretion, to become a Voting Participant (such consent to be required only to the extent and under the circumstances it would be required if such Voting Participant were to become a Lender pursuant to an assignment in accordance with Section 10.3 (any Farm Credit Lender so designated and consented to being called a “Voting Participant”), shall be entitled to vote for so long as such Farm Credit Lender owns such participation and notwithstanding any subparticipation by such Farm Credit Lender (and the voting rights of the selling Lender (including any existing Voting Participant) shall be correspondingly reduced), on a dollar for dollar basis, as if such participant were a Lender, on any matter requiring or allowing a Lender to provide or withhold its consent, or to otherwise vote on any proposed action.  To be effective, each Voting Participant Notification shall, with respect to any Voting Participant, (x) state the full name, as well as all contact information required of an assignee in an Assignment and Assumption and (y) state the dollar amount of the participation purchased in its Commitment or any or all of its Loans.  The selling Lender (including any existing Voting Participant) and the purchasing Voting Participant shall notify the Administrative Agent and the Borrower within 3 Business Days’ of any termination of, or reduction or increase in the amount of, such participation.  The Borrower and the Administrative Agent shall be entitled to conclusively rely on information contained in notices delivered pursuant to this paragraph.  The voting rights hereunder are solely for the benefit of the Voting Participant and shall not inure to any assignee or participant of the Voting Participant that is not a Farm Credit Lender.

 

10.22                 Waiver of Notice of Termination of Existing Credit Agreement.

 

Each of the Lenders party hereto that is party to the Existing Credit Agreement (which Lenders collectively constitute “Required Lenders” (as defined in the Existing Credit Agreement)), in its capacity as a “Lender” under the Existing Credit Agreement, hereby waives

 

106

 

as of the date hereof the notice requirement under Section 2.6 of the Existing Credit Agreement for five Business Days’ (as defined in the Existing Credit Agreement) prior notification of termination of the commitments thereunder.

 

[Remainder of Page Intentionally Left Blank]

 

107

 

Each of the parties hereto has caused this Agreement to be duly executed and delivered as of the date first above written.

 

	
 
    	
OGLETHORPE   POWER CORPORATION (AN ELECTRIC MEMBERSHIP CORPORATION)
    
	
 
    
	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
/s/   Elizabeth B. Higgins
    
	
 
    	
Name:
    	
Elizabeth   B. Higgins
    
	
 
    	
Title:
    	
Executive   Vice President and Chief Financial Officer
    

 

S-1

 

	
 
    	
NATIONAL   RURAL UTILITIES COOPERATIVE FINANCE CORPORATION
    
	
 
    	
as   Administrative Agent
    
	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
/s/   J. Andrew Don
    
	
 
    	
 
    	
 
    
	
 
    	
Name:
    	
J.   Andrew Don
    
	
 
    	
 
    	
 
    
	
 
    	
Title:
    	
Senior   Vice President/CFO
    

 

S-2

 

	
 
    	
NATIONAL   RURAL UTILITIES COOPERATIVE FINANCE CORPORATION
    
	
 
    	
as   an L/C Issuer, the Swing Line Lender and a Lender
    
	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
/s/   J. Andrew Don
    
	
 
    	
 
    	
 
    
	
 
    	
Name:
    	
J.   Andrew Don
    
	
 
    	
 
    	
 
    
	
 
    	
Title:
    	
Senior   Vice President/CFO
    

 

S-3

 

	
 
    	
BANK   OF AMERICA, N.A., as an L/C Issuer and a Lender
    
	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
/s/   Stephanie Pendleton
    
	
 
    	
 
    	
 
    
	
 
    	
Name:
    	
Stephanie   Pendleton
    
	
 
    	
 
    	
 
    
	
 
    	
Title:
    	
Senior   Vice President
    

 

S-4

 

	
 
    	
BANK   OF MONTREAL, as an L/C Issuer and a Lender
    
	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
/s/   Brian L. Banke
    
	
 
    	
 
    	
 
    
	
 
    	
Name:
    	
Brian   L. Banke
    
	
 
    	
 
    	
 
    
	
 
    	
Title:
    	
Director
    

 

S-5

 

	
 
    	
COBANK,   ACB, as an L/C Issuer and a Lender
    
	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
/s/   Jeffrey E. Childs
    
	
 
    	
 
    	
 
    
	
 
    	
Name:
    	
Jeffrey   E. Childs
    
	
 
    	
 
    	
 
    
	
 
    	
Title:
    	
Vice   President
    

 

S-6

 

	
 
    	
The   Bank of Tokyo-Mitsubishi UFJ, Ltd., as a Lender
    
	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
/s/   Lindsay Minneman
    
	
 
    	
 
    	
 
    
	
 
    	
Name:
    	
Lindsay   Minneman
    
	
 
    	
 
    	
 
    
	
 
    	
Title:
    	
Vice   President
    

 

S-7

 

	
 
    	
MIZUHO   BANK, LTD., as a Lender
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/   Leon Mo
    
	
 
    	
 
    	
 
    
	
 
    	
Name:
    	
Leon Mo
    
	
 
    	
 
    	
 
    
	
 
    	
Title:
    	
Authorized Signatory
    

 

S-8

 

	
 
    	
ROYAL BANK OF CANADA, as a Lender
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/ John E. Wells
    
	
 
    	
 
    	
 
    
	
 
    	
Name:
    	
John E. Wells
    
	
 
    	
 
    	
 
    
	
 
    	
Title:
    	
Authorized Signatory
    

 

S-9

 

 

	
 
    	
Wells Fargo Bank, N.A., as a Lender
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/ Patrick Hennessey
    
	
 
    	
 
    	
 
    
	
 
    	
Name:
    	
Patrick Hennessey
    
	
 
    	
 
    	
 
    
	
 
    	
Title:
    	
Senior Vice President
    

 

S-10

 

	
 
    	
FIFTH THIRD BANK, as a Lender
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/ Aaron M. Mays
    
	
 
    	
 
    	
 
    
	
 
    	
Name:
    	
Aaron M. Mays
    
	
 
    	
 
    	
 
    
	
 
    	
Title:
    	
Vice President
    

 

S-11

 

	
 
    	
GOLDMAN SACHS BANK USA, as a Lender
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/ Rebecca Kratz
    
	
 
    	
 
    	
 
    
	
 
    	
Name:
    	
Rebecca Kratz
    
	
 
    	
 
    	
 
    
	
 
    	
Title:
    	
Authorized Signatory
    

 

S-12

 

	
 
    	
U.S. BANK NATIONAL ASSOCIATION, as a Lender
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/ James O’Shaughnessy
    
	
 
    	
 
    	
 
    
	
 
    	
Name:
    	
James O’Shaughnessy
    
	
 
    	
 
    	
 
    
	
 
    	
Title:
    	
Vice President
    

 

S-13

 

	
 
    	
REGIONS BANK, as a Lender
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/ James A. Sharp
    
	
 
    	
 
    	
 
    
	
 
    	
Name:
    	
James A. Sharp
    
	
 
    	
 
    	
 
    
	
 
    	
Title:
    	
Vice President
    

 

S-14

 

	
 
    	
Branch Banking and Trust Company, as a Lender
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/ R. Todd Barnaby
    
	
 
    	
 
    	
 
    
	
 
    	
Name:
    	
R. Todd Barnaby
    
	
 
    	
 
    	
 
    
	
 
    	
Title:
    	
Senior Vice President
    

 

S-15

 

SCHEDULE 1.1

 

COMMITMENTS AND APPLICABLE PERCENTAGES

 

	
Lender
    	
 
    	
Commitment
    	
 
    	
Applicable Percentage
    	
 
    
	
National Rural Utilities   Cooperative Finance Corporation
    	
 
    	
$
    	
235,000,000
    	
 
    	
19.4215
    	
%
    
	
CoBank, ACB
    	
 
    	
$
    	
150,000,000
    	
 
    	
12.3967
    	
%
    
	
The Bank of   Tokyo-Mitsubishi UFJ, Ltd.
    	
 
    	
$
    	
125,000,000
    	
 
    	
10.3306
    	
%
    
	
Mizuho Bank, Ltd.
    	
 
    	
$
    	
100,000,000
    	
 
    	
8.2645
    	
%
    
	
Bank of America, N.A.
    	
 
    	
$
    	
100,000,000
    	
 
    	
8.2645
    	
%
    
	
Royal Bank of Canada
    	
 
    	
$
    	
100,000,000
    	
 
    	
8.2645
    	
%
    
	
Bank of Montreal
    	
 
    	
$
    	
100,000,000
    	
 
    	
8.2645
    	
%
    
	
Wells Fargo Bank, National   Association
    	
 
    	
$
    	
50,000,000
    	
 
    	
4.1322
    	
%
    
	
Fifth Third Bank
    	
 
    	
$
    	
50,000,000
    	
 
    	
4.1322
    	
%
    
	
Goldman Sachs Bank USA
    	
 
    	
$
    	
50,000,000
    	
 
    	
4.1322
    	
%
    
	
U.S. Bank National   Association
    	
 
    	
$
    	
50,000,000
    	
 
    	
4.1322
    	
%
    
	
Regions Bank
    	
 
    	
$
    	
50,000,000
    	
 
    	
4.1322
    	
%
    
	
Branch Banking and Trust   Company
    	
 
    	
$
    	
50,000,000
    	
 
    	
4.1322
    	
%
    
	
Total:
    	
 
    	
$
    	
1,210,000,000.00
    	
 
    	
100.0000
    	
%
    

 

 

SCHEDULE 5.8

 

LITIGATION

 

None.

 

 

SCHEDULE 5.19

 

SUBSIDIARIES, AFFILIATES AND MEMBERS

 

Subsidiaries:

 

Rocky Mountain Leasing Corporation

 

Affiliates:

 

None

 

Members:

 

	
Altamaha EMC
    	
 
    	
GreyStone Power Corporation,   an EMC
    	
 
    	
Rayle EMC
    
	
Amicalola EMC
    	
 
    	
Habersham EMC
    	
 
    	
Satilla Rural EMC
    
	
Canoochee EMC
    	
 
    	
Hart EMC
    	
 
    	
Sawnee EMC
    
	
Carroll EMC
    	
 
    	
Irwin EMC
    	
 
    	
Slash Pine EMC
    
	
Central Georgia EMC
    	
 
    	
Jackson EMC
    	
 
    	
Snapping Shoals EMC
    
	
Coastal EMC (d/b/a Coastal   Electric Cooperative)
    	
 
    	
Jefferson Energy   Cooperative, an EMC
    	
 
    	
Southern Rivers   Energy, Inc., an EMC
    
	
Cobb EMC
    	
 
    	
Little Ocmulgee EMC
    	
 
    	
Sumter EMC
    
	
Colquitt EMC
    	
 
    	
Middle Georgia EMC
    	
 
    	
Three Notch EMC
    
	
Coweta-Fayette EMC
    	
 
    	
Mitchell EMC
    	
 
    	
Tri-County EMC
    
	
Diverse Power Inc., an EMC
    	
 
    	
Ocmulgee EMC
    	
 
    	
Upson EMC
    
	
Excelsior EMC
    	
 
    	
Oconee EMC
    	
 
    	
Walton EMC
    
	
Flint EMC (d/b/a Flint   Energies)
    	
 
    	
Okefenoke Rural EMC
    	
 
    	
Washington EMC
    
	
Grady EMC
    	
 
    	
Planters EMC
    	
 
    	
 
    

 

 

SCHEDULE 5.20

 

GROSS MEMBER REVENUES

 

	
Member
    	
 
    	
Percentage of
   Oglethorpe’s 2014
   Member Revenues
    	
 
    
	
Altamaha
    	
 
    	
1.1
    	
%
    
	
Amicalola
    	
 
    	
1.8
    	
%
    
	
Canoochee
    	
 
    	
1.2
    	
%
    
	
Carroll
    	
 
    	
2.9
    	
%
    
	
Central   Georgia
    	
 
    	
2.6
    	
%
    
	
 Coastal Electric Cooperative
    	
 
    	
0.9
    	
%
    
	
Cobb
    	
 
    	
14.6
    	
%
    
	
Colquitt
    	
 
    	
3.1
    	
%
    
	
Coweta-Fayette
    	
 
    	
5.7
    	
%
    
	
Diverse   Power
    	
 
    	
2.1
    	
%
    
	
Excelsior
    	
 
    	
1.3
    	
%
    
	
Flint
    	
 
    	
0.4
    	
%
    
	
Grady
    	
 
    	
0.9
    	
%
    
	
GreyStone   Power
    	
 
    	
6.1
    	
%
    
	
Habersham
    	
 
    	
1.3
    	
%
    
	
Hart
    	
 
    	
1.6
    	
%
    
	
Irwin
    	
 
    	
0.7
    	
%
    
	
Jackson
    	
 
    	
11.1
    	
%
    
	
Jefferson   Energy
    	
 
    	
1.9
    	
%
    
	
Little   Ocmulgee
    	
 
    	
0.5
    	
%
    
	
Middle   Georgia
    	
 
    	
0.4
    	
%
    
	
Mitchell
    	
 
    	
1.6
    	
%
    
	
Ocmulgee
    	
 
    	
0.6
    	
%
    
	
Oconee
    	
 
    	
0.8
    	
%
    
	
Okefenoke
    	
 
    	
1.7
    	
%
    
	
Planters
    	
 
    	
0.8
    	
%
    
	
Rayle
    	
 
    	
0.8
    	
%
    
	
Satilla
    	
 
    	
2.7
    	
%
    
	
Sawnee
    	
 
    	
10.2
    	
%
    
	
Slash   Pine
    	
 
    	
0.5
    	
%
    
	
Snapping   Shoals
    	
 
    	
4.8
    	
%
    
	
Southern   Rivers
    	
 
    	
1.0
    	
%
    
	
Sumter
    	
 
    	
0.9
    	
%
    
	
Three   Notch
    	
 
    	
0.5
    	
%
    
	
Tri-County
    	
 
    	
1.2
    	
%
    
	
Upson
    	
 
    	
0.5
    	
%
    
	
Walton
    	
 
    	
7.9
    	
%
    
	
Washington
    	
 
    	
1.1
    	
%
    
	
 
    	
 
    	
 
    	
 
    
	
Total
    	
 
    	
100.0
    	
%
    

 

 

SCHEDULE 10.1

 

NOTICES

 

	
Borrower
    	
 
    
	
 
    	
 
    
	
Oglethorpe Power Corporation
    	
 
    
	
(An Electric Membership Corporation)
    	
 
    
	
Elizabeth B. Higgins
    	
 
    
	
Chief Financial Officer
    	
 
    
	
2100 East Exchange Place
    	
 
    
	
Tucker, GA 30084-5336
    	
 
    
	
 
    	
 
    
	
Telephone:
    	
770-270-7942
    	
 
    
	
Fax:
    	
770-270-7325
    	
 
    
	
Email: betsy.higgins@opc.com
    	
 
    
	
 
    	
 
    
	
with copies to:
    	
 
    
	
 
    	
 
    
	
Thomas J. Brendiar
    	
 
    
	
Director, Bank and Investor Relations
    	
 
    
	
2100 East Exchange Place
    	
 
    
	
Tucker, GA 30084-5336
    	
 
    
	
 
    	
 
    
	
Telephone:
    	
770-270-7173
    	
 
    
	
Fax:
    	
770-270-7325
    	
 
    
	
Email: tom.brendiar@opc.com
    	
 
    
	
 
    	
 
    
	
and
    	
 
    
	
 
    	
 
    
	
Charles W. Whitney
    	
 
    
	
SVP, General Counsel
    	
 
    
	
2100 East Exchange Place
    	
 
    
	
Tucker, GA 30084-5336
    	
 
    
	
Telephone:
    	
770-270-7913
    	
 
    
	
Fax:
    	
770-270-7977
    	
 
    
	
Email: chuck.whitney@opc.com
    	
 
    

 

 

	
Administrative Agent
    	
 
    
	
 
    	
 
    
	
National Rural Utilities Cooperative Finance   Corporation
    	
 
    
	
 
    	
 
    
	
Kirstie Balducci
    	
 
    
	
National Rural Utilities Cooperative Finance   Corporation
    	
 
    
	
20701 Cooperative Way
    	
 
    
	
Dulles, VA 20166
    	
 
    
	
Attn: Loan Syndications
    	
 
    
	
Telephone:
    	
703-467-1615
    	
 
    
	
Facsimile:
    	
703-467-5681
    	
 
    
	
Email: loansyndications@nrucfc.coop
    	
 
    
	
 
    	
 
    
	
Pam Amaral
    	
 
    
	
National Rural Utilities Cooperative Finance   Corporation
    	
 
    
	
20701 Cooperative Way
    	
 
    
	
Dulles, VA 20166
    	
 
    
	
Attn: Loan Syndications
    	
 
    
	
Telephone:
    	
703-467-1629
    	
 
    
	
Facsimile:
    	
703-467-5681
    	
 
    
	
Email: loansyndications@nrucfc.coop
    	
 
    

 

Wire Instructions:

 

	
Bank   Name
    	
JP   Morgan Chase
    
	
ABA   Number
    	
021   000 021
    
	
City/State
    	
New   York, NY 10081
    
	
Account   Number
    	
700607596
    
	
Account   Name
    	
National   Rural Utilities Cooperative Finance Corp. Oglethorpe Power Corporation Admin   Agent Account
    
	
Reference
    	
Oglethorpe   Power Corporation Admin Agent Account
    

 

 

EXHIBIT 2.2(a)-1

 

FORM OF COMMITTED LOAN NOTICE

 

Date:                        ,       

 

To:                            National Rural Utilities Cooperative Finance Corporation, as Administrative Agent

 

Borrower Name:  OGLETHORPE POWER CORPORATION (AN ELECTRIC MEMBERSHIP CORPORATION)

 

Facility Name:  Credit Agreement, dated as of March 23, 2015 (as amended, restated, extended, supplemented or otherwise modified in writing from time to time, the “Credit Agreement;” the terms defined therein being used herein as therein defined), among OGLETHORPE POWER CORPORATION (AN ELECTRIC MEMBERSHIP CORPORATION) (the “Borrower”), the Lenders and L/C Issuers from time to time party thereto and National Rural Utilities Cooperative Finance Corporation, as Administrative Agent, Swing Line Lender and an L/C Issuer.

 

Facility Number:     [•] (to be completed by Administrative Agent)

 

Category of Borrowing: Committed Borrowing (revolving loan)

 

Effective Date of Borrowing:                                    (a Business Day)

 

The Borrowing Amount:  $                      

 

Interest Rate Elected (Type of Committed Loans Requested):

 

	
o Base   Rate Loans
    	
o Eurodollar   Rate Loans
    

 

Interest Period Elections if Eurodollar Rate Loans are chosen:

 

	
o 1-month
    	
o 2-months
    	
 
    
	
o 3-months
    	
o 6-months
    	
 
    

 

Wiring Instructions:

 

	
Bank Name
    	
 
    	
 
    
	
City, State
    	
 
    	
 
    
	
ABA No
    	
 
    	
 
    
	
Account No
    	
 
    	
 
    
	
Credit Account Name
    	
 
    	
 
    
	
Additional Instructions
    	
 
    	
 
    

 

 

Certification

 

Acting on behalf of the Borrower, I hereby certify that as of the date below:

 

(1)                                 I am duly authorized to make this certification and to request a Committed Borrowing on the terms specified herein;

 

(2)                                 The Committed Borrowing requested herein complies with the requirements of the provisos to the first sentence of Section 2.1 of the Credit Agreement;

 

(3)                                 On and as of the effective date of the requested Committed Borrowing, immediately after giving effect to the funding and the application thereof, the representations and warranties made by the Borrower in any Loan Document [(other than the representations and warranties set forth in Sections 5.8, 5.15 and 5.16 of the Credit Agreement)](1) are true and correct in all material respects at and as if made as of such date, except to the extent they expressly relate to an earlier date, in which case such representations and warranties shall be true and correct in all material respects as of such earlier date;

 

(4)                                 No Default or Event of Default exists or is continuing or will be caused by giving effect to this Committed Loan Notice; and

 

(5)                                 There shall not have occurred (i) any modification, termination or enactment of any law, rule, regulation, order or decree of any Governmental Authority, including, without limitation, the Georgia Territorial Electric Service Act of 1973, or (ii) any other action or event that, in either case of clause (i) or (ii), would have the effect of materially altering the service area of any Member or eliminating the exclusive right of any Member to distribute electricity within such area (subject to the exception to exclusivity existing on the Closing Date as set forth in the Georgia Territorial Electric Service Act of 1973), in each case of clauses (i) and (ii) so as to adversely affect the ability of a Member to perform its obligations under its Wholesale Power Contract, other than in connection with an assignment of such Member’s service territory and Wholesale Power Contract where such Member’s rights to substantially all of its service territory and obligations under its Wholesale Power Contract are simultaneously assumed by another Member or other assignee; provided that in the case of a non-Member assignee, such assignee must have either (x) a Credit Rating equal to or better than the Credit Rating of the assigning Member as published by S&P, Moody’s or Fitch or (y) if the assigning Member has no such published Credit Rating, a Credit Rating equal to or better than the Borrower’s Credit Rating as published by S&P, Moody’s or Fitch.

 

(1)  Delete bracketed language if requesting Closing Date loans.

 

 

	
Certified   By:
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
Signature
    	
 
    	
Name:
    
	
Date:
    	
 
    	
Title:
    
	
 
    	
 
    	
 
    
	
Attn:   Loan Syndications
    	
 
    	
 
    
	
Fax   Number: (703) 467-5681
    	
 
    	
 
    
	
Email:   loansyndications@nrucfc.coop
    	
 
    	
 
    

 

 

EXHIBIT 2.2(a)-2

 

FORM OF INTEREST ELECTION NOTICE

 

Date:                        ,       

 

To:                            National Rural Utilities Cooperative Finance Corporation, as Administrative Agent

 

Borrower Name:  OGLETHORPE POWER CORPORATION (AN ELECTRIC MEMBERSHIP CORPORATION)

 

Facility Name:  Credit Agreement, dated as of March 23, 2015 (as amended, restated, extended, supplemented or otherwise modified in writing from time to time, the “Credit Agreement;” the terms defined therein being used herein as therein defined), among OGLETHORPE POWER CORPORATION (AN ELECTRIC MEMBERSHIP CORPORATION) (the “Borrower”), the Lenders and L/C Issuers from time to time party thereto and National Rural Utilities Cooperative Finance Corporation, as Administrative Agent, Swing Line Lender and an L/C Issuer.

 

Loan Number:        [•] (to be completed by Administrative Agent)

 

Original Effective Date of Borrowing:                                    (a Business Day)

 

Effective Date of Interest Election:                                         (a Business Day)

 

The Amount of Borrowing*:                                 

 

* If different options are being elected with respect to different portions of the original Borrowing, indicate also the portion of the original Borrowing to be allocated to this Interest Election Request.

 

Interest Rate Elected:

 

	
o Base Rate   Loans
    	
o Eurodollar   Rate Loans
    

 

Interest Period Elections if Eurodollar Rate Loans are chosen:

 

	
o 1-month
    	
o 2-months
    	
 
    
	
o 3-months
    	
o 6-months
    	
 
    

 

 

Certification

 

Acting on behalf of the Borrower, I hereby certify that as of the date below I am duly authorized to make this certification and to make the Interest Election Notice on the terms specified herein.

 

	
Certified   By:
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
Signature
    	
 
    	
Name:
    
	
Date:
    	
 
    	
Title:
    
	
 
    	
 
    	
 
    
	
Attn:   Loan Syndications
    	
 
    	
 
    
	
Fax   Number: (703) 467-5681
    	
 
    	
 
    
	
Email:   loansyndications@nrucfc.coop
    	
 
    	
 
    

 

 

EXHIBIT 2.4

 

FORM OF SWING LINE LOAN NOTICE

 

Date:                        ,          

 

To:                             National Rural Utilities Cooperative Finance Corporation, as Swing Line Lender
 National Rural Utilities Cooperative Finance Corporation, as Administrative Agent

 

Borrower Name:  OGLETHORPE POWER CORPORATION (AN ELECTRIC MEMBERSHIP CORPORATION)

 

Facility Name:  Credit Agreement, dated as of March 23, 2015 (as amended, restated, extended, supplemented or otherwise modified in writing from time to time, the “Credit Agreement;” the terms defined therein being used herein as therein defined), among OGLETHORPE POWER CORPORATION (AN ELECTRIC MEMBERSHIP CORPORATION) (the “Borrower”), the Lenders and L/C Issuers from time to time party thereto and National Rural Utilities Cooperative Finance Corporation, as Administrative Agent, Swing Line Lender and an L/C Issuer.

 

Facility Number:      [•] (to be completed by Administrative Agent)

 

Category of Borrowing:  Swing Line Borrowing

 

Effective Date of Borrowing:                                                     (a Business Day)

 

The Borrowing Amount:  $                              

 

 

Certification

 

Acting on behalf of the Borrower, I hereby certify that as of the date below:

 

(1)                                 I am duly authorized to make this certification and to request a Swing Line Borrowing on the terms specified herein;

 

(2)                                 The Swing Line Borrowing requested herein complies with the requirements of the provisos to the first sentence of Section 2.4(a) of the Credit Agreement;

 

(3)                                 On and as of the effective date of the requested Swing Line Borrowing, immediately after giving effect to the funding and the application thereof, the representations and warranties made by the Borrower in any Loan Document [(other than the representations and warranties set forth in Sections 5.8, 5.15 and 5.16 of the Credit Agreement)](2) are true and correct in all material respects at and as if made as of such date, except to the extent they expressly relate to an earlier date, in which case such representations and warranties shall be true and correct in all material respects as of such earlier date;

 

(4)                                 No Default or Event of Default exists or is continuing or will be caused by giving effect to this Swing Line Loan Notice; and

 

(5)                                 There shall not have occurred (i) any modification, termination or enactment of any law, rule, regulation, order or decree of any Governmental Authority, including, without limitation, the Georgia Territorial Electric Service Act of 1973, or (ii) any other action or event that, in either case of clause (i) or (ii), would have the effect of materially altering the service area of any Member or eliminating the exclusive right of any Member to distribute electricity within such area (subject to the exception to exclusivity existing on the Closing Date as set forth in the Georgia Territorial Electric Service Act of 1973), in each case of clauses (i) and (ii) so as to adversely affect the ability of a Member to perform its obligations under its Wholesale Power Contract, other than in connection with an assignment of such Member’s service territory and Wholesale Power Contract where such Member’s rights to substantially all of its service territory and obligations under its Wholesale Power Contract are simultaneously assumed by another Member or other assignee; provided that in the case of a non-Member assignee, such assignee must have either (x) a Credit Rating equal to or better than the Credit Rating of the assigning Member as published by S&P, Moody’s or Fitch or (y) if the assigning Member has no such published Credit Rating, a Credit Rating equal to or better than the Borrower’s Credit Rating as published by S&P, Moody’s or Fitch.

 

(2)  Delete bracketed language if requesting Closing Date loans.

 

 

	
Certified   By:
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
Signature
    	
 
    	
Name:
    
	
Date:
    	
 
    	
Title:
    
	
 
    	
 
    	
 
    
	
Attn:   Loan Syndications
    	
 
    	
 
    
	
Fax   Number: (703) 467-5681
    	
 
    	
 
    
	
Email:   loansyndications@nrucfc.coop
    	
 
    	
 
    

 

 

EXHIBIT 2.11

 

FORM OF NOTE

 

                 ,      

 

FOR VALUE RECEIVED, OGLETHORPE POWER CORPORATION (AN ELECTRIC MEMBERSHIP CORPORATION) (the “Borrower”), hereby promises to pay to                                 (the “Lender”), at the office of National Rural Utilities Cooperative Finance Corporation (the “Administrative Agent”) as set forth in that certain Credit Agreement, dated as of March 23, 2015, among the Borrower, the Lenders party thereto (including the Lender), the L/C Issuers party thereto and National Rural Utilities Cooperative Finance Corporation, as Administrative Agent, Swing Line Lender and an L/C Issuer (as the same may be amended, modified, extended or restated from time to time, the “Credit Agreement”) or at such other place or places as the holder of this Note may designate, the aggregate principal amount of all advances made by the Lender as Loans (and not otherwise repaid), in Dollars and in immediately available funds, on the dates and in the principal amounts provided in the Credit Agreement, and to pay interest on the unpaid principal amount of each Loan made by the Lender, at such office, in like money and funds, for the period commencing on the date of each Loan until each Loan shall be paid in full, at the rates per annum and on the dates provided in the Credit Agreement.

 

This Note is one of the Notes referred to in the Credit Agreement and evidences Loans made by the Lender thereunder. The Lender shall be entitled to the benefits of the Credit Agreement.  Capitalized terms used in this Note have the respective meanings assigned to them in the Credit Agreement and the terms and conditions of the Credit Agreement are expressly incorporated herein and made a part hereof

 

The Credit Agreement provides for the acceleration of the maturity of the Loans evidenced by this Note upon the occurrence of certain events (and for payment of collection costs in connection therewith) and for prepayments of Loans upon the terms and conditions specified therein. In the event this Note is not paid when due at any stated or accelerated maturity, the Borrower agrees to pay, in addition to the principal and interest, all costs of collection, including reasonable attorney fees.

 

Except as permitted by Section 10.3 of the Credit Agreement, this Note may not be assigned by the Lender to any other Person.

 

The date, amount, type, interest rate and duration of Interest Period (if applicable) of each Loan made by the Lender to the Borrower, and each payment made on account of the principal thereof, shall be recorded by the Administrative Agent and the Lender on their respective books; provided that the failure of the Administrative Agent or the Lender to make any such recordation shall not affect the obligations of the Borrower to make a payment when due of any amount owing hereunder or under this Note in respect of the Loans to be evidenced by this Note, and each such recordation shall be prima facie evidence of the obligations owing under this Note absent manifest error.

 

 

The Borrower, for itself and its successors and assigns, hereby waives diligence, presentment, protest and demand and notice of protest, demand, dishonor and non-payment of this Note.

 

THIS NOTE SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF GEORGIA.

 

IN WITNESS WHEREOF, the Borrower has caused this Note to be executed as of the date first above written.

 

	
 
    	
OGLETHORPE   POWER CORPORATION
    
	
 
    	
(AN   ELECTRIC MEMBERSHIP CORPORATION)
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
 
    
	
 
    	
Name:
    	
 
    
	
 
    	
Title:
    	
 
    

 

 

LOANS AND PAYMENTS WITH RESPECT THERETO

 

	
Date
    	
 
    	
Type of
   Loan Made
    	
 
    	
Amount of
   Loan Made
    	
 
    	
End of
   Interest
   Period
    	
 
    	
Amount of
   Principal or
   Interest
   Paid This
   Date
    	
 
    	
Outstanding
   Principal
   Balance
   This Date
    	
 
    	
Notation
   Made By
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    

 

 

EXHIBIT 3.1(g)-1

 

[FORM OF]

 

U.S. TAX COMPLIANCE CERTIFICATE

(For Foreign Lenders That Are Not Partnerships For U.S. Federal Income Tax Purposes)

 

Reference is hereby made to the Credit Agreement, dated as of March 23, 2015 (as amended, restated, extended, supplemented or otherwise modified in writing from time to time, the “Credit Agreement”), among Oglethorpe Power Corporation (An Electric Membership Corporation) (the “Borrower”), the Lenders and L/C Issuers party thereto and National Rural Utilities Cooperative Finance Corporation, as Administrative Agent, Swing Line Lender and an L/C Issuer.

 

Pursuant to the provisions of Section 3.1 of the Credit Agreement, the undersigned hereby certifies that (i) it is the sole record and beneficial owner of the Loan(s) (as well as any Note(s) evidencing such Loan(s)) in respect of which it is providing this certificate, (ii) it is not a bank within the meaning of Section 881(c)(3)(A) of the Code, (iii) it is not a ten percent shareholder of the Borrower within the meaning of Section 871(h)(3)(B) of the Code and (iv) it is not a controlled foreign corporation related to the Borrower as described in Section 881(c)(3)(C) of the Code.

 

The undersigned has furnished the Administrative Agent and the Borrower with a certificate of its non-U.S. Person status on IRS Form W-8BEN or W-8BEN-E.  By executing this certificate, the undersigned agrees that (1) if the information provided on this certificate changes, the undersigned shall promptly so inform the Borrower and the Administrative Agent, and (2) the undersigned shall have at all times furnished the Borrower and the Administrative Agent with a properly completed and currently effective certificate in either the calendar year in which each payment is to be made to the undersigned, or in either of the two calendar years preceding such payments.

 

Unless otherwise defined herein, terms defined in the Credit Agreement and used herein shall have the meanings given to them in the Credit Agreement.

 

 

	
[NAME OF LENDER]
    	
 
    
	
 
    	
 
    	
 
    
	
By:
    	
 
    	
 
    
	
 
    	
Name:
    	
 
    
	
 
    	
Title:
    	
 
    
	
 
    	
 
    	
 
    
	
Date:                          , 20[  ]
    	
 
    

 

 

EXHIBIT 3.1(g)-2

 

[FORM OF]

 

U.S. TAX COMPLIANCE CERTIFICATE

(For Foreign Participants That Are Not Partnerships For U.S. Federal Income Tax Purposes)

 

Reference is hereby made to the Credit Agreement, dated as of March 23, 2015 (as amended, restated, extended, supplemented or otherwise modified in writing from time to time, the “Credit Agreement”), among Oglethorpe Power Corporation (An Electric Membership Corporation) (the “Borrower”), the Lenders and L/C Issuers party thereto and National Rural Utilities Cooperative Finance Corporation, as Administrative Agent, Swing Line Lender and an L/C Issuer.

 

Pursuant to the provisions of Section 3.1 of the Credit Agreement, the undersigned hereby certifies that (i) it is the sole record and beneficial owner of the participation in respect of which it is providing this certificate, (ii) it is not a bank within the meaning of Section 881(c)(3)(A) of the Code, (iii) it is not a ten percent shareholder of the Borrower within the meaning of Section 871(h)(3)(B) of the Code, and (iv) it is not a controlled foreign corporation related to the Borrower as described in Section 881(c)(3)(C) of the Code.

 

The undersigned has furnished its participating Lender with a certificate of its non-U.S. Person status on IRS Form W-8BEN or W-8BEN-E.  By executing this certificate, the undersigned agrees that (1) if the information provided on this certificate changes, the undersigned shall promptly so inform such Lender in writing, and (2) the undersigned shall have at all times furnished such Lender with a properly completed and currently effective certificate in either the calendar year in which each payment is to be made to the undersigned, or in either of the two calendar years preceding such payments.

 

Unless otherwise defined herein, terms defined in the Credit Agreement and used herein shall have the meanings given to them in the Credit Agreement.

 

 

	
[NAME OF PARTICIPANT]
    	
 
    
	
 
    	
 
    	
 
    
	
By:
    	
 
    	
 
    
	
 
    	
Name:
    	
 
    
	
 
    	
Title:
    	
 
    
	
 
    	
 
    
	
Date:                 ,   20[  ]
    	
 
    

 

 

EXHIBIT 3.1(g)-3

 

[FORM OF]

 

U.S. TAX COMPLIANCE CERTIFICATE

(For Foreign Participants That Are Partnerships For U.S. Federal Income Tax Purposes)

 

Reference is hereby made to the Credit Agreement, dated as of March 23, 2015 (as amended, restated, extended, supplemented or otherwise modified in writing from time to time, the “Credit Agreement”), among Oglethorpe Power Corporation (An Electric Membership Corporation) (the “Borrower”), the Lenders and L/C Issuers party thereto and National Rural Utilities Cooperative Finance Corporation, as Administrative Agent, Swing Line Lender and an L/C Issuer.

 

Pursuant to the provisions of Section 3.1 of the Credit Agreement, the undersigned hereby certifies that (i) it is the sole record owner of the participation in respect of which it is providing this certificate, (ii) its direct or indirect partners/members are the sole beneficial owners of such participation, (iii) with respect such participation, neither the undersigned nor any of its direct or indirect partners/members is a bank extending credit pursuant to a loan agreement entered into in the ordinary course of its trade or business within the meaning of Section 881(c)(3)(A) of the Code, (iv) none of its direct or indirect partners/members is a ten percent shareholder of the Borrower within the meaning of Section 871(h)(3)(B) of the Code and (v) none of its direct or indirect partners/members is a controlled foreign corporation related to the Borrower as described in Section 881(c)(3)(C) of the Code.

 

The undersigned has furnished its participating Lender with IRS Form W-8IMY accompanied by one of the following forms from each of its partners/members that is claiming the portfolio interest exemption: (i) an IRS Form W-8BEN or W 8BEN E, or (ii) an IRS Form W-8IMY accompanied by an IRS Form W-8BEN or W-8BEN-E from each of such partner’s/member’s beneficial owners that is claiming the portfolio interest exemption.  By executing this certificate, the undersigned agrees that (1) if the information provided on this certificate changes, the undersigned shall promptly so inform such Lender and (2) the undersigned shall have at all times furnished such Lender with a properly completed and currently effective certificate in either the calendar year in which each payment is to be made to the undersigned, or in either of the two calendar years preceding such payments.

 

Unless otherwise defined herein, terms defined in the Credit Agreement and used herein shall have the meanings given to them in the Credit Agreement.

 

 

	
[NAME OF PARTICIPANT]
    	
 
    
	
 
    	
 
    
	
 
    	
 
    	
 
    
	
By:
    	
 
    	
 
    
	
 
    	
Name:
    	
 
    
	
 
    	
Title:
    	
 
    
	
 
    	
 
    	
 
    
	
Date:
    	
                   , 20[  ]
    	
 
    

 

 

EXHIBIT 3.1(g)-4

 

 

[FORM OF]

 

U.S. TAX COMPLIANCE CERTIFICATE

(For Foreign Lenders That Are Partnerships For U.S. Federal Income Tax Purposes)

 

Reference is hereby made to the Credit Agreement, dated as of March 23, 2015 (as amended, restated, extended, supplemented or otherwise modified in writing from time to time, the “Credit Agreement”), among Oglethorpe Power Corporation (An Electric Membership Corporation) (the “Borrower”), the Lenders and L/C Issuers party thereto and National Rural Utilities Cooperative Finance Corporation, as Administrative Agent, Swing Line Lender and an L/C Issuer.

 

Pursuant to the provisions of Section 3.1 of the Credit Agreement, the undersigned hereby certifies that (i) it is the sole record owner of the Loan(s) (as well as any Note(s) evidencing such Loan(s)) in respect of which it is providing this certificate, (ii) its direct or indirect partners/members are the sole beneficial owners of such Loan(s) (as well as any Note(s) evidencing such Loan(s)), (iii) with respect to the extension of credit pursuant to this Credit Agreement or any other Loan Document, neither the undersigned nor any of its direct or indirect partners/members is a bank extending credit pursuant to a loan agreement entered into in the ordinary course of its trade or business within the meaning of Section 881(c)(3)(A) of the Code, (iv) none of its direct or indirect partners/members is a ten percent shareholder of the Borrower within the meaning of Section 871(h)(3)(B) of the Code and (v) none of its direct or indirect partners/members is a controlled foreign corporation related to the Borrower as described in Section 881(c)(3)(C) of the Code.

 

The undersigned has furnished the Administrative Agent and the Borrower with IRS Form W-8IMY accompanied by one of the following forms from each of its partners/members that is claiming the portfolio interest exemption: (i) an IRS Form W-8BEN or W-8BEN-E, or (ii) an IRS Form W-8IMY accompanied by an IRS Form W-8BEN or W-8BEN-E from each of such partner’s/member’s beneficial owners that is claiming the portfolio interest exemption.  By executing this certificate, the undersigned agrees that (1) if the information provided on this certificate changes, the undersigned shall promptly so inform the Borrower and the Administrative Agent, and (2) the undersigned shall have at all times furnished the Borrower and the Administrative Agent with a properly completed and currently effective certificate in either the calendar year in which each payment is to be made to the undersigned, or in either of the two calendar years preceding such payments.

 

 

Unless otherwise defined herein, terms defined in the Credit Agreement and used herein shall have the meanings given to them in the Credit Agreement.

 

 

	
[NAME OF LENDER]
    	
 
    
	
 
    	
 
    
	
 
    	
 
    	
 
    
	
By:
    	
 
    	
 
    
	
 
    	
Name:
    	
 
    
	
 
    	
Title:
    	
 
    
	
 
    	
 
    	
 
    
	
Date:
    	
                   , 20[  ]
    	
 
    

 

 

EXHIBIT 6.1(c)

 

FORM OF OFFICER’S CERTIFICATE

 

TO:                           NATIONAL RURAL UTILITIES COOPERATIVE FINANCE CORPORATION, as Administrative Agent

 

RE:                           Credit Agreement, dated as of March 23, 2015, among OGLETHORPE POWER CORPORATION (AN ELECTRIC MEMBERSHIP CORPORATION) (the “Borrower”), the Lenders and L/C Issuers party thereto and National Rural Utilities Cooperative Finance Corporation, as Administrative Agent, Swing Line Lender and an L/C Issuer (as the same may be amended, modified, extended or restated from time to time, the “Credit Agreement”)

 

DATE :                                                                                            ,           

 

Pursuant to the terms of the Credit Agreement, I,                                                         ,                           , of the Borrower, hereby certify on behalf of the Borrower that, as of the quarter/year ending                   ,             , the statements below are accurate and complete in all material respects (all capitalized terms used herein unless otherwise defined shall have the meanings set forth in the Credit Agreement):

 

a.                                      No Default or Event of Default exists under the Credit Agreement, except as indicated on a separate page attached hereto, together with an explanation of the action taken or proposed to be taken by the Borrower with respect thereto.

 

b.                                      The quarterly/annual financial statements for the fiscal period cited above delivered pursuant to Section 6.1(a)/6.1(b) of the Credit Agreement are true and correct and have been prepared in accordance with GAAP (in the case of any quarterly financial statements, subject to changes resulting from audit and normal year-end audit adjustments).  As of the end of such fiscal period, Patronage Capital of the Borrower was at least $675,000,000.

 

c.                                       In connection with the delivery of annual financial statements only, attached hereto as Schedule 1 is an updated Schedule 5.20 (Gross Member Revenues) of the Credit Agreement (calculated as of the last day of the prior fiscal year).

 

	
 
    	
OGLETHORPE   POWER CORPORATION
    
	
 
    	
(AN   ELECTRIC MEMBERSHIP CORPORATION)
    
	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
 
    
	
 
    	
Name:
    	
 
    
	
 
    	
Title:
    	
 
    

 

 

Schedule 1 to Officer’s Certificate

 

Schedule 6.22 (Gross Member Revenues)(1)

 

(1)  In connection with the delivery of annual financial statements only

 

 

EXHIBIT 10.3(b)

 

FORM OF

ASSIGNMENT AND ASSUMPTION

 

This Assignment and Assumption (the “Assignment and Assumption”) is dated as of the Effective Date set forth below and is entered into by and between [the][each](1) Assignor identified in item 1 below ([the][each, an] “Assignor”) and [the][each] (2) Assignee identified in item 2 below ([the][each, an] “Assignee”).  [It is understood and agreed that the rights and obligations of [the Assignors][the Assignees](3) hereunder are several and not joint.](4)  Capitalized terms used but not defined herein shall have the meanings given to them in the Credit Agreement identified below (as amended, the “Credit Agreement”), receipt of a copy of which is hereby acknowledged by [the][each] Assignee.  The Standard Terms and Conditions set forth in Annex 1 attached hereto are hereby agreed to and incorporated herein by reference and made a part of this Assignment and Assumption as if set forth herein in full.

 

For an agreed consideration, [the][each] Assignor hereby irrevocably sells and assigns to [the Assignee][the respective Assignees], and [the][each] Assignee hereby irrevocably purchases and assumes from [the Assignor][the respective Assignors], subject to and in accordance with the Standard Terms and Conditions and the Credit Agreement, as of the Effective Date inserted by the Administrative Agent as contemplated below (i) all of [the Assignor’s][the respective Assignors’] rights and obligations in [its capacity as a Lender][their respective capacities as Lenders] under the Credit Agreement and any other documents or instruments delivered pursuant thereto to the extent related to the amount and percentage interest identified below of all of such outstanding rights and obligations of [the Assignor][the respective Assignors] under the Credit Agreement, and (ii) to the extent permitted to be assigned under applicable law, all claims, suits, causes of action and any other right of [the Assignor (in its capacity as a Lender)][the respective Assignors (in their respective capacities as Lenders)] against any Person, whether known or unknown, arising under or in connection with the Credit Agreement, any other documents or instruments delivered pursuant thereto or the loan transactions governed thereby or in any way based on or related to any of the foregoing, including, but not limited to, contract claims, tort claims, malpractice claims, statutory claims and all other claims at law or in equity related to the rights and obligations sold and assigned pursuant to clause (i) above (the rights and obligations sold and assigned by [the][any] Assignor to [the][any] Assignee pursuant to clauses (i) and (ii) above being referred to herein collectively as [the][an] “Assigned Interest”).  Each such sale and assignment is without recourse to [the][any] Assignor and, except as expressly provided in this Assignment and Assumption, without representation or warranty by [the][any] Assignor.

 

(1)  For bracketed language here and elsewhere in this form relating to the Assignor(s), if the assignment is from a single Assignor, choose the first bracketed language.  If the assignment is from multiple Assignors, choose the second bracketed language.

(2)  For bracketed language here and elsewhere in this form relating to the Assignee(s), if the assignment is to a single Assignee, choose the first bracketed language.  If the assignment is to multiple Assignees, choose the second bracketed language.

(3)  Select as appropriate.

(4)  Include bracketed language if there are either multiple Assignors or multiple Assignees.

 

 

1.                                      Assignor[s]:

 

2.                                      Assignee[s]:

 

[Assignee is an [Affiliate][Approved Fund] of [identify Lender]

 

3.                                      Borrower(s):                                                                             OGLETHORPE POWER CORPORATION (AN ELECTRIC MEMBERSHIP CORPORATION)

 

4.                                      Administrative Agent:                         National Rural Utilities Cooperative Finance Corporation, as the administrative agent under the Credit Agreement

 

5.                                      Credit Agreement:                                             The Credit Agreement, dated as of March 23, 2015, by and among OGLETHORPE POWER CORPORATION (AN ELECTRIC MEMBERSHIP CORPORATION), as borrower (the “Borrower”), the Lenders and L/C Issuers party thereto and National Rural Utilities Cooperative Finance Corporation, as Administrative Agent, Swing Line Lender and an L/C Issuer (as amended, restated, extended, supplemented or otherwise modified in writing from time to time, the “Credit Agreement”)

 

6.                                      Assigned Interest[s]:

 

	
Assignor[s](5)
    	
 
    	
Assignee[s](6)
    	
 
    	
Aggregate Amount of
   Commitment/Loans
   for all Lenders(7)
    	
 
    	
Amount of
   Commitment/Loans
   Assigned(8)
    	
 
    	
Percentage
   Assigned of
   Commitment/
   Loans(8)
    	
 
    	
CUSIP
   Number
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
$
    	
 
    	
 
    	
$
    	
 
    	
 
    	
 
    	
%
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
$
    	
 
    	
 
    	
$
    	
 
    	
 
    	
 
    	
%
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
$
    	
 
    	
 
    	
$
    	
 
    	
 
    	
 
    	
%
    	
 
    	
 
    

 

[7.                                  Trade Date:                                                                                                           ](9)

 

[Page break]

 

(5)  List each Assignor, as appropriate.

(6)  List each Assignee, as appropriate.

(7)  Amount to be adjusted by the counterparties to take into account any payments or prepayments made between the Trade Date and the Effective Date.

(8)  Set forth, to at least 9 decimals, as a percentage of the Commitment/Loans of all Lenders thereunder.

(9)  To be completed if the Assignor(s) and the Assignee(s) intend that the minimum assignment amount is to be determined as of the Trade Date.

 

 

Effective Date:                                    , 20       [TO BE INSERTED BY ADMINISTRATIVE AGENT AND WHICH SHALL BE THE EFFECTIVE DATE OF RECORDATION OF TRANSFER IN THE REGISTER THEREFOR.]

 

The terms set forth in this Assignment and Assumption are hereby agreed to:

 

	
 
    	
ASSIGNOR[S](10)
    
	
 
    	
[NAME   OF ASSIGNOR]
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
 
    
	
 
    	
 
    	
Title:
    
	
 
    	
 
    	
 
    
	
 
    	
[NAME   OF ASSIGNOR]
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
 
    
	
 
    	
 
    	
Title:
    
	
 
    	
 
    	
 
    
	
 
    	
ASSIGNEE[S](11)
    
	
 
    	
 
    
	
 
    	
[NAME   OF ASSIGNEE]
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
 
    
	
 
    	
 
    	
Title:
    
	
 
    	
 
    	
 
    
	
 
    	
[NAME   OF ASSIGNEE]
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
 
    
	
 
    	
 
    	
Title:
    

 

(10)  Add additional signature blocks as needed. Include both Fund/Pension Plan and manager making the trade (if applicable).

(11)  Add additional signature blocks as needed. Include both Fund/Pension Plan and manager making the trade (if applicable).

 

 

[Consented to and](12) Accepted:

 

	
NATIONAL RURAL UTILITIES COOPERATIVE FINANCE   CORPORATION,
    
	
as   Administrative Agent
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
By:
    	
 
    	
 
    
	
 
    	
Title:
    	
 
    
	
 
    	
 
    	
 
    
	
Consented   to:
    	
 
    
	
 
    	
 
    
	
NATIONAL RURAL UTILITIES COOPERATIVE FINANCE   CORPORATION,
    
	
as   Swing Line Lender and as L/C Issuer
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
By:
    	
 
    	
 
    
	
 
    	
Title:
    	
 
    
	
 
    	
 
    	
 
    
	
Consented   to:
    	
 
    
	
 
    	
 
    
	
[NAME   OF L/C ISSUER],
    	
 
    
	
as   L/C Issuer
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
By:
    	
 
    	
 
    
	
 
    	
Title:
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
Consented   to:
    	
 
    
	
 
    	
 
    
	
[NAME   OF L/C ISSUER],
    	
 
    
	
as   L/C Issuer
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
By:
    	
 
    	
 
    
	
 
    	
Title:
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
Consented   to:
    	
 
    
	
 
    	
 
    
	
[NAME   OF L/C ISSUER],
    	
 
    
	
as   L/C Issuer
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
By:
    	
 
    	
 
    
	
 
    	
Title:
    	
 
    

 

(12)  To be added only if the consent of the Administrative Agent is required by the terms of the Credit Agreement.

 

 

	
[Consented   to:
    	
 
    
	
 
    	
 
    
	
OGLETHORPE POWER   CORPORATION
    	
 
    
	
(AN   ELECTRIC MEMBERSHIP CORPORATION),
    	
 
    
	
as   Borrower
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
By:
    	
 
    	
 
    
	
 
    	
Title:](13)
    	
 
    

 

(13)  To be added only if the consent of the Borrower is required by the terms of the Credit Agreement.

 

 

ANNEX 1

 

Credit Agreement, dated as of March 23, 2015, by and among OGLETHORPE POWER CORPORATION (AN ELECTRIC MEMBERSHIP CORPORATION), as the Borrower, the Lenders and L/C Issuers party thereto and National Rural Utilities Cooperative Finance Corporation, as Administrative Agent, Swing Line Lender and an L/C Issuer

 

STANDARD TERMS AND CONDITIONS FOR

ASSIGNMENT AND ASSUMPTION

 

1.                                      Representations and Warranties.

 

1.1                               Assignor[s].  [The][Each] Assignor (a) represents and warrants that (i) it is the legal and beneficial owner of [the][the relevant] Assigned Interest, (ii) [the][such] Assigned Interest is free and clear of any lien, encumbrance or other adverse claim, (iii) it has full power and authority, and has taken all action necessary, to execute and deliver this Assignment and Assumption and to consummate the transactions contemplated hereby and (iv) it is not a Defaulting Lender; and (b) assumes no responsibility with respect to (i) any statements, warranties or representations made in or in connection with the Credit Agreement or any other Loan Document, (ii) the execution, legality, validity, enforceability, genuineness, sufficiency or value of the Loan Documents or any collateral thereunder, (iii) the financial condition of the Borrower, any of its Subsidiaries or Affiliates or any other Person obligated in respect of any Loan Document, or (iv) the performance or observance by the Borrower, any of its Subsidiaries or Affiliates or any other Person of any of their respective obligations under any Loan Document.

 

1.2.                            Assignee[s].  [The][Each] Assignee (a) represents and warrants that (i) it has full power and authority, and has taken all action necessary, to execute and deliver this Assignment and Assumption and to consummate the transactions contemplated hereby and to become a Lender under the Credit Agreement, (ii) it meets all the requirements to be an assignee under Section 10.3 of the Credit Agreement (subject to such consents, if any, as may be required thereunder), (iii) from and after the Effective Date, it shall be bound by the provisions of the Credit Agreement as a Lender thereunder and, to the extent of [the][the relevant] Assigned Interest, shall have the obligations of a Lender thereunder, (iv) it is sophisticated with respect to decisions to acquire assets of the type represented by the Assigned Interest and either it, or the Person exercising discretion in making its decision to acquire the Assigned Interest, is experienced in acquiring assets of such type, (v) it has received a copy of the Credit Agreement, and has received or has been accorded the opportunity to receive copies of the most recent financial statements delivered pursuant to Section 6.1 thereof, as applicable, and such other documents and information as it deems appropriate to make its own credit analysis and decision to enter into this Assignment and Assumption and to purchase [the][such] Assigned Interest, (vi) it has, independently and without reliance upon the Administrative Agent or any other Lender and based on such documents and information as it has deemed appropriate, made its own credit analysis and decision to enter into this Assignment and Assumption and to purchase [the][such] Assigned Interest, and (vii) if it is a Foreign Lender attached to the Assignment and Assumption is any documentation required to be delivered by it pursuant to the terms of the Credit Agreement, duly completed and executed by [the][such] Assignee; and (b) agrees that (i) it will,

 

 

independently and without reliance on the Administrative Agent, [the][any] Assignor or any other Lender, and based on such documents and information as it shall deem appropriate at the time, continue to make its own credit decisions in taking or not taking action under the Loan Documents, and (ii) it will perform in accordance with their terms all of the obligations which by the terms of the Loan Documents are required to be performed by it as a Lender.

 

2.                                      Payments. From and after the Effective Date, the Administrative Agent shall make all payments in respect of [the][each] Assigned Interest (including payments of principal, interest, fees and other amounts) to [the][the relevant] Assignee whether such amounts have accrued prior to, on or after the Effective Date.  The Assignor[s] and the Assignee[s] shall make all appropriate adjustments in payments by the Administrative Agent for periods prior to the Effective Date or with respect to the making of this assignment directly between themselves.  Notwithstanding the foregoing, the Administrative Agent shall make all payments of interest, fees or other amounts paid or payable in kind from and after the Effective Date to [the][the relevant] Assignee.

 

3.                                      General Provisions. This Assignment and Assumption shall be binding upon, and inure to the benefit of, the parties hereto and their respective successors and assigns.  This Assignment and Assumption may be executed in any number of counterparts, which together shall constitute one instrument.  Delivery of an executed counterpart of a signature page of this Assignment and Assumption by facsimile shall be effective as delivery of a manually executed counterpart of this Assignment and Assumption.  This Assignment and Assumption shall be governed by, and construed in accordance with, the law of the State of Georgia.Exhibit 10.22

***Text Omitted and Filed Separately
Execution Copy
with the Securities and Exchange Commission.

Confidential Treatment Requested

Under 17 C.F.R. Section 20080(b)(4) and Rule 406 of the

Securities Act of 1933, as amended.

 

 

 

 

 

 

 

 

 

 

 

RESEARCH COLLABORATION

AND

LICENSE AGREEMENT

 

by and between

 

AMGEN INC.

 

and

 

KITE PHARMA, INC.

 

Dated as of December 31, 2014

 

 

 

 

Amgen Contract No. 2014635177

Execution Copy

 

Table of Contents 

 

	
ARTICLE 1.  DEFINITIONS
	
 1

	
ARTICLE 2.  RESEARCH COLLABORATION
	
 13

	
2.1
	
Management
	
 13

	
ARTICLE 3.  PRECLINICAL DEVELOPMENT ACTIVITIES
	
 16

	
3.1
	
Target Selection
	
 16

	
3.2
	
Substitute Targets
	
 17

	
3.3
	
Amgen Expansion Option; Additional Targets
	
 17

	
3.4
	
Preclinical Development Plan
	
 18

	
3.5
	
Preclinical Development of Products
	
 18

	
3.6
	
Subcontracting
	
 18

	
3.7
	
Data
	
 19

	
3.8
	
Exclusivity
	
 19

	
ARTICLE 4.  LICENSE GRANT
	
 20

	
4.1
	
Grant
	
 20

	
4.2
	
Amgen Optioned Target
	
 21

	
4.3
	
Sublicenses
	
 21

	
4.4
	
Transfer of Amgen Licensed Know-How
	
 21

	
4.5
	
Sharing of Materials
	
 22

	
4.6
	
No Other Rights
	
 22

	
ARTICLE 5.  SUPPLY
	
 22

Amgen Contract No. 2014635177i

Execution Copy

 

	
5.1
	
Supply and Quality Agreement
	
 22

	
5.2
	
Transition of Supply
	
 23

	
5.3
	
Kite Products
	
 24

	
ARTICLE 6.  REGULATORY MATTERS
	
 24

	
6.1
	
Amgen Responsibility
	
 24

	
6.2
	
Manufacturing Matters
	
 24

	
6.3
	
Kite Responsibility
	
 24

	
ARTICLE 7.  DEVELOPMENT AND COMMERCIAL MATTERS
	
 25

	
7.1
	
Amgen Responsibility
	
 25

	
7.2
	
Kite Responsibility
	
 25

	
7.3
	
Diligence
	
 25

	
7.4
	
Reports
	
 25

	
ARTICLE 8.  FEES, ROYALTIES, & PAYMENTS
	
 25

	
8.1
	
Upfront and Milestone Payments
	
 25

	
8.2
	
Royalties
	
 28

	
8.3
	
Mutual Convenience of the Parties
	
 31

	
8.4
	
No Other Compensation
	
 31

	
8.5
	
Method of Payment
	
 31

	
8.6
	
Currency Conversion
	
 32

	
8.7
	
Late Payments
	
 32

ii

Execution Copy

 

	
8.8
	
Records and Audits
	
 32

	
8.9
	
Taxes
	
 33

	
ARTICLE 9.  INTELLECTUAL PROPERTY AND PATENT RIGHTS
	
 33

	
9.1
	
Intellectual Property Ownership
	
 33

	
9.2
	
Patent Prosecution
	
 34

	
9.3
	
Patent Term Extensions
	
 36

	
9.4
	
Defense and Settlement of Third Party Claims
	
 36

	
9.5
	
Enforcement
	
 36

	
9.6
	
Kite Discussions regarding Third Party Intellectual Property
	
 38

	
ARTICLE 10.  REPRESENTATIONS
	
 38

	
10.1
	
Mutual Warranties
	
 38

	
10.2
	
Additional Kite Warranties
	
 39

	
10.3
	
Additional Amgen Warranties
	
 40

	
10.4
	
Disclaimer
	
 40

	
10.5
	
Mutual Covenants
	
 40

	
ARTICLE 11.  INDEMNIFICATION
	
 42

	
11.1
	
Indemnity
	
 42

	
11.2
	
LIMITATION OF DAMAGES
	
 43

	
11.3
	
Insurance
	
 43

	
ARTICLE 12.  CONFIDENTIALITY
	
 43

iii

Execution Copy

 

	
12.1
	
Confidential Information
	
 43

	
12.2
	
Terms of this Agreement; Publicity
	
 45

	
12.3
	
Publications
	
 45

	
12.4
	
Relationship to the Confidentiality Agreement
	
 46

	
12.5
	
Attorney-Client Privilege
	
 46

	
ARTICLE 13.  TERM & TERMINATION
	
 46

	
13.1
	
Term
	
 46

	
13.2
	
Termination by Amgen
	
 48

	
13.3
	
Termination by Kite
	
 48

	
13.4
	
Termination Upon Bankruptcy
	
 49

	
13.5
	
Effects of Termination
	
 49

	
13.6
	
Survival
	
 52

	
ARTICLE 14.  CHANGE OF CONTROL
	
 53

	
14.1
	
Change of Control
	
 53

	
ARTICLE 15.  MISCELLANEOUS
	
 53

	
15.1
	
Entire Agreement; Amendment
	
 53

	
15.2
	
Section 365(n) of the Bankruptcy Code
	
 53

	
15.3
	
Independent Contractors
	
 53

	
15.4
	
Governing Law; Jurisdiction
	
 54

	
15.5
	
Notice
	
 54

iv

Execution Copy

 

	
15.6
	
Compliance with Law; Severability
	
 54

	
15.7
	
Non-Use of Names
	
 55

	
15.8
	
Successors and Assigns
	
 55

	
15.9
	
Sale Transaction or Amgen Acquisition
	
 55

	
15.1
	
Sale Transaction or Kite Acquisition
	
 55

	
15.11
	
Waivers
	
 56

	
15.12
	
No Third Party Beneficiaries
	
 56

	
15.13
	
Headings; Exhibits
	
 56

	
15.14
	
Interpretation
	
 56

	
15.15
	
Counterparts
	
 58

	
15.16
	
HSR
	
 58

 

Exhibit List

Exhibit A  Amgen Patents

Exhibit B  Kite IP

Exhibit C  Preclinical Development Plan

Exhibit D  Amgen Licensed Know-How

Exhibit E  Supply Agreement

Exhibit F  Press Release

 

 

 

 

v

Execution Copy

 

RESEARCH COLLABORATION AND LICENSE AGREEMENT

 

This RESEARCH COLLABORATION AND LICENSE AGREEMENT (this “Agreement”) is entered into as of December 31, 2014 (the “Signing Date”) by and between AMGEN INC., a Delaware corporation having an address at One Amgen Center Drive, Thousand Oaks, California 91320 (“Amgen”), and KITE PHARMA, INC., a Delaware corporation having an address at 2225 Colorado Avenue, Santa Monica, California 90404 (“Kite”).  Kite and Amgen are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.

RECITALS

WHEREAS, Kite is a biopharmaceutical company developing a novel generation of cell-based therapies to treat cancer.

WHEREAS, Amgen possesses research, development, manufacturing and commercialization expertise for the development and commercialization of pharmaceutical and biologics products in the field of oncology. 

WHEREAS, Amgen wishes Kite, and Kite accepts, to perform preclinical development activities up to the filing of an investigational new drug application (“IND”) of certain cell-based therapy products selected pursuant to the terms and conditions of the Agreement. 

NOW THEREFORE, in consideration of the premises and the mutual promises and covenants contained in this Agreement, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto agree as follows:

Article 1.  DEFINITIONS

All references to particular Exhibits, Articles or Sections shall mean the Exhibits to, and Articles and Sections of, this Agreement, unless otherwise specified. For the purposes of this Agreement and the Exhibits hereto, the following words and phrases shall have the following meanings:

Section 1.1   “Abandoned Patent Right” shall have the meaning set forth in Section 9.2.3 (Collaboration Patents). 

Section 1.2   “Additional Milestone Events” shall have the meaning set forth in Section 8.1.5 (Additional Milestone Payments).

Section 1.3   “Additional Milestone Payments” shall have the meaning set forth in Section 8.1.5 (Additional Milestone Payments).

Section 1.4   “Additional Target” shall have the meaning set forth in Section 3.3  (Amgen Expansion Option; Additional Targets). 

Section 1.5   “Affiliate” means, with respect to any Person, any other Person which controls, is controlled by or is under common control with such Person, for as long as such control exists. For purposes of this Section, “control” shall mean the direct or indirect ownership of more than fifty percent (50%) of the voting or economic interest of a Person, or the power, whether 

1

Execution Copy

 

pursuant to contract, ownership of securities or otherwise, to direct the management and policies of a Person. For clarity, once a Person ceases to be an Affiliate of a Party, then, without any further action, such Person shall cease to have any rights, including license and sublicense rights, under this Agreement by reason of being an Affiliate of such Party; but any intellectual property of such Affiliate that is subject to any license granted hereunder shall remain subject to such license grant.  

Section 1.6   “Agreement” shall have the meaning set forth in the Preamble.

Section 1.7   “Alliance Manager” shall have the meaning set forth in Section 2.1.2 (Alliance Managers). 

Section 1.8   “Amgen” shall have the meaning set forth in the Preamble. 

Section 1.9   “Amgen Acquiree” shall have the meaning set forth in Section 15.9  (Sale Transaction or Amgen Acquisition).

Section 1.10   “Amgen Acquisition” shall have the meaning set forth in Section 15.9  (Sale Transaction or Amgen Acquisition).

Section 1.11   “Amgen Expansion Option” has the meaning set forth in Section 3.3  (Amgen Expansion Option; Additional Targets).

Section 1.12   “Amgen Indemnified Parties” shall have the meaning set forth in Section 11.1.2 (By Kite).

Section 1.13   “Amgen IP” means (a) Amgen Patents and Amgen’s interest in the Collaboration Patents and (b) Amgen Licensed Know-How and Amgen’s interest in Collaboration Know-How. 

Section 1.14   “Amgen Licensed Know-How” means all Know-How that both (a) is Controlled by Amgen or its Affiliates (subject to Section 15.9  (Sale Transaction or Amgen Acquisition)) and (b) (i) was actually used by Amgen or its Affiliates in its research and development of the Programs prior to the Effective Date, or (ii) is actually used by Amgen or its Affiliates in its research and development of the Programs on or after the Effective Date and is reasonably useful for the Exploitation of a Kite Product.  For clarity, to the extent any Amgen Licensed Know-How is also claimed or disclosed in any Patent Rights Controlled by Amgen it shall nonetheless remain Amgen Licensed Know-How for purposes of the licenses granted hereunder.  

Section 1.15   “Amgen Optioned Product” means a CAR Product or a TCR Product (as the case may be) directed against the Amgen Optioned Target. 

Section 1.16   “Amgen Optioned Target” means [...***...] pursuant to Section 4.2  (Amgen Optioned Target).

Section 1.17   “Amgen Patents” means the Patent Rights listed on Exhibit A (Amgen Patents).

Section 1.18   “Amgen Product” means (a) as it relates to an Amgen Target, other than an Additional Target, a CAR Product directed against such particular Amgen Target based upon or generated [...***...] for such Amgen Target; and (b) as it relates to an Amgen Additional Target (if any), either a CAR Product or a TCR Product [...***...] directed against such Additional Target based upon or generated [...***...]

***Confidential Treatment Requested

2

Execution Copy

 

[...***...] for such Additional Target.   For clarity, upon Amgen’s exercise of its option to obtain exclusive rights to an Amgen Optioned Target, Amgen Products shall include Amgen Optioned Products. 

Section 1.19   “Amgen Target” means a Target specified as an Amgen Target pursuant to Section 3.1  (Target Selection) or any New Target or Additional Target selected by Amgen.  For clarity, Amgen Target shall exclude any Removed Target.

Section 1.20   “Approved CMO” shall have the meaning set forth in Section 5.2  (Transition of Supply).

Section 1.21   “Attributes” means a particular expression construct or genome modification obtained by nucleases or any other methods, including deletion, insertion or point mutation.  

Section 1.22   “Available” means, with respect to a proposed New Target or Additional Target, as applicable, that at the time written notice is received by the non-requesting Party for such proposed New Target or Additional Target pursuant to Section 3.2  (Substitute Targets) or Section 3.3  (Amgen Expansion Option; Additional Targets), (a) the non-requesting Party is [...***...] with such proposed New Target or Additional Target, as applicable (regardless of modality), (b) the non-requesting Party has [...***...] directed to such proposed New Target or Additional Target, as applicable (regardless of modality); or (c) the non-requesting Party has [...***...] directed to such proposed New Target or Additional Target, as applicable (regardless of modality).

Section 1.23   “Audited Party” shall have the meaning set forth in Section 8.8  (Records and Audits). 

Section 1.24   “Auditing Party” shall have the meaning set forth in Section 8.8  (Records and Audits). 

Section 1.25   “Background IP” means Patent Rights and Know-How (a) Controlled by a Party prior to the Effective Date or (b) Controlled by such Party during the Term, but not generated in the performance of the activities contemplated under this Agreement.

Section 1.26   “Bi-Specific Product” means a pharmaceutical or biologic product which is directed against at least two Targets, one of which is an Amgen Target or a Kite Target, as the case may be, and the other of which is (a) in the case of Amgen, any other Target (including another Amgen Target, but excluding a Kite Target) and (b) in the case of Kite, any other Target (including another Kite Target, but excluding an Amgen Target).  For clarity, a Bi-Specific Product may include a single chain or two independent CARs or TCRs, as long as they are intended to be expressed in the same T cell.

Section 1.27   “Blocking Patent” shall mean as to an Amgen Product in the case of Amgen, or a Kite Product in the case of Kite, any Third Party Patent Rights that claim, in a particular country, the composition or use of such Amgen Product or Kite Product, as the case may be, and which 

***Confidential Treatment Requested

3

Execution Copy

 

such Patent Rights would be infringed by the manufacture, use, offer for sale, sale, import or export of such Amgen Product or Kite Product in such country.  

Section 1.28   “Budget” means the budget for Preclinical Development activities to be performed by Kite and Amgen as defined by the JSC and approved by the Parties on an annual basis, in accordance with Section 3.4  (Preclinical Development Plan).

Section 1.29   “Cabaret License” shall have the meaning set forth in Section 8.2.2 (Additional Amgen Royalty Rate). 

Section 1.30   “CAR” means a chimeric antigen receptor.

Section 1.31   “CAR Product” means a pharmaceutical or biologic product containing an adoptive T cell expressing a CAR directed against a particular Target.

Section 1.32   “Change of Control” means with respect to a specified Party:  (a) the acquisition, directly or indirectly, by a Person or “group” (whether in a single transaction or multiple transactions) of more than 50% of the voting power of such Party or of beneficial ownership of (or the right to acquire such beneficial ownership) of more than 50% of the outstanding equity or convertible securities of such Party (including by tender offer or exchange offer); (b) any merger, consolidation, share exchange, business combination, recapitalization, the sale of substantially all of assets of, or similar corporate transaction involving such Party (whether or not including one or more wholly owned subsidiaries of such Party), other than: (i) transactions involving solely such Party and/or one or more Affiliates, on the one hand, and one or more of such Party’s Affiliates, on the other hand, and/or (ii) transactions in which the stockholders of such Party immediately prior to such transaction hold at least 50% of the voting power of the surviving company or ultimate parent company of the surviving company; or (c) the adoption of a plan relating to the liquidation or dissolution of such Party.  For purposes of this definition, the terms “group” and “beneficial ownership” shall have the meaning accorded in the U.S. Securities Exchange Act of 1934 and the rules of the U.S. SEC thereunder in effect as of the Signing Date hereof.

Section 1.33   “Collaboration IP” means Collaboration Know-How and Collaboration Patents.

Section 1.34   “Collaboration Know-How” means any and all Know-How that is both (i) Controlled by a Party (or by the Parties jointly) and (ii) generated in the performance of the activities contemplated under this Agreement.

Section 1.35   “Collaboration Patents” means Patent Rights Controlled by a Party (or by the Parties jointly) that claim an invention within Collaboration Know-How.  

Section 1.36   “Commercially Reasonable Efforts” means those efforts and resources commensurate with those efforts commonly used in the biopharmaceutical industry by a company [...***...] in connection with the development or commercialization of biopharmaceutical products that are of similar status, including, with respect to commercial potential, the proprietary position of the product, the regulatory status and approval process, the probable profitability of the applicable product, and other relevant factors such as technical, legal, scientific or medical factors.  In determining the level of efforts constituting “Commercially Reasonable Efforts,” the following shall not be taken into account: (a) [...***...] or (b) [...***...]

***Confidential Treatment Requested

4

Execution Copy

 

[...***...]

Section 1.37   “Confidential Information” shall have the meaning set forth in Section 12.1.1 (Confidential Information). 

Section 1.38   “Continuing Party” means (a) Kite, in the case of termination of the Agreement by (i) Amgen pursuant to Section 13.2.2 (Amgen Discretionary Termination) or (ii) Kite pursuant to Section 13.3.1 (Amgen Breach), and (b) Amgen, in the case of termination of the Agreement by (i) Kite pursuant to Section 13.3.2 (Kite Discretionary Termination) or (ii) Amgen pursuant to Section 13.2.1 (Kite Breach).

Section 1.39   “Control” or “Controlled” means, with respect to any Know-How, material, Patent Right, or other intellectual property right, the possession (whether by ownership or license) by a Party or its Affiliate of the ability to grant to the other Party a license or access as provided herein to such Know-How, material, Patent Right, or other intellectual property right, without violating the terms of any agreement or other arrangement with any Third Party,[...***...] (provided, however, that (a) the Kite Patents and Kite Licensed Know-How listed on Exhibit B (Kite IP) shall be deemed to be Controlled by Kite, and (b) if, after the Signing Date, Kite or its Affiliates obtain any Know-How, material, Patent Right, or other intellectual property right that would, [...***...], then Kite shall inform Amgen of such newly obtained Know-How, material, Patent Right, or other intellectual property right, as well as [...***...], and [...***...], then such Know-How, material, Patent Right, or other intellectual property right shall be deemed to be Controlled by Kite, subject to Section 9.6  (Kite Discussions regarding Third Party Intellectual Property)). 

Section 1.40   “Cover” means a Valid Claim would (absent a license thereunder or ownership thereof) be Infringed by the Exploitation of the applicable product; provided, however, that in determining whether a Valid Claim that is a claim of a pending application would be Infringed, it shall be treated as if issued in the form then currently being prosecuted.  Cognates of the word “Cover” shall have correlative meanings.

Section 1.41   “Defending Party” shall have the meaning set forth in Section 9.4  (Defense and Settlement of Third Party Claims). 

Section 1.42   “Derivatives” shall have the meaning set forth in Section 9.1.3 (Joint IP). 

Section 1.43   “Designated Executive Officers” means the Chief Executive Officer of Kite and the Senior Vice President of Research of Amgen, or their duly authorized respective designees with equivalent decision-making authority with respect to matters under this Agreement.

Section 1.44   “directed against” means, as used in connection with a Target, that the product or agent at issue is designed to interact or bind with such Target as its primary mechanism of action.

Section 1.45   “Disclosing Party” shall have the meaning set forth in Section 12.1.1 (Confidential Information).

***Confidential Treatment Requested

5

Execution Copy

 

Section 1.46   “Distracting Product” means any T cell based pharmaceutical or biologic product including without limitation, any CAR Product or any TCR Product, other than any Kite Product or Amgen Product.  For clarity, any bi-specific antibody, including any product incorporating Amgen’s BiTETM antibody platform, shall be excluded from the definition of Distracting Product.

Section 1.47   “DOJ” shall have the meaning set forth in Section 15.16  (HSR). 

Section 1.48   “Effective Date” shall have the meaning set forth in Section 15.16  (HSR). 

Section 1.49   “EMA” means the European Medicines Agency or any successor entity thereto.

Section 1.50   “Enforcing Party” shall have the meaning set forth in Section 9.5.4 (Progress Reports).

Section 1.51   “Exploit” means to research, develop, make, have made, use, offer for sale, sell, import, export or otherwise exploit, or transfer possession of or title in, a product.  Cognates of the word “Exploit” shall have correlative meanings.

Section 1.52   “FDA” means the United States Food and Drug Administration or any successor entity thereto.

Section 1.53   “First Commercial Sale” means, with respect to any Product in any country, the first sale for end use or consumption of such Product in such country after Marketing Approval has been granted in such country. 

Section 1.54   “Final Report” means, on Program-by-Program basis, the full data package for the GLP Toxicology Studies for the corresponding lead Product within such Program and all other data related to the Program not previously provided to Amgen by Kite.  

Section 1.55   “FTC” shall have the meaning set forth in Section 15.16  (HSR). 

Section 1.56   “FTE Rate” means $[...***...] per hour.

Section 1.57   “GAAP” means United States generally accepted accounting principles applied on a consistent basis. Unless otherwise defined or stated herein, financial terms shall be calculated under GAAP. 

Section 1.58   “GLP Toxicology Studies” means all toxicology studies that meet the requirements set forth in 21 CFR Part 58 pertaining to good laboratory practice for use or intended for use in an IND and are required to be included in the filing of an IND, but excluding toxicology studies performed in the course of evaluating compounds prior to selection of a development candidate. 

Section 1.59   “Governmental Authority” means any court, agency, department, authority or other instrumentality of any national, state, county, city or other political subdivision. 

Section 1.60   “HSR Act” shall have the meaning set forth in Section 15.16  (HSR). 

Section 1.61   “Improvement” means an advancement, modification, development or improvement.

Section 1.62   “IND” shall have the meaning set forth in the Recitals.

 

***Confidential Treatment Requested

6

Execution Copy

 

Section 1.63   “Indication” means all indications in a broad therapeutic area (e.g., oncology, inflammation, neurology).  For the avoidance of doubt, the Parties agree that: (a) prevention of a disease or medical condition shall not be a separate Indication from treatment of the same disease or medical condition; (b) the treatment and prevention of separate varieties of the same disease or medical condition shall not be a separate Indication; (c) the treatment and prevention of the same disease or medical condition in a different population shall not be a separate Indication; and (d) the treatment and prevention of diseases or medical conditions in the same therapeutic area (e.g., oncology, inflammation, neurology) shall not be a separate Indication.

Section 1.64   “Infringe” or “Infringement” means any infringement as determined by Law, including, without limitation, direct infringement, contributory infringement or any inducement to infringe.

Section 1.65   “Initiation” means, with respect to a clinical trial, the first dosing in the first patient in such clinical trial. 

Section 1.66   “Issuing Party” shall have the meaning set forth in Section 12.2.2 (Review).

Section 1.67   “Joint Steering Committee” or “JSC” shall have the meaning set forth in Section 2.1.1 (Overview). 

Section 1.68   “Kite” shall have the meaning set forth in the Preamble. 

Section 1.69   “Kite Acquiree” shall have the meaning set forth in Section 15.10  (Sale Transaction or Kite Acquisition).

Section 1.70   “Kite Acquisition” shall have the meaning set forth in Section 15.10  (Sale Transaction or Kite Acquisition).

Section 1.71   “Kite CMO” shall have the meaning set forth in Section 5.1  (Supply and Quality Agreement).

Section 1.72   “Kite Indemnified Parties” shall have the meaning set forth in Section 11.1.1 (By Amgen).  

Section 1.73   “Kite IP” means (a) Kite Patents and Kite’s interest in the Collaboration Patents and (b) Kite Licensed Know-How and any Collaboration Know-How generated by Kite. 

Section 1.74   “Kite Licensed Know-How” means all Know-How that (a) is Controlled by Kite or its Affiliates (subject to Section 15.10  (Sale Transactions or Kite Acquisition)) and (i) was actually used by Kite or its Affiliates in its research and development of the Programs prior to the Effective Date, or (ii) is actually used by Kite or its Affiliates in the conduct of its research and development under one or more of the Programs on or after the Effective Date and is necessary or reasonably useful for the Exploitation of an Amgen Product, or (b) constitutes part of the Kite Platform Technology.  For clarity, to the extent any Kite Licensed Know-How is also claimed or disclosed in any Patent Rights Controlled by Kite it shall nonetheless remain Kite Licensed Know-How for purposes of the licenses granted hereunder.  

Section 1.75   “Kite Patents” means all Patent Rights Controlled by Kite or its Affiliates (subject to Section 15.10  (Sale Transactions or Kite Acquisition)) that Cover the Kite Platform Technology, including the Patent Rights listed on Exhibit B (Kite IP).

 

7

Execution Copy

 

Section 1.76   “Kite Platform Technology” means any Know-How Controlled by Kite and its Affiliates (subject to Section 15.10  (Sale Transaction or Kite Acquisition) and Section 9.6  (Kite Discussions regarding Third Party Intellectual Property)) during the Term, including any Collaboration Know-How, in each case pertaining to engineered T cells directed against Targets and the inventions claimed by or disclosed within the Kite Patents listed on Exhibit B (Kite IP).

Section 1.77   “Kite Product” means (a) as it relates to a Kite Target, other than an Additional Target, a CAR Product directed against such particular Kite Target based upon or generated [...***...] for such Kite Target; and (b) as it relates to a Kite Additional Target (if any) either a CAR Product or a TCR Product [...***...] directed against such Additional Target, based upon or generated [...***...] for such Additional Target.  For clarity, upon Amgen’s exercise of its option to obtain exclusive rights to an Amgen Optioned Target, Kite Products shall exclude Amgen Optioned Products.

Section 1.78   “Kite Target” means a Target specified as a Kite Target pursuant to Section 3.1  (Target Selection) or any New Target selected by Kite.  For clarity, Kite Target shall exclude any Removed Target.  Kite Target excludes any Amgen Optioned Target.

Section 1.79   “Know-How” means techniques, technology, trade secrets, inventions (whether patentable or not), methods, know-how, data and results (including pharmacological, toxicological and clinical data and results), analytical and quality control data and results, regulatory documents, and other information.

Section 1.80   “Law” means, individually and collectively, any and all laws, ordinances, rules, directives, administrative circulars and regulations of any kind whatsoever of any Governmental Authority within the applicable jurisdiction.

Section 1.81   “Licensed Field” means any and all uses.

Section 1.82   “Losses” shall have the meaning set forth in Section 11.1.1 (By Amgen).

Section 1.83   “Marketing Approval” means all approvals, licenses, registrations or authorizations of the Regulatory Authority in a country, necessary for the manufacture, use, storage, import, marketing and sale of a Product in such country.

Section 1.84   “Milestone Events” shall have the meaning set forth in Section 8.1.4 (Milestone Payments).

Section 1.85   “Milestone Payments” shall have the meaning set forth in Section 8.1.4 (Milestone Payments).

Section 1.86   “Net Sales” means, with respect to any Product following its Regulatory Approval, the gross amounts invoiced for sales of such Product  by the Paying Party, its Affiliates or Sublicensee(s) (the “Selling Party”) to Third Parties in an arms’ length transaction, less to the extent specifically and solely allocated to the sale of such Product and actually taken, paid, accrued, allowed, included, or allocated based on good faith estimate, in the gross sales prices with respect to such sales (and consistently applied as set forth below):

 [...***...] 

***Confidential Treatment Requested

8

[...***...]. 

[...***...]. 

[...***...]. 

[...***...]. 

[...***...]. 

[...***...]. 

Net Sales will be determined from books and records maintained in accordance with GAAP, consistently applied throughout the organization and across all products of the entity whose sales of Products are giving rise to Net Sales.

Net Sales shall also include, with respect to any Product sold or otherwise disposed of for any consideration other than an exclusively monetary consideration on bona fide arm’s length terms, an amount equal to [...***...].

Where a Product is sold in combination with other pharmaceutical or biologics products, diagnostic products, or active ingredients (collectively, “Combination Components”) the Net Sales applicable to such transaction shall be calculated by [...***...]

***Confidential Treatment Requested

9

[...***...]. For purposes of the calculation of Net Sales hereunder, [...***...].

[...***...].  For the avoidance of doubt, [...***...].  Also, notwithstanding anything to the contrary above, [...***...].  

Section 1.87   “New Target” shall have the meaning set forth in Section 3.2  (Substitute Targets). 

Section 1.88   “Non-Publishing Party” shall have the meaning set forth in Section 12.3  (Publications). 

Section 1.89   “Patent Rights” means any provisional and non-provisional patents and patent applications, together with all additions, divisions, continuations, continuations-in-part, substitutions, and reissues claiming priority thereto, as well as any re-examinations, extensions, registrations, patent term extensions, supplemental protection certificates, renewals and the like with respect to any of the foregoing and all foreign counterparts thereof.

Section 1.90   “Party” shall have the meaning set forth in the Preamble. 

Section 1.91   “Paying Party” means, in the case of an Amgen Product, Amgen, and, in the case of a Kite Product, Kite.

Section 1.92   “Person” means any corporation, limited or general partnership, limited liability company, joint venture, trust, unincorporated association, governmental body, authority, bureau or agency, any other entity or body, or an individual.

Section 1.93   “Phase 1 Clinical Trial” means any human clinical trial of a Product conducted mainly to evaluate the safety of chemical or biologic agents or other types of interventions (e.g., a new radiation therapy technique) that would satisfy the requirements of 21 C.F.R. § 312.21(a) or its non-United States equivalents.

Section 1.94   “Phase 2 Clinical Trial” means any human clinical trial of a Product conducted mainly to test the effectiveness of chemical or biologic agents or other types of interventions for purposes of identifying the appropriate dose for a Phase 3 Clinical Trial for a particular indication or indications that would satisfy the requirements of 21 CFR § 312.21(b) or its non-United States equivalents.  A “Phase 2/3 Clinical Trial” shall be deemed to be a Phase 2 Clinical Trial with respect to the portion of that clinical trial that is regarded as its Phase 2 component, in accordance with the applicable protocol.

***Confidential Treatment Requested

10

Section 1.95   “Phase 3 Clinical Trial” means any human clinical trial of a Product designed to: (i) establish that such Product is safe and efficacious for its intended use; (ii) define warnings, precautions and adverse reactions that are associated with the Product in the dosage range to be prescribed; and (iii) support regulatory approval of such Product, that would satisfy the requirements of 21 CFR § 312.21(c) or its non-United States equivalents.  A “Phase 2/3 Clinical Trial” shall be deemed to be a Phase 3 Clinical Trial with respect to the portion of that clinical trial that is regarded as its Phase 3 component, in accordance with the applicable protocol. 

Section 1.96   “Preclinical Development” shall mean, with respect to a particular Program, any research, preclinical and process development activities relating to such particular Program, up to the delivery of a Final Report. 

Section 1.97   “Preclinical Development Plan” means, for each Program, the comprehensive plan, overall strategy and timelines, and any updates thereto, for the Preclinical Development of Products directed to the applicable Target for such Program, including a description of the Preclinical Development activities, expected timelines, the preclinical, clinical, manufacturing, regulatory, as well as product risk assessment planned activities up to the issuance of the Final Report by Kite to Amgen.  The Preclinical Development Plan shall include, but not be limited to, a reasonably detailed description of the schedule of work activity, the responsibility for the work activities and an associated budget. As the circumstances may require, the JSC may propose from time to time amendments to the Preclinical Development Plan in accordance with Section 2.1.3(b) (Function and Powers of the JSC). 

Section 1.98   “Preclinical Development Term” means, on a Program-by-Program basis, the duration of [...***...] from the Program Starting Date, renewable upon written agreement by the Parties, during which the Parties will perform the Preclinical Development activities. 

Section 1.99   “Product” means, either (a) as it relates to any Amgen Target or Kite Target which is not an Additional Target, a CAR Product directed against such Target; or (b) as it relates to any Additional Target, either a CAR Product or a TCR Product [...***...] directed against such Additional Target, as selected pursuant to Section 3.3  (Amgen Expansion Option; Additional Targets).  For clarity, Products mean Amgen Products or Kite Products, as the case may be.

Section 1.100   “Program” means, on a Target-by-Target basis, any and all preclinical development, clinical development, manufacturing and commercialization activities with respect to any and all Products directed to such Target. 

Section 1.101   “Program Starting Date” means the date of approval by the JSC of the applicable Preclinical Development Plan for a Program.

Section 1.102   “Publishing Party” shall have the meaning set forth in Section 12.3  (Publications). 

Section 1.103   “Receiving Party” shall have the meaning set forth in Section 12.1.1 (Confidential Information).

***Confidential Treatment Requested

11

Section 1.104   “Regulatory Approval” means any and all approvals, licenses, registrations or authorizations by a Governmental Authority necessary for the development, manufacturing and commercialization of a Product. 

Section 1.105   “Regulatory Authority” means any Governmental Authority or other authority responsible for granting Marketing Approvals for Products, including the FDA, EMA and any corresponding national or regional regulatory authorities.

Section 1.106   “Regulatory Exclusivity” means, with respect to a Product, any exclusive marketing rights or data exclusivity rights conferred by the applicable Regulatory Authority with respect to the Product other than a Patent Right.

Section 1.107   “Regulatory Filing” means any filing with any Governmental Authority in the Territory with respect to the research, development, manufacture, distribution, pricing, reimbursement, marketing or sale of a Product. 

Section 1.108   “Release” shall have the meaning set forth in Section 12.2.2 (Review).

Section 1.109   “Removed Target” shall have the meaning set forth in Section 3.2  (Substitute Targets). 

Section 1.110   “Reviewing Party” shall have the meaning set forth in Section 12.2.2 (Review).

Section 1.111   “Royalty Term” shall have the meaning set forth in Section 8.2.3 (Royalty Term).

Section 1.112   “Sale Transaction” shall have the meaning set forth in Section 15.8  (Successors and Assigns). 

Section 1.113   “Signing Date” shall have the meaning set forth in the Preamble.

Section 1.114   “Standard Preclinical Development” means a Preclinical Development, with a defined set of Attributes, within the frame outlined in Exhibit C (Preclinical Development Plan), and [...***...]. 

Section 1.115   “Sublicensee(s)” shall mean any Person other than (a) an Affiliate of Kite to which Kite has granted a sublicense under this Agreement, and (b) an Affiliate of Amgen to which Amgen has granted a sublicense under this Agreement. 

Section 1.116   “Target” means an antigen expressed on or in a tumor cell.  

Section 1.117   “TCR” means a T cell receptor.

Section 1.118   “TCR Product” means a pharmaceutical or biologic product containing an adoptive T cell expressing a native or engineered TCR directed against a particular Target.

Section 1.119   “Term” shall have the meaning set forth in Section 13.1  (Term).

Section 1.120   “Terminated Party” means (a) Amgen, in the case of termination of the Agreement by (i) Amgen pursuant to Section 13.2.2 (Amgen Discretionary Termination) or 

 

***Confidential Treatment Requested

12

Execution Copy

 

(ii) Kite pursuant to Section 13.3.1 (Amgen Breach), and (b) Kite, in the case of termination of the Agreement by (i) Kite pursuant to Section 13.3.2 (Kite Discretionary Termination) or (ii) Amgen pursuant to Section 13.2.1 (Kite Breach). 

Section 1.121   “Territory” means the entire world. 

Section 1.122   “Third Party” means a Person other than (a) Amgen or any of its Affiliates and (b) Kite or any of its Affiliates.

Section 1.123   “Third Party Acquirer” shall have the meaning set forth in Section 15.9  (Sale Transaction or Amgen Acquisition).

Section 1.124   “Transitioned Manufacturing” shall have the meaning set forth in Section 5.2.1 (Cooperation). 

Section 1.125   “Valid Claim” means a claim of any issued and unexpired patent or patent application within the Amgen Patents, Kite Patents or Collaboration Patents, as applicable, that has not been held invalid or unenforceable by a final decision of a court or governmental agency of competent jurisdiction, which decision can no longer be appealed or was not appealed within the time allowed; provided, however, that if a claim of a pending patent application within the Amgen Patents, Kite Patents or Collaboration Patents shall not have issued within seven (7) years after the earliest filing date from which such claim takes priority, such claim shall not constitute a Valid Claim for the purposes of this Agreement unless and until a Patent Right issues with such claim (from and after which time the same would be deemed a Valid Claim).

Section 1.126   “VAT” shall have the meaning set forth in Section 8.9.2 (VAT).

Article 2.  RESEARCH COLLABORATION

Section 2.1   Management.

2.1.1Overview.  Within fifteen days (15) days after the Effective Date, the Parties shall establish a cross-functional, joint steering committee (the “Joint Steering Committee” or the “JSC”) which shall manage the pre-clinical research collaboration between the Parties.

2.1.2Alliance Managers.  Each of Amgen and Kite shall appoint one representative who possesses a general understanding of development, regulatory, manufacturing and commercialization matters to act as its respective alliance manager(s) for this relationship (an “Alliance Manager”).  Each Party may replace its respective Alliance Manager at any time upon written notice to the other in accordance with this Agreement.  Any Alliance Manager may designate a substitute to temporarily perform the functions of that Alliance Manager.  Each Alliance Manager shall be charged with creating and maintaining a collaborative work environment within the Joint Steering Committee.  Consistent with the Preclinical Development Plan, each Alliance Manager, will also be responsible for:

	
(a)
	
providing a primary single point of communication responsible for the flow of communication and for seeking consensus both within the respective Party’s organization and together with the other Party regarding key strategy and plan issues;

13

	
(b)
	
ensuring awareness of the governance procedures and rules set forth herein and monitoring compliance therewith;

	
(c)
	
identifying and raising disputes to the JSC for discussion in a timely manner; and

	
(d)
	
planning and coordinating internal and external communications in accordance with the terms of this Agreement.

The Alliance Managers shall have the right to attend all subcommittees meetings, as a non-voting member. Consistent with Section 2.1.3(c) (Frequency of Meetings), each Alliance Manager may bring any matter to the attention of the JSC where such Alliance Manager reasonably believes that such matter requires attention of the JSC.

Within ten (10) days after the Effective Date, each Party shall appoint and notify the other Party of the identity of their representative to act as its Alliance Manager under this Agreement.  

2.1.3Joint Steering Committee.

(a)Composition.  The Joint Steering Committee shall be comprised of three (3) named representatives of each Party (or such other number as the Parties may agree) in addition to each Party’s Alliance Manager who are members ex-officio.  The JSC will be led by two (2) co-chairs, one (1) appointed by each of the Parties.  Within fifteen (15) days after the Effective Date, each Party shall designate by written notice to the other Party its initial representatives on the JSC.  Each Party may replace one or more of its representatives, in its sole discretion, effective upon written notice to the other Party of such change. 

(b)Function and Powers of the JSC. The JSC shall, in line with the terms and conditions set forth in the Agreement: 

	
(i)
	
define each Program, prepare and approve each Preclinical Development Plan and associated Budget on a semi-annual, or any amendments thereto, and review progress against the goals in such plans; 

	
(ii)
	
oversee the implementation of the Preclinical Development Plan(s);  

	
(iii)
	
define and coordinate regulatory strategy for IND filing;

	
(iv)
	
direct and oversee any operating subcommittee on all significant issues; 

	
(v)
	
validate and back-up the intellectual property strategy;  

	
(vi)
	
establish subcommittees, as appropriate;

	
(vii)
	
resolve disputed matters that may arise at the subcommittees; 

14

	
(viii)
	
assume a general role of leadership in the partnership;

	
(ix)
	
review and discuss potential Targets for consideration as potential New Targets and Additional Targets; and

	
(x)
	
perform any and all tasks and responsibilities that are expressly attributed to the JSC under the Agreement. 

(c)Frequency of Meetings.  The Joint Steering Committee shall meet at least once per quarter or more or less often as otherwise agreed by the Parties, and such meetings may be conducted by telephone, videoconference or in person as determined by the co-chairs; provided that no less than one (1) meeting during each calendar year shall be conducted in person.  The first meeting shall be no later than thirty (30) days after the Effective Date. As appropriate, and provided that not less than two (2) business days’ prior written notice has been given to the other Party, other employees of the Parties may attend Joint Steering Committee meetings as observers, but a Party shall not bring a Third Party to a meeting without the other Party’s prior consent.  Each Party may also call for special meetings of the Joint Steering Committee with reasonable prior written notice (it being agreed that at least five (5) business days shall constitute reasonable notice) to resolve particular matters requested by such Party and within the decision-making responsibility of the Joint Steering Committee.  Each co-chair shall ensure that its Joint Steering Committee members receive adequate notice of such meetings.  Each Party shall be responsible for all of its own expenses incurred in connection with participating in all such meetings.

(d)Subcommittees.  The JSC may establish and disband such subcommittees as deemed necessary by the JSC. Each such subcommittee shall consist of the same number of representatives designated by each Party, which number shall be mutually agreed by the Parties. Each Party shall be free to change its representatives on written notice to the other Party or to send a substitute representative to any subcommittee meeting. Each Party’s representatives and any substitute for a representative shall be bound by the obligations of confidentiality set forth in Article 12 (Confidentiality).  Except as expressly provided in this Agreement, no subcommittee shall have the authority to bind the Parties hereunder and each subcommittee shall report to the JSC.  Each Party shall be responsible for all of its own expenses incurred in connection with participating in all such meetings.

2.1.4Cooperation.  Each Party shall provide the JSC such information as required under the Preclinical Development Plan, or as reasonably requested by the other Party and reasonably available, relating to the progress of the goals or performance of activities under the Preclinical Development Plan.

2.1.5Decisions.  Other than as set forth herein, in order to make any decision required of it hereunder, the Joint Steering Committee must have present (in person, by videoconference or telephonically) at least the co-chair of each Party (or his/her designee for such meeting). Decisions of the JSC shall be by consensus, with each Party having one (1) vote.  If the JSC cannot reach consensus or a dispute arises which cannot be resolved within the JSC within fifteen (15) days, the co-chair of either Party may cause such dispute to be referred to the Designated Executive Officers for resolution within thirty (30) days.  In the event that consensus 

15

Execution Copy

 

cannot be reached with respect to a decision after a meeting of the Designated Executive Officers, then, (a) if the decision relates solely to an Amgen Target or the Program therefor, the decision will be made by the co-chair of the JSC appointed by Amgen (unless such decision is a change to a Preclinical Development Plan that would (i) require an increase in a Budget under such Preclinical Development Plan that Amgen has not agreed to cover, (ii) requires Kite to hire additional FTEs or broaden or initiate any subcontracting relationship, or (iii) have a material adverse impact to Kite’s IP, Kite Platform Technology or partnerships with any Third Party, in any  such event consensus would be required), and (b) if the decision relates solely to a Kite Target or the Program therefor, the decision will be made by the co-chair of the JSC appointed by Kite (unless such decision is a change to a Preclinical Development Plan that would require Amgen to conduct additional Preclinical Development, in such event consensus would be required).  If a dispute arises which cannot be resolved by a subcommittee, the co-chair of either Party may cause such dispute to be referred to the Joint Steering Committee for resolution.  

2.1.6Exceptions.  Notwithstanding the foregoing, neither Party in exercising its right to finally resolve a dispute pursuant to Section 2.1.5 (Decisions) shall have any power to amend, modify, or waive compliance with the terms of this Agreement. 

2.1.7Authority.  The JSC and any subcommittee shall have only the powers assigned expressly to it in this Article 2 (Research Collaboration) and elsewhere in this Agreement, and shall not have any power to amend, modify or waive compliance with this Agreement.  In furtherance thereof, each Party shall retain the rights, powers and discretion granted to it under this Agreement and no such rights, powers or discretion shall be delegated or vested in the JSC or subcommittee unless such delegation or vesting of rights is expressly provided for in this Agreement or the Parties expressly so agree in writing.

2.1.8Discontinuation of JSC. The JSC shall continue to exist until the first to occur of (a) the Parties mutually agreeing to disband the JSC or (b) on a Program-by-Program basis, until the first (1st) anniversary of the filing of an IND for such Program.  

Article 3.  PRECLINICAL DEVELOPMENT ACTIVITIES

Section 3.1   Target Selection.  As of the Effective Date, Amgen hereby elects to initiate Preclinical Development with respect to the following [...***...] Targets, and Kite hereby elects to initiate Preclinical Development with respect to the following [...***...] Targets:

Amgen Targets-  [...***...]

 

 

 

***Confidential Treatment Requested

16

Kite Targets- [...***...]

 

Section 3.2   Substitute Targets.  Prior to the [...***...] anniversary of the Effective Date, either Party shall have the right to substitute up to [...***...] of its Targets (each, a “Removed Target”) and replace each Removed Target with a new Target (each, a “New Target”); provided, that:

	
(a)
	
such proposed New Target is Available at the time written notice is received for substitution as required by this Section 3.2  (Substitute Targets); 

	
(b)
	
the Preclinical Development of the Removed Target has been terminated prior to initiation of activities for CAR Design and Functional Validation under the applicable Preclinical Development Plan for such Removed Target; and

	
(c)
	
the Parties mutually agree to include the proposed Target as such New Target. 

The Party requesting to substitute a Removed Target shall provide the other Party with written notice of its intent to substitute a Removed Target, and the identity of the proposed New Target, and the other Party shall provide written notice within [...***...] of receipt thereof as to whether such proposed New Target is Available.  If all of the conditions in clause (a) through (c) have been met, then the list of Targets set forth in Section 3.1  (Target Selection) shall automatically be amended by substituting the New Target for the Removed Target.  If such proposed New Target is not Available, then the requesting Party shall have the option to either (i) propose another Target as the New Target (in which case the process outlined above would apply again, until a proposed New Target is approved), or (ii) terminate the Agreement with respect to such Removed Target.  Notwithstanding the provisions of Section 8.1.3 (Preclinical Development Costs), [...***...].  

Section 3.3   Amgen Expansion Option; Additional Targets.  Until the [...***...] anniversary of the Effective Date, Amgen shall have the right to elect to select up to [...***...] additional Targets as Amgen Targets for inclusion under this Agreement, exercisable upon [...***...] prior notice (the “Amgen Expansion Option”).  If Amgen exercises the Amgen Expansion Option, Kite shall in turn have the right to elect to select [...***...] additional Target as a Kite Target for inclusion under this Agreement (such additional Amgen Targets and Kite Target referred to individually as an “Additional Target”).  Amgen shall provide in its
 

***Confidential Treatment Requested

17

notice of exercise of the Amgen Expansion Option, its proposed Additional Target(s), and Kite shall provide written notice within [...***...] of receipt thereof as to whether each such Additional Target is Available.  If a proposed Additional Target is Available, then the list of Amgen Targets set forth in Section 3.1  (Target Selection), as may have been amended to include any New Target, shall automatically be amended by adding the Additional Target.  If any such proposed Additional Target is not Available, then Amgen shall have the option to continue to select another proposed Additional Target until [...***...] Additional Targets selected by Amgen are Available (unless Amgen has exercised the Amgen Expansion Option only for a single Additional Target), it being understood that the process of selection and qualification of proposed Additional Targets may extend beyond the [...***...] anniversary of the Effective Date.  After the inclusion of Amgen’s Additional Target(s), Kite shall have a period of [...***...] to select an Additional Target.  For clarity, Kite shall have the right to select such Additional Target whether Amgen elects to exercise the Amgen Expansion Option for only [...***...] Additional Targets.  Kite shall provide Amgen with written notice of its proposed Additional Target, and Amgen shall provide written notice within [...***...] of receipt thereof as to whether such Additional Target is Available.  If such Additional Target is Available, then the list of Kite Targets set forth in Section 3.1  (Target Selection), as may have been amended to include any New Target, shall automatically be amended by adding the Additional Target.  If such Additional Target is not Available, then Kite shall have the option to continue to select another proposed Additional Target until an Additional Target selected by Kite is Available. The Party selecting the Additional Target shall have the right to elect to pursue either a CAR Product or a TCR Product (but not both) directed against its Additional Target, by providing in its written notice selecting such Additional Target which it desires to pursue.  The Parties shall promptly generate a Preclinical Development Plan for the Program for such Additional Target in accordance with Section 3.4  (Preclinical Development Plan).

Section 3.4   Preclinical Development Plan.  The JSC shall promptly direct the Parties to generate a Preclinical Development Plan with respect to each Program (including the assignment of activities between the Parties), as well as the corresponding Budget.  The Parties shall prepare any such Preclinical Development Plan by modeling it after the Standard Preclinical Development.  For any non-Standard Preclinical Development of a Product or for any Preclinical Development of a Product bearing different Attributes than the original Product, the Parties shall meet in order to define the technical and financial conditions for such additional activity.  

Section 3.5   Preclinical Development of Products.  Upon approval by the JSC of the applicable Preclinical Development Plan and associated Budget, each Party shall commence and conduct Preclinical Development activities assigned to it under, and in accordance with, such Preclinical Development Plan.  During the applicable Preclinical Development Term, each Party shall use its reasonable efforts to conduct its Preclinical Development activities of the corresponding Product in accordance with the corresponding Preclinical Development Plan. 

Section 3.6   Subcontracting.  Either Party may engage its Affiliates, or Third Party subcontractors (including contract research organizations (but excluding contract manufacturing organizations)) to perform certain of its obligations under this Agreement.  Any Third Party subcontractor to be engaged by such Party to perform its obligations set forth in this Agreement will meet the qualifications typically required by such Party for the performance of work similar in scope and complexity to the subcontracted activity.  The activities of any such Third Party

***Confidential Treatment Requested

18

subcontractors will be considered activities of such Party under this Agreement.  The subcontracting Party will be responsible for ensuring compliance by any such Third Party subcontractors with the terms of this Agreement, as if such Third Party(ies) are such Party hereunder.  Each Party will, and will contractually require that its Affiliates and subcontractors, if any, conduct the relevant Preclinical Development activities in accordance with  such Party’s commitments with respect to such Programs.  

Section 3.7   Data.  During the Preclinical Development Term, Kite shall, at Amgen’s written request, promptly make available to Amgen all data generated by Kite and its Affiliates or on their behalf, related to each Program, and Amgen shall, at Kite’s written request, promptly make available to Kite all data generated by Amgen and its Affiliates or on their behalf, related to each Program.

Section 3.8   Exclusivity.   

3.8.1Kite’s Obligations.  With respect to a particular Amgen Target, during the Term, Kite (and, subject to Section 15.10  (Sale Transaction or Kite Acquisition), its Affiliates) shall not conduct or participate in, or advise, assist or intentionally enable any Third Party to conduct or participate in the preclinical or clinical development, manufacture or commercialization of any Distracting Product that has as [...***...], or its being developed with the [...***...].  The foregoing restriction shall expire on an Amgen Target-by-Amgen Target basis upon the termination of the Agreement with respect to the applicable Program for such Amgen Target.  Additionally, during the Term, Kite (and, subject to Section 15.10  (Sale Transaction or Kite Acquisition), its Affiliates ) shall not conduct or participate in, or advise, assist or intentionally enable any Third Party to conduct or participate in the preclinical or clinical development, manufacture or commercialization of any Distracting Product that has as [...***...], or its being developed with the [...***...].  The foregoing restriction shall expire on a Kite Target-by-Kite Target basis upon the termination of the Agreement with respect to the applicable Program for such Kite Target.  Notwithstanding the foregoing, Kite shall have the right, and it shall not be a breach of its foregoing exclusivity obligation, to Exploit a Bi-Specific Product directed against both (i) a Kite Target (but not an Amgen Target) and (ii) another Target which is not an Amgen Target, in which event such Bi-Specific Product, to the extent it contains a Kite Product, shall be deemed a Kite Product for all purposes, including financial provisions, under this Agreement.

3.8.2Amgen’s Obligations. With respect to a particular Kite Target, during the Term, Amgen (and, subject to Section 15.9  (Sale Transaction or Amgen Acquisition), its Affiliates) shall not conduct or participate in, or advise, assist or intentionally enable any Third Party to conduct or participate in the preclinical or clinical development, manufacture or commercialization of any Distracting Product that has [...***...], or its being developed with [...***...].  The foregoing restriction shall expire on a Kite Target-by-Kite Target basis upon the termination of the Agreement with respect to the applicable Program for such Kite Target.  During the Term, Amgen (and, subject to Section 15.9  (Sale Transaction or Amgen Acquisition), its Affiliates) shall not conduct or participate in, or advise, assist or
 

***Confidential Treatment Requested

19

intentionally enable any Third Party to conduct or participate in preclinical or clinical development, manufacture or commercialization of any Distracting Product that has [...***...], or its being developed with [...***...].  The foregoing restriction shall expire on an Amgen Target-by-Amgen Target basis upon the termination of the Agreement with respect to the applicable Program for such Amgen Target.  Notwithstanding the foregoing, Amgen shall have the right, and it shall not be a breach of its foregoing exclusivity obligation, to Exploit a Bi-Specific Product directed against both (i) an Amgen Target (but not a Kite Target) and (ii) another Target which is not a Kite Target, in which event such Bi-Specific Product, to the extent it contains an Amgen Product, shall be deemed an Amgen Product for all purposes, including financial provisions, under this Agreement.

Article 4.  LICENSE GRANT

Section 4.1   Grant.  

4.1.1Preclinical License.  On a Program-by-Program basis, during the applicable Preclinical Development Term, Kite hereby grants to Amgen a non-exclusive, worldwide, royalty-free right under Kite IP solely to conduct Preclinical Development as contemplated under the applicable Preclinical Development Plan. On a Program-by-Program basis, during the applicable Preclinical Development Term, Amgen hereby grants to Kite a non-exclusive, worldwide, royalty-free right under Amgen IP solely to conduct Preclinical Development as contemplated under the applicable Preclinical Development Plan.  

4.1.2Kite Grant.  Subject to the terms and conditions of this Agreement, Kite hereby grants to Amgen (a) an exclusive (even as to Kite and its Affiliates), royalty bearing, sublicenseable (but only in accordance with Section 4.3  (Sublicenses)), license under the Kite Patents and its interest in the Collaboration Patents and (b) a non-exclusive, royalty bearing, sublicenseable (but only in accordance with Section 4.3  (Sublicenses)) license under the Kite Licensed Know-How and its interest in the Collaboration Know-How, in each case, to Exploit Amgen Product(s) in the Licensed Field in the Territory during the Term.  Notwithstanding the foregoing, the Kite Licensed Know-How and Collaboration Know-How shall be sublicenseable only in connection with the rights of Amgen with respect to Amgen Products and not with respect to any other products or services.  For clarity, no license is hereby extended to Amgen to Exploit any products under the Kite Patents, Kite’s interest in the Collaboration Patents, the Kite Licensed Know-How or its interest in the Collaboration Know-How which are other than Amgen Products or directed against any Targets which are other than Amgen Targets.

4.1.3Amgen Grant.  Subject to the terms and conditions of this Agreement, Amgen hereby grants to Kite (a) an exclusive (even as to Amgen and its Affiliates), royalty bearing, sublicenseable (but only in accordance with Section 4.3  (Sublicenses)), license under the Amgen Patents and its interest in the Collaboration Patents and (b) a non-exclusive, royalty bearing, sublicenseable (but only in accordance with Section 4.3  (Sublicenses)) license under the Amgen Licensed Know-How and its interest in the Collaboration Know-How, in each case, to Exploit Kite Product(s) in the Licensed Field in the Territory during the Term.  Notwithstanding the foregoing, except as otherwise provided for under Section 9.1.2 (Collaboration IP), the Amgen Licensed Know-How and Collaboration Know-How shall be 

***Confidential Treatment Requested

20

sublicenseable only in connection with the rights of Kite with respect to Kite Products and not with respect to any other products or services. For clarity, no license is hereby extended to Kite to Exploit any products under the Amgen Patents, Amgen’s interest in the Collaboration Patents, the Amgen Licensed Know-How or its interest in the Collaboration Know-How, which are other than Kite Products or directed against any Targets which are other than Kite Targets.

Section 4.2   Amgen Optioned Target.  [...***...]  For clarity, Amgen’s option under this Section 4.2  (Amgen Optioned Target) is [...***...]. If Amgen exercises its option under this Section 4.2  (Amgen Optioned Target), Kite [...***...].

Section 4.3   Sublicenses.  

4.3.1Sublicenses by Amgen.  Amgen and its Affiliates shall be entitled, without the prior consent of Kite, to grant one or more sublicenses under the licenses granted to Amgen under Section 4.1  (Grant), in full or in part, by means of written agreement to any Affiliate or to one or more Third Parties (with the right to sublicense through multiple tiers), provided, however, that as a condition precedent to and requirement of any such sublicense: (a) any such permitted sublicense shall be consistent with and subject to the terms and conditions of this Agreement; and (b) Amgen will continue to be responsible for full performance of Amgen’s obligations under the Agreement and will be responsible for all actions of such Sublicensee as if such Sublicensee were Amgen hereunder.

4.3.2Sublicenses by Kite.  Kite and its Affiliates shall be entitled, without the prior consent of Amgen, to grant one or more sublicenses under the licenses granted to Kite under Section 4.1  (Grant), in full or in part, by means of written agreement to any Affiliate or to one or more Third Parties (with the right to sublicense through multiple tiers), provided, however, that as a condition precedent to and requirement of any such sublicense: (a) any such permitted sublicense shall be consistent with and subject to the terms and conditions of this Agreement; and (b) Kite will continue to be responsible for full performance of Kite’s obligations under the Agreement and will be responsible for all actions of such Sublicensee as if such Sublicensee were Kite hereunder. 

Section 4.4   Transfer of Amgen Licensed Know-How.  Promptly following the Effective Date, Amgen shall transfer to Kite the Amgen Licensed Know-How listed on Exhibit D (Amgen Licensed Know-How) in accordance with the protocols listed on Exhibit D (Amgen Licensed Know-How). 

 

 

 

 

 

 

***Confidential Treatment Requested

21

Section 4.5   Sharing of Materials.  In the event that it becomes necessary for one Party to provide the other Party with tangible research or biological materials (other than an Amgen Product for clinical or commercial use), the Parties will enter into an appropriate material transfer agreement related thereto, which agreement will be subject to this Agreement and will be interpreted consistent with the terms hereof. 

Section 4.6   No Other Rights.  Each Party acknowledges that the rights and licenses granted to it under this Article 4 (License Grant) and elsewhere in this Agreement are limited to the scope expressly granted.  Accordingly, except for the rights expressly granted under this Agreement, no right, title, or interest of any nature whatsoever is granted whether by implication, estoppel, reliance, or otherwise, by the other Party to such Party.  All rights that are not specifically granted herein are reserved to the possessing Party.

Article 5.  SUPPLY 

Section 5.1   Supply and Quality Agreement.   Kite shall be responsible for manufacturing and supplying, itself or through a mutually selected contract manufacturing organization (a “Kite CMO”), Amgen’s requirements for Amgen Products, subject to the limitation set forth in Section 5.1.1 (Kite or Kite CMO Manufacturer), pursuant to a supply agreement and quality agreement, to be negotiated in good faith and entered into by the Parties within [...***...] after the Effective Date.  The terms of such supply agreement shall be consistent with this Article 5 (Supply) and Exhibit E (Supply Agreement) in all material respects.  Pursuant to the foregoing, upon approval by the JSC of the first Preclinical Development Plan for an Amgen Target, Kite shall elect to either itself serve or have a Kite CMO serve as the manufacturer of Amgen Products directed against such Amgen Target.  To the extent a Kite CMO serves as the manufacturer of Amgen Products, Kite shall have no responsibility for the performance of the Kite CMO, other than to enforce Kite’s contractual rights against the Kite CMO for the benefit of Amgen. For clarity, Kite shall be responsible for the management and oversight of the activities of the Kite CMO with respect to the manufacture of the Amgen Products. Additionally, Amgen shall have the right to transition such manufacturing to Amgen (or a mutually agreed upon designee of Amgen) at any time upon [...***...] prior written notice, subject to Section 5.1.2 (Kite Future Manufacture). 

5.1.1Kite or Kite CMO Manufactures.  Kite or the Kite CMO, as the case may be, shall be responsible for clinical or commercial supply of all Amgen Products directed against a particular Amgen Target, until, on an Amgen Target-by-Amgen Target basis, [...***...] from the date of completion of the first Phase 2 Clinical Trial for the first Amgen Product directed against such Amgen Target.  Additionally, Kite shall transition manufacturing of Amgen Products to Amgen (or a mutually agreed upon designee of Amgen) in accordance with Section 5.2  (Transition of Supply).  For clarity, neither Kite nor any Kite CMO shall be required to (i) develop any process to improve upon the Phase 1 Clinical Trial clinical product manufacturing of any Amgen Product for any Phase 2 Clinical Trial clinical manufacturing of such Amgen Product, or (ii) develop a commercial process for any Amgen Product, and any commercial product sold during such period by Amgen shall be manufactured according to the process used to manufacture clinical product.

***Confidential Treatment Requested

22

 

5.1.2Kite Future Manufacture.  To the extent Amgen seeks to have a Third Party contract manufacturing organization perform manufacture of any Amgen Product after the period of Kite’s manufacture (itself or through the Kite CMO) of such Amgen Product under Section 5.1  (Supply and Quality Agreement) or Section 5.1.1 (Kite or Kite CMO Manufactures), it shall first inform Kite of such intent.  If Kite notifies Amgen in writing of its interest in performing such manufacture on behalf of Amgen within [...***...] of such notice from Amgen, Amgen agrees to meet with Kite to discuss in good faith such potential manufacture and supply and the terms thereof for a period of [...***...].   

Section 5.2   Transition of Supply.  

5.2.1Cooperation.  With respect to any transition of the manufacturing of Amgen Products (the “Transitioned Manufacturing”) to an alternate source pursuant to Section 5.1  (Supply and Quality Agreement) or Section 5.1.1 (Kite or Kite CMO Manufactures), Amgen and Kite shall cooperate to transition the Transitioned Manufacturing to Amgen (or to a mutually selected contract manufacturing organization the “Approved CMO”).  Kite shall use diligent efforts either to have its contract with such Approved CMO (if such Approved CMO is a Kite CMO) with respect to such Amgen Product (and potentially other Amgen Products) assigned to Amgen, or facilitate discussions between Amgen and such Approved CMO with respect to a new contract to be entered into between them with respect to continued supply of such Amgen Product for Amgen’s further supply needs.  In any event, Kite shall cooperate to provide to Amgen (or to such Approved CMO under obligations of confidentiality) all existing manufacturing information then in Kite’s possession and control and reasonably required for Amgen (or such Third Party) to perform such transitioned manufacturing of Amgen Products.  Kite shall also, in connection therewith, grant to such Approved CMO a non-exclusive license to use such manufacturing technology solely for the purposes of performing the transitioned manufacturing of Amgen Products for Amgen.  Amgen shall be responsible for all costs associated with the transition to Amgen (or to such Approved CMO) (including payment at the FTE Rate for hours of consulting support provided by Kite).  Amgen shall be responsible for all costs associated with the purchase of Amgen Products from any such Approved CMO.  

5.2.2Continued Supply.  The Parties shall use their commercially reasonable efforts to complete the transition of the Transitioned Manufacturing as soon as practicable, as applicable.   

5.2.3Transition Plan.  The transfer of transitioned manufacturing and continued supply of Amgen Products, if any, pursuant to this Section 5.2  (Transition of Supply), Section 5.1  (Supply and Quality Agreement) and Section 5.1.1 (Kite or Kite CMO Manufactures) shall be conducted in accordance with a transition plan which shall be mutually approved by the Parties and which sets forth responsibilities and schedules for transferring the transitioned manufacturing as expeditiously as reasonably practicable.  The transition plan shall set forth a limited number of hours of consulting support that Kite will provide as reasonably requested and necessary to facilitate the transition of the transitioned manufacturing for Amgen Products. 

***Confidential Treatment Requested

23

Section 5.3   Kite Products.  Except to the extent included in a Preclinical Development Plan funded pursuant to Section 8.1.3 (Preclinical Development Costs), Kite shall be solely responsible for, and shall bear all costs associated with, the manufacture of Kite Products.

Article 6.  REGULATORY MATTERS

Section 6.1   Amgen Responsibility.  Except as provided in Section 6.2  (Manufacturing Matters) and as provided under a Preclinical Development Plan, Amgen will be solely responsible for the preparation, submission and maintenance of all Regulatory Filings and obtaining all Regulatory Approvals (including any Marketing Approvals) with respect to Amgen Products.  Kite will cooperate with Amgen, at its reasonable request, with respect to any regulatory matters related to Amgen Products.  Amgen will own all right, title and interest in and to any and all Regulatory Filings and Regulatory Approvals directed to Amgen Products and all such Regulatory Filings and Regulatory Approvals will be held in the name of Amgen, and Kite will execute all documents and take all actions as are reasonably requested by Amgen to vest such title in Amgen.  To the extent not prohibited by Law, Amgen shall provide correspondence from Regulatory Authorities related to any IND filings in Amgen’s name if such correspondence would reasonably relate to any Kite Products and related Regulatory Filings.

Section 6.2   Manufacturing Matters.  Notwithstanding the provisions of Section 6.1  (Amgen Responsibility), with respect to Amgen Products manufactured by Kite, Kite shall assist with the [...***...] for any such Amgen Product, with sufficient information to satisfy [...***...].  Additionally, Kite shall provide Amgen with copies of all supporting documentation in its possession reasonably necessary to generate the [...***...].  Working with Amgen, Kite shall prepare the [...***...] for the first Amgen Product directed against the first Amgen Target. If requirements are identified for additional countries by Amgen, then, upon notification, Amgen may request additional regulatory information from Kite be provided.  Kite will meet this request if the data is [...***...].  In addition, in order to address questions Amgen may receive from health authorities (globally) in response to submissions of Regulatory Filings, Kite will assist in the preparation of responses based on information that would be found in: various technical reports, notebooks, executed batch records, master batch records, SOPs, validation protocols and reports, vendor certificates, and third party study reports and other CMC related documents not otherwise included in the [...***...].  Amgen shall reimburse all of Kite’s costs and expenses (including internal FTE costs at the FTE Rate) incurred in connection therewith.  

Section 6.3   Kite Responsibility.  Kite will be solely responsible for the preparation, submission and maintenance of all Regulatory Filings and obtaining all Regulatory Approvals (including any Marketing Approvals) with respect to Kite Products.  Kite will own all right, title and interest in and to any and all Regulatory Filings and Regulatory Approvals directed to Kite Products and all such Regulatory Filings and Regulatory Approvals will be held in the name of Kite, and Amgen will execute all documents and take all actions as are reasonably requested by Kite to vest such title in Kite. To the extent not prohibited by Law, Kite shall provide correspondence from Regulatory Authorities related to any IND filings in Kite’s name if such correspondence would reasonably relate to any Amgen Products and related Regulatory Filings (including with respect to Kite’s [...***...]).

***Confidential Treatment Requested

24

Article 7.  DEVELOPMENT AND COMMERCIAL MATTERS

Section 7.1   Amgen Responsibility.  Following the Effective Date and at all times during the Term (except as expressly stated otherwise herein), except as set forth in Section 8.1.3 (Preclinical Development Costs), Amgen shall be responsible for, and shall bear all costs associated with, the clinical development and commercialization of Amgen Products, including development, distribution, marketing and sales activities.  For clarity, after completion of the Preclinical Development Plan, Amgen shall continue to have the right to conduct preclinical development with respect to all Amgen Products.  Subject to the express written terms of this Agreement, all decisions concerning the development, marketing and sales of Amgen Products including the clinical and regulatory strategy, design, sale, price and promotion of Amgen Products covered under this Agreement shall be within the sole discretion of Amgen.

Section 7.2   Kite Responsibility.  Following the Effective Date and at all times during the Term (except as expressly stated otherwise herein), except as set forth in Section 8.1.3 (Preclinical Development Costs), Kite shall be responsible for, and shall bear all costs associated with, the clinical development and commercialization of Kite Products, including development, distribution, marketing and sales activities.  Subject to the express written terms of this Agreement, all decisions concerning the development, marketing and sales of Kite Products including the clinical and regulatory strategy, design, sale, price and promotion of Kite Products covered under this Agreement shall be within the sole discretion of Kite.

Section 7.3   Diligence.  On an Amgen Target-by-Amgen Target basis, Amgen shall (directly and/or through one or more Affiliates and/or Sublicensees) use Commercially Reasonable Efforts to develop and, if successful, commercialize an Amgen Product directed against such Amgen Target.  On a Kite Target-by-Kite Target basis, Kite shall (directly and/or through one or more Affiliates and/or Sublicensees) use Commercially Reasonable Efforts to develop, and if successful, commercialize a Kite Product directed against such Kite Target.  

Section 7.4   Reports.  On an Amgen Target-by-Amgen Target basis, until the Marketing Approval Milestone Payment set forth in Section 8.1.4 (Milestone Payments) has been made with respect to the first Amgen Product directed against such Amgen Target, on [...***...], Amgen shall submit to Kite a report providing a status of Amgen’s and its Affiliates’ and Sublicensees’ activities related to the Exploitation of Amgen Products directed against such Amgen Target during the preceding [...***...] period.  On a Kite Target-by-Kite Target basis, until the Marketing Approval Milestone Payment set forth in Section 8.1.4 (Milestone Payments) has been made with respect to the first Kite Product directed against such Kite Target, on [...***...], Kite shall submit to Amgen a report providing a status of Kite’s and its Affiliates’ and Sublicensees’ activities related to the Exploitation of Kite Products directed against such Kite Target during the preceding [...***...]. 

Article 8.  FEES, ROYALTIES, & PAYMENTS

Section 8.1   Upfront and Milestone Payments.  

8.1.1Upfront Payment.  As partial consideration for the rights granted to Amgen by Kite pursuant to the terms of this Agreement, for access to the Kite Platform Technology and Kite undertaking Preclinical Development under each of the Programs, Amgen will pay to Kite a non-refundable, non-creditable payment equal to Sixty Million Dollars 

***Confidential Treatment Requested

25

(US$60,000,000.00) within [...***...] after the Effective Date.  

8.1.2Amgen Optioned Target Payment.  If Amgen elects to exercise the option set forth in Section 4.2  (Amgen Optioned Target) to [...***...] after the written notice of such option exercise is received by Kite.  

8.1.3Preclinical Development Costs.  On a Target-by-Target basis (including for any Additional Targets), upon approval by the JSC of the applicable Preclinical Development Plan, Amgen shall be responsible for the first [...***...] of costs and expenses for Preclinical Development of the Parties under each such plan.  All internal FTE costs of Kite shall be billed to Amgen at the FTE Rate.  For each Kite Target, Kite shall reimburse Amgen for any amounts paid by Amgen to Kite for Preclinical Development related to the applicable Program for such Kite Target, within [...***...] after the filing of an IND for the first Kite Product under such Program, unless Amgen has elected to exercise the option set forth in Section 4.2  (Amgen Optioned Target) with respect to [...***...].  If Amgen elects to exercise the option set forth in Section 4.2  (Amgen Optioned Target), Amgen shall [...***...].  For clarity, other than with respect to Amgen obligations under this Section 8.1.3 (Preclinical Development Costs), each Party shall be responsible for, and shall bear all costs associated with, the clinical development and commercialization of its Products, including development, distribution, marketing and sales activities.  

8.1.4Milestone Payments.  Amgen shall pay to Kite, on an Amgen Target-by-Amgen Target basis, and Kite shall pay to Amgen, on a Kite Target-by- Kite Target basis, one-time milestone payments (“Milestone Payments”) following the first occurrence of the corresponding milestone events with respect to one or more Amgen Products directed against such Amgen Target, or one or more Kite Products directed against such Kite Target, asapplicable, as set forth in the following table (the “Milestone Events”):

	
Milestone Event
	
Milestone Payment

	
[...***...]
	
[...***...]

	
[...***...]
	
[...***...]

***Confidential Treatment Requested

26

	
Milestone Event
	
Milestone Payment

	
[...***...]
	
[...***...]

	
[...***...]
	
[...***...]

	
[...***...]
	
[...***...]

 

For a particular Target, the Paying Party shall pay to the non-Paying Party the applicable Milestone Payment in the manner described below after the first occurrence of such applicable Milestone Event with respect to a Product  directed against the particular Target.  For clarity, each Milestone Payment is payable only once; and the maximum amount payable for Amgen Products directed against a particular Amgen Target, or Kite Products directed against a particular Kite Target under this Section 8.1.4 (Milestone Payments) is Five Hundred Twenty-Five Million Dollars ($525,000,000). No Milestone Payment shall be payable for subsequent or repeated achievements of such Milestone Event with one or more of the same or different Products directed against a particular Target.  Each of the Milestone Payments shall be non-refundable and non-creditable.  The Paying Party shall report to the non-Paying Party its achievement of each Milestone Event for which payment to the non-Paying Party is due, within [...***...] after the Paying Party determines such achievement has occurred, and the non-Paying Party shall invoice the Paying Party for the applicable Milestone Payment.  The Paying Party will pay each such invoice within [...***...] of its receipt thereof.

***Confidential Treatment Requested

27

8.1.5Additional Milestone Payments.  With respect to the Amgen Optioned Target, if any, Amgen shall pay to Kite the following additional milestone payments to those set forth in Section 8.1.4 (Milestone Payments) with respect to Amgen Optioned Products directed against such Amgen Optioned Target (“Additional Milestone Payments”) following the first occurrence of the corresponding milestone events set forth in the following table (the “Additional Milestone Events”):

	
Additional Milestone Event
	
Additional Milestone Payment

	
[...***...]
	
[...***...]

	
[...***...]
	
[...***...]

 

Amgen shall pay to Kite the applicable Additional Milestone Payment in the manner described below after the first occurrence of such applicable Additional Milestone Event with respect to an Amgen Optioned Product directed against the Amgen Optioned Target.  For clarity, each Additional Milestone Payment is payable only once; no Additional Milestone Payment shall be payable for subsequent or repeated achievements of such Additional Milestone Event with one or more of the same or different Amgen Optioned Products directed against such Amgen Optioned Target.  Each of the Additional Milestone Payments shall be non-refundable and non-creditable.  Amgen shall report to Kite its achievement of each Additional Milestone Event for which payment to Kite is due, within [...***...] after Amgen determines such achievement has occurred, and Kite shall invoice Amgen for the applicable Additional Milestone Payment.  Amgen will pay each such invoice within [...***...] of its receipt thereof.

 

Section 8.2   Royalties.  

8.2.1Royalty Rate.   Amgen shall pay to Kite with respect to all Amgen Products directed against a particular Amgen Target, and Kite shall pay to Amgen with respect to all Kite Products directed against a Kite Target, royalties on annual Net Sales of such Product sold by the Selling Party during the Royalty Term for each such Product.  Such annual Net Sales for Products shall be aggregated for all Products directed against the same Target in order to 

***Confidential Treatment Requested

28

determine the royalty rate applicable to the corresponding incremental portion of such aggregate annual Net Sales, as set forth in the table below.  

 

	
Aggregate Annual Net Sales
	
Royalty Rate

	
Portion of aggregate annual Net Sales [...***...]
	
[...***...]

	
Portion of aggregate annual Net Sales [...***...]
	
[...***...]

	
Portion of aggregate annual Net Sales [...***...]
	
[...***...]

	
Portion of aggregate annual Net Sales [...***...]
	
[...***...]

	
For Amgen Optioned Products, the royalty rate shall be [...***...]with respect to the Net Sales of all Amgen Optioned Products sold by the Selling Party during the Royalty Term for such Amgen Optioned Product.

8.2.2Additional Amgen Royalty Rate.  In further consideration for the licenses granted hereunder, Amgen shall pay to Kite the additional royalties set forth in the following table on annual Net Sales of such Amgen Product sold by a Selling Party during the applicable Royalty Term for such Amgen Product:

 

	
Territory
	
Royalty Rate

	
Net Sales in the U.S.
	
[...***...]

	
Net Sales outside the U.S.
	
[...***...]

 

Provided, however, that a portion of the above royalty rates ([...***...] percentage points of the [...***...]% royalty owed in the U.S. and [...***...] percentage points of the [...***...]% owed outside the U.S.) shall be reduced to the extent that the royalties owed by Kite under that certain License Agreement by and between Kite and Cabaret Biotech Ltd, dated as of December 12, 2013 (the “Cabaret License”) on sales of Amgen Products are reduced for the U.S. or countries outside 

***Confidential Treatment Requested

29

the U.S., as the case may be, whether due to expiration or invalidity of the patents licensed thereunder, or otherwise, in proportion to such reduction.  For example, if the royalties owed by Kite under the Cabaret License are reduced in the U.S. by one-half of the amount owed thereunder as of the Signing Date, the royalty rate owed under this Section 8.2.2 (Additional Amgen Royalty Rate) on Net Sales in the U.S. of the applicable Amgen Product would be one-half of [...***...]%, or [...***...]%.  In addition, to the extent the Kite Patents set forth in Table B of Exhibit B (Kite IP) do not Cover the Exploitation of an Amgen Patent in the U.S. or in a country outside the U.S., the royalty rates applicable under this Section 8.2.2 (Additional Amgen Royalty Rate) shall be [...***...] percentage points in the U.S., and by [...***...] percentage point in a country outside the U.S., from the rates otherwise then in effect under this Section 8.2.2 (Additional Amgen Royalty Rate).  

8.2.3Royalty Term.  Royalties will be payable on a [...***...] basis; any such payments shall be made within [...***...] after the end of the [...***...] during which the applicable Net Sales occurred.  The Paying Party’s obligation to pay royalties with respect to a particular Product in a particular country shall commence upon the First Commercial Sale of such Product in such country and shall expire on the later of (a) the date on which the Exploitation of such Product is no longer Covered by a Valid Claim of (i) a Kite Patent or Collaboration Patent (in the case of an Amgen Product) in such country or (ii) an Amgen Patent or Collaboration Patent (in the case of a Kite Product) in such country, (b) the loss of Regulatory Exclusivity for the Product in such country, or (c) the [...***...] anniversary of the First Commercial Sale of the first Product in such Program in such country (the “Royalty Term”).  

8.2.4Single Royalty.  It is expressly agreed that to the extent a Party’s Product hereunder is composed of a product which either is directed against at least two Targets, both of which are Amgen Targets, in the case of Amgen, or Kite Targets, in the case of Kite, that only a single royalty would be owed on such Product, which royalty rate would be based upon the highest royalty rate applicable to either of such Amgen Targets, or Kite Targets, as applicable.

8.2.5Royalty Reduction.  On a country-by-country and Product-by-Product basis, in the event that the Exploitation of a Product is not Covered by a Valid Claim of (a) a Kite Patent or Collaboration Patent (in the case of an Amgen Product) in such country or (b) an Amgen Patent or Collaboration Patent (in the case of a Kite Product) in such country, then the royalty rates set forth in Section 8.2.1 (Royalty Rate) with respect to Net Sales for such Product in such country shall be [...***...] percent ([...***...]%), effective as of the date such Product is no longer Covered by a Valid Claim of (i) a Kite Patent or Collaboration Patent (in the case of an Amgen Product) in such country or (ii) an Amgen Patent or Collaboration Patent (in the case of a Kite Product) in such country.

8.2.6Third-Party Intellectual Property.  In the event that a Third Party Controls intellectual property that is reasonably necessary for the Exploitation of a Product, then the Paying Party shall have the right (but not the obligation) to obtain such license to such Third Party intellectual property.  In such an event, [...***...] percent ([...***...]%) of the royalties, milestones or other payments that the Paying Party actually pays to such Third Party for the Exploitation of such Product in a country during a calendar quarter may be credited 

***Confidential Treatment Requested

30

against royalties otherwise 

***Confidential Treatment Requested

31

payable by the Paying Party to the non-Paying Party under Section 8.2  (Royalties) for such Product in such country in such calendar quarter, subject to Section 8.2.7 (Maximum Reduction).

8.2.7Maximum Reduction.  The maximum aggregate reduction with respect to any Product in any calendar quarter during the applicable Royalty Term in any country pursuant to Sections 8.2.5 (Royalty Reduction) and 8.2.6 (Third-Party Intellectual Property) shall be [...***...] percent ([...***...]%).

Section 8.3   Mutual Convenience of the Parties.  The royalty and other payment obligations set forth hereunder have been agreed to by the Parties for the purpose of reflecting and advancing their mutual convenience, including the ease of calculating and paying royalties and other amounts required hereunder.  

Section 8.4   No Other Compensation.  Other than as explicitly set forth in this Agreement or in connection with the supply of Amgen Products by Kite to Amgen pursuant to the applicable supply agreements, neither Party will be obligated to pay any additional fees, milestone payments, royalties or other payments of any kind to the other hereunder.

Section 8.5   Method of Payment.  Unless otherwise agreed by the Parties, all payments due from the Paying Party to other Party under this Agreement shall be paid in U.S. Dollars by wire transfer or electronic funds transfer of immediately available funds to the following accounts:

 

			
	
If Kite is the Paying Party:

	
Beneficiary Name:
	
 
	
[...***...]

	
Beneficiary Account #:
	
 
	
[...***...]

	
Bank Name:
	
 
	
[...***...]

	
ABA#:
	
 
	
[...***...]

	
Swift Code:
	
 
	
[...***...]

 

			

***Confidential Treatment Requested

32

	
If Amgen is the Paying Party:

	
Bank Name:
	
 
	
[...***...]

	
Bank Address:
	
 
	
[...***...]

	
Bank Contact:
	
 
	
[...***...]

	
ABA:
	
 
	
[...***...]

	
Account Name:
	
 
	
[...***...]

	
Account No.:
	
 
	
[...***...]

 

Either Party may change the accounts listed above with thirty (30) days written notice to the Paying Party.  On a Target-by-Target basis, after the First Commercial Sale of the first Product to such Target and until expiration of the last applicable Royalty Term, the Paying Party shall prepare and deliver to the other Party royalty reports of the sale of Products to such Target by the Selling Parties for each [...***...] within [...***...] specifying in the aggregate and on a Product-by-Product and country-by-country basis: (a) total gross amounts for Products sold or otherwise disposed of by a Selling Party; (b) amounts deducted by category in accordance with Section 1.86  (“Net Sales”) from gross amounts to calculate Net Sales; (c) Net Sales; and (d) royalties payable.  

Section 8.6   Currency Conversion.  In the case of sales outside the United States, payments received by the Paying Party will be expressed in the U.S. Dollar equivalent calculated on a quarterly basis in the currency of the country of sale and converted to their U.S. Dollar equivalent using the average rate of exchange over the applicable calendar quarter to which the sales relate, in accordance with GAAP and the then current standard methods of the Paying Party or the applicable Sublicensee, to the extent reasonable and consistently applied; provided, however, that if, at such time, the Paying Party does not use a rate for converting into U.S. Dollar equivalents that is maintained in accordance with GAAP, then the Paying Party shall use a rate of exchange which corresponds to the rate of exchange for such currency reported in The Wall Street Journal, Internet U.S. Edition at www.wsj.com, as of the last day of the applicable reporting period (or, if unavailable on such date, the first date thereafter on which such rate is available).  The Paying Party will inform the other Party as to the specific exchange rate translation methodology used for a particular country or countries.

Section 8.7   Late Payments.  In the event that any payment due hereunder is not made when due, the payment shall accrue interest beginning on the day following the due date thereof, calculated at the annual rate of [...***...] quoted by The Wall Street Journal, Internet U.S. Edition at www.wsj.com on the date said payment is due, the interest being compounded on the last day of each calendar quarter; provided, however, that in no event shall said annual interest rate exceed the maximum rate permitted by Law. Each such payment when made shall be accompanied by all interest so accrued.  Said interest and the payment and acceptance thereof shall not negate or waive the right of any Party to seek any other remedy, legal or equitable, to which it may be entitled because of the delinquency of any payment including, but not limited to termination of this Agreement as set forth in Article 13 (Term & Termination).

Section 8.8   Records and Audits.  The Paying Party will keep complete and accurate records of the underlying revenue and expense data relating to the calculations of Net Sales generated in the then current calendar year and payments required under this Agreement (or Kite with respect to 

***Confidential Treatment Requested

33

any costs and expenses payable by Amgen hereunder), and during the preceding [...***...].  The non-Paying Party  (or Amgen with respect to any costs and expenses payable by Amgen hereunder) (the “Auditing Party”) will have the right, once annually at its own expense, to have a nationally recognized, independent, certified public accounting firm, selected by it and subject to the Paying Party’s (or Kite’s with respect to any costs and expenses payable by Amgen hereunder) prior written consent (which shall not be unreasonably withheld), review any such records of the Paying Party (or Kite with respect to any costs and expenses payable by Amgen hereunder) and its Affiliates and Sublicensees (the “Audited Party”) in the location(s) where such records are maintained by the Audited Party upon reasonable written notice (which shall be no less than thirty (30) days’ prior written notice) and during regular business hours and under obligations of strict confidence, for the sole purpose of verifying the basis and accuracy of payments made under Section 8.2  (Royalties) within the [...***...] period preceding the date of the request for review.  No calendar year will be subject to audit under this Section 8.8  (Records and Audits) more than once. The Audited Party will receive a copy of each such report concurrently with receipt by the Auditing Party. Should such inspection lead to the discovery of a discrepancy to the Auditing Party’s detriment, the Audited Party will, within [...***...] after receipt of such report from the accounting firm, pay any undisputed amount of the discrepancy together with interest at the rate set forth in Section 8.7  (Late Payments).  The Auditing Party will pay the full cost of the review unless the 

***Confidential Treatment Requested

34

underpayment of amounts due to the Auditing Party is [...***...] percent ([...***...]%) of the amount due for the entire period being examined, in which case the Audited Party will pay the cost charged by such accounting firm for such review. Should the audit lead to the discovery of a discrepancy to the Audited Party’s detriment, the Audited Party may credit the amount of the discrepancy, without interest, against future payments payable to the Auditing Party under this Agreement, and if there are no such payments payable, then the Auditing Party shall pay to the Audited Party the amount of the discrepancy, without interest, within [...***...] of the Auditing Party’s receipt of the report.

Section 8.9   Taxes.

8.9.1Withholding.  In the event that any Law requires the Paying Party to withhold taxes with respect to any payment to be made by the Paying Party pursuant to this Agreement, the Paying Party will notify the non-Paying Party of such withholding requirement prior to making the payment to the non-Paying Party and provide such assistance to the non-Paying Party, including the provision of such standard documentation as may be required by a tax authority, as may be reasonably necessary in the non-Paying Party’s efforts to claim an exemption from or reduction of such taxes.  The Paying Party will, in accordance with such Law withhold taxes from the amount due, remit such taxes to the appropriate tax authority, and furnish the non-Paying Party with proof of payment of such taxes within [...***...] following the payment.   If taxes are paid to a tax authority, the Paying Party shall provide reasonable assistance to the non-Paying Party to obtain a refund of taxes withheld, or obtain a credit with respect to taxes paid.

8.9.2VAT.  All payments due to the non-Paying Party from the Paying Party pursuant to this Agreement shall be paid exclusive of any value-added tax (“VAT”) (which, if applicable, shall be payable by the Paying Party upon receipt of a valid VAT invoice).  If the non-Paying Party determines that it is required to report any such tax, the Paying Party shall promptly provide the non-Paying Party with applicable receipts and other documentation necessary or appropriate for such report.  For clarity, this Section 8.9.2 (VAT) is not intended to limit the Paying Party’s right to deduct value-added taxes in determining Net Sales.

Article 9.  INTELLECTUAL PROPERTY AND PATENT RIGHTS

Section 9.1   Intellectual Property Ownership. 

9.1.1Background IP. Each Party will own all right, title and interest in its Background IP. 

9.1.2Collaboration IP. Ownership of Collaboration IP shall follow inventorship.  Inventorship will be determined according to United States Patent Law (without reference to any conflict of law principles).  Amgen, on behalf of itself and its Affiliates, hereby grants and agrees to grant to Kite a fully paid up, perpetual, worldwide, non-exclusive license, with a right to grant sublicenses, under Collaboration IP solely owned by it, solely to the extent such Collaboration IP claims an Improvement to Kite Platform Technology, to Exploit such Improvement to Kite Platform Technology for all purposes.  

***Confidential Treatment Requested

35

9.1.3Joint IP. Except as expressly provided in this Agreement, it is understood that neither Party will have any obligation to obtain any approval or consent of, nor pay a share of the proceeds to or account to, the other Party to practice, enforce, license, assign or otherwise exploit inventions or intellectual property owned jointly by the Parties hereunder, including any Collaboration IP, and each Party hereby waives any right it may have under the laws of any jurisdiction to require such approval, consent or accounting.  Each Party agrees to cooperate with the other Party, as reasonably requested, and to take such actions as may be required to give effect to this Section 9.1.3 (Joint IP) in a particular country within the Territory.  Notwithstanding the foregoing, Amgen shall retain all rights to [...***...].

Section 9.2   Patent Prosecution.

9.2.1Kite Patent(s). Kite will be solely responsible, at its own cost, for preparing, filing, prosecuting (including, but not limited to provisional, reissue, continuing, continuation-in-part, and substitute applications and any foreign counterparts thereof), and maintaining all Kite Patents and conducting any interferences and oppositions or similar proceedings relating to Kite Patents.  Amgen acknowledges and agrees that (a) neither Kite nor any of its Affiliates will have any liability of any kind relating to the preparation, filing, prosecution and maintenance of Kite Patent Rights as provided in this Section 9.2.1 (Kite Patent(s)); and (b) as between the Parties, Kite and its Affiliates have the right to cease all activities relating to the preparation, filing, prosecution or maintenance of any Kite Patent Rights as provided in this Section 9.2.1 (Kite Patent(s)) for any reason, in which case Kite will promptly inform Amgen of such planned cessation.

9.2.2Amgen Patent(s). Amgen will be solely responsible, at its own cost, for preparing, filing, prosecuting (including, but not limited to provisional, reissue, continuing, continuation-in-part, and substitute applications and any foreign counterparts thereof), and maintaining all Amgen Patents and conducting any interferences and oppositions or similar proceedings relating to Amgen Patents.  Kite acknowledges and agrees that (a) neither Amgen nor any of its Affiliates will have any liability of any kind relating to the preparation, filing, prosecution and maintenance of Amgen Patent Rights as provided in this Section 9.2.2 (Amgen Patent(s)); and (b) as between the Parties, Amgen and its Affiliates have the right to cease all activities relating to the preparation, filing, prosecution or maintenance of any Amgen Patent Rights as provided in this Section 9.2.2 (Amgen Patent(s)) for any reason, in which case Amgen will promptly inform Kite of such planned cessation.

9.2.3Collaboration Patents.  Kite will be primarily responsible, at its own cost, for preparing, filing, prosecuting (including, but not limited to provisional, reissue, continuing, continuation-in-part, and substitute applications and any foreign counterparts thereof), and maintaining all Patent Rights constituting (a) Collaboration Patents that solely claim Improvements to Kite Platform Technology (regardless of ownership), (b) Collaboration 

***Confidential Treatment Requested

36

Patents that both (i) solely claim Collaboration Know-How (regardless of ownership) generated during the applicable Preclinical Development Term and (ii) solely Cover Kite Products, or (c) Collaboration Patents that solely claim Collaboration Know-How generated solely by Kite after the applicable Preclinical Development Term, and in each case, conducting any interferences and oppositions or similar proceedings relating to such Patent Rights.  Amgen will be primarily responsible, at its own cost, for preparing, filing, prosecuting (including, but not limited to provisional, reissue, continuing, continuation-in-part, and substitute applications and any foreign counterparts thereof), and maintaining all other Patent Rights constituting Collaboration Patents and conducting any interferences and oppositions or similar proceedings relating to such Patent Rights. The filing Party will provide the non-filing Party with copies of and an opportunity to review and comment upon the text of the applications relating to the applicable Collaboration Patents at least [...***...] before filing; provided, however, that if it is not reasonably practicable to provide such application in such [...***...] period, then the filing Party will provide either a draft copy of such application or a statement of intent to file such application in such [...***...] period.  The filing Party will provide the non-filing Party with a copy of each submission made to and document received from a patent authority, court or other tribunal regarding any Collaboration Patent reasonably promptly after making such filing or receiving such document, including a copy of each application for each Collaboration Patent as filed together with notice of its filing date and application number.  The filing Party will keep the non-filing Party advised of the status of all material communications, and actual and prospective filings or submissions regarding the Collaboration Patents, and will give the non-filing Party copies of and an opportunity to review and comment on any such material communications, filings and submissions proposed to be sent to any patent authority or judicial body.  The filing Party will consider in good faith the non-filing Party’s comments on such communications, filings and submissions for the Collaboration Patents.  With respect to any filings or other materials provided to the non-filing Party under this Section 9.2.3 (Collaboration Patents), the filing Party will have the right to redact information relating to any product other than Products or any Know-How other than Collaboration Know-How from any such filings and materials.  In the event either Party declines to file, prosecute or maintain any of the foregoing Patent Rights, elects to allow any Patent Rights to lapse in any country, or elects to abandon any Patent Rights (in each case to the extent contained in the Collaboration Patents) before all appeals within the respective patent office have been exhausted (each, an “Abandoned Patent Right”), then: (i) such Party shall provide the other Party with reasonable notice of such decision so as to permit the non-abandoning Party to decide whether to file, prosecute or maintain such Abandoned Patent Rights and to take any necessary action (which notice shall, in any event, be given no later than [...***...] prior to the next deadline for any action that may be taken with respect to such Abandoned Patent Right with the U.S. Patent & Trademark Office or any foreign patent office); (ii) the non-abandoning Party, at the non-abandoning Party’s expense, may assume control of the filing, prosecution or maintenance of such Abandoned Patent Rights, except for Collaboration Patents that solely cover Improvements to the Kite Platform Technology that Kite has determined, in its reasonable discretion, not to file in light of the impact of such filings on Kite’s overall patent strategy with respect to the Kite Platform Technology; (iii) the non-abandoning Party shall have the right, at its expense, to transfer the responsibility for such filing, prosecution and maintenance of such Abandoned Patent Rights to patent counsel (outside or internal) selected by the non-abandoning Party; and (iv) the abandoning Party shall, at the non-abandoning Party’s reasonable request and at the non-

 

***Confidential Treatment Requested

37

Execution Copy

 

abandoning Party’s expense, assist and cooperate in the filing, prosecution and maintenance of such Abandoned Patent Rights. 

Section 9.3   Patent Term Extensions.  The Parties will cooperate with each other in gaining Patent Right term extension where applicable to Amgen Products and Kite Products and in the case of any disagreement, Amgen would have the final say as to term extension for any Patent Right claiming the composition or method of use of an Amgen Product, and Kite would have the final say as to term extension for any Patent Right claiming the composition or method of use of a Kite Product.    

Section 9.4   Defense and Settlement of Third Party Claims.  If either (a) any Amgen Product or Kite Product Exploited by or under authority of either Party becomes the subject of a Third Party’s claim or assertion of infringement of a patent, or (b) if a declaratory judgment action is brought naming either Party as a defendant and alleging invalidity of any of the Patent Rights contained in Collaboration Patents, Kite Patents or Amgen Patents, the Party first having notice of the claim or assertion shall promptly notify the other Party, and the Parties shall promptly confer to consider the claim or assertion and the appropriate course of action.  Unless the Parties otherwise agree in writing, each Party shall have the right to defend itself against a suit that names it as a defendant (the “Defending Party”).  None of the Parties shall enter into any settlement of any claim described in this Section 9.4  (Defense and Settlement of Third Party Claims) that admits to the invalidity or unenforceability of any Patent Right Controlled by the other Party (or otherwise effects the scope, validity or enforceability of such Patent Right), incurs any financial liability on the part of any other Party or requires an admission of liability, wrongdoing or fault on the part of the other Party without such other Party’s written consent.  In any event, the other Party shall reasonably assist the Defending Party and cooperate in any such litigation at the Defending Party’s request and expense.  Additionally, if the Defending Party is not the Party that Controls the Patent Right in question, then the other Party has the right to join any such action.

Section 9.5   Enforcement. 

9.5.1Notice of Infringement.  The Parties hereto shall inform each other promptly of any infringement or colorable cause of action for infringement of any Patent Right within the Collaboration Patents, Kite Patents or Amgen Patents, and the Parties shall promptly confer to consider the best appropriate course of action.  

9.5.2Kite Enforcement.  In the event that such infringement or alleged infringement is with respect to a product that has the same primary mechanism of action as a Kite Product, then Kite shall have the right to enforce the following Patent Rights against any such infringement or alleged infringement thereof – with respect to (i) a Kite Patent, such right shall be a sole right, (ii) (a) Amgen Patents and/or (b) Collaboration Patents that Cover Amgen Products (other than Collaboration Patents that Cover an Improvement to the Kite Platform Technology), such right shall require the prior written consent of Amgen, (iii) any Patent Right within the Collaboration Patents generated by Kite (whether solely by Kite or jointly with Amgen) that solely covers an Improvement to the Kite Platform Technology, such right shall not require the prior written consent of Amgen; and (iv) any Patent Right within the Collaboration Patents that does not Cover Amgen Products, such right shall not require the prior written 

38

consent of Amgen.  Kite shall at all times keep Amgen informed as to the status thereof.  In such case, Kite may, at its own expense, institute suit against any infringer or alleged infringer and control and defend such suit in a manner consistent with the terms and provisions hereof and recover any damages, awards or settlements resulting therefrom, subject to Section 9.5.5 (Recoveries).  Amgen shall reasonably cooperate in any such litigation at Kite’s expense.  Kite shall not enter into any settlement of any claim described in this Section 9.5.2 (Kite Enforcement) that admits to the invalidity or unenforceability of any Amgen Patents or Collaboration Patents (or otherwise effects the scope, validity or enforceability of such Amgen Patents or Collaboration Patents), incurs any financial liability on the part of Amgen or requires an admission of liability, wrongdoing or fault on the part of Amgen without Amgen’s prior written consent.  In the event that Kite does not elect to enforce any Patent Right within the Amgen Patents or Collaboration Patents, then Amgen shall be entitled to do so, unless Kite has a good faith belief that Amgen’s enforcement of such Patent Rights would be reasonably likely to jeopardize the Exploitation of a Kite Product.  Amgen shall not enter into any settlement of any claim described in this Section 9.5.2 (Kite Enforcement) that admits to the invalidity or unenforceability of any Collaboration Patents (or otherwise effects the scope, validity or enforceability of such Collaboration Patents), incurs any financial liability on the part of Kite or requires an admission of liability, wrongdoing or fault on the part of Kite without Kite’s prior written consent.  

9.5.3Amgen Enforcement.  In the event that such infringement or alleged infringement is with respect to a product that has the same primary mechanism of action as an Amgen Product, then Amgen shall have the right to enforce the following Patent Rights against any such infringement or alleged infringement thereof – with respect to (i) an Amgen Patent, such right shall be a sole right, (ii) (a) Kite Patents, (b) Collaboration Patents that Cover Kite Products, and (c) Collaboration Patents generated solely by Kite that solely Cover any Improvement to the Kite Platform Technology, such right shall require the prior written consent of Kite, and (iii) any Patent Right within the Collaboration Patents that does not Cover Kite Products (other than Collaboration Patents generated solely by Kite that solely Cover any Improvement to the Kite Platform Technology), such right shall not require the prior written consent of Kite.  Amgen shall at all times keep Kite informed as to the status thereof.  In such case, Amgen may, at its own expense, institute suit against any infringer or alleged infringer and control and defend such suit in a manner consistent with the terms and provisions hereof and recover any damages, awards or settlements resulting therefrom, subject to Section 9.5.5 (Recoveries).  Kite shall reasonably cooperate in any such litigation at Amgen’s expense.  Amgen shall not enter into any settlement of any claim described in this Section 9.5.3 (Amgen Enforcement) that admits to the invalidity or unenforceability of any Kite Patents or Collaboration Patents (or otherwise effects the scope, validity or enforceability of such Kite Patents or Collaboration Patents), incurs any financial liability on the part of Kite or requires an admission of liability, wrongdoing or fault on the part of Kite without Kite’s prior written consent.  In the event that Amgen does not elect to enforce any Patent Right within the Kite Patents or Collaboration Patents, then Kite shall be entitled to do so, unless Amgen has a good faith belief that Kite’s enforcement of such Patent Rights would be reasonably likely to jeopardize the Exploitation of an Amgen Product.  Kite shall not enter into any settlement of any claim described in this Section 9.5.3 (Amgen Enforcement) that admits to the invalidity or unenforceability of any Collaboration Patents (or otherwise effects the scope, validity or enforceability of such Collaboration Patents), incurs any financial liability on the part of Amgen

1.1.1

39

Execution Copy

 

or requires an admission of liability, wrongdoing or fault on the part of Amgen without Amgen’s prior written consent.  

9.5.4Progress Reporting.  The Party initiating any such enforcement action (the “Enforcing Party”) shall keep the other Party reasonably informed of the progress of any such enforcement action, and such other Party shall have the individual right to participate with counsel of its own choice at its own expense, except with respect to the enforcement of Kite Patents. 

9.5.5Recoveries.  Except as otherwise provided, the costs and expenses of the Party bringing suit under Section 9.5  (Enforcement) shall be borne by such Party, and any damages, settlements or other monetary awards recovered shall be shared as follows: (1) the amount of such recovery actually received by the Party controlling such action shall first be applied to the out-of-pocket costs of each Party in connection with such action; and then (2) the remainder of the recovery shall be shared as follows:

	
(a)
	
If Kite is the Enforcing Party under Section 9.5.2 (Kite Enforcement) or Amgen is the Enforcing Party under Section 9.5.3 (Amgen Enforcement), then [...***...] percent ([...***...]%) to the Enforcing Party (with such recovery being treated as Net Sales under this Agreement); and

	
(b)
	
If Kite is the Enforcing Party under Section 9.5.3 (Amgen Enforcement) or Amgen is the Enforcing Party under Section 9.5.2 (Kite Enforcement), [...***...] percent ([...***...]%) to the Enforcing Party and [...***...] percent ([...***...]%) to the non-Enforcing Party.

9.5.6Kite Patents.  Notwithstanding anything to the contrary herein, Amgen shall have no right to enforce any Kite Patent unless and until Kite consents to such enforcement in writing, such consent to be given in Kite’s sole discretion.

Section 9.6   Kite Discussions regarding Third Party Intellectual Property. If, during the Term, Kite is in discussions with a Third Party regarding the acquisition, license or other access to intellectual property rights of such Third Party which are directly relevant to one or more Amgen Targets or Amgen Products, and such acquisition, license or other access does not include rights to use such intellectual property to Exploit Amgen Products, Kite will inform Amgen of such discussions and discuss with Amgen expanding the scope of such acquisition, license or other access to such intellectual property rights to include the right to use such intellectual property to Exploit Amgen Products, and the costs for such expansion.  If Amgen and Kite do not agree to the appropriate costs of such expansion, no such intellectual property rights shall be subject to the terms of this Agreement. 

Article 10.  REPRESENTATIONS

Section 10.1   Mutual Warranties.  As of the Signing Date, each of Amgen and Kite represent and warrant that:

	
(a)
	
it is duly organized and validly existing under the Law of the jurisdiction of its incorporation, and has full corporate power and authority to enter into this Agreement and to carry out the provisions hereof;

 

***Confidential Treatment Requested

40

Execution Copy

 

	
(b)
	
it is duly authorized to execute and deliver this Agreement and to perform its obligations hereunder, and the individual executing this Agreement on its behalf has been duly authorized to do so by all requisite corporate action; and

	
(c)
	
this Agreement is legally binding upon it and enforceable in accordance with its terms.  The execution, delivery and performance of this Agreement by it does not conflict with any agreement, instrument or understanding, oral or written, to which it is a party or by which it may be bound, nor violate any material applicable Law.

Section 10.2   Additional Kite Warranties.  As of the Signing Date, Kite warrants to Amgen that:

	
(a)
	
Kite has full legal or beneficial title and ownership of, or an exclusive license to, the Kite Patents listed on Exhibit B (Kite IP) as is necessary to grant the licenses (or sublicenses) to Amgen to such Kite Patents that Kite purports to grant pursuant to this Agreement;

	
(b)
	
Exhibit B (Kite IP) is a complete and accurate list of all Patent Rights (i) owned by Kite or its Affiliates and (ii) to which Kite or its Affiliates have rights, in each case that claim or cover Kite Platform Technology;

	
(c)
	
Kite has the rights necessary to grant the licenses to Amgen to Kite Licensed Know-How that Kite purports to grant pursuant to this Agreement;

	
(d)
	
The Kite Patents owned by Kite are not subject to, and to Kite’s knowledge the Kite Patents licensed to Kite are not subject to, any liens or encumbrances and Kite has not granted to any Third Party any rights or licenses under such Patent Rights or Kite Licensed Know-How that would conflict with the licenses granted to Amgen hereunder.  Except as expressly identified on Exhibit B (Kite IP), none of the Kite Patents are in-licensed by Kite.  No patent application or registration within the Kite Patents is subject of any pending interference, opposition, cancellation or patent protest; 

	
(e)
	
Table A of Exhibit B (Kite IP) lists all Third Party licenses and agreements pursuant to which Kite or its Affiliates has obtained rights to Kite Patents and Kite Licensed Know-How, and Kite has shared with Amgen complete and accurate copies of all such licenses and agreements;

	
(f)
	
No Third Party has made any claim or allegation to Kite or its Affiliates in writing that a Third Party has any right or interest in or to the Kite Patents listed on Exhibit B (Kite IP); and

	
(g)
	
Kite has no knowledge of any claim or litigation that has been brought or threatened in writing by any Third Party alleging that (i) the Kite Patents are invalid or unenforceable or (ii) the manufacture, use, sale, offer for sale, or importation of the Amgen Products (based upon the Amgen 

41

		
Targets existing as of the Signing Date) or products made using Kite Platform Technology infringes or misappropriates or would infringe or misappropriate any right of any Third Party.

Section 10.3   Additional Amgen Warranties.  As of the Signing Date, Amgen warrants to Kite that:

	
(a)
	
Amgen has full legal or beneficial title and ownership of, or an exclusive license to, the Amgen Patents as is necessary to grant the licenses (or sublicenses) to Kite to such Amgen Patents that Amgen purports to grant pursuant to this Agreement;

	
(b)
	
The Amgen Patents owned by Amgen are not subject to, and to Amgen’s knowledge the Amgen Patents licensed to Amgen are not subject to, any liens or encumbrances and Amgen has not granted to any Third Party any rights or licenses under such Patent Rights that would conflict with the licenses granted to Kite hereunder.  No patent application or registration within the Amgen Patents is subject of any pending interference, opposition, cancellation or patent protest;

	
(c)
	
No Third Party has made any claim or allegation to Amgen or its Affiliates in writing that a Third Party has any right or interest in or to the Amgen Patents; and

	
(d)
	
Amgen has no knowledge of any claim or litigation that has been brought or threatened in writing by any Third Party alleging that (i) the Amgen Patents are invalid or unenforceable or (ii) the manufacture, use, sale, offer for sale, or importation of the Kite Products (based upon the Kite Targets existing as of the Signing Date) infringes or misappropriates or would infringe or misappropriate any right of any Third Party.

Section 10.4   Disclaimer.  EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS ARTICLE 10 (REPRESENTATIONS), NEITHER PARTY MAKES ANY REPRESENTATIONS OR EXTENDS ANY WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY, QUALITY, FITNESS FOR A PARTICULAR PURPOSE, NONINFRINGEMENT, OR VALIDITY OF PATENT CLAIMS. NOTHING IN THIS AGREEMENT SHALL BE CONSTRUED AS A REPRESENTATION MADE OR WARRANTY GIVEN BY EITHER PARTY THAT EITHER PARTY WILL BE SUCCESSFUL IN OBTAINING ANY PATENT RIGHTS, OR THAT ANY PATENTS WILL ISSUE BASED ON A PENDING APPLICATION.  WITHOUT LIMITING THE RESPECTIVE RIGHTS AND OBLIGATIONS OF THE PARTIES EXPRESSLY SET FORTH HEREIN, EACH PARTY SPECIFICALLY DISCLAIMS ANY GUARANTEE THAT THE PRODUCTS WILL BE SUCCESSFUL, IN WHOLE OR IN PART. 

Section 10.5   Mutual Covenants.  Each Party covenants to the other Party that:

	
(a)
	
it will use its commercially reasonable best efforts to conduct, and will cause its contractors to conduct, all preclinical and clinical studies for Amgen Products and Kite Products, as applicable, and manufacturing of such products, in accordance with (i) all U.S. Laws and the Laws of the 

42

		
country in which such clinical studies are conducted, and (ii) the known or published standards of the FDA and the Regulatory Authority in such country.  Neither such Party, nor any officer, employee or agent of such Party, will knowingly make an untrue statement of a material fact to any Regulatory Authority with respect to Amgen Products and Kite Products, as applicable (whether in any submission to such Regulatory Authority or otherwise), and neither will knowingly fail to disclose a material fact required to be disclosed to any Regulatory Authority with respect to such products; 

	
(b)
	
it will not knowingly  use in connection with any Preclinical Development activities or Program activities hereunder any employee, contractor, investigator or consultant that has been debarred by the FDA (or subject to a similar sanction of a Regulatory Authority), or that is subject of an FDA debarment investigation or proceeding (or similar proceeding of a Regulatory Authority); 

	
(c)
	
it will not grant to any Third Party any right or license, or enter into any agreement, that would conflict with the licenses and rights granted to the other Party hereunder;

	
(d)
	
in connection with its activities hereunder, it shall use its commercially reasonable best efforts to comply with all applicable (i) U.S. Laws prohibiting the re-export, directly or indirectly, of certain controlled U.S.-origin items without a license to parties located in certain countries or appearing on certain U.S. Government lists of restricted parties; (ii) U.S. Laws prohibiting participation in non-U.S. boycotts that the United States does not support; and (iii) U.S. Laws prohibiting the sale of products to parties from any country subject to U.S. economic sanctions or who are identified on related U.S. Government lists of restricted parties; and 

	
(e)
	
as of the Effective Date to and through the expiration or termination of this Agreement, (1) it, and, to the best of its knowledge, its owners, directors, officers, employees, or any agent, representative, subcontractor or other third party acting for or on such its behalf, shall not, directly or indirectly, offer, pay, promise to pay, or authorize such offer, promise or payment, of anything of value, to any Person for the purposes of obtaining or retaining business through any improper advantage in connection with this Agreement, or that would otherwise violate any applicable Laws, rules and regulations concerning or relating to public or commercial bribery or corruption, and (2) that its books, accounts, records and invoices related to this Agreement or related to any work conducted for or on behalf of the other Party are and will be complete and accurate in all material respects.  Each Party may request from time to time that the other Party complete a compliance certification regarding the foregoing.

43

Article 11.  INDEMNIFICATION

Section 11.1   Indemnity.

11.1.1By Amgen.  Amgen agrees to defend Kite and its (and its Affiliates’) directors, officers, employees and agents (the “Kite Indemnified Parties”) at Amgen’s cost and expense, and will indemnify and hold Kite and the other Kite Indemnified Parties harmless from and against any claims, losses, costs, damages, fees or expenses (including legal fees and expenses) (collectively, “Losses”) to the extent resulting from any Third Party claim (including product liability claims) arising out of or otherwise relating to (a) the negligence or willful misconduct of Amgen or its Affiliates in connection with its activities under this Agreement, (b) the material breach of this Agreement or the representations, warranties and covenants made hereunder by Amgen, or (c) the Exploitation of any Amgen Product by or on behalf of Amgen, its Affiliates, or their respective Sublicensees (including from product liability and intellectual property infringement claims); except, in each case, to the extent such Losses result from clause (a), (b), or (c) of Section 11.1.2 (By Kite).  In the event of any such claim against the Kite Indemnified Parties by a Third Party, the foregoing indemnity obligations shall be conditioned upon (x) Kite promptly notifying Amgen in writing of the claim (provided, however, that any failure or delay to notify shall not excuse any obligations of Amgen except to the extent Amgen is actually prejudiced thereby) and (y) Kite granting Amgen sole management and control, at Amgen’s sole expense, of the defense of the claim and its settlement (provided, however, that Amgen shall not settle any such claim without the prior written consent of Kite if such settlement does not include a complete release from liability or if such settlement would involve Kite undertaking an obligation (including the payment of money by a Kite Indemnified Party), would bind or impair a Kite Indemnified Party, or includes any admission of wrongdoing or that any intellectual property or proprietary right of Kite or this Agreement is invalid, narrowed in scope or unenforceable), and (z) the Kite Indemnified Parties cooperating with Amgen (at Amgen’s expense).  The Kite Indemnified Parties may, at their option and expense, be represented in any such action or proceeding by counsel of their own choosing.  

11.1.2By Kite.  Kite agrees to defend Amgen and its (and its Affiliates’) directors, officers, employees and agents (the “Amgen Indemnified Parties”) at Kite’s cost and expense, and will indemnify and hold Amgen and the other Amgen Indemnified Parties harmless from and against any Losses to the extent resulting from any Third Party claim (including product liability claims) arising out of or otherwise relating to (a) the negligence or willful misconduct of Kite, its Affiliates, or their respective Sublicensees in connection with its activities under this Agreement, (b) the material breach of this Agreement or the representations, warranties and covenants made hereunder by Kite, or (c) the Exploitation of any Kite Product by or on behalf of Kite, its Affiliates, or their respective Sublicensees (including from product liability and intellectual property infringement claims); except, in each case, to the extent such Losses result from clause (a), (b), or (c) of Section 11.1.1 (By Amgen).  In the event of any such claim against the Amgen Indemnified Parties by a Third Party, the foregoing indemnity obligations shall be conditioned upon (x) Amgen promptly notifying Kite in writing of the claim (provided, however, that any failure or delay to notify shall not excuse any obligation of Kite except to the extent Kite is actually prejudiced thereby) and (y) Amgen granting Kite shall sole management and control, at Kite’s sole expense, the defense of the claim and its settlement (provided, however, that Kite shall not settle any such claim without the prior written consent of 

44

Amgen if such settlement does not include a complete release from liability or if such settlement would involve undertaking an obligation (including the payment of money by an Amgen Indemnified Party), would bind or impair an Amgen Indemnified Party, or includes any admission of wrongdoing or that any intellectual property or proprietary right of Amgen or this Agreement is invalid, narrowed in scope or unenforceable), and (z) the Amgen Indemnified Parties cooperating with Kite (at Kite’s expense).  The Amgen Indemnified Parties may, at their option and expense, be represented in any such action or proceeding by counsel of their own choosing.   

Section 11.2   LIMITATION OF DAMAGES.  IN NO EVENT SHALL EITHER PARTY BE LIABLE HEREUNDER TO THE OTHER PARTY FOR ANY PUNITIVE, INDIRECT, SPECIAL, INCIDENTAL OR CONSEQUENTIAL DAMAGES (INCLUDING LOST REVENUE, LOST PROFITS, OR LOST SAVINGS) HOWEVER CAUSED AND UNDER ANY THEORY, EVEN IF IT HAS NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. THE LIMITATIONS SET FORTH IN THIS SECTION 11.2 (LIMITATION OF DAMAGES) SHALL NOT APPLY WITH RESPECT TO (A) ANY BREACH OF ARTICLE 12 (CONFIDENTIALITY) OR (B) THE INTENTIONAL MISCONDUCT OR GROSS NEGLIGENCE OF A PARTY.  NOTHING IN THIS SECTION 11.2 (LIMITATION OF DAMAGES) IS INTENDED TO LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF A PARTY UNDER THIS ARTICLE 11 (INDEMNIFICATION) WITH RESPECT TO ANY DAMAGES PAID BY THE OTHER PARTY TO A THIRD PARTY IN CONNECTION WITH A THIRD PARTY CLAIM.  

Section 11.3   Insurance.  Each of the Parties will, at their own respective expense (and not subject to cost sharing hereunder) procure and maintain during the Term, insurance policies adequate to cover their obligations hereunder and consistent with the normal business practices of prudent biopharmaceutical companies of similar size and scope (or reasonable self-insurance sufficient to provide materially the same level and type of protection).  Such insurance will not create a limit to either Party’s liability hereunder.

Article 12.  CONFIDENTIALITY

Section 12.1   Confidential Information.

12.1.1Confidential Information.  Each Party (“Disclosing Party”) may disclose to the other Party (“Receiving Party”), and Receiving Party may acquire during the course and conduct of activities under this Agreement, certain proprietary or confidential information of Disclosing Party in connection with this Agreement.  The term “Confidential Information” will mean all ideas and information of any kind, whether in written, oral, graphical, machine-readable or other form, whether or not marked as confidential or proprietary, which are transferred, disclosed or made available by Disclosing Party or at the request of Receiving Party, including any of the foregoing of Third Parties.  Disclosure of Confidential Information under this agreement, including the transfer of material between the Parties or the sublicensees and contractors, shall be a private disclosure and not a commercial sale of the material.

 

45

Execution Copy

 

12.1.2Restrictions.  During the Term and for [...***...] thereafter, Receiving Party will keep all Disclosing Party’s Confidential Information in confidence with the same degree of care with which Receiving Party holds its own confidential information (but in no event less than a commercially reasonable degree of care).  Receiving Party will not use Disclosing Party’s Confidential Information except for in connection with the performance of its obligations and exercise of its rights under this Agreement.  Receiving Party has the right to disclose Disclosing Party’s Confidential Information without Disclosing Party’s prior written consent, to the extent and only to the extent reasonably necessary, to Receiving Party’s Affiliates and their employees, subcontractors, consultants or agents who have a need to know such Confidential Information in order to perform its obligations and exercise its rights under this Agreement and who are required to comply with the restrictions on use and disclosure in this Section 12.2.1 (Restrictions).  Receiving Party will use diligent efforts to cause those entities and persons to comply with the restrictions on use and disclosure in this Section 12.1.2 (Restrictions).  Receiving Party assumes responsibility for those entities and persons maintaining Disclosing Party’s Confidential Information in confidence and using same only for the purposes described herein.

12.1.3Exceptions.  Receiving Party’s obligation of nondisclosure and the limitations upon the right to use the Disclosing Party’s Confidential Information will not apply to the extent that Receiving Party can demonstrate that the Disclosing Party’s Confidential Information:  (a) was known to Receiving Party or any of its Affiliates prior to the time of disclosure; (b) is or becomes public knowledge through no fault or omission of Receiving Party or any of its Affiliates; (c) is obtained by Receiving Party or any of its Affiliates from a Third Party under no obligation of confidentiality to Disclosing Party; or (d) has been independently developed by employees, subcontractors, consultants or agents of Receiving Party or any of its Affiliates without the use of Disclosing Party’s Confidential Information, as evidenced by contemporaneous written records.

12.1.4Permitted Disclosures.  Receiving Party may disclose Disclosing Party’s Confidential Information to the extent (and only to the extent) such disclosure is reasonably necessary in the following instances:

	
(a)
	
in order to comply with applicable law (including any securities law or regulation or the rules of a securities exchange) or with a legal or administrative proceeding;

	
(b)
	
in connection with prosecuting or defending litigation, Marketing Approvals and other regulatory filings and communications, and filing, prosecuting and enforcing Patent Rights in connection with Receiving Party’s rights and obligations pursuant to this Agreement; and 

	
(c)
	
in connection with exercising its rights hereunder, to its Affiliates; potential and future collaborators, licensees or sublicensees and vendors; potential and permitted acquirers or assignees; and potential investment bankers, investors and lenders; 

provided, however, that (1) with respect to Sections 12.1.4(a) or 12.1.4(b), where reasonably possible, Receiving Party will notify Disclosing Party of Receiving Party’s intent to make any disclosure pursuant thereto 

***Confidential Treatment Requested

46

Execution Copy

 

sufficiently prior to making such disclosure so as to allow Disclosing Party adequate time to take whatever action it may deem appropriate to protect the confidentiality of the information to be disclosed, and (2) with respect to Section 12.1.4(c), each of those named people and entities are required to comply with the restrictions on use and disclosure in Section 12.1.2 (Restrictions) (other than investment bankers, investors and lenders, which must be bound prior to disclosure by commercially reasonable obligations of confidentiality).

Section 12.2   Terms of this Agreement; Publicity.

12.2.1Restrictions.  The Parties agree that the terms of this Agreement will be treated as Confidential Information of both Parties, and thus may be disclosed only as permitted by Section 12.1.4 (Permitted Disclosures) or as required under the Cabaret License.  Except as required by Law, and except for the press release attached hereto as Exhibit F (Press Release) to be issued on or after the Signing Date, each Party agrees not to issue any press release or public statement disclosing information relating to this Agreement or the transactions contemplated hereby or the terms hereof without the prior written consent of the other Party not to be unreasonably withheld (or as such consent may need to be obtained in accordance with Section 12.2.2 (Review) or Section 12.3  (Publications)).  

12.2.2Review.  In the event either Party (the “Issuing Party”) desires to issue a press release or other public statement disclosing information relating to this Agreement or the transactions contemplated hereby or the terms hereof, the Issuing Party will provide the other Party (the “Reviewing Party”) with a copy of the proposed press release or public statement (the “Release”).  The Issuing Party will specify with each such Release, taking into account the urgency of the matter being disclosed, a reasonable period of time within which the Receiving Party may provide any comments on such Release (but in no event less than [...***...]). If the Receiving Party provides any comments, the Parties will consult on such Release and work in good faith to prepare a mutually acceptable Release. Either Party may subsequently publicly disclose any information previously contained in any Release, provided, however, that the other Party provided its written consent hereto as stated in 12.2.1 (Restrictions).  For the avoidance of doubt (and notwithstanding anything contained in this Agreement to the contrary), (a) Kite, in its sole discretion, may make disclosures relating to the development or commercialization of a Kite Product, including the results of research and any clinical trial conducted by Kite or any health or safety matter related to a Kite Product, and (b) Amgen, in its sole discretion, may make disclosures relating to the development or commercialization of an Amgen Product, including the results of research and any clinical trial conducted by Amgen or any health or safety matter related to an Amgen Product.

Section 12.3   Publications. Kite will have the sole right to publish and make scientific presentations with respect to Kite Platform Technology and Kite Products, and to issue press releases (except with respect to the terms of this Agreement, which is governed by Section 12.2  (Terms of this Agreement; Publicity)) or make other public disclosures regarding any such Kite Platform Technology and Kite Products, and Amgen will not do so without Kite’s prior written consent, except as required by Law; provided, however, that any publication or presentation to be made by Kite that names Amgen will require the prior consent of Amgen.  Amgen will have the sole right to publish and make scientific presentations with respect to Amgen Products, and

***Confidential Treatment Requested

47

to issue press releases (except with respect to the terms of this Agreement, which is governed by Section 12.2  (Terms of this Agreement; Publicity)) or make other public disclosures regarding any such Amgen Products, and Kite will not do so without Amgen’s prior written consent, except as required by Law; provided, however, that any publication or presentation to be made by Amgen that names Kite will require the prior consent of Kite.  The Party that is entitled hereunder to make a publication or presentation (the “Publishing Party”) will deliver to the other Party (the “Non-Publishing Party”) a copy of any proposed written publication or outline of presentation to be made by the Publishing Party in advance of submission for publication or presentation at least [...***...] in advance of submission (or, where a copy of such publication or presentation is not available at such time, a draft or outline of such publication or a description of such presentation), and the Non-Publishing Party will have the right to: (i) require a delay in submission of not more than [...***...] to enable patent applications protecting any product; and (ii) prohibit disclosure of any of its Confidential Information in any such proposed publication or presentation.  If there is any dispute between the Parties with regard to a proposed publication, presentation or other communication regarding this Agreement, such dispute shall be referred to the JSC for resolution.

Section 12.4   Relationship to the Confidentiality Agreement.  This Agreement supersedes that certain Confidential Disclosure Agreement between the Parties dated March 3, 2014; provided, however, that all “Confidential Information” disclosed or received by the Parties thereunder will be deemed “Confidential Information” hereunder and will be subject to the terms and conditions of this Agreement. 

Section 12.5   Attorney-Client Privilege.  Neither Party is waiving, nor will be deemed to have waived or diminished, any of its attorney work product protections, attorney-client privileges or similar protections and privileges recognized under the applicable Law of any jurisdiction as a result of disclosing information pursuant to this Agreement, or any of its Confidential Information (including Confidential Information related to pending or threatened litigation) to the receiving Party, regardless of whether the disclosing Party has asserted, or is or may be entitled to assert, such privileges and protections.  The Parties may become joint defendants in proceedings to which the information covered by such protections and privileges relates and may determine that they share a common legal interest in disclosure between them that is subject to such privileges and protections, and in such event, may enter into a joint defense agreement setting forth, among other things, the foregoing principles but are not obligated to do so.

Article 13.  TERM & TERMINATION

Section 13.1   Term.  The term of this Agreement (the “Term”) shall commence on the Effective Date, and unless terminated earlier as provided in this Article 13 (Term & Termination), shall continue in full force and effect until, on a Target-by-Target basis, expiration of the last-to-expire Royalty Term for any Product directed against such Target in the Territory.  Upon expiration of this Agreement with respect to a particular Target, the licenses granted to Kite by Amgen under this Agreement to Exploit Kite Products directed against such Kite Target shall be fully paid-up, irrevocable and non-exclusive, and the licenses granted to Amgen by Kite under this Agreement to Exploit Amgen Products to such Amgen Target shall be fully paid-up, irrevocable and non-exclusive.

 

 

***Confidential Treatment Requested

48

Execution Copy

 

Section 13.2   Termination by Amgen.

13.2.1Kite Breach.  Amgen will have the right to terminate this Agreement, either on a Target-by-Target basis or in full, upon delivery of written notice to Kite in the event of any material breach by Kite of any material term or condition of this Agreement, provided, however, that such termination will not be effective if such breach has been cured within [...***...] after written notice thereof is given by Amgen to Kite specifying in reasonable detail the nature of the alleged breach.  Notwithstanding the foregoing in this Section 13.2.1 (Kite Breach), in the event of a good faith dispute as to whether  any such material breach has occurred, including any good faith dispute as to any payment due under this Agreement, the foregoing cure period with respect thereto will be tolled pending resolution of such dispute in accordance with the terms of this Agreement; provided that, if such dispute relates to payment, such tolling of the cure period will only apply with respect to payment of the disputed amounts, and not with respect to any undisputed amount.

13.2.2Amgen Discretionary Termination.   On an Amgen Target-by-Amgen Target basis, at any time prior to the Initiation of the first Phase 1 Clinical Trial for the first Amgen Product directed against such Amgen Target, Amgen will have the right to terminate this Agreement with respect to such Amgen Target [...***...] after delivery of written notice to Kite thereof.  On an Amgen Target-by-Amgen Target basis, at any time after the Initiation of the first Phase 1 Clinical Trial for the first Amgen Product to such Amgen Target, Amgen will have the right to terminate this Agreement with respect to such Amgen Target [...***...] after delivery of written notice to Kite thereof.  Following any notice of termination by Amgen under this Section 13.2.2 (Amgen Discretionary Termination), Amgen shall have no further obligation pursuant to Section 7.3  (Diligence) to further Exploit any Amgen Products directed against such terminated Amgen Target, however, Amgen shall use its reasonable efforts to facilitate a smooth, orderly and prompt transition from Amgen to Kite of any Amgen Products against such Amgen Target Controlled by Amgen prior to the effective date of termination of this Agreement with respect to such Amgen Target.

Section 13.3   Termination by Kite.

13.3.1Amgen Breach.  Kite will have the right to terminate this Agreement, either on a Target-by-Target basis or in full, upon delivery of written notice to Amgen in the event of any material breach by Amgen of any material term or condition of this Agreement, provided, however, that such termination will not be effective if such breach has been cured within [...***...] after written notice thereof is given by Kite to Amgen specifying in reasonable detail the nature of the alleged breach.  Notwithstanding the foregoing in this Section 13.3.1 (Amgen Breach), in the event of a good faith dispute as to whether any such material breach has occurred, including any good faith dispute as to any payment due under this Agreement, the foregoing cure period with respect thereto will be tolled pending resolution of such dispute in accordance with the terms of this Agreement; provided that, if such dispute relates to payment, such tolling of the cure period will only apply with respect to payment of the disputed amounts, and not with respect to any undisputed amount.

13.3.2Kite Discretionary Termination.   On a Kite Target-by-Kite Target basis, at any time prior to the Initiation of the first Phase 1 Clinical Trial for the first Kite Product directed against such Kite Target, Kite will have the right to terminate this Agreement with 

***Confidential Treatment Requested

49

respect to such Kite Target [...***...] after delivery of written notice to Amgen thereof.  On a Kite Target-by-Kite Target basis, at any time after the Initiation of the first Phase 1 Clinical Trial for the first Kite Product to such Kite Target, Kite will have the right to terminate this Agreement with respect to such Kite Target [...***...] after delivery of written notice to Amgen thereof.  Following any notice of termination by Kite under this Section 13.3.2 (Kite Discretionary Termination), Kite shall have no further obligation pursuant to Section 7.3  (Diligence) to further Exploit any Kite Products directed against such terminated Kite Target, however, Kite shall use its reasonable efforts to facilitate a smooth, orderly and prompt transition from Kite to Amgen of any Kite Products against such Kite Target Controlled by Kite prior to the effective date of termination of this Agreement with respect to such Kite Target.

Section 13.4   Termination Upon Bankruptcy.  Either Party may terminate this Agreement if, at any time, the other Party files in any court or agency pursuant to any statute or regulation of any state, country or jurisdiction, a petition in bankruptcy or insolvency or for reorganization or for an arrangement or for the appointment of a receiver or trustee of that Party or of its assets, or if the other Party proposes a written agreement of composition or extension of its debts, or if the other Party is served with an involuntary petition against it, filed in any insolvency proceeding, and such petition is not dismissed within [...***...] after the filing thereof, or if the other Party proposes or becomes a Party to any dissolution or liquidation, or if the other Party makes an assignment for the benefit of its creditors.

Section 13.5   Effects of Termination.  Upon termination of the Agreement pursuant to Section 13.2  (Termination by Amgen) or Section 13.3  (Termination by Kite), the following provisions shall apply in connection with the applicable terminated Target (or, if applicable, all Targets): 

	
(a)
	
The Terminated Party will responsibly wind-down, in accordance with accepted biopharmaceutical industry norms and ethical practices, any on-going clinical studies for which it has responsibility hereunder in which patient dosing has commenced or, if reasonably practicable and not adverse to patient safety and requested by the Continuing Party, the Terminated Party shall complete such trials and the Continuing Party shall reimburse the Terminated Party its reasonable, out-of-pocket costs and internal labor costs at the FTE Rate associated therewith.  For the purpose of clarity, except as provided for above, the Terminated Party may wind-down any ongoing clinical trials prior to the date of termination in accordance with accepted biopharmaceutical industry norms and ethical practices and the Terminated Party will be responsible for any costs associated with such wind-down.  Any reagents of the Terminated Party relating to the applicable terminated Target shall be destroyed, or, at the request of the Continuing Party, transferred to the Continuing Party, at the Continuing Party’s expense.

	
(b)
	
A termination of this Agreement will automatically terminate any and all sublicenses granted by the Terminated Party pursuant to Section 4.3  (Sublicenses). 

	
(c)
	
All rights and licenses granted by the Continuing Party to the Terminated Party in Article 4 (License Grant) will terminate, and the Terminated Party and its Affiliates, and Sublicensees will cease all Exploitation of any  Products, except to the extent required or expressly permitted hereunder.

***Confidential Treatment Requested

50

	
(d)
	
Upon the Continuing Party’s request within [...***...] after receipt of the applicable termination notice, all Marketing Approvals and other regulatory filings and regulatory communications owned (in whole or in part) or otherwise controlled by the Terminated Party and its Affiliates, and Sublicensees, and all other documents reasonably relating to or reasonably necessary to further Exploit any Products, as such items exist as of the effective date of such termination (including all documents related to completed and ongoing clinical studies) will be assigned to the Continuing Party to the extent practicable (or, if not so assigned, the Terminated Party shall make the benefit of the foregoing reasonably available to the Continuing Party), and the Terminated Party will provide to the Continuing Party one (1) copy of the foregoing and all documents contained in or referenced in any such items, together with the raw and summarized data for any clinical studies (and where reasonably available, electronic copies thereof).  All expenses in relation to such assignment will be borne by the Continuing Party.  In the event of any failure to obtain assignment, the Terminated Party hereby consents and grants to the Continuing Party the right to access and reference (without any further action required on the part of the Terminated Party, whose authorization to file this consent with any Regulatory Authority is hereby granted) any such item.

	
(e)
	
Upon the Continuing Party’s request within [...***...] after receipt of the applicable termination notice, the Terminated Party will grant, and hereby does grant, effective upon such request, to the Continuing Party and its Affiliates, and the Continuing Party and its Affiliates will (i) automatically have, a worldwide, exclusive license, with the right to grant sublicenses through multiple tiers, solely for use in Exploiting Products, under Know-How and Patent Rights that are Controlled by the Terminated Party or any of its Affiliates and Sublicensees prior to termination and that are solely related to Products and which are necessary for Exploiting Products, and (ii) automatically have, a worldwide, non-exclusive license, with the right to grant sublicenses through multiple tiers, solely for use in Exploiting Products, under Know-How and Patent Rights that are Controlled by the Terminated Party or any of its Affiliates and Sublicensees that are not solely related to Products but that directly relate to and are necessary for Exploiting Products.  For the purpose of clarity, such license shall be effective only as of and after the effective date of such termination.  Notwithstanding the foregoing, in order to protect the confidentiality of proprietary manufacturing technology, the Terminated Party shall have the right to transfer any proprietary manufacturing information contained in such Know-How to a reputable, third-party contract manufacturer for provision of the relevant Product(s) to the Continuing Party, rather than transfer such manufacturing technology to the Continuing Party.  Notwithstanding the foregoing, in the event that any of the foregoing Know-How or Patent Rights are not Controlled by the

***Confidential Treatment Requested

51

Terminated Party (or any of its Affiliates and Sublicensees) due to the fact that such party would be obligated to make any payments to a Third Party in connection with the grant of the foregoing licenses, then if the Continuing Party agrees to assume such payment obligations, and all other directly related contractual obligations under such license agreement due to the Third Party, such Know-How and Patent Rights shall be included in such license grant.

	
(f)
	
Upon the Continuing Party’s request within [...***...] after receipt of the applicable termination notice, the Terminated Party will assign (or, if applicable, will cause its Affiliates or Sublicensees to assign) to the Continuing Party all of the Terminated Party’s (and such Affiliates’ and Sublicensees’) right, title and interest in and to any registered or unregistered trademarks or internet domain names that are specific to a Product worldwide, provided that such assignment is in accordance with the Terminated Party’s policy on trademarks (it being understood that the foregoing will not include any trademarks or internet domain names that contain the corporate or business name(s) of the Terminated Party). 

	
(g)
	
Upon the Continuing Party’s request within [...***...] after receipt of the applicable termination notice, the Terminated Party agrees (and shall cause its Affiliates and Sublicensees as a condition of the grant of the applicable Sublicense to so agree) to reasonably cooperate with the Continuing Party and its designee(s) to facilitate a smooth, orderly and prompt transition of the Exploitation of Products to the Continuing Party and/or its designee(s).  Upon request by the Continuing Party, the Terminated Party shall transfer to the Continuing Party some or all quantities of applicable Products in its possession.  If the Terminated Party is, at the time of such termination of this Agreement, party to any Third Party contracts with respect to a Product, then it shall provide the Continuing Party notice of and (to the extent permitted to do so), copies thereof (which may be redacted for information related to other products or technologies or which is not relevant to the applicable terminated Products).  The Terminated Party shall assign to the Continuing Party any such contracts requested by the Continuing Party, to the extent relating to the Product and to the extent it has the right under such contract(s) to do so (and shall use commercially reasonable efforts to obtain any required consents, which efforts shall not require making any payments or incurring any liabilities unless the Continuing Party agrees to reimburse the Terminated Party therefor (and the Terminated Party shall inform the Continuing Party of any such required payment or liability)).  In addition, if the Terminated Party terminates the Agreement after Initiation of a Phase 2 Clinical Trial hereunder, then the Terminated Party shall, at the Continuing Party’s cost and expense, (i) provide any cooperation reasonably requested by the Continuing Party to ensure uninterrupted supply of Products (including the Terminated Party’s employees’ time at the FTE Rate), and (ii) if the Terminated Party manufactured a Product at the time of termination, continue to provide for manufacturing of such 

***Confidential Treatment Requested

52

Product for the Continuing Party, at [...***...] percent ([...***...]%) of the fully-burdened manufacturing cost therefor (or [...***...] percent ([...***...]%) of the costs paid to Third Parties for the manufacture of such supply, if the Terminated Party uses a Third Party manufacturer), from the date of notice requesting transition of the Product until the sooner to occur of such time as the Continuing Party is able, using commercially reasonable efforts to do so, to secure an acceptable alternative commercial manufacturing source from which sufficient quantities of Product may be procured and legally sold in the Territory or [...***...] from the effective date of termination of this Agreement.  

	
(h)
	
If (i) Amgen is the Terminated Party, (ii) Amgen is terminating the Agreement with respect to an Amgen Target prior to delivery of the applicable Final Report, and (iii) Kite has requested that Amgen take any of the actions set forth in clauses (d) through (g) above, then Kite shall reimburse Amgen for any amounts paid by Amgen under Section 8.1.3 (Preclinical Development Costs) with respect to such Program for such Amgen Target as well as any of its costs and expenses for Preclinical Development with respect to such Program in excess thereof.

	
(i)
	
If (i) Kite is the Terminated Party, (ii) Kite is terminating the Agreement with respect to a Kite Target prior to delivery of the applicable Final Report, and (iii) Amgen has requested that Kite take any of the actions set forth in clauses (d) through (g) above, then Amgen shall reimburse Kite for any amounts in excess of those paid by Amgen under Section 8.1.3 (Preclinical Development Costs) with respect to such Program for such Amgen Target.

Section 13.6   Survival.  In addition to the termination consequences set forth in Section 13.5  (Effects of Termination), the following provisions will survive termination or expiration of this Agreement: Articles Article 1 (Definitions), 11 (Indemnification), 12 (Confidentiality), and 15 (Miscellaneous) and Sections 4.6 (No Other Rights), 8.1 (Upfront and Milestone Payments) (with respect to milestones reached prior to such expiration or termination), 8.2 (Royalties) (with respect to sales made before such expiration or termination), 8.5 through 8.9 (inclusive) (with respect to periods with sales of Products made before such expiration or termination), 9.4 through 9.5 (inclusive) (with respect to any action initiated prior to such expiration or termination), 10.4 (Disclaimer), 15.9 (Sale Transaction or Amgen Acquisition), 15.10 (Sale Transaction or Kite Acquisition) and this Section 13.6   (Survival).  Termination or expiration of this Agreement are neither Party’s exclusive remedy and will not relieve the Parties of any liability or obligation which accrued hereunder prior to the effective date of such termination or expiration nor preclude either Party from pursuing all rights and remedies it may have hereunder or at law or in equity with respect to any breach of this Agreement nor prejudice either Party’s right to obtain performance of any obligation.  All other rights and obligations will terminate upon expiration of this Agreement.  

***Confidential Treatment Requested

53

Article 14.  CHANGE OF CONTROL

Section 14.1   Change of Control.  Kite shall give Amgen written notice within [...***...] after the public announcement or disclosure of any proposed Change of Control of Kite.  Upon such notice, Amgen shall have the right to transfer some or all Preclinical Development activities on Amgen Targets from Kite to Amgen by written notice to Kite.  Additionally, Amgen shall have the right to initiate early a transfer of manufacturing of Amgen Products from Kite to Amgen in accordance with Section 5.2  (Transition of Supply).  Upon any Change of Control of Kite, Amgen would no longer be responsible for the reimbursement of Kite’s costs and expenses related to Preclinical Development activities for Kite Targets pursuant to Section 8.1.3 (Preclinical Development Costs).  Additionally, Kite would promptly reimburse Amgen for Amgen’s costs and expenses related to Preclinical Development activities for Kite Targets, except if such Change of Control of Kite involves the acquisition by, or merger, consolidation, share exchange, business combination, recapitalization, sale of a majority of assets or similar transaction with, an un-Affiliated entity that, together with such entity’s Affiliates existing as of the time immediately preceding the Change of Control, has a market capitalization of less than [...***...].

Article 15.  MISCELLANEOUS

Section 15.1   Entire Agreement; Amendment.  This Agreement and all Exhibits attached to this Agreement constitute the entire agreement between the Parties as to the subject matter hereof.  All prior and contemporaneous negotiations, representations, warranties, agreements, statements, promises and understandings with respect to the subject matter of this Agreement are hereby superseded and merged into, extinguished by and completely expressed by this Agreement.  None of the Parties shall be bound by or charged with any written or oral agreements, representations, warranties, statements, promises or understandings not specifically set forth in this Agreement.  No amendment, supplement or other modification to any provision of this Agreement shall be binding unless in writing and signed by all Parties.

Section 15.2   Section 365(n) of the Bankruptcy Code.  All rights and licenses granted under or pursuant to any section of this Agreement are, and shall otherwise be deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code, licenses of rights to “intellectual property” as defined under Section 101(35A) of the U.S. Bankruptcy Code to the extent permitted thereunder. The Parties shall retain and may fully exercise all of their respective rights and elections under the U.S. Bankruptcy Code. Upon the bankruptcy of any Party, the non-bankrupt Party shall further be entitled to a complete duplicate of (or complete access to, as appropriate) any such intellectual property, and such, if not already in its possession, shall be promptly delivered to the non-bankrupt Party, unless the bankrupt Party elects to continue, and continues, to perform all of its obligations under this Agreement.  

Section 15.3   Independent Contractors.  The relationship between Kite and Amgen created by this Agreement is solely that of independent contractors.  This Agreement does not create any agency, distributorship, employee-employer, partnership, joint venture or similar business relationship between the Parties.  Neither Party is a legal representative of the other Party, and neither Party can assume or create any obligation, representation, warranty or guarantee, express or implied, on behalf of the other Party for any purpose whatsoever.  Each Party shall use its own discretion and shall have complete and authoritative control over its employees and the details of 

Section 1.1   

***Confidential Treatment Requested

54

Execution Copy

 

performing its obligations under this Agreement.

Section 15.4   Governing Law; Jurisdiction.  This Agreement and its effect are subject to and shall be construed and enforced in accordance with the law of the State of New York, without regard to its conflicts of laws, except as to any issue which depends upon the validity, scope or enforceability of any Amgen Patent, Kite Patent or Collaboration Patent, which issue shall be determined in accordance with the laws of the country in which such patent was issued, and except with respect to any issue of inventorship of any Collaboration IP, which shall be determined in accordance with U.S. federal law.  Each of the Parties hereby irrevocably and unconditionally consents to submit to the exclusive jurisdiction of the courts of the State of New York for any matter arising out of or relating to this Agreement and the transactions contemplated hereby, and agrees not to commence any litigation relating thereto except in such courts.  Each of the Parties hereby irrevocably and unconditionally waives any objection to the laying of venue of any matter arising out of this Agreement or the transactions contemplated hereby in the courts of the State of New York and hereby further irrevocably and unconditionally waives and agrees not to plead or claim in any such court that any such matter brought in any such court has been brought in an inconvenient forum.  The Parties agree that a final judgment in any such matter shall be conclusive and may be enforced in other jurisdictions by suits on the judgment or in any other manner provided by law.  Any proceeding brought by either Party under this Agreement shall be exclusively conducted in the English language. 

Section 15.5   Notice.  All notices or communication required or permitted to be given by either Party hereunder shall be deemed sufficiently given if delivered in person, mailed by registered mail or certified mail, return receipt requested, or sent by overnight courier, such as Federal Express, to the other Party at its respective address set forth below or to such other address as one Party shall give notice of to the other from time to time hereunder. Mailed notices shall be deemed to be received on the third (3rd) business day following the date of mailing. Notices sent by overnight courier shall be deemed received the day delivered by the courier (provided it maintains a record tracking the date of delivery).  Notices delivered in person shall be deemed received as of the date of delivery.

 

			
	
 
	
If to Kite:
	
Kite Pharma, Inc.

	
 
	
 
	
2225 Colorado Avenue

	
 
	
 
	
Santa Monica, California 90404

	
 
	
 
	
Attn:  Corporate Counsel

	
 
	
 
	
 

	
 
	
 
	
 

	
 
	
If to Amgen:
	
Amgen Inc.

	
 
	
 
	
One Amgen Center Drive

	
 
	
 
	
Thousand Oaks, CA 91320

	
 
	
 
	
Attn:  Corporate Secretary

 

55

Section 15.6   Compliance With Law; Severability.  Nothing in this Agreement shall be construed to require the commission of any act contrary to Law.  If any one or more provisions of this Agreement is held to be invalid, illegal or unenforceable, the affected provisions of this Agreement shall be curtailed and limited only to the extent necessary to bring it within the applicable legal requirements and the validity, legality and enforceability of the remaining 

56

provisions of this Agreement shall not in any way be affected or impaired thereby. 

Section 15.7   Non-Use of Names.  Amgen shall not use the name, trademark, logo, or physical likeness of Kite or any of its officers, directors or employees, or any adaptation of any of them, in any advertising, promotional or sales literature, without such Kite’s prior written consent. Amgen shall require its Affiliates to comply with the foregoing.  Kite shall not use the name, trademark, logo, or physical likeness of Amgen or any of its officers, directors or employees, or any adaptation of any of them, in any advertising, promotional or sales literature, without Amgen’s prior written consent.  Kite shall require its Affiliates and Sublicensees to comply with the foregoing in connection with each such Sublicensee’s sublicense.  

Section 15.8   Successors and Assigns.  Neither this Agreement nor any of the rights or obligations created herein  may be assigned by either Party, in whole or in part, without the prior written consent of the other Party, not to be unreasonably withheld or delayed except that either Party shall be free to assign this Agreement (i) to an Affiliate of such Party (for so long as such Affiliate remains an Affiliate) provided that such Party shall remain liable and responsible to the other Party for the performance and observance of all such duties and obligations by such Affiliate, or (ii) in connection with any merger, sale of such Party or sale of all or substantially all of the assets of the Party that relate to this Agreement (a “Sale Transaction”), without the prior consent of the non-assigning Party. This Agreement shall bind and inure to the benefit of the successors and permitted assigns of the Parties hereto.  Any assignment of this Agreement in contravention of this Section 15.8  (Successors and Assigns) shall be null and void.

Section 15.9   Sale Transaction or Amgen Acquisition.  In the event of (x) a Sale Transaction involving Amgen, or (y) the acquisition by Amgen of all or substantially all of the business of a Third Party (together with any entities that were Affiliates of such Third Party immediately prior to such acquisition, an “Amgen Acquiree”), whether by merger, sale of stock, sale of assets or otherwise (an “Amgen Acquisition”), intellectual property rights of the acquiring party in a Sale Transaction, if other than one of the Parties to this Agreement (together with any entities that were affiliates of such Third Party immediately prior to such Sale Transaction, a “Third Party Acquirer”), or the Amgen Acquiree, as applicable, shall not be included in the Patent Rights or Know-How licensed hereunder by Amgen to Kite or otherwise subject to this Agreement, except that to the extent the Amgen Acquiree or Third Party Acquirer owns any Blocking Patents relative to any Kite Product, Amgen shall and hereby does grant to Kite a non-exclusive license, for no additional consideration (provided, however, that in the event that Amgen would be obligated to make any payments to a Third Party in connection with the grant of the foregoing license to any Blocking Patents, then unless Kite agrees to assume such payment obligations, such license grant will exclude a license under the applicable Blocking Patents), until the expiration of the last to expire of such Blocking Patents, on a country-by-country basis, or termination of this Agreement relative to such Kite Product, whichever comes first, provided that at the time of such Sale Transaction or Amgen Acquisition, such non-exclusive license rights are available for such grant and have not been exclusively licensed to any Third Party.  

Section 15.10   Sale Transaction or Kite Acquisition.  In the event of (x) a Sale Transaction involving Kite, or (y) the acquisition by Kite of all or substantially all of the 

57

business of a Third Party (together with any entities that were Affiliates of such Third Party immediately prior to such acquisition, a “Kite Acquiree”), whether by merger, sale of stock, sale of assets or otherwise (a “Kite Acquisition”), intellectual property rights of the Third Party Acquirer in a Sale Transaction, or the Kite Acquiree, as applicable, shall not be included in the Patent Rights or Know-How licensed hereunder by Kite to Amgen, or otherwise subject to this Agreement, except that to the extent the Kite Acquiree or Third Party Acquirer owns any Blocking Patents relative to any Amgen Product, Kite shall and hereby does grant to Amgen a non-exclusive license, for no additional consideration (provided, however, that in the event that Kite would be obligated to make any payments to a Third Party in connection with the grant of the foregoing license to any Blocking Patents, then unless Amgen agrees to assume such payment obligations, such license grant will exclude a license under the applicable Blocking Patents), until the expiration of the last to expire of such Blocking Patents, on a country-by-country basis or termination of this Agreement relative to such Amgen Product, whichever comes first, provided that at the time of such Sale Transaction or Kite Acquisition, such non-exclusive license rights are available for such grant and have not been exclusively licensed to any Third Party.

Section 15.11   Waivers.  A Party’s consent to or waiver, express or implied, of any other Party’s breach of its obligations hereunder shall not be deemed to be or construed as a consent to or waiver of any other breach of the same or any other obligations of such breaching Party.  A Party’s failure to complain of any act, or failure to act, by the other Party, to declare the other Party in default, to insist upon the strict performance of any obligation or condition of this Agreement or to exercise any right or remedy consequent upon a breach thereof, no matter how long such failure continues, shall not constitute a waiver by such Party of its rights hereunder, of any such breach, or of any other obligation or condition.  A Party’s consent in any one instance shall not limit or waive the necessity to obtain such Party’s consent in any future instance and in any event no consent or waiver shall be effective for any purpose hereunder unless such consent or waiver is in writing and signed by the Party granting such consent or waiver. 

Section 15.12   No Third Party Beneficiaries.  Nothing in this Agreement shall be construed as giving any Person, other than the Parties hereto and their successors and permitted assigns, any right, remedy or claim under or in respect of this Agreement or any provision hereof, except for the provisions of Article 11 (Indemnification) (with respect to which the persons to which Article 11 (Indemnification) applies shall be Third Party beneficiaries for Article 11 (Indemnification) only in accordance with the terms and conditions of Article 11 (Indemnification)).

Section 15.13   Headings; Exhibits.  Article and Section headings used herein are for convenient reference only, and are not a part of this Agreement. All Exhibits are incorporated herein by this reference.

Section 15.14   Interpretation.  Except where the context otherwise requires, wherever used, the singular shall include the plural, the plural the singular, the use of any gender shall be applicable to all genders and the word “or” is used in the inclusive sense (and/or). The term “including” as used herein shall mean including, without limiting the generality of any description preceding such term. All references to a “business day” or “business days” in this Agreement means any day other than a day which is a Saturday, a Sunday or any day banks are authorized or required to be closed in the United States.  The language in all parts of this 

58

Agreement shall be deemed to be the language mutually chosen by the Parties. The Parties and their counsel have cooperated in the drafting and preparation of this Agreement, and this Agreement therefore shall not be construed against any Party by virtue of its role as the drafter thereof.

 

Section 1.1   

59

Execution Copy

 

Section 15.15   Counterparts.  This Agreement may be executed in counterparts by a single Party, each of which when taken together shall constitute one and the same agreement, and may be executed through the use of facsimiles or .pdf documents.   

Section 15.16   HSR.  As soon as is reasonably practicable following the Signing Date and in any event within thirty (30) days of the Signing Date, each of Amgen (or its Affiliate, as appropriate) and Kite (or its Affiliate, as appropriate) shall prepare and submit appropriate filings under the United States Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”) and the rules promulgated thereunder, and request early termination of the waiting period under the HSR Act.  The Parties shall furnish, or cause their respective Affiliates to furnish, as the case may be, promptly to the United States Federal Trade Commission (the “FTC”) and the Antitrust Division of the United States Department of Justice (the “DOJ”) any additional information requested within their authority under the HSR Act, use reasonable efforts to obtain antitrust clearance for the transactions contemplated hereunder as soon as practicable, and otherwise cooperate with each other in the United States governmental antitrust clearance process.  Subject to applicable Law relating to the exchange of information, Amgen shall have the right to direct all matters with respect to the FTC and DOJ hereunder, consistent with its obligations hereunder.  Amgen shall have the right to review in advance any filing or submission to be made by Kite, and Kite shall consider in good faith the view of Amgen in light of Amgen’s right to direct issues related to reviews by the FTC and DOJ.  To the extent practicable, Amgen will consult with Kite on, and consider in good faith the views of Kite in connection with, all of the information relating to Kite that appears in any filing or form (excluding attachments or exhibits thereto) made with or submitted to the FTC or DOJ in connection with this Section 15.16  (HSR).  Amgen shall bear all fees in connection with any filing under this Section 15.16  (HSR) and each Party shall bear their respective attorneys’ fees in connection therewith.  This Agreement shall bind the Parties upon execution and continue in full force and effect unless and until the termination or expiration of the Agreement by its terms, provided, however, that each Party’s grant of license rights hereunder, Amgen’s obligation to make the payments hereunder, and the Parties’ other rights and obligations hereunder in connection with the Exploitation of the Amgen Products and the Kite Products shall not become effective unless and until each of the following conditions are met: (i) the waiting period provided by the HSR Act shall have expired or been terminated (and all antitrust clearance has been obtained), (ii) no court or administrative challenges to the transactions are pending, and (iii) no court or administrative orders are outstanding blocking the completion of the transactions, (the date of such, the “Effective Date”).  Nothing in this Agreement shall require or be deemed to require either Party (or their Affiliates) to commit to any divestitures or licenses or agree to hold separate any assets or agree to any similar arrangements or commit to conduct its business in a specified manner, or to submit and respond to a formal discovery procedure initiated by the FTC or DOJ (i.e., a “Request for Additional Information and Documentary Materials” also known as a “second request”, or Civil Investigative Demand if a filing is not required under the HSR Act), in each case as a condition to obtaining antitrust clearance for the transactions contemplated hereunder.  If antitrust clearance is not received on or before [...***...] after the date on which both Parties have submitted to the FTC and DOJ their respective initial filings to request antitrust clearance of the transactions hereunder, then either Party shall have the right to terminate this Agreement without liability therefor at any time thereafter, but prior to receipt of antitrust clearance of the transactions contemplated hereunder,by written notice to the other Party. 

***Confidential Treatment Requested

60

[signature page follows]

 

61

Execution Copy

 

IN WITNESS WHEREOF, the Parties have executed this Agreement as of the date first set forth above.

 

	
KITE PHARMA, INC.
	
 
	
AMGEN INC.

	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 

	
By:
	
/s/ Cynthia M. Butitta
	
 
	
By:
	
/s/ Robert A. Bradway

	
Name:
	
Cynthia M. Butitta
	
 
	
Name:
	
Robert A. Bradway

	
Title:
	
Chief Operating Officer and
	
 
	
Title:
	
Chairman & Chief Executive Officer

	
 
	
Chief Financial Officer
	
 
	
 
	
 

 

 

 

S-1

Execution Copy

 

EXHIBIT A

AMGEN PATENTS

 

 

 

 

Patent Rights to the [...***...].

 

 

***Confidential Treatment Requested

Exhibit A - 1

Execution Copy

 

EXHIBIT B

KITE IP

 

Table A

Cabaret patents:

	
1.
	
U.S. patent 5,906,936

	
2.
	
U.S. patent 7,741,465

	
3.
	
U.S. patent 6,319,494

	
4.
	
U.S. patent 5,712,149

	
5.
	
U.S. patent 5,741,899

	
6.
	
U.S. patent 6,077,947

	
7.
	
U.S. patent 5,843,728

	
8.
	
U.S. patent 5,851,828

	
9.
	
U.S. patent 5,912,170

	
10.
	
U.S. patent 6,004,811

	
11.
	
U.S. patent 8,211,422

Table B

Manufacturing:

	
12.
	
[...***...]

	
13.
	
[...***...]

 

 

***Confidential Treatment Requested

Exhibit B - 1

Execution Copy

 

EXHIBIT C

PRECLINICAL DEVELOPMENT PLAN

Proposed Kite / Amgen CAR Collaboration Plan

This proposal outlines a research plan for a potential collaboration between Kite Pharma Inc and Amgen Inc for the purposes of designing, developing, characterizing, optimizing and advancing to clinic novel Chimeric Antigen Receptors (CARs) for specified targets as potential IND candidates.  The intent of this outline is to draft a general and flexible framework for the scope and priorities of the collaboration- more specific guidance with respect to research directions will be provided by a Joint Research Committee.

Research Plan

Goal

The parties will agree to [...***...] or more pre-validated targets for which CARs will be developed for further investigation and evaluation with a goal to advance them to IND filing. [ 

 

[...***...]

***Confidential Treatment Requested

Exhibit C - 1

Execution Copy

 

[...***...]

***Confidential Treatment Requested

Exhibit C - 2

Execution Copy

 

[...***...]

***Confidential Treatment Requested

Exhibit C - 3

Execution Copy

 

[...***...]

***Confidential Treatment Requested

Exhibit C - 4

Execution Copy

 

[...***...]

***Confidential Treatment Requested

Exhibit C - 5

Execution Copy

 

[...***...]

 

 

 

 

***Confidential Treatment Requested

Exhibit C - 6

Execution Copy

 

EXHIBIT D

AMGEN LICENSED KNOW-HOW

 

 

Certain [...***...] directed against the Amgen Targets and Kite Targets listed below generated as of the Effective Date and otherwise during the Term.

Within [...***...] of the approval of the applicable Preclinical Development Plan, Amgen will provide [...***...].  Thereafter, Amgen shall select additional [...***...] directed against the remaining Amgen Targets and Kite Targets from either previously generated sequences or as generated after the Effective Date.  

Amgen Targets- [...***...]

 

Kite Targets- [...***...]

 

 

 

***Confidential Treatment Requested

Exhibit D - 1

Execution Copy

 

EXHIBIT E

CLINICAL SUPPLY AGREEMENT

 

[...***...]

***Confidential Treatment Requested

Exhibit E - 1

Execution Copy

 

[...***...]

 

 

***Confidential Treatment Requested

Exhibit E - 2

Execution Copy

 

EXHIBIT F

PRESS RELEASE

 

	
 

 
	

 

 

Amgen and Kite Pharma ANNOUNCE STRATEGIC CANCER IMMUNOTHERAPY COLLABORATION to Advance the Application of Novel Chimeric Antigen Receptor (CAR) T Cell Therapies 

 

Alliance Combines Amgen’s Oncology Targets and Kite’s Leading CAR T Cell Therapy Platform to Develop new Therapeutic Candidates 

Kite to Receive a $60 Million Upfront Payment from Amgen and Eligible for up to $525 Million in Regulatory and Sales Milestone Payments per Amgen Program; Plus, Tiered High Single- to Double-Digit Royalties for Sales and License of Kite’s Intellectual Property for CAR T Cell Products

Amgen Eligible to Receive up to $525 Million in Milestone Payments per Kite Program; Plus, Tiered Single-Digit Sales Royalties

Kite to Host Conference Call Today at [TIME]

THOUSAND OAKS, Calif., and SANTA MONICA, Calif. (Jan. 5, 2014) – Amgen (NASDAQ:AMGN) and Kite Pharma (NASDAQ:KITE) announced today that the two companies have entered into a strategic research collaboration and license agreement to develop and commercialize the next generation of novel Chimeric Antigen Receptor (CAR) T cell immunotherapies based on Kite’s engineered autologous cell therapy (eACTTM) platform and Amgen’s extensive array of cancer targets. The collaboration brings together Amgen’s commitment to and capabilities in advancing new approaches in immuno-oncology and Kite’s industry-leading presence in CAR T cell therapy. 

Under the terms of the agreement, Amgen will contribute cancer targets, and Kite will leverage its proprietary CAR platform, research and development (R&D) and manufacturing capabilities, 

Exhibit F - 1

Execution Copy

 

and expertise. Kite will be responsible for conducting all preclinical research and cell manufacturing and processing through Investigational New Drug (IND) filing. Each company will then be responsible for clinical development and commercialization of their respective CAR therapeutic candidates, including all related expenses. Kite will receive from Amgen an upfront payment of $60 million, as well as funding for R&D costs through IND filing. Kite will be eligible to receive up to $525 million in milestone payments per Amgen program based on the successful completion of regulatory and commercialization milestones, plus tiered high single- to double-digit royalties for sales and the license of Kite’s intellectual property for CAR T cell products. Amgen is eligible to receive up to $525 million in milestone payments per Kite program, plus tiered single-digit sales royalties.  Further terms of the agreement are not being disclosed.

“The intersection of immunology and oncology represents one of the most promising approaches to delivering significant impact for patients with cancer,” said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. “With our existing immuno-oncology portfolio of cutting-edge technologies and expertise, we believe joining forces with Kite Pharma will leverage our targets and their leading CAR T cell platform to advance another new promising therapeutic approach to fight cancer.” 

“Amgen is an ideal partner for us, based on their strong presence in oncology and the company’s broad array of cancer targets optimally suited for combining with our CAR technologies. We are proud to announce this unique collaboration and its validation of our R&D expertise, intellectual property position, and therapeutic manufacturing and processing capabilities,” stated Arie Belldegrun, M.D., FACS, Kite Pharma’s president and chief executive officer. “We believe that the therapeutic candidates resulting from the collaboration will have the potential to dramatically transform CAR approaches and to become some of the most powerful therapies for the treatment of cancer.”

Kite Pharma will host a conference call and webcast today at [time tbd] to discuss the transaction. The dial-in number to access the call is (XXX) XXX-XXXX, or from international locations dial (XXX) XXX-XXXX. A taped replay of the call will be available by calling (XXX) XXX-XXXX with access pass code XXXXXXXX. The replay may be accessed from international locations by dialing (XXX) XXX-XXXX and using the same pass code. This replay will remain in effect until midnight Eastern Standard Time, Jan. XX, 2015.  To access the live webcast, please visit Kite Pharma’s Investor Relations website at http://ir.kitepharma.com.

About CAR T Immunotherapies

Kite Pharma’s broadly enabling eACTTM technology platform allows a patient’s T cells to be genetically modified to express cancer-targeting receptors. Engineered CAR T cells contain a single chain antibody domain, which recognizes and binds to a cell surface tumor antigen, as well as intracellular T cell-activating domains. CAR T cells are designed to traffic directly to tumor sites and become activated upon engagement with the target tumor antigen, selectively eradicating the tumor cells.

 

 

 

About Amgen

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human 

Exhibit F - 2

Execution Copy

 

therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

 

Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's largest independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

 

For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.

 

About Kite Pharma

Kite Pharma, Inc., is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a primary focus on eACTTM designed to restore the immune system's ability to recognize and eradicate tumors. In partnership with the NCI Surgery Branch through a Cooperative Research and Development Agreement (CRADA), Kite is advancing a pipeline of proprietary eACTTM product candidates, both CAR (chimeric antigen receptor) and TCR (T cell receptor) products, directed to a wide range of cancer indications. Kite is based in Santa Monica, Calif.. For more information on Kite Pharma, please visit www.kitepharma.com.

 

Amgen Forward-Looking Statements

This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen Inc. and its subsidiaries (Amgen, we or us) and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission (SEC) reports filed by Amgen Inc., including Amgen Inc.'s most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and Form 8-K. Please refer to Amgen Inc.'s most recent Forms 10-K, 10-Q and 8-K for additional information on the uncertainties and risk factors related to our business. Unless otherwise noted, Amgen is providing this information as of Jan. 5, 2015, and expressly disclaims any duty to update information contained in this news release.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for us and our partners to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may 

Exhibit F - 3

Execution Copy

 

have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development.

In addition, sales of our products (including products of our wholly-owned subsidiaries) are affected by the reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement. Government and others' regulations and reimbursement policies may affect the development, usage and pricing of our products. In addition, we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products. We believe that some of our newer products, product candidates or new indications for existing products, may face competition when and as they are approved and marketed. Our products may compete against products that have lower prices, established reimbursement, superior performance, are easier to administer, or that are otherwise competitive with our products. In addition, while we and our partners routinely obtain patents for our and their products and technology, the protection of our products offered by patents and patent applications may be challenged, invalidated or circumvented by our or our partners' competitors and there can be no guarantee of our or our partners' ability to obtain or maintain patent protection for our products or product candidates. We cannot guarantee that we will be able to produce commercially successful products or maintain the commercial success of our existing products. Our stock price may be affected by actual or perceived market opportunity, competitive position, and success or failure of our products or product candidates. Further, the discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to integrate the operations of companies we have acquired may not be successful. Cost savings initiatives may result in us incurring impairment or other related charges on our assets. We may experience difficulties, delays or unexpected costs and not achieve anticipated benefits and savings from our recently announced restructuring plans. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase common stock.

The scientific information discussed in this news release related to our product candidates is preliminary and investigative. Such product candidates are not approved by the U.S. Food and Drug Administration, and no conclusions can or should be drawn regarding the safety or effectiveness of the product candidates.

 

Kite Pharma Forward-Looking Statements

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, 

Exhibit F - 4

Execution Copy

 

outlook, analyses or current expectations concerning, among other things: our ability to research and develop new therapeutic candidates; our expectations regarding the clinical effectiveness and safety of  CAR T cell therapies; our ability to manufacture and process CAR T cell therapies; and our ability to protect our proprietary technology and enforce our intellectual property rights. Various factors may cause differences between Kite's expectations and actual results as discussed in greater detail in Kite's filings with the Securities and Exchange Commission, including without limitation in its Form 10-Q for the quarter ended Sept. 30, 2014. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

 

### 

 

CONTACT: 

Amgen, Thousand Oaks

Kristen Davis, 805-447-3008 (media)

Trish Hawkins, 805-447-5631 (media)

Arvind Sood, 805-447-1060 (investors)

 

Kite Pharma 

Cynthia M. Butitta

Chief Financial Officer and Chief Operating Officer

310-824-9999

 

For Media: Justin Jackson

For Investor Inquiries: Nancy Yu

Burns McClellan

212-213-0006

jjackson@burnsmc.com

nyu@burnsmc.com

Exhibit F - 5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00242-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00242-of-00352.parquet"}]]